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Abstract 
Diffuse large B-cell lymphoma (DLBCL) is an aggressive disorder of mature  
B-lymphocytes presenting with 40% of novel lymphoma cases worldwide the most 
common subtype of adult Non-Hodgkin lymphoma. DLBCL is characterised by a 
high degree of heterogeneity regarding clinical, pathologic and molecular genetic 
issues. Gene expression profiling revealed distinct molecular DLBCL subtypes 
resembling germinal centre B-cells (GCB DLBCL) and activated B-cells (ABC 
DLBCL). Despite advances in therapy, the 3-year progression free survival rates of 
GCB and ABC DLBCL upon immunochemotherapy are still at 74% and 40%, 
respectively. Consequently, there is an obvious need for identifying new molecular 
targets and biomarkers serving as starting points to develop new, more efficient 
therapeutic strategies especially of the adverse ABC DLBCL subtype. 
 
In the present study we were able to demonstrate that IκBNS is constitutively 
expressed in ABC DLBCL cell lines and human biopsies, whereas IκBNS 
expression is absent in GCB DLBCL. We noticed that two IκBNS isoforms were 
detectable, the described p35 and a second larger IκBNS isoform exhibiting an 
additional N-terminal unstructured portion. Silencing of IκBNS led to a reduced 
growth of ABC DLBCL cell lines, suggesting an oncogenic function of IκBNS. 
Promoter studies suggested that IκBNS expression is under the control of NF-κB 
and NFAT signalling. Interestingly, we detected constitutive activation of NFAT in 
DLBCL cell lines, which was necessary to drive the expression of IκBNS in ABC 
DLBCL. Calcineurin inhibitors, which decrease the activity of NFAT proteins, did not 
only impair the expression of IκBNS, but also induced cell death in multiple ABC 
DLBCL cell lines. The expression of the pro-survival cytokines IL-6/-10 was 
markedly reduced by calcineurin inhibition, which might at least partially explain their 
toxicity in ABC DLBCL cell lines. With the help of phosphoproteomics, we identified 
several new calcineurin substrates in ABC DLBCL, including CD79, suggesting a 
more central role of calcineurin in tumorigenesis. 
 
Taken together, these results provide first insights into the essential function of 
IκBNS in the development of ABC DLBCL. Furthermore, we suggest IκBNS as a 
promising biomarker to discriminate ABC from GCB DLBCL. Finally, we propose 
that calcineurin inhibitors could have therapeutic potential for the treatment of 
aggressive ABC DLBCL. 
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Zusammenfassung 
Das diffus großzellige B-Zell-Lymphom (DLBCL) ist eine aggressive Erkrankung 
reifer B-Lymphozyten. Diese ist mit einem Anteil von bis zu 40% an allen weltweit 
neu auftretenden Lymphomen der am häufigsten auftretende Subtyp der adulten 
Non-Hodgkin Lymphome. DLBCL sind durch ein hohes Maß an Heterogenität 
hinsichtlich klinischer, pathologischer und molekular genetischer Aspekte 
charakterisiert. Genexpressionsanalysen haben verschiedene molekulare DLBCL 
Subtypen aufge-deckt, die Keimzentrums-B-Zellen (GCB DLBCL) und aktivierten B-
Zellen ähneln (ABC DLBCL). Trotz Fortschritten in der DLBCL-Therapie, liegt das 
3-Jahres progressionsfreie Über-leben nach einer Immunchemotherapie noch 
immer bei 74% für GCB DLBCL und lediglich 40% für ABC DLBCL. Es besteht somit 
ein offensichtlicher Bedarf an der Identifizierung neuer therapeutischer Ziele und 
Biomarker, die als Ausgangspunkt der Entwicklung neuer Behandlungsstrategien 
vor allem des ungünstigeren ABC DLBCL Subtypes dienen. 
 
Diese Arbeit zeigt, dass IκBNS ausschließlich im ABC DLBCL Subtyp exprimiert ist. 
Interessanterweise konnten zwei IκBNS-Isoformen detektiert werden. Zum einen 
war die in der Literatur bereits beschriebene p35 Form zu sehen, zum anderen eine 
längere Isoform, die sich durch einen zusätzlichen unstrukturierten N-Terminus 
auszeichnet.  
Wenn die Expression von IκBNS durch shRNA verhindert wurde, reagierten  
die ABC DLBCL Zelllinien mit einem verlangsamten Zellwachstum. Dies lässt  
eine onkogene Funktion von IkBNS vermuten. Mit Hilfe von Promotoranalysen 
konnte NFAT als essentieller Transkriptionsfaktor für die IkBNS Expression 
identifiziert werden. Überraschenderweise war eine konstitutive NFAT Aktivierung 
in allen DLBCL Zelllinien nachweisbar. Die Hemmung der NFAT Aktivität durch 
Calcineurin-Inhibitoren erniedrigte nicht nur die IkBNS Expression, sondern 
induzierte zudem Zelltod in mehreren ABC DLBCL Zelllinien. Die IL-6/-10 
Expression, die das Wachstum der Krebszellen fördert, war durch Calcineurin-
Inhibitoren stark erniedrigt.  
Eine Analyse des Phosphoproteoms mit MS deckte neue Calcineurin-Substrate in 
ABC DLBCL Zellen auf. Unter anderem konnte CD79 identifiziert werden, was auf 
eine zentrale Rolle von Calcineurin in den onkogenen DLBCL Signalwegen 
impliziert. 
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Zusammenfassend bietet diese Arbeit erste Erkenntnisse über die Rolle des IκBNS 
Proteins in der Entwicklung von ABC DLBCL. Die IκBNS Expression in Tumorzellen 
könnte ein vielversprechender Biomarker sein, um GCB und ABC DLBCL 
histologisch einfach voneinander zu unterscheiden. Die gewonnenen Ergebnisse 
legen ferner nahe, dass die Anwendung von Calcineurin Inhibitoren eine nützliche 
Option in zukünftigen Behandlungsstrategien von ABC DLBCL mit bestimmten 
Mutationsmustern sein könnte. 
 
Table of Contents 
VI 
 
Table of Contents 
Abstract ................................................................................................ III 
Zusammenfassung ............................................................................. IV 
Abbreviations ....................................................................................... X 
1. Introduction ....................................................................................... 1 
1.1 B-cell lymphoid malignancies ............................................................................ 1 
1.1.1 Diffuse large B-cell lymphoma (DLBCL) ..................................................... 1 
1.1.1.1 GCB DLBCL..................................................................................... 3 
1.1.1.2 ABC DLBCL ..................................................................................... 6 
1.1.1.3 PMBL ............................................................................................... 10 
1.1.2 Mantle cell lymphoma (MCL) ................................................................... 11 
1.2 Transcription factor families involved in B-cell lymphomagenesis ................... 14 
1.2.1 The NF-κB family ..................................................................................... 14 
1.2.2 NF-κB signaling ........................................................................................ 15 
1.2.3 Canonical or classical NF-κB signaling .................................................... 16 
1.2.4 Non-canonical or alternative NF-κB signaling .......................................... 18 
1.2.5 Inhibitors of NF-κB signaling .................................................................... 20 
1.2.5.1 Classical NF-κB inhibitors ................................................................ 20 
1.2.5.2 Atypical NF-κB inhibitors .................................................................. 22 
1.2.5.3 The atypical NF-κB inhibitor IκBNS .................................................. 25 
1.2.6 The NFAT family ...................................................................................... 28 
1.2.6.1 Transgenic mice ............................................................................... 29 
1.2.6.2 Common protein structure of NFAT proteins.................................... 30 
1.2.6.3 Ca2+ signaling and NFAT activation ................................................. 31 
1.2.6.4 Pharmacologic inhibitors of NFAT signaling .................................... 33 
1.2.6.5 NFAT activity modulators ................................................................. 33 
1.2.6.6 NFAT transcriptional activity ............................................................ 35 
1.2.6.7 Role of NFAT in B-cells .................................................................... 36 
1.2.6.8 NFAT in solid cancers ...................................................................... 37 
1.2.6.9 NFAT in hematopoietic malignancies ............................................... 37 
1.2.6.10 NFAT signaling summary ............................................................... 38 
1.2.7 The AP-1 family ....................................................................................... 38 
1.3 Antigen receptor signaling: B-cell receptor (BCR) and T-cell receptor (TCR) 
signaling .......................................................................................................... 46 
1.4 The major histocompatibility complex (MHC) .................................................. 51 
2. Material and Methods...................................................................... 61 
2.1 Materials ......................................................................................................... 61 
  Table of Contents 
 
VII 
 
2.1.1 Providers .................................................................................................. 61 
2.1.2 Chemical reagents ................................................................................... 62 
2.1.2 Commonly used Buffers and Solutions and their composition ................. 63 
2.1.3 Pharmacological inhibitors ....................................................................... 65 
2.1.4 Enzymes .................................................................................................. 65 
2.1.5 Media and buffers for cell culturing .......................................................... 66 
2.1.6 Media for bacterial culturing ..................................................................... 66 
2.1.7 Kits ........................................................................................................... 67 
2.2 Biological material ........................................................................................... 67 
2.2.1. Size markers for DNA and proteins ......................................................... 67 
2.2.2. Antibodies ............................................................................................... 68 
2.2.3 Oligonucleotides ...................................................................................... 69 
2.2.3.1 RNAi mediated gene expression knockdown: .................................. 69 
2.2.3.2 Oligonucleotides used in Crispr/Cas9 mediated gene expression 
knockout........................................................................................... 70 
2.2.3.3 Oligonucleotide primers applied in qRT-PCR experiments .............. 70 
2.2.3.4 Oligonucleotide primers used for sequencing of plasmids ............... 70 
2.2.4 Bacterial strains ....................................................................................... 70 
2.2.5 Continuous human cell lines .................................................................... 70 
2.2.6 Plasmids .................................................................................................. 71 
2.3 Additional materials ......................................................................................... 72 
2.3.1 Devices used for conducting experiments ................................................ 73 
2.4 Methods .......................................................................................................... 73 
2.4.1 Experimental procedures in molecular biology ......................................... 73 
2.4.1.1 Isolation of whole cell RNA .............................................................. 73 
2.4.1.2 Determination of nucleic acid concentrations and purity .................. 73 
2.4.1.3 Reverse transcription of RNA........................................................... 73 
2.4.1.4 Quantitative RT-PCR ....................................................................... 73 
2.4.1.5 RNAseq analysis .............................................................................. 74 
2.4.1.6 Digesting DNA strands with restriction endonucleases .................... 74 
2.4.1.7 Agarose gel electrophoresis............................................................. 74 
2.4.1.8 Extraction of DNA fragments from agarose...................................... 75 
2.4.1.9 Ligation ............................................................................................ 75 
2.4.1.10 Transformation of competent E.coli bacteria .................................. 75 
2.4.1.11 Analytical plasmid preparation ....................................................... 75 
2.4.1.12 Sequencing .................................................................................... 76 
2.4.1.13 Preparative plasmid isolation ......................................................... 76 
2.4.1.14 Polymerase chain reaction (PCR) .................................................. 76 
Table of Contents 
 
 
VIII 
 
2.4.1.15 Cloning of PCR fragments ............................................................. 77 
2.4.1.16 Generation of shRNA expressing vectors ...................................... 77 
3.4.1.17 Generation of CRISPR/Cas9 expressing vectors ........................... 77 
2.4.1.18 Luciferase IkBNS promoter reporter generation............................. 78 
2.4.2 Experimental procedures in cell biology ................................................... 78 
2.4.2.1 Determination of cell concentrations ................................................ 78 
2.4.2.2 Cryoconservation of cells ................................................................. 78 
2.4.2.3 Thawing of cells ............................................................................... 78 
2.4.2.4 Culture of lymphoma cells ................................................................ 79 
2.4.2.5 Transfection of DNA by calcium phosphate precipitation ................. 79 
2.4.2.6 Lentiviral transduction of DNA.......................................................... 80 
2.4.2.7 Transfection of DNA by electroporation ........................................... 80 
2.4.2.8 Dual luciferase reporter assay ......................................................... 80 
2.4.2.9 MTS Assay....................................................................................... 81 
2.4.2.10 Generation of protein lysates for Western Blot ............................... 81 
3.4.2.11 Protein quantification ..................................................................... 82 
2.4.2.12 Fractionation of cytosolic and nuclear proteins .............................. 82 
2.4.2.13 Stimulation of cells ......................................................................... 83 
2.4.2.14 Cycloheximide treatment of ABC DLBCL cell lines ........................ 83 
3.4.2.15 Stable isotope labeling by/with amino acids in cell culture ............. 83 
2.4.3 Immunobiological methods ...................................................................... 84 
2.4.3.1 Staining of lymphoma cell surface markers and analysis by FACS . 84 
2.4.3.2 Legend screen™ .............................................................................. 84 
2.4.3.3 ELISA ............................................................................................... 84 
2.4.3.4 Sodium dodecylsulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) .................................................................................... 85 
2.4.3.5 Immunoblotting ................................................................................ 85 
3. Results ............................................................................................. 87 
3.1 IκBNS regulation in lymphocytes .................................................................... 87 
3.2 Role of IκBNS in ABC DLBCL ....................................................................... 101 
3.3 Role of calcineurin in DLBCL ........................................................................ 113 
3.4 Expression of IκBNS isoforms in B and T-cell lymphoma cell lines ............... 130 
3.5 Regulation of HLA-DR expression by IκBNS ................................................ 144 
3.6 CD Marker screen of GCB and ABC DLBCL ................................................ 150 
4. Discussion ..................................................................................... 159 
4.1 Significance of DLBCL research ................................................................... 159 
4.2 The expression of IκBNS in DLBCL subtypes ............................................... 160 
  Table of Contents 
 
IX 
 
4.3 The mutual transcriptional regulation of IκBNS by NF-κB and NFAT ............ 161 
4.4 Calcineurin as positive regulator of BCR signaling ....................................... 167 
4.5 Characterisation of two IκBNS isoforms ........................................................ 179 
4.6 IκBNS is essential for ABC DLBCL survival and might promote immune 
escape of ABC DLBCL by regulating MHCII surface expression .................. 182 
4.7 Calcineurin inhibitor administration as additional therapeutic option to R-
CHOP in the treatment of ABC DLBCL ......................................................... 185 
4.8 IκBNS and its relative IκBζ ............................................................................ 186 
4.9 Seeking new surface markers and molecular targets for classifying and 
combat DLBCL .............................................................................................. 189 
4.10 Summary: The pivotal role of calcineurin and IκBNS in ABC DLBCL 
biology......................................................................................................... 195 
5. References ..................................................................................... 198 
6. List of Figures ............................................................................... 226 
7. List of Tables ................................................................................. 226 
Danksagungen/Acknowledgements ................................................ 229 
 
 
 
 
Abbreviations 
 
 
X 
 
Abbreviations 
aa amino acid 
ABC Activated B-cell like 
AKAP79 A-kinase anchor protein 
ANK Ankyrin repeat 
AP-1  Activator protein-1  
APC  Antigen Presenting Cell 
APS  Ammonium persulfate  
ARD Ankyrin repeat domain 
ARE Antioxidant-response element 
B2M  β2-microglobulin 
BAD Bcl-2-associated death promoter  
BAFF  B cell activating factor  
BAFF-R B-cell activating factor receptor 
BCAP B cell adaptor for phosphoinositide 3-kinase  
Bcl  B cell lymphoma  
BCR B-cell Receptor 
BIRC Baculoviral IAP repeat containing  
BLK B lymphoid tyrosine kinase 
BLNK B-cell linker protein 
BSA  Bovine serum albumin  
BTK Bruton’s Tyrosine Kinase 
bZIP Basic Leucine Zipper  
C/EBPβ  CCAAT/enhancer binding protein β  
CABIN1 Calcineurin-binding protein 1 
CaM Calmodulin 
CBM  CARD11, BCL10 and MALT1 
CC Coiled-coil 
CCL CC-chemokine ligand  
CCND1 CyclinD1 
CD  cluster of differentiation  
CD40L  Cluster of differentiation 40 ligand  
ChIP  Chromatin immunoprecipitation  
cIAP  Cellular inhibitor of apoptosis  
CIITA class II, major histocompatibility complex, transactivator 
CIN85 Cbl-interacting protein of 85 kDa 
CK1 Casein kinase1 
CLIP  Class II-associated li peptide 
c-Maf  v-Maf musculoaponeurotic fibrosarcoma oncogene homolog  
CML Chronic myelogenous (or myeloid or myelocytic) leukemia (CML)  
cMyc  Avian myelocytomatosis virus oncogene cellular homolog  
CnA/B Calcineurin subunit A / B 
COPD  Chronic pulmonary obstructive diseases  
CRAC calcium-release-activated calcium  
CRE cAMP-responsive element 
CREB cAMP response element-binding protein 
CSP Calcipressin 
DAG Diacylglycerol 
dATP  2′-Deoxyadenosine 5′-triphosphate  
DBD DNA binding domain 
DC  Dendritic cell  
DD Death-Domain 
DLBCL  Diffuse Large B-cell Lymphoma 
DMEM  Dulbecco's modified eagle medium  
DMSO  Dimethyl sulfoxide  
DNA  Deoxyribonucleic acid  
dNTP  2'-Deoxynucleoside 5'-triphosphate  
DOK Downstream of kinase 
DRiPS  Defective ribosomal products  
dsDNA  Double-stranded deoxyribonucleic acid  
dsRNA  Double-stranded ribonucleic acid  
DTT  Dithiothereitol  
DYRK Dual-specificity tyrosine-phosphorylation regulated kinase 
E2F E2 Transcription Factor 
EAE Experimental allergic encephalomyelitis 
ECL  Enhanced chemoluminiscence  
  Abbreviations 
 
XI 
 
ECM Extracellular matrix 
EDTA  Ethylenediaminetetraacetic acid  
ELISA  Enzyme-linked immuno sorbent assay  
ER Endoplasmic reticulum  
ERAD  ER associated protein degradation 
ERK Extracellular signal–regulated kinase 
EZH2 Histone H3 lysine 27 methyltransferase enhancer of zeste homolog 2 
FACS  Fluorescence-activated cell sorting  
FCS  Fetal calf serum  
FcγRIIB-1 Low affinity immunoglobulin gamma Fc region receptor II-b  
FITC  Fluorescein isothiocyanate  
FOXP Forkhead box P 
GADS GRB2-related adaptor downstream of Shc 
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase  
GCB  Germinal center B-cell like 
G-CSF  Granulocyte colony-stimulating factor  
GEF  Guanine nucleotide exchange factor  
GM-CSF  Granulocyte macrophage colony-stimulating factor  
GPCR G protein–coupled receptor 
GRB2 Growth factor receptor-bound protein 2  
GRR Gylcine rich region 
GSK3β Glycogen synthase kinase 3 beta 
GST Glutathione S-transferase 
GTP Guanosine-5'-triphosphate 
HAT Histone acetyltransferase 
HDACs Histone deacetylases 
HEPES  4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid  
HLA Human leukocyte antigen  
HLH Helix-Loop-Helix 
HRP  Horseradish peroxidase  
I Ionomycin 
IFNα/β/γ Interferon α/β/γ  
Ig Immunoglobulin 
IHC  Immunohistochemistry  
IKK  IκB kinase  
IL  Interleukin  
IP  Immunoprecipitation  
IP-10 Interferon gamma-induced protein 1 
IP3 Inositol 1,4,5-trisphosphate  
IRAK  IL-1R-associated kinase  
IRF Interferon Regulatory Factor 
ITAM Immunoreceptor tyrosine-based activation motif 
ITIM Immunoreceptor tyrosine-based inhibition motif 
iTreg Induced regulatory T cells  
IκB  Inhibitor of κB/inhibitor of NF-κB  
IκBNS Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, 
delta 
JAK  Janus-associated kinase  
JDP Jun dimerization protein 
JNK c-Jun amino-terminal kinase 
JNK/SAPK c-Jun N-terminal kinases/ Stress-activated protein kinase 
kDa Kilo Dalton 
LAT Linker of Activated T-cells 
LCK Lymphocyte-specific protein tyrosine kinase 
LPS  Lipopolysaccharide  
LPS Lipopolysaccharides  
LTβ  Lymphotoxin β  
LUBAC  Linear ubiquitin chain assembly complex  
LYN Lck/Yes novel tyrosine kinase 
LZ Leucine-Zipper 
MAIL  Molecule possessing ankyrin repeats induced by lipopolysaccharide  
MAPK  Mitogen-activated protein kinase  
MARE MAF-recognition elements 
MCL Mantle Cell Lymphoma 
MCMV Murine cytomegalovirus 
MCP(-1)  Monocyte chemoattractant protein(-1)  
M-CSF  Macrophage colony-stimulating factor  
MDC Macrophage-derived chemokine 
Abbreviations 
 
 
XII 
 
MDM2 Mouse double minute 2 
MEF  Mouse embyrionic fibroblast  
MHCI Major histocompatibility complex 1 
MHCII  Major histocompatibility complex 2  
MIP-1α Macrophage Inflammatory Protein 
MiR microRNA 
MS  Mass spectrometry  
mTOR Mammalian Target Of Rapamycine 
MUM1 Multiple Myeloma Oncogene 1 
MyD88  Myeloid differentiation primary response protein 88  
NEMO  NF-κB essential modulator  
NFAT nuclear factor of activated T-cells 
NF-κB  Nuclear factor kappa light chain enhancer of activated B cells  
NHL Non-Hodgkin-Lymphoma 
NIK  NF-κB-inducible kinase  
NLS Nuclear localisation signal 
NP-40  Nonidet P-40  
NRON Non-coding repressor of NFAT 
P/I  PMA and Ionomycin 
PAMP  Pathogen-associated molecular pattern  
PAX5 
CARD11 
Paired box protein 5 
Caspase recruitment domain-containing protein 11 
PBS  Phosphate-buffered saline  
PCR  Polymerase chain reaction  
PD-1 Programmed cell death protein 1 
PE  Phycoerythrin  
PH Pleckstrin homology domain 
PI3K  Phosphoinositide 3 kinase  
PIP2 Phosphatidylinositol 4,5-bisphosphate 
PIP3 Phosphatidylinositol (3,4,5)-trisphosphate 
PKC  Protein kinase C  
PLC Phospholipase-C 
PMA  Phorbol 12-myristate 13-acetate  
PMBL Primary Mediastinal B-cell lymphoma 
PPAR peroxisome proliferator-activated receptors 
PRDM1 PR domain zinc finger protein 1  
PRDM1 (BLIMP-1) PR domain zinc finger protein 1  
PTEN Phosphatase and Tensin homolog 
PTM Posttranslational modification 
qPCR  Quantitative polymerase chain reaction  
qRT-PCR  Quantitative reverse transcription-polyermase chain reaction  
Rac/Rho Ras homologue/  Ras-related C3 botulinum toxin substrate 1 
RAF1 rapidly accelerated fibrosarcoma 
RANKL  Receptor activator of nuclear factor κB ligand  
R-CHOP Rituximab-Cyclophosphamide,Hydroxydaunorubicin, 
Vincristine(Oncovin™), and Prednisone 
RHD  Rel homology domain  
RHD REL homology domain 
RING  Really interesting new gene  
RNA  Ribonucleic acid  
ROR  Related orphan receptor  
ROS  Reactive oxygen species  
RT  Reverse transcription  
RTK Receptor tyrosine kinase 
RU  Relative units  
S/T Serine/Threonine 
SD  Standard deviation  
SDS  Sodium dodecyl sulphate  
SDS-PAGE  Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
SEM  Standard error of the mean  
SFK Src-Family Kinase 
SHIP SH2 domain-containing inositol 5’-phosphatase 1 
SHP SH2 domain-containing phosphatase  
SLP SH2-domain-containing leukocyte protein 
SOCE “ store operated Ca2+ entry 
SOS Son of sevenless 
Src  Sarcoma 
SRR serine rich region 
  Abbreviations 
 
XIII 
 
STAT  Signal transducers and activators of transcription  
STIM  Stromal interaction molecule 
SYK Spleen Tyrosine Kinase 
TAB  TAK1-binding protein  
TAD  Transactivation domain  
TAE  Tris acetic acid EDTA  
TAK1  TGF-β-activated kinase 1  
T-ALL T-cell acute lymphoblastic leukaemia 
TAP Transporter associated with antigen processing  
TBK1  TRAF family member-associated NF-κB activator TANK-binding kinase  
TBS  Tris-buffered saline  
TBS/T  Tris-buffered saline/polysorbat 20  
TCR T-cell Receptor  
TEMED  Tetramethylethylenediamine  
TGFβ  Transforming growth factor β  
TIR  Toll/IL-1R  
TLR  Toll-like receptor  
TNFSFRs Tumor necrosis factor superfamily receptors 
TNF-α  Tumour necrosis factor-α  
TonEBP Tonicity enhancer binding protein 
TOP  Thimet oligopeptidase 
TRAF  TNF receptor-associated factor  
TRAF TNF-receptor-associated factor 
TRAM  TRIF-related adaptor molecule  
TRE TPA-responsive element 
Treg Regulatory T cells 
Tris  Tris(hydroxymethyl)aminomethane  
Tween  Polysorbat 20  
UTR  Untranslated region  
VCAM  Vascular cell adhesion molecule  
VEGF  Vascular endothelial growth factor  
WT Wild-type 
XBP1s X-box binding protein 1 
ZAP-70 Zeta-chain (TCR) associated protein kinase 70 kDa 
ZF Zinc-Finger 
κB site  NF-κB binding site  
 
 
 
 
Introduction 
1 
 
1. Introduction 
The following chapters provide the required background knowledge of the topics 
that are relevant for the understanding of this study. Chapter 1.1 introduces the 
characteristics and molecular abnormalities of the different subtypes of diffuse large  
B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Moreover, it also 
covers the function and relevance of intracellular NF-κB inhibitors with a particular 
focus on the atypical NF-κB inhibitor IκBNS. The ensuing Chapter 1.2 focuses on 
the components, relevance, the molecular characteristics and signaling of 
transcription factor families that are involved in B-cell lymphoma genesis and are 
part of investigations conducted in this study. The subsequent chapter 1.3 describes 
the antigen-receptor signaling pathways of B- and T-cells. Lastly, Chapter 1.4 deals 
with MHCI and II molecules, their structure, assembly, function and what is known 
so far about their role in DLBCL. 
1.1 B-cell lymphoid malignancies 
1.1.1 Diffuse large B-cell lymphoma (DLBCL) 
DLBCL account for 30% to 40% of all adult lymphoid malignancies world-wide and 
are therefore the most common form of Non-Hodgkin’s lymphoma (The Non-
Hodgkin's Lymphoma Classification Project, 1997; Coiffier et al., 1997). The disease 
can be observed at any age and is evenly distributed between genders (Armitage 
et al., 1998). The median age of onset is the seventh decade of life whereby 60% 
of patients are older than 60 years at diagnosis (Groves et al., 1995). Notably, there 
are considerable differences between ethnicities concerning the average age of 
disease onset, as African Americans in the United States are diagnosed at younger 
ages (Shenoy et al., 2011; Sinha et al., 2013). As the name “Diffuse large B-cell 
lymphoma” already implies it is a hematologic disorder of mature large B lymphoid 
cells (mean diameter ≥ 20 µm), growing diffusely. Most commonly the neoplastic B-
cells eliminate the normal underlying lymph node architecture, thereby frequently 
causing rapidly swelling of lymph nodes. Up to 40% of patients exhibit extranodal 
primary lymphoma sites whereby the most common spots are the gastrointestinal 
tract, head and neck, skin and soft tissue and the genitourinary system (Hunt and 
Reichard, 2008; Castillo et al., 2014). Untreated, the median life expectancy of 
DLBCL patients is less than one year, indicating the aggressive nature of DLBCL 
(Sinha et al., 2013). The CHOP regime including Cyclophosphamide, 
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Hydroxydaunorubicin, Vincristine (Oncovin™) and Prednisone was first applied in 
the 1970s has been considered as the standard chemotherapeutic therapy 
approach for DLBCL. CHOP treatment was found to have an impact in only 40% to 
50% of elderly DLBCL patients and results in an overall survival of 35% to 40% 
(Sonneveld et al., 1995). The CHOP based chemotherapy was complemented in 
1997 by the introduction of the immunochemotherapeutic IgG1 monoclonal antibody 
Rituximab targeting the pan-B-cell marker CD20. The administration of the new R-
CHOP therapy for initial DLBCL treatment improved complete response rates and 
prolongs progression-free and overall survival significantly in elderly DLBCL 
patients notably without excess of toxicity and is for these now the standard of care 
(Coiffier et al., 2002; Feugier, 2015). Despite this advance in treatment still nearly 
40% of patients eventually die of relapsed or refractory DLBCL (Vaidya and Witzig, 
2014). DLBCL are characterised by a high degree of heterogeneity in respect of 
clinical presentation and courses, pathology, morphology, molecular abberations 
and treatment response (Sinha et al., 2013; Carbone et al., 2014; Castillo et al., 
2014). The wide spectrum of this single diagnostic category can be partially 
explained by the distinct molecular features of the tumors revealed by the 
investigation of DLBCL tumor samples using cDNA microarrays. Three distinct 
DLBCL disease entities were discovered by gene expression profiling (GEP) 
differing in their treatment outcomes after standard chemotherapy regimens, thus 
defining prognostic categories (Alizadeh et al., 2000). The newly established DLBCL 
subtypes seem to be derived from different stages in B-cell maturation as they 
exhibit gene expression patterns of non-transformed cells at different stages in  
B-cell differentiation. Alizadeh et al. used this distinctiveness in gene expression 
patterns to subdivide DLBCL and named the most common major DLBCL subtypes 
after the differentiation status of their cell of origin namely the germinal B-cell like 
(GCB) DLBCL subtype with accounting for 17% of B-cell malignancies, the activated 
B-cell like (ABC) DLBCL subtype making up 15% of B-cell malignancies. The 
primary mediastinal B-cell lymphoma (PMBL) accounting for 6% of B-cell 
malignancies, was defined as the third molecular DLBCL entity and named after the 
site of its manifestation. 
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1.1.1.1 GCB DLBCL 
The germinal centre (GC) B-cell is the non-cancerous counterpart of the GCB 
DLBCL subtype. Patients suffering from GCB DLBCL show a drastically better  
3-year overall survival rate with approximately 80% than patients diagnosed with the 
so called ABC DLBCL subtype with approximately 45% under R-CHOP regimen 
therapy (Lenz et al., 2008). On the molecular level the as GCB subtype classified 
lymphoma are characterised by the overexpression of several genes common for 
germinal centre B-cells such as the BCL6, LMO2 and the surface markers CD10 
and CD38 (Schuetz et al., 2012; Alizadeh et al., 2000). For an overview of the 
molecular characteristics of GCB DLBCL see Figure 1. BCL6, a transcriptional 
repressor is expressed at high levels in mature B-cells within the germinal centre. 
BCL6 binds regulatory regions of several thousand genes in germinal centre B-cells 
and constitutes hence a well-established germinal centre marker. Hence, BCL6 is a 
master transcriptional regulator in germinal center B-cell differentiation and is 
constitutively expressed due to chromosomal translocation or mutations altering its 
promoter region in 45% of DLBCL cases that cause a deregulation of BCL6 
expression (Lo Coco et al., 1994; Migliazza et al., 1995). For instance, BCL6 
represses genes afflicted in inflammatory processes such as STAT1, important for 
interferon (IFN) response or the expression of the chemokines IL-10 and CCL3 
(Toney et al., 2000). Moreover, BCL6 was revealed to have a crucial role in the 
regulation of apoptosis in GC B-cells. It acts as direct transcriptional of the anti-
apoptotic BCL2 protein repressor by suppressing MIZ1 triggered BCL2 expression. 
However, this repressor function of BCL6 over BCL2 was found to be lost in DLBCL 
due to promoter mutations and chromosomal translocations of BCL2 and the 
deregulation of MIZ1 (Saito et al., 2009; Ci et al., 2009). Furthermore, BCL6 was 
reported by Phan et al. (2004) to be an active repressor of p53 expression in 
germinal center B-cells by binding to two specific sequences within the p53 
promoter. Consequently, high levels of BCL6 as present in germinal center B-cells 
were found by Phan et al. to protect the cells from DNA-damage induced apoptosis 
by functional inactivation of p53. Thus, deregulated BCL6 expression as in GCB 
DLBCL contributes considerably to lymphomagenesis by the inactivation of p53. 
Additionally, important for cancerogenesis as well, is the property of BCL6 to repress 
pivotal cell-cycle regulators such as the cyclin-dependent kinase (CDK) inhibitors 
p21 and p27kip1. With this, BCL-6 enables unregulated cell-cycle progression 
  Introduction 
 
 
4 
 
(Shaffer et al., 2000; Phan et al., 2005). The histone H3 lysine 27 methyltransferase 
enhancer of zeste homolog 2 (EZH2) is highly upregulated in GC derived B-cells 
and thus constitutively activated in GC-derived NHL. Morin et al. (2010) discovered 
a recurrent somatic EZH2 missense mutation in 21, 7% of investigated cases GCB 
DLBCL in exon 15 of the EZH2 gene exchanging tyrosine 641 for a histidine. 
The mutation is located in the catalytic component of the enzyme and responsible 
for adding methyl groups to substrates. The Y641H amino acid substitution is 
leading to reduced enzymatic turnover in vitro. Functionally, EZH2 cooperates with 
BCL6 by regulating the BCL6 repressor function on a subset of target genes in GC 
B-cells, probably mediating the GC B-cell phenotype and under aberrant conditions 
inducing lymphomagenesis of GC origin such ach GCB DLBCL (Caganova et al., 
2013). Moreover, EZH2 impairs GC responses and silences BLIMP1 a major factor 
for terminal maturation to plasmocytes. Béguelin et al. (2013) proved in mice bearing 
DLBCL xenografts and in primary human DLBCLs that the combinatorial 
administration of BCL6 and EZH2 inhibitors synergistically kills DLBCL. 
The chromosomal translocation t(14; 18)(q32; q21) is reported to be associated with 
the GCB gene expression profile and CD10 expression and thus present in roughly 
30% to 40% of all GCB DLBCL cases. This chromosomal abnormality brings the 
locus of the anti-apoptotic gene BCL2 under the regulatory control of the heavy-
chain locus leading to BCL2 overexpression and simultaneous relieve of BCL6 
repression (Zhang et al., 2011). The BCL2 gene was also found to be the most 
commonly mutated gene in GCB DLBCL. GC B-cells and their malignant 
counterparts of the GCB DLBCL subtype show only very minor activity of NF-κB 
due, in part, to the overexpression of the NF-κB negative regulator BCL2 and the 
fact that BCL6 inhibits the expression of p50 and was also observed to colocalise 
with RelA unfolding repressive transcriptional activity on various NF-κB target genes 
(Grimm et al., 1996; Shaffer et al. 2001; Li et al., 2005; Schuetz et al., 2012). 
Also contributing to GCB DLBCL pathogenesis is the frequent heterogeneous 
deletion of PTEN in ~10% and the complete loss of PTEN expression in 55% of 
GCB DLBCL as revealed by IHC (Pfeifer et al., 2013). The PTEN phosphatase is 
the major negative regulator of the PI3K/AKT pathway, is inversely correlated with 
p-AKT levels and was described to be crucial for growth, proliferation and survival 
of a subset of GCB DLBCL. Cells exhibiting PTEN loss were found to be addicted 
to PI3K/AKT signaling. Moreover, also the proto-oncogene MYC plays a crucial role 
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in GCB DLBCL. The loss of PTEN in GCB DLBCL and the subsequent constitutive 
PI3K/AKT signaling lead by the inhibition of GSK3β to the up regulation of MYC 
which is important for proliferation. Thus, the ectopic expression of PTEN in PTEN-
deficient GCB DLBCL induced toxicity as PI3K/AKT signaling is consequently 
diminished and MYC expression reduced. Therefore, GCB DLBCL showing PTEN 
loss are suggested to be vulnerable to PI3K/AKT inhibition (Pfeifer et al., 2013; 
Roschewski et al., 2014). Noteworthy as well, for understanding GCB DLBCL 
lymphomagenesis is the microRNA cluster miR-17-92 which is amplified and 
overexpressed in 12,5% of GCB DLBCL cases but never in ABC DLBCL. miR-17-
92 expression results in elevated MYC and related targets expression (Lenz et al., 
2008). Murine cells expressing miR-17-92 also display down modulation of PTEN in 
turn leading to enhanced PI3K/AKT signaling and the repression of p21 altogether 
leading to promotion of cell growth and anti-apoptotic signaling (Xiao et al., 2008; 
Inomata et al., 2009; Olive et al., 2009). 
Figure 1. Overview of key 
signaling pathways affected  
and characteristic genetic 
aberrations involved in 
GCB DLBCL pathogenesis. 
(a) Signaling pathways 
afflicted in the pathogenesis 
of GCB DLBCL. Illustrated 
are possible targets for 
therapy approaches of GCB 
DLBCL by small molecule 
inhibitors (Figure adapted 
from: Roschweski et al., 
2014). (b) Summary of  
recurrent genetic aberrations 
and deregulated pathways 
found in GCB DLBCL. 
Depicted on the right-hand 
site, the frequency of the 
distinct molecular 
abnormalities, if they are loss 
or gain of function, in which 
regulatory category they 
belong and to what kind of 
malignant phenotype they 
lead (Figure adapted from: 
Shaffer et al., 2012). 
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1.1.1.2 ABC DLBCL 
ABC DLBCL derive from B-cells at the plasmablastic differentiation stage. This 
DLBCL entity shows a more aggressive behaviour than the GCB subtype, thus 
exhibiting a distinctly inferior cure rate of 40% in 2015 (Roschweski et al., 2015).                                  
The major molecular hallmark of ABC DLBCL subtype is the constitutively active 
classical NF-κB signaling sustaining viability, proliferation and anti-apoptotic 
signaling contributing to the lymphoma’s aggressiveness and poor outcome of 
therapeutic approaches (Frick et al., 2011). An overview of recurrent genetic 
aberrations and signaling pathways such as NF-κB that are implicated in ABC 
DLBCL lymphomagenesis is depicted in Figure 2. As found by Davis et al. in 2001,  
the transduction of a dominant negative IκBα or IKKβ inhibiting NF-κB signaling is 
selectively toxic for ABC DLBCL cell lines what was indicating an addiction of ABC 
DLBCL to NF-κB activation. The permanent NF-κB activity is achieved by multiple 
molecular mechanisms in upstream signaling (Figure 2). A participation of B-cell 
receptor (BCR) signaling in the pathomechanistic context of ABC DLBCL was first 
revealed by an RNAi screen showing a toxic impact of shRNAs directed against 
CARD11, BCL10 and MALT1, the core components of the CBM complex (Ngo et 
al., 2006). The ternary complex serves as a signaling hub and is required to activate 
IKKβ downstream of the BCR, thus relaying signals from the BCR to the classical 
NF-κB pathway (Ngo et al., 2006). Hence, the CBM complex is critical for antigen 
receptor induced activation of classical NF-κB signaling. CARD11, also known as 
CARMA1, is a multidomain protein adapter. It functions as a signaling scaffold in the 
CBM complex, coordinating the activation of the NF-κB positive regulator IKKβ 
(Rawlings et al., 2006). Approximately 10% of ABC DLBCL cases harbour somatic 
activating mutations of CARD11 such as G1116S and L244P leading to increased 
NF-κB pathway activity independent from upstream BCR signaling (Lenz et al., 
2008). The linear ubiquitin chain assembly complex (LUBAC) is associated with the 
CBM complex.Single nucleotide polymorphisms in the LUBAC subunit RNF31, 
especially enriched in ~8% of ABC DLBCL augment the ability of LUBAC to attach 
linear ubiquitin to IKKγ, thereby enhancing NF-κB signaling and consequently 
promoting the survival of the ABC DLBCL (Yang et al., 2014).  Since IKKγ 
ubiquitination is required for IKK activation the knock down of LUBAC complex 
components is fatal for ABC DLBCL (Yang et al., 2014; Dubois et al., 2014). A RNA 
interference screen conducted by Davis et al. (2010) proved the Bruton’s tyrosine 
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kinase (BTK) as an essential element for survival of ABC DLBCL with wild type 
CARD11 proteins. Moreover, the study also revealed that the shRNA mediated 
knockdown of the heavy and light chain of BCR, the components of the BCR  
co-receptor heterodimer CD79A/B and downstream BCR signaling key signaling 
molecules SYK, BLNK, PLCγ2, PKCβ results in the death of wild-type CARD11 
bearing ABC DLBCL cell lines. In addition to that, Davis et al also identified CD79A/B 
ITAM sequences to be mutated in 21, 1% of ABC DLBCL and only in 3,1% in GCB 
DLBCL cases. In 18% of investigated ABC DLBCL biopsies, CD79B was mutated 
in the membrane-proximal ITAM tyrosine (Y) residue, whereas CD79A mutations 
occurred rarely in only 2,9% of examined biopsies. For instance, the ABC DLBCL 
model cell lines HBL-1 and TMD8 harbour a heterozygous missense mutation 
affecting the first tyrosine of the CD79B ITAM Y196F and Y196H, respectively.  
The ITAM mutations were shown to reduce the activity of the BCR signaling 
negative regulator LYN and to promote increased BCR surface expression. 
Together with the finding of the vital importance of more distal BCR signaling 
elements such as BTK or PKCβ these findings suggest that chronic active BCR 
signaling is a key mechanism in ABC DLBCL with wild type CARD11 resulting in 
constitutively active NF-κB signaling. Besides BCR signaling, a second signaling 
pathway was uncovered to contribute to constantly active NF-κB. Ngo et al. (2011) 
describe the dependence of ABC DLBCL cell lines on MYD88 which was observed 
to be mutated in 39% of ABC DLBCL, and the associated kinases IRAK1/4. MYD88 
is a signaling adapter downstream of toll like receptors (TLRs) activating NF-κB 
upon ligand engagement of TLRs. Among the ABC DLBCL MYD88 mutations, the 
Ngo group describes an ABC DLBCL exclusive gain-of-function driver mutation. 
With a frequency of 29% this single amino acid exchange, L265P, located in the 
MYD88 Toll/IL-1 receptor domain, constitutes the most common MYD88 mutation 
in ABC DLBCL cases. Functionally, this particular L265P mutation led to promoted 
cell survival by IRAK1/4 assembly and activation in turn leading to  
NF-κB signalling, IFN-β production and by JAK/STAT3 mediated signaling the 
secretion of IL-6, IL-10 and. Notably, 34% of ABC DLBCL cases harbouring a 
MYD88 L265P mutation also exhibited a coincident mutation of CD79B/A and in 
some cases the MYD88 L265P mutation was coincident with CARD11 mutation. 
Thus, MYD88, CD79A/B and CARD11 mutations are not exclusive and can be 
observed in one tumor or the respective model cell lines like HBL1 (MYD88 L265P; 
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CD79B Y196F), TMD8 (MYD88 L265P; CD79B Y196H) or OCI-LY3 (MYD88 
L265P; CARD11 L244P). Furthermore, Ngo et al. observed that the knock down of 
MYD88 in addition to shRNA mediated knockdown of CD79B or CARD11 in ABC 
cells lines, addicted to chronic active BCR signaling enhanced the killing of cells 
harbouring a combination of the earlier described mutations. This suggests a non-
redundant synergising effect of aberrant BCR and MYD88 signalling in order to 
maintain ABC DLBCL survival. Additional NF-κB signaling promoting factors 
reported in the ABC DLBCL subtype is for instance the inactivation of the NF-κB 
negative regulatory, ubiquitin editing enzyme A20. Roughly 30% of ABC DLBCL 
patients exhibit biallelic A20 inactivation by mutations and/or deletions and 
epigenetic silencing of the A20 encoding gene (Compagno et al., 2009). Moreover, 
the TAB2-associated TGF-β-activated kinase (TAK1) was described to be mutated 
in the ABC DLBCL cell line U2932 and in 5% of patient derived samples (Compagno 
et al., 2009; Fontan et al., 2012). TAK1 is recruited and activated by TAB1 which in 
turn is recruited by TRAF6 upon TLR stimulation and subsequent MYD88 and 
IRAK1/4 activation. TAK1 promotes cell survival through activation of NF-κB 
signaling downstream of the CBM complex and the adaptor protein MYD88 by the 
phosphorylation of IKKβ and is therefore an essential mediator of proliferation and 
cytokine secretion (Wang et al., 2001; Sun et al., 2004 Moreno-García et al., 2013; 
Ansel et al., 2014).  
Apart from NF-kB signaling there are several other proteins and signaling pathways 
afflicted in the molecular pathogenesis of ABC DLBCL. As already mentioned, ABC 
DLBCL derive from B-cells that are in the transition to become plasma cells.                     
This maturation is blocked by several genetic aberrations in ABC DLBCL that for 
instance finally lead to the inactivation of the PRDM1 gene and its expression 
product BLIMP-1 (Rosenwald et al., 2002; Frick et al., 2011; Shaffer et al., 2012). 
Roughly one quarter of ABC DLBCL samples show inactivating truncations, 
nonsense and splice site mutations, deletions or epigenetically silencing of the 
PRDM1 gene encoding one master regulator of further cell differentiation, 
“the transcriptional repressor and plasmacytic differentiation driver B lymphocyte-
induced maturation protein-1” (BLIMP-1) (Pasqualucci et al. 2006; Tam et al. 2006). 
This transcription factor orchestrates the transformation into plasma cells by shutting 
down mature B-cell gene expression programs for example the expression of PAX5 
and SPIB and the exit of cell cycle (Shaffer et al., 2002). SPIB and its DNA binding 
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partner IRF4 are both highly expressed in ABC DLBCL and critical for ABC DLBCL 
survival as revealed by an RNAi screen (Yang et al., 2012). Also BCL6 which is a 
BLIMP-1 repressor as well, is found to be affected by translocations observable in 
25% of ABC DLBCL patients (Iqbal et al., 2007; Tunyaplin et al., 2004; Shaffer et 
al., 2000). The ETS family transcription factor SPIB which is repressed by BLIMP-1 
is highly expressed in ABC DLBCL and represses in turn BLIMP-1 constituting a 
negative feedback loop (Shapiro-Shelef et al., 2005; Lenz et al., 2008; Schmidlin et 
al., 2008). Together, SPIB and its DNA binding partner IRF4 which is highly 
expressed since it is induced by constitutively active NF-κB signaling are crucial for 
the expression of CARD11 (Young et al., 2015). In this manner NF-κB signaling, 
IRF4/SPIB and CARD11 shape a positive feedback loop pivotal for ABC DLBCL 
survival (Shaffer et al., 2012; Young et al., 2015). Furthermore, they act together in 
repressing cell cycle arrest and apoptosis promoting type I interferon response 
secretion in ABC DLBCBL that is induced by MYD88 signaling (Stark et al., 1998; 
Yang et al., 2012). 
Figure 2. Overview of  
key signaling pathways 
affected and characteristic 
molecular aberrations 
involved in ABC DLBCL 
pathogenesis. (a) Signaling 
pathways afflicted in the 
pathogenesis of GCB DLBCL. 
Depicted in yellow stars, 
protein mutations leading to 
constitutively active NF-κB 
signaling. Illustrated are 
possible targets for therapeutic 
approaches of GCB DLBCL 
by small molecule inhibitors 
(Figure adapted from: 
Roschweski et al., 2014). 
(b) Summary of recurrent 
genetic aberrations and 
deregulated pathways found in 
ABC DLBCL. Depicted on the 
right-hand site, the frequency 
of the distinct molecular 
abnormalities, if they are loss 
or gain of function, in which 
regulatory category they 
belong and to what kind of 
malignant phenotype they lead 
(Figure adapted from: Shaffer 
et al., 2012). 
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1.1.1.3 PMBL 
PMBL arise from a rare subset of B-cells residing in the thymus and is a clinically 
aggressive lymphoma (Dunleavy and Wilson, 2015; Shaffer et al., 2012).                       
The malignancy predominantly affects adolescents and young adults with a median 
age of onset between 30 to 35 years, much earlier than the GCB and ABC DLBCL 
subgroups (Swerdlow et al., 2008). According to Rosenwald et al., (2003) the 5-year 
survival rate was with 64% relatively favourable after anthracycline multiagent based 
chemotherapy with some patients receiving radiation therapy. The clinical 
presentation and molecular characteristics are different from the other DLBCL 
subtypes and resemble “nodular sclerosing Hodgkin Lymphoma”. Notably, over one 
third of genes expressed in PMBL were also characteristic for Hodgkin Lymphoma 
(Dunleavy and Wilson, 2015; Rosenwald et al., 2003). PMBL exhibit a B-cell 
phenotype as they express CD20 and CD79A and show surface expression of GC-
markers such as CD10, BCL6 and CD23 (Möller et al., 1987; Calaminici et al., 2004; 
Salama et al., 2010). A genetic hallmark found in PMBL are gains/amplifications in 
the p24 region of chromosome 9 (Joos et al., 1996; Lenz et al., 2008). The molecular 
characteristics of PMBL involved pathogenesis are summarised in Figure 3. The 
9p24 chromosomal region encodes JAK2 the activator of STAT6 which was shown 
to transcriptionally repress BCL-6 (Ritz et al., 2013). Moreover, also in the 9p24 
region located are the genes coding for the ligands for the inhibitory PD-1 receptor 
on the surface of T-cells, PDL1 and 2 which are rearranged at a frequency of 20% 
in PMBL, indicating a mechanism of immune evasion of PMBL (Green et al., 2010; 
Steidl et al., 2011; Twa et al., 2014). All genes in this 9p24 region JAK2, PDL1 and 
2 are highly expressed in PMBL whereby PDL2 is according to Rosenwald et al. 
(2003) the best discriminator for PMBL. Epigenetic abnormalities seem to play a key 
role in the pathogenesis of PMBLs since the histone H3K9 demethylase “JMJD2C” 
which is also located in the 9p24 region cooperates with the earlier mentioned JAK2 
in decreasing heterochromatin throughout the whole genome (Rui et al., 2010). Due 
to this JAK2/JMJD2C mediated epigenetic alterations, many genes are induced in 
PMBL such as MYC. Knockdown of JMJD2C and JAK2 resulted in the epigenetically 
silencing of MYC as a consequence of heterochromatin formation (Rui et al., 2010).  
Noteworthy 38% of PMBL show a translocation of CIITA, the master transactivator 
of MHC class II genes (Steidl et al., 2011). This translocation inactivates one CIITA 
gene copy leading to decreased MHCII on the cell surface and augmented immune 
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evasion and thus to inferior survival of PMBL patients. Alike ABC DLBCL, PMBL are 
addicted to constitutive activity of the NF-κB pathway (Lam et al., 2005; Rosenwald 
et al., 2003; Savage et al., 2003). One putative reason could be the inactivation of 
the deubiquitinating enzyme A20 (Schmitz et al., 2009).   
 
Figure 3. Overview of recurrent genetic aberrations and dysregulated signaling pathways 
involved in PMBL lymphomagenesis. Shown are the frequencies of the distinct molecular 
abnormalities, if they are loss or gain of function, in which regulatory category they belong and to 
what kind of malignant phenotype they lead (Figure adapted from: Shaffer et al., 2012). 
 
1.1.2 Mantle cell lymphoma (MCL) 
MCL were first described in 1975 by K. Lennert. MCL account for 3 to 10% of all 
NHL in the western world, predominantly affecting men (Anderson et al., 1998; Zhou 
et al., 2008). MCL describe an aggressive neoplasm of mature B-cell deriving from 
cells surrounding the germinal centres. In the early stages the neoplastic cells 
replace the mantle zone pattern of the lymph node (Tiemann et al., 2005). In more 
advanced stages MCL show a rather diffuse growth pattern (Bertoni et al., 2007). 
The median age of diagnosis is ≤ 60 years and the median overall survival lies 
between 3 to 5 years, thus exhibiting the poorest long-term survival among B-cell 
lymphoma (Zucca et al., 1995; Herrmann et al., 2009). So far, conventional 
chemotherapy approaches are not curative and MCL show a high frequency of 
remissions up to 90% in a short time range of 1 to 2 years. The normal counterpart 
of the malignant MCL cell seems to be the pre-germinal center B-cell (Pérez-Galán 
2011). MCL display mature B-cell markers on their cell surface such as IgM and 
CD20 (Ghielmini et al., 2009; Pérez-Galán 2011). Molecularly, MCL share the 
expression of BCL2, CD5 and the hallmark chromosomal translocation the 
t(11,14)(q13;q32) bringing the CCND1 gene under the transcriptional control of the 
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Ig heavy chain promoter leading to an overexpression of the MCL prototypic 
oncogene cyclin D1 (Ghielmini et al., 2009; Pérez-Galán et al., 2011). A summary 
of genetic aberrations implicated in MCL lymphomagenesis is depicted in Figure 4. 
Observed as well in MCL were frequent deletions or the epigenetically silencing of 
the INK4a/arf locus that is coding for p16 and INK4arf that block the cell cycle and 
activate p53 (Rosenwald et al., 2003; Beà et al., 2001). HDM2 and HDM4, both 
negative regulators of p53 that synergistically promote proteasome-mediated p21 
and p53 degradation were found to be overexpressed. HDM4 also inhibits the p53-
mediated transcriptional activation of p21 a negative cell-cycle regulatory protein 
and inhibitor of cyclin D1 leading to the promotion of cell-cycle progression (Liang 
et al., 2010). Also DNA damage response pathways are afflicted in MCL 
pathogenesis since recurrent chromosomal deletions in chr.11q22-23 affect the 
functionality of the p53 upstream kinase ATM by gene truncation or missense 
mutations. By large scale pharmacological profiling Rahal et al. (2014) identified a 
subset of MCL cell line models that are sensitive to BCR signaling inhibitors ibrutinib 
(targeting BTK) and sotrastaurin (targeting PKC). They revealed that inhibitor 
sensitive MCL cell lines exhibit constitutively active BCR-signaling driven classical 
NF-κB signaling in contrast to resistant cell lines that show activation of the non-
canonical NF-κB signaling. Moreover, the group also unveiled recurrent mutations 
in TRAF2 and BIRC3, proteins involved in the non-canonical NF-κB pathway in 15 
% of examined patient samples by transcriptome sequencing. TRAF2 and 3 interact 
with BIRC2 and 3 in order to downregulate NIK which fosters the transition of the 
p100 precursor into the active mature p52 protein. RNAseq data obtained from MCL 
cell line models identified a TRAF2 nonsense mutant, TRAFW114* and a biallelic 
TRAF3 deletion. These mutations impair TRAF2 and 3 inhibitory properties on non-
canonical NF-kB signaling. Furthermore, when they conducted targeted sequencing 
of key elements implicated in non-canonical NF-kB signaling in primary MCL 
samples they found frequent mutations of TRAF in 6% and BIRC3 in 10% of cases. 
Two patient derived BIRC3 mutant variants, the nonsense mutation S441* and the 
missense mutation C560S were investigated in more detail. The coexpression of 
NIK with BIRC3S441* or BIRC3C560S resulted in less efficient NIK destabilisation and 
increased p52 production compared to wild type BIRC3 coexpression. This result 
was confirmed when both BIRC3 mutant proteins were expressed in a cell line 
exhibiting low p52 levels. BIRC3S441* or BIRC3C560S expression in this cell line clearly 
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led to an increase of p100 cleavage to p52 whereas expression wild-type BIRC3 did 
not affect steady state p52 protein levels. In addition to that, inhibitor insensitive 
MCL cell lines with alterations in non-canonical NF-kB signaling were found to be 
addicted to NIK activity in vitro and in vivo. Also in this B-cell lymphoma malignancy, 
the NF-kB negative regulatory ubiquitin editing enzyme A20 is commonly inactivated 
by deletions, mutations or its transcription is epigenetically dampened by increased 
promoter methylation (Honma et al., 2009). Moreover, MCL were found to be 
addicted to IRF4 and SYK as revealed by knock down approaches (Friedberg et al., 
2009; Shaffer et al., 2012). Several more secondary genetic alterations were 
discovered contributing to MCL lymphomagenesis including prosurvival and 
proliferative pathways like the PI3K/AKT/mTOR pathway, the WNT and Hedgehog 
pathway (Pérez-Galàn et al., 2011), critical cell-cycle regulating genes and DNA 
damage response and repair genes, indicating the MCL’s unique biology. 
 
                   
Figure 4. Overview of recurrent genetic aberrations involved in MCL 
lymphomagenesis. Shown are the frequencies of the distinct molecular abnormalities, if they are 
loss or gain of function, in which regulatory category they belong and to what kind of malignant 
phenotype they lead (Figure adapted from Shaffer et al., 2012). 
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1.2 Transcription factor families involved in B-cell 
lymphomagenesis 
1.2.1 The NF-κB family 
The nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) was 
discovered in 1986 and described as a constitutive nuclear B-cell specific inducible 
transcription factor regulating the expression of the Ig kappa light chain (Sen et al., 
1986). As result of intensive research during the last decades it was revealed that              
NF-κB is present in all cells and that the NF-κB family of transcription factors                
consists of five members termed p65/RelA, RelB and c-Rel. All NF-κB family 
members (depicted in Figure 5) are encoded by a distinct gene, RELA, RELB and 
REL (Gerondakis et al., 1999). They all share the presence of an N-terminal 
structural domain, the conserved 300 amino acid (aa) Rel homology domain (RHD). 
This protein motif comprises a sequence for DNA binding, a nuclear localisation 
signal (NLS) and a site for the interaction with other REL proteins for homo- and 
heterodimerization or NF-κB inhibitors (IκBs) (Baeuerle and Henkel., 1994; Baldwin, 
1996). Each of the NF-κB subunits has a unique DNA binding domain and therefore 
exhibits its own characteristic DNA binding affinity, as well. Thus, every subunit 
contributes to the overall DNA binding affinity of a NF-κB dimer leading to different 
dimer specific DNA binding consensus sequences (Wang et al., 2003; Siggers et 
al., 2011; Wong et al., 2011).Only RelA/p65, c-Rel and RelB exhibit a C-terminal 
transcriptional activation domain (TAD) which is necessary for the recruitment of 
coactivators and thus the transcriptional positive regulation of a certain NF-κB target 
gene (Hayden and Ghosh, 2012). As indicated earlier, NF-κB members form homo-
and heterodimers that bind NF-κB consensus sites (κB sites) within 
promoters/enhancers of a target gene (Pahl, 1999; Hayden and Ghosh, 2004). For 
this reason only NF-κB dimers including either at least one RelA, c-Rel or RelB 
subunit are able to act as transcriptional inducers. In most cell types, the 
predominant dimer in NF-κB signaling is the RelA/p50 heterodimer (Li and Verma, 
2002; Oeckinghaus and Ghosh, 2009). Noteworthy, RelB does not homodimerize 
and only forms dimers with p100, p52 or p50 whereas the other NF-κB subunits are 
being found in all possible hetero-or homodimer combinations (Ryseck et al., 1992; 
Bauerele et al., 1994; Bobrzanski et al., 1994). Unlike RelA, c-Rel or RelB, the 
N-terminal proteolytic cleavage products of p105 and p100, p50 and p52, 
Introduction 
 
15 
 
respectively lack a TAD. As a consequence of this, NF-κB homodimers consisting 
of p50 or p52 can only function as transcriptional repressors of their respective 
target gene. 
Those transactivation incapable dimers can negatively regulate transcription by 
constitutively occupying κB sites in a NF-κB responsive promoter sequence until 
they are displaced by a competitive TAD comprising NF-κB dimer. In this manner, 
p50 and p52 homodimers can establish an activation threshold of a NF-κB target 
gene (Hayden and Gosh, 2012). Moreover, p50/p52 dimers were also shown to act 
as epigenetic modifiers by recruiting gene-silencing proteins such as histone 
deacetylases (HDACs) to inhibit transcription (for review see Chen and Greene, 
2004). Taking into account the different NF-κB dimer compositions acting as gene 
inducers and repressors, distinct DNA binding site specificities depending on dimer 
combination, the large number of IκB sites in the genome and the multitude of 
NF-κB target genes makes the NF-κB transcription family and the regulated 
downstream signaling network highly complex and versatile. 
1.2.2 NF-κB signaling 
The induction of transcriptionally active NF-κB dimers by NF-κB signaling is 
classified into two main pathways termed as the canonical (classical) NF-κB 
pathway and the noncanonical (alternative) NF-κB pathway (pathways are 
schematically shown in Figure 6) (Sun, 2012). Both NF-κB inductive pathways share 
the activation of differently composed IκB kinase complexes and lead to the 
liberation of distinct NF-κB dimers. The activation of the pathways is under the 
control of a wide range of soluble and membrane-bound extracellular ligands 
originating from various extracellular sources (Hayden and Ghosh, 2012). 
Regarding the immune system, the NF-κB family coordinates various genes that 
control immune responses to a multitude of immune system stimulating agents for 
instance proinflammatory cytokines or pathogen derived substances recognised by 
pattern-recognition receptors such as LPS, peptidoglycans, lipoproteins, 
unmethylated bacterial DNA or dsRNA of viral origin (Li and Verma, 2002). 
Therefore, NF-κB signaling plays an important role in regulating the innate and 
adaptive immune system. Noteworthy, NF-κB activity was shown to be required for 
the rapid expression induction of acute-phase antimicrobial defence genes as 
response to invading pathogens. In adaptive immune system it plays a role in T-cell 
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development and function, Ig class switch of B-cells, germinal center formation or 
proper B-cell maturation (Gerondakis et al., 1998). Moreover, NF-κB signaling is 
also crucial for an appropriate response that is followed upon ligand binding of 
antigen-receptors implicated in the immune system like for example those of B- and 
T-cells (Schuster et al., 2012). In addition to that, there are also multiple intracellular 
pathways activating and regulating NF-κB activity such as DNA damage response, 
ionizing radiation, intracellular pattern recognition receptors and a plethora of other 
physical and chemical stresses (Li et al., 2001; Mohan and Meltz, 1994; Gilmore, 
2008). 
 
 
Figure 5. Molecular structures of members of the NF-κB family and the ternary IKK 
complex. (a) NF-κB family with indicated characteristic protein domains. p100 and p105  have dual 
role in NF-κB signaling as they exhibit IkB properties and when proteolytically processed to p52 and 
p50 they can act as activating NF-κB members. (b) Subunits of the high molecular IKK complex 
with indicated protein domains. ANK, ankyrin-repeat; CC, coiled-coil; DD, death domain; GRR, 
glycine-rich region; HLH, helix–loop–helix; IKK, IκB kinase; LZ, leucine-zipper; NBD, NF-κB-
essential-modulator-binding domain; RHD, REL homology domain; TAD, transactivation domain; 
ZF, zinc-finger. Figure adapted from Ghosh and Hayden, 2008. 
1.2.3 Canonical or classical NF-κB signaling  
The canonical or also called classical NF-κB pathway is activated by signals 
emanating from of a variety of structurally diverse membrane bound receptors upon 
ligand binding. Among them are tumor necrosis factor super-family receptors 
(TNFSFRs), interleukin receptors (ILRs), pattern recognition receptors (PRRs) such 
as Toll-like receptors (TLRs) or antigen receptors like the B- or T-cell receptor 
(Hyaden and Ghosh, 2012). Receptor ligation is followed by the recruitment of 
receptor proximal specific adapter protein complexes. In canonical signaling these 
are mostly RIP (receptor interacting protein) and TNF-receptor-associated factor 
(TRAF) family member protein complexes generally in conjunction with the TGFβ-
activated kinase-1 (TAK1) that is required as IKK kinase (IKK-K) for further 
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downstream signaling to the IκB kinase (IKK) (Hayden and Ghosh, 2008). Whereas 
TRAF proteins are utilised by both NF-κB pathway inducing pathways, RIP family 
members are exclusively used in the canonical signaling pathway Hayden and 
Ghosh, 2012). Receptor signaling culminates in the activation of IKKβ which is part 
of the trimeric cytoplasmic IKK complex consisting of the catalytic subunits IKKα and 
IKKβ, and the regulatory IKKγ (NEMO) subunit (Hacker and Karin, 2006). The 
activation of this ternary kinase complex requires the phosphorylation of IKKβ and 
the ubiquitination of IKKγ. Once activated, IKKβ in turn phosphorylates IκB proteins. 
The 37 kDa protein IκBα, the prototypical IκB is bound to the RHD of a NF-κB 
protein. IκBα mainly binds and thus regulates RelA/p50 or c-Rel/p50 heterodimers 
in the resting state by its repetitive ankyrin repeats thereby masking the NLS of 
either RelA or c-Rel. The p50 precursor protein p105 is constitutively processed 
through a cotranslational mechanism which is regulated by a glycine rich region 
(GRR) (Lin and Gshosh, 1996; Orian et al., 1999). On the other hand, also p105 
phosphorylation at certain C-terminal serine residues by IKKβ was reported that was 
followed by inducible procession to p50. The NLS of p50 is still accessible as 
unveiled by crystallographic investigations (Huxford et al., 1998; Jacobs and 
Harrison, 1998; Malek et al., 2001, 2003). In combination with the impact of nuclear 
export signals (NES) within the protein sequences of RelA, c-Rel and IκBα, the p50 
NLS accessibility is leading to the capability of the RelA/p50 or c-Rel/p50 complexes 
to shuttle between nucleus and cytoplasm under steady state conditions. But the 
masking of the RelA and c-REL NLS and the NES of IκBα results in the 
predominantly cytoplasmic localisation of NF-kB in the steady-state (Johnson et al., 
1999; Huang et al., 2000). This dynamic balance of cytosolic and nuclear 
localisation is shifted towards the nucleus by the activation of NF-kB signaling. Upon 
the activation of canonical NF-κB signaling, IκBα is phosphorylated by IKKβ at two 
conserved N-terminal serine (S) residues 32 and 36 within the so-called destruction 
box (aa-sequence: DSGXXS). These phosphorylated serines are subsequently 
recognized and IκBα gets K48-linked polyubiquitinated by the E3 ubiquitin ligase 
SCFβTrCP leading to proteasomal degradation of IκBα (Hayden and Ghosh, 2008; 
Henkel 1993; Chen, 1995; Yaron, 1997). In this way, the NLS is of RelA/p50 or  
c-Rel/p50 is accessible again and the sequestration of the NF-κB dimers in the 
cytoplasm is ceased. Upon release, the NF-κB factors migrate to the nucleus where 
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they accumulate and bind DNA, recruit cofactors and so activate the transcription of 
NF-κB responsive target genes (Hayden and Ghosh, 2004, 2008). 
1.2.4 Non-canonical or alternative NF-κB signaling 
The second NF-κB inducing signaling pathway, the Non-canonical or alternative         
NF-κB signaling displays distinct kinetics and regulatory components (Razani et al., 
2011). In contrast to the canonical NF-κB signaling this pathway is induced by a 
rather small variety of stimuli. A subset of TNFSFRs comprising lymphotoxin β 
receptor (LTβR), B-cell activating factor receptor (BAFF-R), OX40L (CD134), 
receptor activator of NF-κB (RANK), Fn14, and CD27 were revealed to induce non-
canonical NF-κB signaling (Claudio et al., 2002; Coope et al., 2002; Dejardin et al., 
2002; Novack et al.,2003; Ramakrishnan et al., 2004; Saitoh et al., 2003). 
The central regulatory mechanism in non-canonical NF-κB signaling involves the 
degradation modulation of the key kinase in this pathway, the NF-κB-inducing 
kinase (NIK) (Sun, 2011). Under steady state conditions, NIK is recruited to a 
cytosolic complex made up of TRAF2/3-cIAP1/2. NIK is brought together with the 
ubiquitin ligase cIAP1/2 by TRAF2/3. NIK K48-linked ubiquitination by cIAP1/2 
results in constant NIK proteasomal degradation (Zarnegar et al., 2008). As soon as 
for instance TNFSFRs engage their respective ligands, receptor dimerization is 
induced as in the case of CD40 and the TRAF2/3-cIAP1/2 is recruited to the 
intracellular portion of the receptor. Ensuing downstream signaling is best 
characterised for CD40, and LTβR as follows. In CD40 proximal signaling instead 
of NIK, TRAF3 is now due to TRAF2 mediated K63 ubiquitination, the new target of 
the K48 ubiquitin ligase activity of cIAP1/2. In this fashion, newly synthesizes NIK 
proteins are not degraded anymore and can accumulate. Enriched and activated 
NIK then phosphorylates and activates IKKα kinase activity which prevails in a 
homodimeric complex. The active IKKα dimer then phosphorylates p100 C-terminal 
serine residues which in turn results in the recruitment of the ubiquitin ligase 
complex SCFβTrCP. K48-linked ubiquitination of a distinct C-terminal lysine in p100, 
targets the protein C-terminus for proteolytic cleavage in which a GRR in close 
proximity to the ubiquitination plays an important role. This proteolytic processing of 
p100 ends up in leaving an N-terminal portion, named p52. NF-kB dimers that are 
generated as the end-product of this signaling cascade, consist of p52 and RelB.  
Full length p100 binds RELB which needs this association for stability. Prior to the 
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formation of mature p52, the NLS sequences of both subunits are hidden intra-
molecularly by C-terminal p100 ankyrin repeats that are structurally homologue  
to those of IκBs, establishing the C-terminal part of p100 as IκB. In the course of 
p52 generation, also the NLS masking p100 ankyrin repeats are eliminated.  
Thus, the IκB-like function of p100 is abrogated and NF-kB dimers composed of 
RelB and p52 are not sequestered in the cytoplasm anymore and can translocate in 
the nucleus, initiating the positive transcriptional regulation of corresponding target 
genes. (For noncanonical NF-kB signaling review see Bonizzi and Karin et al., 2004; 
Oeckinghaus, Hayden & Ghosh, 2011, Razani et al., 2011; Sun et al., 2012) 
 
Figure 6. Exemplary TNF and LT-β triggering of canonical (classical, left) and 
noncanonical (alternative, right) NF-κB signaling. In canonical signaling, NF-κB dimers are 
bound by IκB proteins masking their NLS and thus, sequestering them in an inactive NF-κB state in 
the cytoplasm. Upon stimulus induced receptor, the IκB kinase (IKK) complex, consisting of the 
kinases IKKα, IKKβ and the regulatory IKKγ-subunit (NEMO), phosphorylates the IκB and 
targeting it for ubiquitination and eventual proteasomal degradation. NF-κB dimers are subsequently 
liberated and can migrate to the nucleus to bind transcription regulatory sites of NF-κB responsive 
genes. The canonical pathway (left) is triggered by a multitude of stimuli, represented here by TNFR1 
signaling. TNF binding of TNFR1 results in the binding of TRAD, providing a platform for FADD 
and TRAF2 assembly. TRAF2 in turn associates with RIP1 to activate the IKK complex which 
phosphorylates IκBα in an IKKβ-and NEMO-dependent manner. In most cases p65-containing 
heterodimers are then released and translocate to the nucleus. NF-κB activity is further fine-tuned by 
modifying subunits with different PTMs. The noncanonical pathway, is induced by only certain TNF 
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family cytokines like CD40L, BAFF and as represented here, by lymphotoxin-β (LT-β). Upon 
receptor triggering, a complex consisting of TRAF3, TRAF2 and additional ubiquitin ligases 
regulates the stabilisation of NIK. This kinase phosphorylates IKKα which in turn phosphorylates 
p100 that is associated with RelB. This leads to proteolytic cleavage of p100 and the generation of 
p52 that pairs with RelB, generating active NF-κB dimers that migrate to the nucleus to exert 
transcriptional regulation of NF-κB target genes. (Figure taken from Oeckinghaus, Hayden & Ghosh, 
2011) 
1.2.5 Inhibitors of NF-κB signaling 
NF-κB is critical for the regulation of multiple physiological processes such as cell 
differentiation, survival and proliferation. Moreover, the NF-κB signaling network is 
also a key player of more comprehensive mechanisms including embryonic 
development, the functionality of innate and adaptive immune system and tissue 
homeostasis (Annemann et al., 2016). For this reason, a fine-tuned regulation of 
NF-κB activity is essential for the regular functioning of intracellular and superior 
mechanisms of the human body. This task is achieved by intracellular inhibitors of 
NF-κB signaling, the IκB proteins. The NF-κB regulatory “IκB protein family” is 
according to structural and deduced functional properties subdivided into the 
classical and a distinct group of atypical (also referred to as the BCL-3 subfamily) 
NF-κB inhibitors (an overview of classical and atypical IκBs is shown in Figure 7). 
All IκB proteins, no matter from which subfamily, are characterised by the presence 
of an ankyrin repeat domain (ARD), containing six to eight ankyrin repeats (ANK), 
a 33 amino acid structural motif exhibiting a helix-loop-helix conformation (Hinz et 
al., 2012). The ARD of an IκB regulates protein stability and mediates protein-protein 
interaction with the RHDs of NF-κB dimers (Annemann et al., 2016).  
1.2.5.1 Classical NF-κB inhibitors 
In resting cells, classical IκB proteins bind NF-κB dimers mediated by their ARD and 
functionally inactivate the dimers by retaining them in the cytoplasm as                                 
a consequence of the molecular masking of their NLS located within the RHD  
(Hinz et al., 2012). In this fashion, the binding of NF-κB dimers to κB DNA sequences 
in enhancers or promoters of target genes is prevented. The protein family consists 
so far of five cytoplasmic (classical) IκBs, namely the prototypic IκBα, IκBβ, IκBε, 
p105 (NF-κB1) and p100 (NF-κB2). In mice, all members are quite ubiquitously 
expressed exhibiting specific elevated levels for IκBα and IκBβ in spleen, IκBβ and 
IκBε in testis, IκBα in thymus, and IκBε in lung (Thompson et al., 1995; Li et al., 
1997; Whiteside et al., 1997; Lernbecher et al., 1994). IκBε primarily expressed in 
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hematopoietic cells (Hayden and Ghosh, 2008). p105 and p100 can be 
proteolytically processed to p50 and p52 by the cleavage of a C-terminal portion 
that serves as IκB, sequestering the NLS of a Rel protein, thus preventing the 
translocation of a NF-κB dimer to the nucleus (Bours et al., 1992; Beinke and Ley., 
2004; Sun, 2012). Accordingly NF-κB1 and NF-κB2 exhibit both, a NF-κB and a 
cytoplasmic IκB functionality (Hinz et al., 2012). Structurally, classical IκBs are 
defined by exhibiting six ANK and share an unfolded structure N-terminal to the ARD 
(Hinz et al., 2012). This unfolded aa-stretch comprises a degron motif also called 
“destruction box”, which includes two serines that are stimulus-dependent 
phosphorylated by IKKβ, namely S32 and S36 of IκBα, S19 and S23 of IκBβ and 
S157 and S161 for IκBε (Brown et al., 1995 ;DiDonato et al., 1996; Shirane et al., 
1999; Hinz et al., 2012). The phosphorylated residues are recognised and 
polyubiquitinated by the E3 ligase SCFβTrCP, followed by rapid the proteasomal 
degradation of the IκBs and release of NF-κB dimers (Henkel, 1993; Chen, 1995; 
Yaron, 1997; Winston1999; Ben-Neriah, 2002). Exclusive for IκBα and IκBβ is the 
presence of a region termed PEST, a peptide sequence rich in proline (P), glutamic 
acid (E), serine (S), and threonine (T) mediating fast protein turnover (Hinz et al., 
2012). Regarding NF-κB signaling modulation, IκBs influence the transcriptional 
specificity of differently composed NF-κB dimers by their ability to preferentially 
associate with certain members of the NF-κB family. For example, the RelA/p50 
heterodimer which is involved canonical NF-κB signaling is predominantly, albeit not 
exclusively, regulated by IκBα (Hayden and Ghosh, 2008). Classical IκB proteins 
also seem to have redundant functions. For instance the combined depletion of 
IκBα, IκBβ and IκBε resulted in an only minor increase of nuclear RelA levels 
(Tergaonkar et al., 2005). It is suggested that the inhibitory function of the three IκB 
was compensated by p105 and p100. Furthermore, IκBβ replacing the genomic IκBα 
was found to serve analogously to IκBα (Hayden and Ghosh, 2008 and 2012).  
On the other hand, studies in mouse embryonic fibroblasts (MEFs) investigating NF-
κB responses upon knocking out one, two or all three of IκBα, IκBβ or IκBε revealed 
that the inhibitors have distinctive unique functions even within one signaling 
pathway (Hayden and Ghosh, 2008). Hoffmann et al. (2002) postulate that the 
distinct functional features of IκBα, IκBβ and IκBε are the consequence of 
differences in their degradation and resynthesis. The degradation and resynthesis 
of IκBε for instance occurs with remarkable delayed kinetics in comparison to that 
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of IκBα (Kearns et al., 2006). Cell type and temporal specific degradation of for 
example IκBε suggests that different IκBs also have unique functions in regulating 
NF-κB responses (Hayden and Ghosh, 2008). In this regard, the major physiological 
feature of the classical NF-κB inhibitor IκBα is its capability to rapidly but strictly 
transiently induce a NF-κB mediated response to a canonical NF-κB pathway 
specific stimulus. This characteristic suggested that IκBα constitutes an 
autoregulatory feedback loop with NF-κB in which activated NF-κB drives the 
synthesis of IκBα that in turn inhibits the activity of NF-κB by regulating 
predominantly, but not exclusively RelA/p50 dimers. This hypothesis was promoted 
by the finding that the IκBα promoter was found to comprise κB sites within its 
sequence (Ito et al., 1994). Moreover, Mice, knock-out for IκBα show a significantly 
delayed termination of NF-κB signaling in response to canonical stimuli as for 
example TNF-α, substantiating the existence of this negative feedback loop 
(Gerondakis et al., 2006; Pasparakis et al., 2006). Thus, due to this negative 
feedback mechanism, IκBα is able to facilitate the maintenance of the transient 
effect induced by multiple agents on the transcription of NF-κB responsive genes. 
Obviously, the duration of the NF-κB response relies heavily on the kinetics of the 
feedback pathway determined by a distinct IκB, demonstrating the importance of the 
NF-κB response regulation by classical IκB proteins. 
1.2.5.2 Atypical NF-κB inhibitors 
In 1990, the (B-cell lymphoma 3 protein) BCL-3 was initially identified by Ohno et al. 
as rearranged proto-oncogene expressed in patients suffering from B-cell chronic 
lymphocytic leukemia that is characterised by a specific chromosomal translocation. 
Two years later in 1992 the seven ANK of BCL-3 were found to be closely related  
to those common in classical IκB proteins and shown to mediate complex formation 
with NF-kB dimers by binding the dimerization domain of NF-κB. Further, BCL3 was 
proven to bind p50 and p52 homodimers and to be co-localised with those in the 
nucleus. These observations and further findings such as the capability of BCL3  
to inhibit p50 DNA binding and the reversal of p50 homodimer-mediated 
transcription inhibition, revealed the protein as the first founding member of the 
atypical IκB family or also called BCL-3 subfamily (Franzoso et al., 1992; Hatada et 
al., 1992; Wulczyn et al., 1992; Nolan et al., 1993). Today, Bcl-3, IκBζ, IκBNS, IBη 
and IκBL belong to the group of atypical NF-κB inhibitors (Handel-Fernandnez et 
al., 1999; Kitamura et al., 2000; Fiorini et al., 2002; Yamauchi et al., 2010). 
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The atypical IκBs can be distinguished from classical IκBs by several distinct 
characteristics. In contrast to classical NF-κB inhibitors this protein group shows a 
completely different subcellular localisation as they are located predominantly in the 
nucleus where they exert their various functions by interacting with different NF-κB 
dimers in contrast to classical IκB which mainly bind NF-κB in the cytoplasm. 
However, the interaction of atypical IκB with different NF-κB dimers seems to be cell 
specific and dependent from the type of NF-κB stimulus or posttranslational 
modifications of the atypical IκBs. Furthermore, atypical IκB exhibit different 
activation and degradation kinetics. In detail, upon the induction of NF-κB signaling 
by extrinsic stimuli or antigen receptor derived signaling the expression of atypical 
nuclear IκBs is induced whereas classical IκB are initially degraded. Therefore, 
nuclear IκBs generally mediate their effects late in the transcriptional response or 
during secondary responses. The most important hallmark of the atypical IκBs that 
discriminates them from their classical relatives is their ability to either enhance, 
TAD sequences were found in BCL-3 and IκBζ, or diminish the transcriptional 
activity of target genes by the interaction with transcriptionally active DNA-
associated NF-κB dimers. In contrast to the cytoplasmic IκBs, that can only act as 
negative regulators of NF-κB activity (for review see Schuster et al., 2013; Hinz et 
al., 2012; Annemann et al., 2016). These mechanism are not the only differences 
between the two NF-κB inhibitor classes. Atypical IκBs not only act as NF-κB 
repressors but are also known to fine tune NF-κB activation and transcriptional 
response in the nucleus. This occurs for instance by adding post translational 
modifications to NF-κB subunits such as acetylation, phosphorylation and 
ubiquitination. These modifications regulate NF-κB dimer exchange on the DNA, 
stabilise DNA associated NF-κB dimers or recruit and displace histone deacetylases 
(HDACs) and histone acetyltransferases (HATs) to epigenetically alter target gene 
expression (for review see Mankan et al., 2001 Cheng and Greene, 2004). Most 
atypical IκBs are part of a negative feedback loop to limit the duration of NF-κB 
signaling. Bcl-3, IκBε, IκBζ and IκBNS are transcriptional targets of NF-κB except 
for IκBη that is regulated almost independently of NF-κB. Additionally, Bcl-3 and 
IκBζ mRNA translation was found to be negatively regulated by microRNAs miR-
125b and miR-124a, respectively (Guan et al., 2011; Lindenblatt et al., 2009).  
The knockout of a sole atypical IκB in mice was observed to be not lethal and results 
in normal growth after birth. However, the mice show multiple defects in organ 
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structures and immune system functions. Therefore, atypical IκB knockout mice 
suffer from autoimmune diseases and are for instance not able to mount proper 
defences against invading pathogens. Bcl-3 for example was shown to be important 
for correct splenic architecture, and the pathogen specific humoral immune 
response since knockout out mice are incapable of clearing listeria monocytogenes, 
streptococci pneumonia and toxoplasma gondii infections (Franzoso et al., 1997; 
Schwarz, 1997; Tassi et al., 2015). This impaired response to pathogens is in this 
case partially based on reduced IL-12p70 and IFNγ levels that are caused by the 
increased production of anti-inflammatory IL-10 by macrophages (Riemann et al., 
2005). On the other hand, mice lacking Bcl-3 are more susceptible to diabetes type 
I, display higher levels of IL-17 and do not show signs of autoimmunity (Ruan et al., 
2010). On the contrary, adult mice lacking IκBζ expression develop various 
symptoms of autoimmunity such as atopic dermatitis and chronic conjunctivitis. 90% 
of IκBζ deficient mice do not survive embryogenesis but the remaining fraction 
grows regularly after birth. IκBζ plays also an important role in adaptive immunity 
since it binds together with RORγ or RORα, to the IL-17a locus, promoting TH17 
cell development. Together with its function to positively regulate IL-6 production 
upon LPS exposure, the previous finding establishes IκBζ as proinflammatory IκB 
(Okamoto et al., 2010). In contrast to that, the proinflammatory TNFα transcription 
is suppressed by IκBζ and knockout mice are more resistant to experimental 
autoimmune encephalomyelitis (EAE) due to the impairment of TH17 cell 
development and susceptible to MCMV infection (Motoyama et al., 2005; Miyake et 
al., 2010; Okamoto et al., 2010). These examples of the dual IκBζ function in pro-
and anti-inflammatory mechanisms and processes clearly illustrates the versatile 
and complex role of atypical IκBs in the regulation of immune homeostasis and 
reaction. To sum it up, in this context atypical IκBs were revealed during the last 
decades to regulate the expression of surface markers, chemokines, cytokines and 
other effector proteins such as antibodies of immune cells, thus consequently 
regulating their maturation, differentiation and activation (for further review see Beg 
and Baldwin, 1993; Gosh et al., 1998; Li and Verma, 2002; Hayden and Gosh, 2004; 
Hayden and Gosh, 2008; Hinz et al., 2012; Hayden and Gosh, 2012; Schuster et 
al., 2013; Annemann et al., 2016). 
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Figure 7. Schematic overview of the molecular structure of murine cytoplasmic and 
nuclear IκB proteins. IκBs are characterised by the presence of an ankyrin repeat domain 
consisting of six to eight ankyrin repeats (ANK). IκBNS belongs to the nuclear or atypical IκB 
subfamily and consists of 6 ankyrin repeats and short N-terminal and C-terminal tails. Figure taken 
from: Annemann et al., 2016. 
 
1.2.5.3 The atypical NF-κB inhibitor IκBNS  
IκBNS, also called TA-NFKBH and NFKBID is encoded on chromosome 19q13.12 
in the Nfkbid gene and consists of 313 aa (human) or 327 aa (mouse). The protein 
comprises in human and mice six ANK for protein-protein interactions and short  
N-and C-terminal portions. IκBNS was first identified by Fiorini et al. in 2002 by 
investigating genes that are induced upon antigen induced negative selection of  
T-cells, bearing auto-reactive TCRs in the thymus. Soon afterwards it revealed to 
be inducibly expressed in several cell types. It was shown to be induced by stimuli 
like LPS, IL-10, CD40 and antigen ligands activating BCR and TCR signaling. IκBNS 
interacts with several NF-κB family members depending on the cell type. By 
conducting pulldown experiments with GST-IκBNS fusion proteins, Fiorini et al. 
(2002) have also shown the interaction of IκBNS with cytoplasmic and nuclear p50, 
as well as nuclear p52, p65, RelB and c-Rel in stimulated N14 TCR transgenic 
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thymocytes. In RAW264.7 macrophages overexpressed IκBNS interacts with p50 
but not with RelA (Hirotani et al., 2005). Co-IPs using nuclear extracts from 
fractionised P/I stimulated regulatory T-cells (Tregs) cell lysates, Schuster et al. 
(2012) revealed strong interaction of endogenous IκBNS with p50 and mild 
interaction with c-Rel. IκBNS-deficient mice breed and grow regularly. They do not 
show signs of spontaneous autoimmunity and are like IκBζ knockout mice more 
resistant to TH17-dependent EAE (Kobayashi et al., 2014). Furthermore, they found 
decreased expression of IL17A, IL-17-related genes and RORγt in response to 
Transforming Growth Factor (TGF-β1) and IL-6 stimulation in IκBNS deficient 
T-cells. TH17 cells depend on the expression of RORγt as the driving transcription 
factor of the TH17 phenotype which is also primarily characterised by the production 
of IL-17 (Ivanov et al., 2006). Considering the results described by Kobayashi et al., 
IκBNS negative T-cells are thus impaired in differentiating in proinflammatory TH17 
cells in response to TGF-β1 and IL6. For this reason, Kobayashi et al. concluded 
that IκBNS plays a crucial role in the generation of TH17 cells and in the control of 
TH17-dependent EAE. These results are in accordance with the findings of 
Annemann et al., 2015. They found IκBNS to be required for TH17 cell differentiation 
during gut inflammation and to regulate the expression of multiple key TH17 
cytokines such as IL-17A, IL17-F; IL-2, IL-10, GM-CSF, and MIP-1α.  
The requirement of IκBNS for the TH17 key cytokine IL-17 production was also 
observed by Jeltsch et al. by using a shRNA mediated knockdown approach in 
mouse CD4+ T-cells. Jeltsch et al. (2014) also demonstrated that Roquin and 
Regnase-1 repress mRNA encoding IκBNS, thereby inhibiting the expression of 
IκBNS and as a result of this also impair TH17 cell differentiation. Moreover, 
Annemann et al. (2015) report further that IκBNS exhibits increased binding to the 
IL-10 gene locus in stimulated TH17 cells in comparison to unstimulated TH17 cells. 
Therefore, the authors assume that IL-10 is a direct target of IκBNS expression and 
that IκBNS partially regulates TH17 differentiation by direct transcriptional control 
over TH17 phenotype determining cytokine expression. Furthermore, they reveal 
that IκBNS expression is not restricted to a specific T-cell subset, but drives besides 
TH17 also the development of TH1 cells in vitro. Consequently, they could observe 
reduced amounts of TH17 and TH1 cells, as result of a proliferation defect in IκBNS 
deficient mice. The group also describes that IκBNS mice display an impaired TH17 
development. TH17 cells are required for the clearance of Citrobacter rondentium 
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infections in the gut, which induce a strong TH17 response. Thus, as IκBNS was 
found to be indispensable for proper TH17 development it is consequently required 
for restricting Citrobacter rondentium infections in the gut and IκBNS knockout mice 
were unveiled to be highly susceptible to Citrobacter rondentium infections. The 
knockout proved IκBNS also not to have a considerable role in thymic negative 
selection, as indicated by the results obtained by Fiorini et al. (2002), since CD4+ 
and CD8+ T-cell numbers were not altered between wild-type and knockout mice.              
Alike IκBζ, IκBNS exhibits a dual role as negative and positive regulator of NF-κB 
target genes. T-cells lacking IκBNS produce significantly less IL-2 and IFN-γ and 
exhibit slightly impaired proliferation upon anti-CD3/28 stimulation, demonstrating 
its ability to act as transcriptional inducer (Touma et al., 2007). In contrast, 
stimulation of bone marrow-derived dendritic cells (DCs), lacking IκBNS with LPS 
show clearly increased and longer expression of the MYD88 dependent genes 
IL-6, IL-12p40 and IL-18. This result indicated that IκBNS is needed for termination 
of NF-kB activity at certain gene promoters such as in case of IL-6 (binding of IκBNS-
p50 complexes) and IL-12p40 that are induced late after TLR stimulation (Kuwata 
et al., 2006). The investigated knockout mice of this study were also highly 
susceptible to intestinal inflammation and LPS-mediated endotoxin shock. This 
outcome led to the conclusion that IκBNS is a regulator of inflammatory responses 
by inhibiting TLR-induced genes via the modulation of NF-kB activity. B-cell 
development and function are affected by IκBNS deficiency as well, since knockout 
mice exhibit for instance a complete absence of their peritoneal B1 B-cell repertoire 
and reduced mature B-cell numbers in the marginal zone of the spleen (Arnold et 
al., 2012). Furthermore, Touma et al. (2011) also describe that IκBNS deficient B-
cells show a decreased proliferation upon LPS and anti-CD40 exposure whereas 
proliferation was not affected upon BCR-stimulation. Moreover, also the effector 
function of B-cells in the humoral immune response was impaired by the absence 
of IκBNS. In addition to the observation of impaired in vitro plasma cell 
differentiation, IgG3 class switch was defective, the amount of serum IgM and IgG3 
was significantly diminished. Although B-cells of IκBNS deficient mice exhibit higher 
surface IgM levels. Also antigen-restricted antibody production in response to 
influenza A virus was decreased. As already mentioned earlier, IκBNS expression 
can be induced by IL-10. In this regard Fujita et al., showed high expression of 
IκBNS in mouse regulatory DCs in comparison to their conventional counterparts. 
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Those, regulatory DCs exhibit high levels of IL-10 but reduced levels of 
proinflammatory cytokines upon LPS exposure. This suggests that IκBNS 
participates in the suppression of the NF-κB-mediated production of 
proinflammatory cytokines. Schuster et al. showed in 2012 that IκBNS drives the 
expression of Forkhead box P3 (Foxp3) in mouse cells, the key     transcription factor 
controlling development and phenotypic maintenance of the immunosuppressive 
regulatory T-cell (Treg) phenotype. IκBNS binds together with p50 and c-Rel to the 
Foxp3 the promoter and a conserved non-coding sequence in the Foxp3 locus. 
Noteworthy, IκBNS expression is in turn suppressed by Foxp3 upon its induction, 
establishing a negative feedback loop (Marson et al., 2007). As a consequence of 
this, IκBNS positive regulation of Foxp3 expression, the loss of IκBNS in mice results 
in a substantial decrease of ~ 50% in mature Treg cell numbers due to an 
impairment of precursor Foxp3- Treg cell development in the thymus. Moreover, 
IκBNS also critically regulates induced Treg (iTreg) cell development during gut 
inflammation, and prevents IL-2 secretion of Treg cells (Schuster et al., 2012). 
Taken together, IκBNS has versatile roles in regulating immune homeostasis and 
response and is therefore an important player within the innate and adaptive 
immune system. Since IκBNS carries out functions in immune system activating as 
well as in immune suppressive mechanisms, it cannot be specified as pro- or anti-
inflammatory signaling protein. 
1.2.6 The NFAT family 
The nuclear factor of activated T-cells (NFAT) was first identified by Shaw et al. in 
1988 as a rapidly inducible transcription factor that switches on interleukin-2 
expression by binding to the IL-2 promoter in activated T-cells. Research in the 
following years revealed several more members of the NFAT family, it became 
obvious that NFAT expression is not restricted to T-cells but is expressed in almost 
all cell types, including other cells of the immune system, as well. The NFAT family 
now includes five members that are evolutionary related to the Rel/NF-κB family: 
NFAT1 (NFATc2/NFATp), NFAT2 (NFATc1/NFATc), NFAT3 (NFATc4), NFAT4 
(NFATc3/NFATx) and NFAT5 (tonicity enhancer binding protein TonEBP) (Hogan 
et al., 2003; Miyakawa et al., 1999).   Almost every cell type expresses one of the 
NFAT family members, including cells of hematopoietic and non-hematopoietic 
origin (Rao et al., 1997; Hogan et al., 2003; Graef et al., 2001; Crabtree and Olson, 
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2002). In general, the majority of NFAT proteins in lymphocytes, however, make up 
NFAT1 and NFAT2 (Rao et al. 1997). Research on NFAT proteins uncovered their 
regulatory roles in the central nervous system such as axonal guidance, 
angiogenesis, heart (e.g. cardiac valve formation), kidney, pancreas, skin, bone 
homeostasis, skeletal and smooth muscle development, the hematopoietic system, 
inflammatory response and the development and function of the immune system 
(Hogan et al., 2003; Graef et al., 2001; Crabtree and Olson, 2002; Kiani et al., 2004; 
Heit et al., 2006; Horsley et al., 2008; Pan et al., 2013). In more detail, in the context 
of lymphocyte development NFAT family members are expressed in peripheral 
lymphocytes except for NFAT3 which is primarily expressed outside of the immune 
system. NFAT1 is predominantly expressed in single positive thymocytes whereas 
NFAT2 is mainly expressed in double negative thymocytes and B-cells. In contrast 
to NFAT4 which is preferentially found in double positive thymocytes (Oukka et al., 
1998; Amasaki et al., 1998). NFAT5 is expressed in almost all cells and is activated 
as response to osmotic stress. For instance it regulates the expression of cytokines 
such as TNF-α and LTβ in lymphocytes under osmotic stress (Miyakawa et al., 1999; 
Lopez-Rodriguez et al., 2001). NFAT1-4 are regulated by calcium signaling whereas 
NFAT5 exhibits a truncated NFAT homology region (NHR) and thus lacks the 
calcineurin binding site (in 2.4.2 more about NFAT protein structure).  
For this reason, this certain NFAT protein is insensitive to calcium and calcineurin.  
1.2.6.1 Transgenic mice 
Studies of mouse models deficient in various NFAT members unveiled diverse 
phenotypes indicating unique roles of the different NFAT proteins. NFATc1 knockout 
mice for instance, exhibit a lymphoproliferative disorder and TH2-like responses 
(Ranger et al. 1998b; Yoshida et al., 1998). Mice with a NFATc2 loss, show modestly 
increased immune responses with TH2 characteristics (Hodge et al., 1996; 
Xanthoudakis et al., 1996; Kiani et al., 1997; Schuh et al., 1998). NFATc3 deletion 
results in increased lymphocyte apoptosis, hyperactive peripheral T-cells and the 
loss of CD4/CD8 double positive thymocytes (Oukka et al., 1998). Animals with 
a NFATc2 and NFATc3 double knockout exhibit spontaneous differentiation of 
T-cells into TH2 cells, overshooting IgE secretion, lymphadenopathy and the TH2-
predominant syndrome comprising allergic blepharitis and pneumonitis (Ranger et 
al., 1998c). As NFATc1 and NFATc2 exhibit the same DNA binding specificity, they 
were expected to be redundant in function. To figure this out, Peng et al. (2001) 
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reconstituted irradiated RAG2-deficient host mice with fetal livers taken from 
NFATc1/c2 double knockout mice. By doing this they confirmed the redundancy of 
NFATc1 and c2. They also investigated lymphocyte functions of NFATc1 or c2 
deficient animals. Peng et al. found that NFATc1 and c2 are indispensable for the 
activation of certain cytokine encoding genes since lymphocytes did not produce 
any IL-2, IL-4 or TNF-α and reduced IL-5 levels. Mice harbouring a constitutively 
active NFATc1 mutant show a global inflammatory response without affectation of 
thymocyte development (Pan et al., 2007). 
1.2.6.2 Common protein structure of NFAT proteins 
Structurally, all NFAT classified proteins share a moderately conserved regulatory       
N-terminal NFAT homology region (NHR) (~300 aa) that includes a potent 
transactivation domain, a NLS, serine rich regions (SRR1, 2), KTS and SPXX-repeat 
motifs (SP1-3), whereby X denotes any amino acid. Furthermore, the NHR also 
comprises the docking sites for calcineurin (SPRIEIT), the casein kinase1 (CK1) 
(FSILF) and for further NFAT kinases (Müller and Rao, 2010). Together, these 
kinases regulate the activation of NFAT by determining the phosphorylation status 
of the many serine residues in the SRRs and SP motifs that are contained by the 
NHR protein domain. Moreover, the NFAT proteins have in common a highly 
conserved DNA binding domain (DBD) that shares high homology with the Rel 
homology domain found in Rel/NF-κB proteins, therefore also termed RHD (Chen 
et al., 1998). The RHD contains points of contact for the interaction with the 
activating protein-1 (AP-1) transcription family members FOS and JUN. Each NFAT 
protein has two or more isoforms that are can be distinguished by their length 
variable N-and C-terminal tails (Luo et al., 1996; Imamura et al., 1998; Park et al., 
1996; Chuvpilo et al., 1999). Noteworthy, there are existing three isoforms of NFAT1 
(called A, B, C) and six of NFAT2 (called αA, βA, αB, βB, αC, βC) and four of NFAT4 
(called 1, 2, 3 and 4). These isoforms are generated by alternative splicing or by the 
usage of different promoter sites. The functional difference between the isoforms 
can be for instance the constitutive or inducible expression as in the case of NFAT2 
(NFATc1) which encompasses five permanently expressed and one isoform (αA) 
induced by T- or B-cell stimulation (Macian, 2005).  
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Figure 8. Schematic illustration of the common NFAT family protein structure.                                    
NFAT family proteins exhibit a characteristic N-terminal regulatory NFAT homology region 
(NHR), a DNA-binding domain which is due to its high similarity called REL-homology 
domain RHD and a C-terminal domain which is variable in length and that specifies 
isoforms. The NHR contains a transactivation domain (TAD) and docking sites for casein 
kinase 1 (CK1), termed FSILF, and calcineurin, termed SPRIEIT. The NHR includes as well 
multiple serine-rich motifs (SRR1, SP1, SP2, SRR2, SP3 and KTS) that provide 
phosphorylation sites for controlling NFAT activity and a nuclear localization sequence 
(NLS). Figure adapted from Müller and Rao, 2010. 
 
1.2.6.3 Ca2+ signaling and NFAT activation 
The activation of receptor tyrosine kinases (RTKs), G-protein coupled receptors 
(GPCRs), immunoreceptors such as antigen specific T-cell and B-cell receptors and 
Fc receptors on mast cells, monocytes and NK cells result in the initiation of a signal 
transduction cascade which leads to an increase of the intracellular Ca2+ 
concentration. Receptor engagement and thus activation leads to the activation of 
phospholipase C-γ (PLC-γ1 in T-cells and mast cells; PLC-γ2 in B-cells). PLC-γ in 
turn hydrolyses phosphatidylinositol-3,4-bisphosphate (PIP2) to generate the 
second messengers inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 
then binds to IP3 receptors located in the endoplasmic reticulum (ER) membrane 
inducing the release of ER stored calcium. This Ca2+ storage depletion is sensed by 
the high-affinity ER calcium sensors “stromal interaction moelcule1 or 2” (STIM1 or 
2) which are then activated. STIM1 proteins subsequently form oligomers and 
migrate to the contact site between ER and the cytoplasma membrane. STIM1 
oligomers bind then to specialised store-operated calcium-release-activated 
calcium (CRAC) channels crossing the plasma membrane, including ORAI1. This 
STIM1-CRAC channel binding triggers a conformational change and ensuing 
opening of CRAC channels such as ORAI1 in the plasma membrane. The described 
mechanism provides sustained Ca2+ influx into the cell (also called “store operated 
Ca2+ entry” (SOCE)) and maintenance of increased intracellular calcium. Calcium 
ions bind the Ca2+-sensor calmodulin (CaM), which in turn binds and activates the 
serine-threonine (S/T) phosphatase calcineurin. Calcium binding by the calcineurin 
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regulatory B subunit (CnB) under increased intracellular Ca2+ conditions leads to the 
exposure of the calmodulin-binding site on the catalytically active calcineurin A 
(CnA) subunit. Together, both events result in the release of an autoinhibitory 
peptide in the catalytic pocket of CnA and the S/T phosphatase calcineurin is now 
capable of converting substrates such as the calcium/calcineurin signaling 
dependent NFAT family members NFAT1-4. In order to effectively dephosphorylate 
NFAT proteins, calcineurin has to bind to a specific peptide motif within the NHR 
that is highly conserved in the NFAT family and exhibits the consensus aa-sequence 
“PXIXIT” (X designates any aa). This main calcineurin binding site on NFAT proteins 
was also exploited to create a specific with calcineurin for NFAT binding competing 
peptide. This competitive inhibitor mimics the calcineurin NFAT binding site and thus 
blocks NFAT activation by calcineurin mediated dephosphorylation. The competitive 
peptide is termed VIVIT according to its aa-sequence. In studies VIVIT was found 
to prolong xenograft survival in mice and attenuating the invasion of breast cancer 
cells (Noguchi et al., 2004; Jauliac et al., 2002). The catalytic activity of calcineurin 
is tightly regulated since it is not only controlled by calcium and CaM but also by 
other negatively regulating inhibitors like the calcineurin-binding protein 1 (CABIN1), 
the A-kinase anchor protein AKAP79 and the calcineurin inhibitor family of 
calcipressins (CSPs). In resting cells, NFAT proteins are present in a 
hyperphosphorylated, inactive conformation in the cytoplasm. NFAT proteins exhibit 
20 serine phosphorylation sites from which the regulatory region NHR comprises 18 
in the SSR1 and SP1-3 motifs. The dephosphorylation of the SP2, SP3 and SRR1 
motif serine residues by calcineurin unmasks the NFAT NLS, consequently resulting 
in the nuclear import of the NFAT protein (Macian, 2005). Moreover, in the nucleus 
calcineurin also sustains the dephosphorylated state of NFAT. In the nucleus, NFAT 
then cooperates with members of other transcription factor families (described later 
in more detail) such as AP-1 or NF-κB. These transcription factor families are 
activated downstream of DAG which induces the MAPK signaling pathway and PKC 
pathways, to regulate the transcription of target genes. Termination of NFAT 
transcriptional activity is achieved by its nuclear export and cytoplasmic relocation 
and accumulation. Responsible for this were found several regulating mechanisms 
as for example the inhibition of calcineurin activity. The inhibition of the calcineurin 
S/T phosphatase activity prevents NFAT transcriptional impact on target genes 
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because NFAT cannot migrate into the nucleus anymore and is also no longer 
retained there.  
1.2.6.4 Pharmacologic inhibitors of NFAT signaling 
Cyclosporin A (CsA, a cyclic peptide) and tacrolimus (FK506, macrolid lactone) are 
immunosuppressive drugs and function as pharmacological inhibitors of calcineurin 
which is their primary target. Both compounds are structurally unrelated but form 
complexes with intracellular immunophilins cyclophilinA and FRKBP12 (McCaffrey 
et al., 1993; Liu et al., 1991). These complexes in turn competitively inhibit 
calcineurin S/T phosphatase activity by binding to a hydrophobic groove between 
the catalytic (CnA) and regulatory subunit (CnB), thereby preventing substrate 
access to the active centre. Consequently, by inhibiting calcineurin, CsA and FK506 
act as well as inhibitors of NFAT signaling which is necessary for T-cell mediated 
immunity as it is indispensable for inducing interleukin (IL)-2 transcription and T-cell 
activation. CsA is due to its potent immunosuppressive abilities commonly used in 
the clinic to prevent immune-mediated transplant rejection and in therapy of 
autoimmune diseases. However, in cancer chemotherapy both calcineurin/NFAT 
inhibitors are not applied yet because of non-proven effectiveness. 
1.2.6.5 NFAT activity modulators 
Also multiple cytoplasmic and nuclear NFAT targeting S/T kinases modulate NFAT 
transcriptional activity. These distinct NFAT kinases precisely maintain the 
subcellular localisation of NFAT proteins and with this their function as transcription 
factors.        The kinases act as either maintenance or export kinases by sequestering 
NFAT in the cytoplasm by keeping NFAT fully phosphorylated or assist in NFAT 
nuclear export by rephosphorylating NFAT. A kinase that exhibits both 
functionalities is the casein kinase 1 (CK1) that phosphorylates the SRR1 motif. 
An example for an export kinase is the constitutively active glycogen synthase 
kinase 3 (GSK3) which phosphorylates the SP2 motif of NFAT1 and the SP2 and 
SP3 motifs of NFAT2. Another class of NFAT kinases, modifying the subcellular 
localisation of NFAT are the dual specificity tyrosine phosphorylation-regulated 
kinases (DYRKs). The family members DYRK1 and 2 phosphorylate the SP3 motif 
of NFAT1, providing the prerequisites for the phosphorylation of SP2 and SRR1 by 
GSK3 and CK1. DYRK1 facilitates the nuclear export of NFAT, whereas DYRK2 
phosphorylates NFAT in the cytoplasm, thereby preventing it from migration to the 
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nucleus, thus acting as maintenance kinase. Moreover, also JNK and p38 MAPKs 
can phosphorylate SSRs of NFAT1 and 2. Phosphorylations are not the only kind of 
NFAT post-translational modifications and mechanism determining the subcellular 
localisation and with this NFAT transcriptional activity. Sumoylation for instance was 
described to result in nuclear relocalistation of NFAT1 and 2 (Terui et al., 2004; 
Nayak et al., 2009). Yoeli-Lerner et al. (2005) report that in breast cancer cells, 
NFAT1 is ubiquitinated and thereby targeted for degradation by the E3 ubiquitin 
ligase MDM2. Furthermore, the cytoplasmic proteins HOMER2 and 3 were 
found to compete with calcineurin for NFAT binding, thus preventing NFAT 
dephosphorylation and nuclear translocation. In addition to that, a non-coding RNA 
was discovered called non-coding repressor of NFAT (NRON) that was identified as 
specific inhibitor of NFAT nuclear trafficking (Willingham et al., 2005).  
 
 
 
Figure 9. Schematic overview of Ca2+ - NFAT signaling. Ligand binding of immunoreceptors 
such as T-and B-cell receptors and receptor tyrosine kinases (RTKs) lead to the activation of 
phospholipase Cγ (PLCγ). PLCγ in turn hydrolyses phosphatidyl-4, 5-bisphosphate (PIP2) to 
generate diacylglycerol (DAG) and inositol-1, 4, 5-trisphosphate (InsP3). InsP3 binds to the InsP3 
receptor in the endoplasmic reticulum (ER) membrane and induces the depletion of the ER Ca2+ 
store. Stromal interaction molecule 1 or 2 (STIM1 or STIM2) subsequently detect the emptying of 
the ER Ca2+storage and form small clusters. STIM1 and 2 interact with the calcium-release-activated 
calcium ion channel (CRAC) protein ORAI in the plasma membrane to trigger store-operated Ca2+ 
entry (SOCE). Calmodulin as calcium sensing protein binds Ca2+ and activates calcineurin. 
Calcineurin in turn dephosphorylates NFAT, which then translocate to the nucleus where NFAT can 
cooperate with various transcriptional partners such as AP1 to regulate gene expression of target 
genes. Activation of transcriptional partners is controlled by for instance MAPK signaling and other 
pathways. Multiple NFAT kinases mediate the inactivation of NFAT proteins by rephosphorylating 
them. These are for example the glycogen-synthase kinase 3 (GSK3), Casein kinase1 (CK1) and the 
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dual-specificity tyrosine-phosphorylation regulated kinase 1 (DYRK1) and DYRK2. Calcineurin 
phosphatase activity is regulated by endogenous calcineurin inhibitors like calcineurin-binding 
protein 1 (CABIN1), A-kinase anchor protein 79 (AKAP79) and Down's syndrome critical region 1 
(DSCR1). Cyclosporin A (CsA) and FK506 are efficient pharmacological inhibitors of calcineurin. 
Endogenous negative regulators of NFAT signaling are the Non-coding repressor of NFAT (NRON) 
and caspase 3. Different scaffold proteins were shown to participate in NFAT regulation. 
Abbreviations: GADS, GRB2-related adaptor protein; ITK, IL-2-inducible T-cell kinase; LAT, 
linker for activation of T cells; Lck lymphocyte-specific protein tyrosine kinase; MAPK, mitogen-
activated protein kinase; MAPKK, MAPK kinase; SLP76, SH2-domain-containing leukocyte protein 
of 76 kDa; TCR, T cell receptor; ZAP70, ζ-chain-associated protein kinase of 70 kDa. Figure adapted 
from Müller and Rao, 2010. 
 
1.2.6.6 NFAT transcriptional activity 
Once entered the nucleus, active NFAT members interact with DNA as homodimers 
or heterodimers and the DNA binding domain is able to cooperate with those of 
other transcription factors families in the nucleus to enable functional synergies 
(Giffin et al., 2003). The interaction of NFAT with members of other transcription 
families is also needed to execute transcription regulation as NFAT exhibits only 
weak DNA binding properties. For example, the binding of NFAT and AP-1 to 
neighbouring DNA binding sites results in an ~ 20-fold increase in the stability of the 
NFAT-AP1-DNA complex in comparison with binding of NFAT to its DNA binding 
site alone (Jain et al., 1993). The interaction of NFAT proteins with other 
transcription factors is feasible thanks to a highly flexible linker region located 
between the RHD and the C-terminal domain that has contact only with the 
phosphate backbone of the DNA (Stroud and Chenpark, 2003). NFAT interacts with 
several transcription factors as for instance AP-1, GATA4, IRF4, MEF2, NF-kB, 
PPARγ, EGR, and FOXP2 & 3 (Yang et al., 2000; Molkentin et al., 1998; Crabtree 
and Olson, 2002; Rengarajan et al., 2002; Hogan et al., 2003; Macian et al., 2001; 
Macian, 2005; Pham et al., 2005; Wu et al., 2001; Hu et al., 2002; Hermann-Kleiter 
and Baier, 2010, Müller and Rao, 2010). This versatile cooperation of NFAT 
members with other transcription factors makes it possible to combine different 
signaling pathways in turn to activate specifically rendered gene programmes 
leading to different phenotypes and specific responses to various stimuli. The best 
characterised example is the interaction of NFAT with AP-1 members. Fos-Jun 
dimers form quaternary complexes with NFATs and DNA on corresponding NFAT-
AP1 sites to regulate the transcription of diverse inducible genes. This NFAT-AP1 
cooperation complex is needed in T-cell activation and integrates to main signaling 
  Introduction 
 
 
36 
 
pathways of T-cell stimulation. Namely calcium signaling leading to NFAT activation 
and the MAP-kinase pathway inducing FOS and JUN expression (Chen et al., 1998; 
Jain et al., 1992). AP1 proteins are thus the main transcriptional partners of NFAT 
during T-cell activation and together they are inducing a distinct gene program that 
characterises the activated T-cell phenotype (Macian et al., 2001; Jain et al., 1992). 
Among the NFAT transcription factor family, NFAT5 is the only protein that is not 
capable to form cooperative complexes with AP-1 members on composite DNA 
elements. NFAT5 does not require a nuclear partner for its activity (Lopez-
Rodriguez et al., 1999; Macian et al., 2001; Pan et al., 2013). Interestingly Macian 
et al. (2002), found that under conditions where AP-1 is not activated and NFAT-
AP1 cooperation is not taking place, NFAT activity alone in T-cell activation leads to 
the activation of a different gene set resulting in lymphocyte anergy a completely 
opposing genetic program than the productive activated state mediated by NFAT-
AP-1 complexes. Also a cooperation between NFAT and NF-κB was observed by 
several groups. Sica et al. (1997) for instance describe coordinate activities of NFAT 
and RelA/p50 NF-kB dimers binding at same site within the IFN-γ promoter in order 
to enhance IFN-γ transcription, the TH1 defining cytokine. Another study proves 
NFAT and NF-κB to act synergistically to activate IL-4 gene expression in T-cells 
(Li-Weber et al., 2004). Moreover, NFAT is also implicated in cooperation with 
different partners from different transcription factor families in the regulation of 
multiple other genes playing an important role in the regulation of the immune 
system. This includes for instance the cytokines IL-2, IL-3, IL-5, IL-6, IL-13, TNF-α 
and GM-CSF, the chemokines IL-8 and Mip-1α, the surface proteins Igk, CD5, 
CD25, CD40L and CD95L (Rao et al., 1997; Macian et al., 2001). 
Thus, it is likely that NFAT signaling has a significant impact on chemokines in cells 
that are part of the tumor environment. This is from interest since leukaemia and 
lymphoma mouse models were revealed to harbour hyperactive NFAT as a result 
of paracrine signalling in the tumor environment (Medyouf et al., 2007; Pham et al., 
2005).  
1.2.6.7 Role of NFAT in B-cells 
Regarding B-cells, mice lacking NFAT2 exhibit a complete loss of splenic and 
peritoneal B-1 cells. In contrast, NFAT1 deficient mice showed a normal repertoire 
of B-1a cells. Winslow et al. (2006) describe a more indirect role of NFAT in B-cell 
function. The group was investigating mice with a B-cell specific deletion of the 
Introduction 
 
37 
 
regulatory subunit B of calcineurin. As a consequence of this, the mice showed 
decreased plasma cell development, fewer immunoglobulin production, reduced 
numbers of B1a cells and a B-cell proliferation defect downstream of the BCR.  
1.2.6.8 NFAT in solid cancers 
NFAT signaling participates in the regulation of growth, survival, differentiation and 
development of many cell types and organ systems. Due to this, abnormalities in 
NFAT proteins and/or the dysregulation of NFAT signaling are potent to be 
associated with the development of neoplasms originating from various tissues. 
Indeed, aberrant NFAT signaling, mostly overexpression and/or hyperactivity, was 
documented to play roles in malignant transformation, tumor angiogenesis, invasive 
migration, and therefore in the development and pathogenesis of solid neoplasms. 
This is the case for instance in breast cancer (NFAT1, 5), pancreatic cancer 
(NFAT2), melanoma (NFAT2, 4), prostate cancer and endometrial cancer (Robbs 
et al., 2008; Mancini and Toker, 2009; Yoeli-Lerner et al., 2005 and 2009; Buchholz 
et al., 2006; Koenig et al., 2010; Flockhart et al., 2009; Lehen’kyi et al., 2007; Sales 
et al., 2009 and 2010). 
1.2.6.9 NFAT in hematopoietic malignancies  
NFAT family members and thus Ca2+/NFAT signaling were also revealed by multiple 
studies to be implicated in the pathogenesis of haematological malignancies like           
B- and T-cell lymphoma (Pham et al., 2005; Fu et al., 2006; Glud et al., 2005; 
Medyouf et al., 2007). An immunohistological evaluation of almost 300 lymphoma 
samples conducted by Marafioti et al. in 2004 found NFAT2 to be overexpressed in 
most lymphoid neoplasms. Moreover, NFAT2 exhibiting a nuclear localisation was 
observed in 30% of DLBCL and 70% of Burkitt lymphoma samples, indicating in vivo 
activation of the NFAT pathway in those malignancies. Other studies report that in 
patient samples derived from DLBCL and T-All NFAT2 nuclear localisation or 
dephosphorylation of NFAT2 and 1 were observed (Fu et al., 2006; Medyouf et al., 
2007). In line with this, another study conducted by Pham et al (2005) reports that 
NFAT is constitutively activated in LBCL. Moreover, they demonstrate that NFAT2 
and c-Rel cooperatively bind at the CD154 promoter at similar binding sites. 
Thereby, they directly interact and synergistically regulate CD154 transcription in 
lymphoma B-cell lines. This result was supported by the finding from Srahna et al. 
(2001). They report an additive effect of NF-κB inhibitors and the NFAT inhibitor CsA 
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in inhibiting the expression of CD154 (CD40L) on both, the mRNA and protein level 
upon P/I mediated T-cell stimulation. In DLBCL and MCL it was found that NFAT2 
regulates the expression of B-cell survival factors like CD40L (CD154) and B-
lymphocyte stimulator (BLYS) (Pham et al., 2005; Fu et al., 2006). Mouse T-cell 
acute lymphoblastic leukemia (T-ALL) models that were treated with calcineurin 
inhibitors exhibited reduced proliferation and induction of apoptosis of leukemic blast 
cells, fast tumor clearance and consequently prolonged survival (Medyouf et al., 
2007). Notably, NFAT2 was found to play an important role in cancer therapy 
resistance as the activation of Ca2+-NFAT signaling was associated with the 
acquired resistance of chronic myeloid leukemia (CML) towards tyrosine kinase 
inhibitors (Gregory et al., 2010).  
1.2.6.10 NFAT signaling summary 
In summary, taking into account the almost ubiquitous expression of NFAT, the 
number of NFAT family members and their distinct isoforms, the multitude of NFAT 
binding partners from other transcription families on target genes, the abundance of 
NFAT activity modulators and the involvement of NFAT signaling in the regulation 
of a wide range of genes and physiological processes makes NFAT signaling to a 
complex and vital component of human cell organisation. Therefore, NFAT signaling 
constitutes a promising subject for further research in order to develop therapy 
approaches for a variety of malignancies. 
1.2.7 The AP-1 family 
The activator protein 1 (AP-1) transcription factor was discovered in 1987 as DNA 
binding protein in HeLa nuclear extracts that recognises a distinct DNA element 
(TGACTCA) within the promoter and enhancer region of the SV40 and 
metallothionein IIA gene (Lee et al., 1987) Today, the AP-1 transcription factor 
family comprises dimeric complexes made up of over 20 different protein subunits 
that are functionally and structurally related and categorised in five subfamilies 
termed JUN (v-Jun, c-Jun, JUNB and JUND), FOS/FRA (v-Fos, c-FOS, FosB, Fra1, 
Fra2), JDP (JDP1/2),  ATF/CREB (ATF1, ATF2, ATF3/LRF1, ATF4, ATF5, ATF6a, 
ATF6b, ATF7, B-ATF; ATFa0, CREB) and MAF (v-Maf, c-Maf, MafB, MafF, MafG, 
MafK, Nrl). These subunits can form a multitude of homo- and heterodimeric 
combinations that exhibit different DNA binding specificities and affinities towards 
gene expression regulatory elements within promoters and enhancers of AP-1 
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responsive genes. The dimers also exhibit partially redundant functions and are 
differently regulated. Thus, the manifold dimer combinatorial possibilities determine 
the range of regulated genes. For instance, Jun containing dimers preferentially bind 
the AP-1 DNA recognition element also called the TPA-responsive element (TRE). 
But besides TRE there are several more different AP-1 responsive sequences that 
are preferentially bound by distinct dimer pairs. Some are favoured over others or 
are exclusively bound by a specific dimer composition. These are the cAMP-
responsive element (CRE) which is preferentially bound by ATF proteins, the MAF-
recognition elements (MAREs I/II) and the antioxidant-response elements (AREs). 
c-Jun homodimers for instance, favour TRE over CRE site binding whereas  
c-Jun/ATF4 heterodimers exclusively bind to CRE sites and c-FOS/MAFB/F/G/K 
heterodimers bind only to MARE I/II responsive elements (Eferl and Wagner, 2003). 
Such AP-1 binding elements were among others found in regulatory regions of 
genes that are induced during T-cell activation. This led to the assumption that 
proteins of the AP-1 transcription factor family could consequently regulate the 
expression of those genes. Promoter analysis of such a gene, the human IL-2 gene, 
encoding interleukin-2 an important growth factor for B-cells and critical for T-cell 
proliferation, differentiation and mounting of a T-cell dependent immune responses 
was identified to harbour two AP-1 responsive sites. Furthermore, the IL-2 promoter 
was also shown to bind partially purified AP-1 proteins and mutation of one of those 
sites resulted in diminished or abrogated induction of IL-2. The functionality of this 
AP-1 responsive site within the IL-2 promoter was validated by a cotransfection of 
IL-2-chloramphenicol acetyltransferase encoding plasmid together with c-FOS 
and/or c-Jun leading to an enhanced induction of IL-2-chloramphenicol 
acetyltransferases activity (Jain et al., 1992). In accordance with this, transgenic 
mice, overexpressing c-FOS exhibit enhanced IL-2 gene expression and cytokine 
production. Whereas mice expressing a dominant negative form of the CRE-binding 
protein (CREB) that is known to induce various AP-1 encoding genes show less  
IL-2 production with simultaneous decreased c-Jun, c-FOS, Fra2 and FosB mRNA 
levels (Ochi et al., 1994; Barton et al., 1996). Thus, AP-1 plays a pivotal role in the 
transcriptional regulation of the IL-2 gene. AP-1 members can also form complexes 
with non-bZIP proteins likeNF-κB and NFAT (Stein et al., 1993; Jain et al., 1992). 
AP-1 and NFAT were found to bind cooperatively to composite DNA binding sites 
and from stable complexes. This is the case for instance at the murine IL-4 promoter. 
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Together, NF-κB and NFAT bind at a composite site within the sequence of the  
IL-4 promoter. Therefore, AP-1 is together with the transcription factor NFAT critical 
for full activity of the murine IL-4 promoter. IL-4 is involved in the differentiation of 
precursor T-helper (TH) cells into the TH2 phenotype. Depending on the 
investigated T-cell line, c-FOS, Fra-2, Fra-1, c-Jun, JunB, and JunD were found to 
be involved in the transcriptional regulation of this leukocyte modulatory interleukin 
4 (Le Gros et al., 1990; Chuvpilo et al., 1993; Rooney et al., 1995; Li-Weber et al., 
1997). Consequently, loss of JunB in TH2 cells in vitro results in deregulated TH2 
cytokine expression and the expression of TH1 characteristic key regulators 
(Hartenstein et al., 2002). Moreover, also IL-10 expression of TH2 cells is positively 
controlled by JunB/AP-1, c-Jun/AP-1 transcription complexes. In contrast to that, 
Meixner et al., 2004 found reduced IL-4 levels in JunD overexpressing lymphocytes 
and consistently with that higher IL-4 and IL-10 expression in JunD negative TH2-
cells. This suggests that JunD unlike its relatives JunB and c-Jun suppresses TH2 
differentiation and the expression of TH2 specific cytokines. The cooperation 
between AP-1 and NFAT was also observed in controlling the induction of IL-5. In 
the gene promoter of this cytokine which is predominantly produced by TH2 cells, a 
DNA element was found to which NFAT and c-FOS/c-Jun dimers bind cooperatively 
(Lee et al., 1995; Wang et al., 1994; Karlen et al., 1996). Furthermore, also in the 
promoters of IL-3 and IL-9 AP-1 sites were identified. Thus, AP-1 was reported to 
enhance the expression of an IL-3 reporter construct and c-FOS/c-Jun were found 
to bind to the IL-3 promoter in stimulated T-cells (Mathey-Prevot et al., 1990; Park 
et al., 1993). A mutational analysis revealed that AP-1 enhances IL-9 promoter 
activity in T-cells (Zhu et al., 1996). Moreover, also IFN-γ and TNF-α were described 
to be regulated by AP-1 proteins in cooperation with other transcription factors. For 
instance, in Jurkat T-cells AP-1 was found by Barbulescu et al. (1997) to be pivotal 
for the induction of IFN-γ expression. In line with this, an AP-1 heterodimer 
consisting of c-Jun and ATF2 was shown to interact and transactivate IFN-γ 
promoter constructs in T-cells (Penix et al., 1996). Additionally, AP-1 family 
members were reported to induce the macrophage inflammatory protein-1β  
(MIP-1β) and upon IL-1β stimulation of endothelial cells in cooperation with 
RelA/p50 the chemoattractant protein-1 (MCP-1) (Martin and Dorf, 1991). In calcium 
stimulated T-cells, an AP-1 dimer consisting of c-Jun/ATF-2 cooperates with 
NFATc2 to bind to a CRE site in order to induce TNF-α expression, whereas in LPS 
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stimulated THP-1 cells, c-Jun comprising AP-1 complexes cooperate with RelA/p50 
dimers to increase TNF-α transcription (Tsai et al., 1996; Yao et al., 1997).  
AP-1 family members were also reported to act as transcriptional repressors 
especially those exhibiting weak transactivation capacities such as JunB and JunD, 
Fra1 and Fra2. These AP-1 proteins can competitively out bind AP-1 subunits of 
transcriptionally active AP-1 dimers binding at the same DNA promoter site as they 
do. The Jun and Fos AP-1 subfamilies are the major AP-1 proteins. Notably, Jun 
proteins homo- and heterodimerize whereas FOS members are incapable of 
homodimerisation but pair stably with Jun proteins and some ATF family members. 
FOS proteins possess negatively charged residues adjacent to their leucine zipper 
domain leading to an electrostatic destabilisation of FOS homodimers, therefore 
favouring instead the formation of Jun-Fos heterodimers (Halazonetis et al., 1988). 
AP-1 proteins are composed of basic leucine zippers (bZIPs), heptad repeats of 
leucine residues. For this reason, AP-1 members are referred to as bZIP proteins. 
The bZIP forms an amphipathic α-helix and is associated with the leucine zipper of 
the second AP-1 member within the dimer in a coiled-coil arrangement facilitating 
the dimerization of the AP-1 subunits. Furthermore, AP-1 proteins comprise another 
α-helical region that includes several basic amino acid residues responsible for the 
interaction of the transcription factor with the phosphate backbone of the DNA. 
Moreover, AP-1 proteins also contain a transactivation domain called delta domain, 
determining transcriptional activation. AP-1 is activated by a wide array of different 
stimuli such as ligand engagement of BCR, TCR or TLRs, cellular stress, radiation, 
growth factors, neurotransmitters, peptide hormones, pathogens and cytokines. 
Hence, AP-1 signaling is involved in several cellular processes like apoptosis, 
inflammation proliferation, cellular migration, wound healing, survival and 
differentiation. Depending on the stimulus, different AP-1 subfamilies are induced 
by different upstream signaling pathways. Antigen receptor activation for instance 
results in the induction/activation of Jun (c-Jun, JunB), FOS (c-FOS) and ATF 
(ATF2, ATF3) proteins. Growth factors for example, induce AP-1 transcriptional 
activity by the activation of the S/T kinases mitogen-activated protein kinase (MAPK) 
subgroup of extracellular signal-regulated kinase (ERK) proteins which migrate to 
the nucleus where they activate ternary complex factors which in turn bind FOS 
promoters. The MAPK family members c-Jun N-terminal kinase (JNK) and p38 
mainly activate AP-1 as response to pro-inflammatory cytokines, genotoxic stress 
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and some mitogenic signals. JNK which encompasses at least ten isoforms 
encoded by three different genes (JNK1, 2, 3) regulates the expression and activity 
of Jun family proteins. Subsequently to their nuclear translocation, JNK isoforms 
phosphorylate c-Jun, JUNB, JunD and less efficiently also ATF2 which then trigger 
the activation and formation of AP-1 dimers. For instance, JNK phosphorylation of 
c-Jun and ATF2 increases their transcriptional activity, stability and induces their 
heterodimerization. c-Jun/ATF2 heterodimers can then bind different sites in the 
c-Jun promoter. On the other hand, under non-stimulated conditions, 
phosphorylation inactive JNKs were shown by Fuchs et al. (1998) to degrade c-Jun 
and ATF2. As soon as the JNK phosphorylation enzyme activity is turned on,  
c-Jun and ATF2 degradation is abolished (Musti et al., 1997). AP-1 induction by p38 
is facilitated by direct phosphorylation and activation of ATF2 and MEF2C.  
In order to reveal whether c-Jun is essential for lymphocyte function, Chen et al. 
(1994) injected c-Jun deficient mouse embryonic stem cells into blastocysts derived 
from RAG2 lacking mice that do not develop mature lymphocytes. The resulting 
chimeric mice showed altered thymus structure and changes in the ratios of 
thymocyte populations but produced T-and B-cells exhibiting normal phenotypes. 
For this reason, c-Jun was not supposed to be required for lymphopoiesis. 
Moreover, also c-FOS deficient mice did not display any obvious differences in T-
cell activation and proliferation (Jain et al., 1994). On the other hand, FosB2 (lacking 
a transactivation domain) overexpressing mice display strong alterations in thymic 
structures and composition. Furthermore, in comparison to their wild-type 
counterparts these mice show elevated amounts of αβ-TCR expressing thymocytes 
and reduced fractions of DP thymocytes. Research in c-FOS and c-Jun negative 
murine cells suggests that those proteins are not necessary for proper induction  
of apoptosis. This assumption was further strengthened by the occurrence of 
apoptosis in mouse embryos deficient in either c-FOS, c-Jun or both c-FOS and  
c-Jun (Roffler-Tarlov et al., 1996). Moreover, also splenic and thymic primary 
cultures from c-FOS knockout mice showed inducible apoptosis in cell culture 
experiments (Gajate et al., 1996). In contrast, a study conducted by Colotta et al. 
(1992) suggests that AP-1 plays a role in growth factor withdrawal-induced 
apoptosis of lymphoid cells. 
It was reported that several FOS and JUN members associate alone or in 
conjunction with other transcription factors such as NFAT with the promoters of 
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genes coding for cytokines characteristic for TH1 and TH2 cells. Both T-cell 
subtypes were shown to express several AP-1 members upon activation (Rincon et 
al., 1998). TH1 cells express c-FOS and c-Jun whereas TH2 cells exhibit high levels 
of c-FOS, c-Jun and also of JunB. This indicates that different AP-1 expression 
patterns result in a distinct cytokine expression. AP-1 members also participate in 
hematopoietic differentiation as c-FOS was revealed with the aid of c-FOS deficient 
mice to be a unique regulator of bone marrow macrophage differentiation 
(Grigoriadis et al., 1993). The regulatory role of c-FOS in macrophages is also 
illustrated by c-FOS deficient macrophages that were found to produce higher IL-12 
levels upon LPS stimulation than c-FOS positive controls (Roy et al., 1999). 
Regarding B-cell biology, surface immunoglobulin (mIg) crosslinking was unveiled 
to induce several AP-1 family proteins in a primarily PKC dependent manner.                             
For instance, c-FOS expression was induced in primary B-cells and model B-cell 
lines (Klemsz et al., 1989). Moreover, elevated levels of the AP-1 proteins JunB, 
FosB and JunD were observed as well in mIg stimulated primary B-cells (Tilzey et 
al., 1991; Tanguay et al., 1994; Huo and Rothstein, 1995 and 1996; Amato et al., 
1996). On the other hand, also a predominantly PKC independent induction of the 
AP-1 proteins c-FOS, JunB and JunD by CD40 was observed (Huo and Rothstein, 
1995; Francis et al., 1995; Kawakami et a., 1992). Unlike in other cell types, the 
induction of AP-1 DNA binding in B-cells was described not to increase AP-1 
transactivation or cell-cycle progression. For instance, in the murine B-cell 
lymphoma line BAL-17.7.1 (BAL-17) which is a model for primary B-lymphocyte 
responses, induced AP-1 proteins did not transactivate a transiently transfected 
TRE binding site containing human collagenase gene promoter (Chiles and 
Rothstein, 1992). Kobayashi et al. (1997) report that in splenic B-cells derived from 
IFNα, β inducible c-FOS transgenic mice the cell cycle was arrested in the G1-phase 
as a consequence of IFNα/β application within half a day after anti-IgM stimulation. 
From this observation they concluded that induced c-FOS overexpression in the  
G1-phase interferes with the activation of cell cycle regulating mechanisms. In 
further investigating this, they found that IFN induced c-FOS overexpression in anti-
IgM stimulated B-cells is responsible for preventing the down regulating of p27 as a 
result of abolished CDK2 kinase activity in late G1 phase. From this they drew the 
conclusion that c-FOS is able to negatively affect cell cycle regulatory mechanisms 
in anti-IgM stimulated B-cells (Kobayashi et al., 1997). Moreover, AP-1 dimers also 
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seem to be involved in antibody production as they were found to transcriptionally 
induce the kappa light chain and the Ig heavy chain gene (Schanke et al., 1994; 
Grant et al., 1995). In this respect, transgenic mice overexpressing c-FOS under the 
control of the H-2kb promoter showed abnormalities in Ig class switch, an inability to 
produce primary IgG antibodies in response to antigens and no generation of 
memory B-cells in the spleen (Takao et al., 1991). 
Members of the AP-1 family were observed to be frequently overexpressed in 
lymphoma such as c-jun, JunD, JunB and c-FOS in B-cell NHL of the splenic 
marginal zone. c-Jun and JunB were found to be overexpressed in primary and 
cultivated tumor cells of cHL patients and in anaplastic large cell lymphoma. JunB 
was also described to be overexpressed in cutaneous lymphoma and in an array of 
CD30+ lymphoma (Trøen et al., 2004; Mathas et al., 2002; Rassidakis et al., 2005). 
Regarding DLBCL, Blonska et al. (2015) have shown that c-Jun is frequently 
activated. By conducting a DNA microarray they revealed a number of c-Jun 
positively regulated genes that were coding for signaling and adhesion molecules, 
surface receptors, enzymes and cytokines. Thus, c-Jun knockdown resulted in 
decrease of cell adhesion to extracellular matrix (ECM) components, down 
regulation of ABC DLBCL (OCI-Ly3 and OCI-Ly10 cell lines) released cytokines 
such as macrophage-derived chemokine (MDC), interferon-inducible protein 10 (IP-
10), IL-6, IL-10 and IL-12. Furthermore, c-Jun knockdown led to a reduction of tumor 
growth and cell invasiveness into the bone marrow of a mouse DLBCL xenograft 
model. Moreover, in cell lines classified as the ABC DLBCL subtype derived from 
patients in an advanced disease stage, they observed elevated c-Jun expression 
levels. In accordance with this study, Juilland et al. (2016) revealed that ABC DLBCL 
exhibit constitutively upregulated CARMA1 and MYD88 mediated expression of the 
AP-1 proteins c-Jun, JunB and ATF3. By conducting chemical cross-linking 
experiments, the indicated JUN family members were revealed to form constitutive 
dimers with ATF2 and ATF7 in both GCB- and ABC DLBCL cell lines. In contrast, 
ATF3 was found to be expressed exclusively in ABC DLBCL cell lines where it 
formed dimeric complexes with c-Jun, JunB and JunD. The group also reports that 
the usage of a competitive AP-1 inhibitor had an impairing effect selectively on ABC 
DLBCL viability. An additional shRNA mediated silencing approach of either ATF2, 
ATF3 or ATF7 in the ABC DLBCL cell line HBL-1 showed that ATF2 and ATF3 
expression is pivotal for ABC DLBCL survival, whereas ATF7 silencing had only little 
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impairing effects on survival. Moreover, the analysis of 350 DLBCL patient samples 
by immunohistochemistry unveiled a strong nuclear presence of ATF3 in nodal ABC 
DLBCL samples, identifying ATF3 expression as a hallmark of the ABC DLBCL 
subtype. These results are consistent with observations made by Ruland et al. 
(2015). The group generated a mouse model expressing the human DLBCL derived 
CARD11 (L225LI) gain-of-function mutant that was uncovered by Ruland et al. to 
induce CBM dependent simultaneous NF-κB and JNK signaling in purified splenic 
B-cells. In line with the induced JNK signaling activity, they could observe high 
amounts of the phosphorylated AP-1 JNK substrates c-Jun and ATF2 in nuclear 
extracts of transgenic CARD11 (L225LI) expressing murine splenic B-cells. When 
they conducted gel mobility shift assays with these nuclear extracts, they found 
markedly increased NF-κB and AP-1 DNA binding activity in CARD11 (L225LI) 
expressing transgenic B-cells compared to wild-type B-cells. Furthermore, 
transfection of the mature B-cell lymphoma line Bal-17 with CARD11 (L225LI) led 
to increased nuclear c-Jun, RelA, c-Rel and p50 levels. Moreover, in order to figure 
out if the results that were obtained by the transgenic mouse model would also hold 
true for human DLBCL cases, they performed an immunohistochemistry based 
analysis to check for the presence of activated JNK in 67 human primary DLBCL 
samples patients. Indeed, in more than 55% of the investigated ABC DLBCL cases 
they found phosphorylated JNK indicating a constitutive JNK enzyme activity, 
whereas no GCB DLBCL classified cases were found to exhibit active JNK. 
Consequently, they tested established human ABC DLBCL model cell lines for the 
presence of phosphorylated i.e. activated JNK and revealed three of four cell lines 
to harbour constitutively phosphorylated JNK. Constitutive active JNK in these 
DLBCL could be further substantiated by conducting an in vitro kinase assay with 
the JNK AP-1 substrate c-Jun. In addition, alike in the murine Bal-17 cell line the 
transduction of the GCB DLBCL cell line BJAB with the CARD11 (L225LI) mutant 
caused the besides NF-kB also the activation of JNK as proven by p-JNK detection 
and JNK kinase activity assays. Finally, they treated ABC DLBCL with a JNK 
inhibitor and unveiled that all cell lines exhibiting JNK activity died upon JNK inhibitor 
treatment in a dose-dependent manner, indicating the relevance of the JNK pathway 
and associated AP-1 signaling for the survival of ABC DLBCL subtype.  
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1.3 Antigen receptor signaling: B-cell receptor 
(BCR) and T-cell receptor (TCR) signaling  
B- and T-lymphocytes are central elements of the adaptive immune system.                          
Both lymphocyte subsets bear highly diverse antigen receptors on their surfaces 
with each lymphocyte possessing its own unique antigen receptor namely the B-cell 
receptor (BCR) or the T-cell receptor (TCR) which a single antigen specificity. 
Therefore, the abundance of this receptor class enables the immune system to 
recognise a wide range of different pathogens. Whereas T-cells play a central role 
in cell-mediated immunity by killing cancerous or infected cell and activating other 
immune cells, the correct activation of B-cells is substantial for mounting an effective 
humoral immune response. The terminal effector cells of the B-cell lineage are 
plasma cells and memory B-cells emerging from mature activated B-cells that 
underwent a highly regulated differentiation process. Plasma cells are capable to 
neutralise invading pathogens such as bacteria and viruses by secreting high-affinity 
antigen specific immunoglobulins. Memory B-cells confer long-lasting protection 
against recurrent infections. B-cell activation begins with the engagement of the 
correspondent antigen by the B-cell antibody receptor (BCR) (for an overview of 
BCR-signaling see Figure 10). The BCR is a multiprotein complex made up of the 
ligand binding membrane bound immunoglobulin (mIg) heavy and light chains and 
an associated disulfide-linked heterodimer consisting of Igα (CD79A) and Igβ 
(CD79B) that are capable of transducing downstream signaling. The T-cell receptor 
(TCR) on the other hand, consists of the highly variable heterodimer forming antigen 
recognition chains TCRα and TCRβ. Moreover, the accessory CD3 complex is 
associated with the antigen-recognising portion by electrostatic interactions 
between aa-residues within their transmembrane domains. The CD3 complex 
comprises several invariant proteins, one CD3γ, one CD3δ and two CD3ε chains 
that consist of an extracellular Ig-like structure and cytoplasmic tails bearing one 
ITAM each. Further, the complex is associated with two ζ chains representing a 
mainly intracytoplasmic disulfide-linked homodimer bearing six ITAMs in total, 
responsible for TCR downstream signaling. Monovalent ligands binding to the BCR 
of mature B-cells are not able to activate the BCR. Instead, in order to properly 
active the BCR and ensuing downstream signal cascades, ligand engagement has 
to crosslink BCRs resulting in the formation of BCR aggregation clusters (Küppers, 
2005). However, some studies report that in the absence of antigens, BCRs are 
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present on the surface of resting cells in oligomers that exhibit an autoinhibitory 
confirmation and are dissolved as a result of antigen binding (Fiala et al., 2013; Yang 
and Reth, 2010). The first step of signal propagation upon mIg antigen ligand 
binding is the phosphorylation of the CD79A/B immunoreceptor tyrosine-based 
activation motif (ITAM) tyrosins. Each CD79 subunit harbours a single ITAM in its 
cytoplasmic domain that incorporates two tandem tyrosines that are phosphorylated 
by the B-cell predominantly expressed LYN and also FYN, BLK or LCK kinases of 
the src family. Phosphorylation of the TCR associated CD3 invariant chains and the 
ζ-chains in T-cells is conducted by LCK. The phosphorylated ITAM tyrosines of 
CD79 (CD3 invariant chains and ζ-chains in TCR signaling) bind and activate the 
spleen tyrosine kinase also known as SYK (ZAP-70 in T-cells) as the dually 
phosphorylated ITAMs of the signaling chains provide a specific, spatially defined 
binding site for the SYK SH2 domains. SYK in turn is critical for coupling the BCR 
to downstream signaling events. Activated SYK autophosphorylates (ZAP-70 
however is activated by LCK in T-cells) and in turn creates docking sites for further 
distal signaling proteins. SYK also interacts with and phosphorylates various 
proteins like the phospholipase Cγ2 (PLCγ2), the Tec-family protein Bruton's 
tyrosine kinase BTK, BCAP and the B-cell linker protein (BLNK; also known as SH2-
domain-containing leukocyte protein SLP65). In TCR-signaling, ZAP-70 
phosphorylates LAT and SLP76 (LCP2) to which SLP65 has strong sequence 
homologies. BLNK contains a SH2 domain and more than five sites for tyrosine 
phosphorylation that were unveiled to bind SH2 domains of effector molecules (Chiu 
et al., 2002). Thus, BLNK functions as a molecular scaffold for the coordinated 
formation of a signalosome in which BLNK provides the platform for the assembly 
of signaling proteins that spread BCR signaling into distinct signal transduction 
pathways. This signalosome consists besides SYK and BLNK of several signaling 
molecules like Vav, BTK, PI3K and PLCγ2. The BCR co-receptor CD19, an integral 
transmembrane protein that positively modulates CD79 signaling by recruiting and 
activating LYN, PI3K, BTK and VAV is phosphorylated in its cytoplasmic tail by Lyn 
in a BCR activation dependent manner (Buhl and Cambier et al., 1999; Fujimoto et 
al., 2000). CD19 phosphorylation by LYN provides a binding site for the PI3K p85 
subunit. Together with the adaptor protein BCAP, CD19 localises the PI3K to the 
cytoplasma membrane where PI3K generates phosphatidylinositol-3,4,5-
trisphosphate (PIP3), a docking site for BTK. Subsequent to the recruitment in the 
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signalosome, BTK gets activated and together with SYK it activates PLCγ2 (PLCγ1 
in T-cells) by phosphorylation and recruits it to the cytoplasma membrane where 
PLCγ2 can bind phosphoinositides by its pleckstrin (PH) homology domain. PLCγ2 
hydrolyses phosphatidylinositol-4,5-bisphosphate (PIP2) in order to generate the 
second messengers inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 binds 
to IP3 receptors in the ER membrane leading to emptying the intracellular Ca2+ 
storage what in turn leads to the influx of extracellular calcium into the cell. Elevated 
intracellular Ca2+ levels and DAG activate protein kinase C beta (PKCβ), in T-cells 
the isoform PKCθ (Isakov and Altman et al., 2002). The phosphorylation of CARD11 
(also known as CARMA1) by PKCβ or PKCθ releases the intramolecular inhibitory 
interaction between the linker and the coiled-coiled domain of CARD11 and leads 
to the recruitment of BCL10 and MALT1 and consequently the formation of the CBM 
complex that triggers canonical NF-kB signaling (1.3.3). Another subset of proteins 
that is activated through BCR signaling is the mitogen activated protein kinase 
(MAPK) family with the subfamilies of extracellular signal regulated kinase (ERK), 
c-Jun NH2-terminal kinase (JNK/SAPK) and p38 MAPKs. These protein families in 
turn activate ETS-1, c-MYC and members of the transcription factor family AP-1 
(2.5). There are several proposed mechanisms how BCR signaling facilitates the 
integration of MAPK signaling. For instance, Vav a Rac/Rho-specific guanine 
nucleotide exchange factor and adaptor for GRB2/SOS associates as well with 
phosphorylated BLNK, thus part of the signalosome, is able to activate the RAC and 
RAS MAPK family pathways. Furthermore, RasGRP3 phosphorylation by PKCβ 
promotes the formation of RAS-GTP which in turn activates RAF1 and subsequently 
the MAP kinases ERK1/2. Furthermore, it was also suggested that BCR ITAM 
tyrosine phosphorylation recruits the adaptor protein SHC which in turn associates 
with GRB2 and SOS. This ternary complex is proposed to activate the 
RAS/RAF/MEKK cascade (D’Ambrosio et al., 1996; Nagai et al., 1995). 
Conventionally, SYK was attributed to phosphorylate SHC. However, Pao et al. 
(1998) suggest an SYK independent pathway in which mono-phosphorylated CD79 
binds SHC leading to its phosphorylation. This indicates that SRC-kinases are 
implicated in this mechanism. Also JNK activation was shown to require SYK and 
to a lesser extent BTK, whereas Lyn activity is not needed (Chan et al., 1998; Ishiai 
et al., 1999). Also PLCγ2 and the generation of IP3 were shown to be involved in 
the BCR mediated activation of JNK and p38 MAPK (Hashimoto et al., 1998). 
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In T-cells linking TCR signaling to MAPKs is facilitated by the adaptor protein GADS, 
a homologue of GRB2 which is recruited by phosphorylated LAT. GADS in turn uses 
SOS to recruit RAS. The serine/threonine kinase AKT is a further signaling protein 
that is integrated by downstream BCR signaling (Datta et al., 1997; del Peso et al., 
1997). AKT is known to regulate transcription factors and other proteins that are 
involved in controlling apoptosis. Due to its PH domain, AKT is recruited by the 
generation of PIP3 to the cytoplasma membrane. This results in a conformational 
change through which serine and threonine residues can be phosphorylated that 
are necessary for full activation of the enzyme. A substrate of AKT kinase activity is 
BAD, a pro-apoptotic BCL-2 family protein promoting apoptosis by binding and 
thereby neutralising the anti-apoptotic BCL-XL. The phosphorylation of BAD by AKT 
leads to the dissociation from BCL-XL and the subsequent binding of AKT to 14-3-
3 proteins ceasing BAD mediated BCL-XL neutralisation. AKT directly regulates 
several more transcription factors such as NF-kB, E2F and CREB and the forkhead 
transcription family (Brennan et al., 1997; Brunet et al., 1999; Kane et al., 1999; 
Kops et al., 1999; Plas and Thompson et al., 2003). Moreover, also GSK3 a kinase 
that participates in cell-cycle regulation and NFAT signaling as nuclear export kinase 
was found to be negatively regulated by AKT (Beals et al., 1997; Cross et al., 1995; 
Ikeda et al., 1998). Another transcription factor family that is activated by proximal 
BCR signaling is NFAT which is linked to BCR signaling through the increase of the 
intracellular Ca2+ concentration and the followed activation of the S/T kinase 
calcineurin (reviewed in 2.4.).  
Negative modulators are an important component of BCR and TCR signaling as 
their loss usually results in self-reactive lymphocytes instead of anergy or deletion 
leading to the abrogation of tolerance and autoimmunity (Cornall et al., 1998; Cyster 
and Goodnow, 1995 and 1997). The group of negative regulators includes CD22, 
LYN, SH2 domain-containing phosphatase 1 and 2 (SHP1,2), SH2 domain-
containing inositol 5’-phosphatase 1 (SHIP1) and the Fc receptor for IgG (FcγRIIB-
1). Upon BCR aggregation, the src-family kinase LYN which has also a positive 
regulatory role, phosphorylates the three immunoreceptor tyrosine-based inhibitory 
motifs (ITIMs) located in the cytoplasmic tail of the inhibitory coreceptor CD22. The 
negative impact conferred by CD22 to BCR signaling is partially caused by its 
recruitment of SHP-1 (Blasioli et al., 1999). SHP-1 is a protein tyrosine phosphatase 
that removes phosphates that were previously added by tyrosine kinases. 
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Substrates of SHP-1 include CD79A, CD79B, SYK, VAV, BLNK and CD22 (Mizuno 
et al., 2000; Tamir et al., 2000; Wu et al., 1998). FcγRIIB-1, a low affinity IgG 
receptor also harbours regions that are phosphorylated in a LYN-dependent fashion. 
Upon ITIM phosphorylation, FcγRIIB-1 primarily recruits SHIP1 which removes the 
5’phosphate group from PI(3,4,5)P3 to generate PI(3,4)P3 thereby preventing 
PI(3,4,5)P3 accumulation and hampering further BCR proximal signaling 
(Scharenberg et al., 1998; Fong et al., 2000). In vitro data suggest also an 
association of FcγRIIB-1 with SHP1 and SHP2 (Famiglietti et al., 1999; Hippen et 
al., 1997; Nakamura et al., 2000). FcγRIIB-1 was also observed to colligate with the 
BCR and subsequently to cause early termination of PIP2 hydrolysis and thus Ca2+ 
signaling. Moreover, SHIP can also recruit the adaptor protein downstream of kinase 
(DOK) that acts in inhibiting more proximal pathways such as RAS/ERK. The 
initiation of BCR signaling is fine-tuned regulated by two antagonistic non-BCR 
associated proteins namely CD45 and the C-terminal src tyrosine kinase (CSK). 
CD45 or also well-established as the pan B-cell marker B220, is a transmembrane 
glycoprotein with tyrosine phosphatase activity. CD45 is capable of removing 
inhibitory phosphate groups form src-family kinases thus acting in a BCR signaling 
promotive manner. For instance in CD45 deficient mice, LYN was shown by Pao et 
al. (1997) to be hyperphosphorylated at the C-terminal inhibitory tyrosine residue 
and was thus predominantly present in its inhibited conformation. The expression of 
a hyperactive CD45 variant by Majeti et al. (2000) resulted in autoimmunity and 
neoplasma growth. In contrast, CSK which is already constitutively active in resting 
cells, phosphorylates the C-terminal inhibitory tyrosine of src-family kinases 
promoting their inhibited state even when the kinases are already phosphorylated 
at their activating tyrosine. This mechanism was proven by the hypophosphorylation 
of the C-terminal tyrosine residue of LYN in CSK negative cells (Hata et al., 1994). 
(For further review see Dal Porto et al., 2004) 
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Figure 10. Schematic overview of BCR signaling and integrated proximal pathways. 
For a more detailed description see continuous text. The red asterisks designate protein domains 
commonly affected by mutations in human lymphoid malignancies. Abbreviations: BLNK, B-cell 
linker protein; BTK, Bruton’s tyrosine kinase; CARD11, caspase recruitment domain-containing 
protein 11; CBM, CARD11–BCL-10–MALT1; CIN85, Cbl-interacting protein of 85 kDa; DAG, 
diacylglycerol; IKK, inhibitor of NF-κB kinase; IgH, immunoglobulin heavy chain; IgL, 
immunoglobulin light chain; IP3, inositol trisphosphate; MALT1, mucosa-associated lymphoid 
tissue lymphoma translocation protein 1; MAPK, mitogen-activated protein kinase; mTOR, 
mammalian target of rapamycin; NF-κB, nuclear factor-κB; NFAT, nuclear factor of activated T 
cells; PI3K, phosphoinositide 3-kinase; PIP2, phosphatidylinositol-4,5-bisphosphate; PIP3, 
phosphatidylinositol-3,4,5-trisphosphate; PKCβ, protein kinase Cβ; PLCγ, phospholipase Cγ; SFK, 
SRC family kinase. Figure and caption adapted from Young and Staudt, 2013. 
 
1.4 The major histocompatibility complex (MHC) 
The major histocompatibility complex (MHC) are cell surface glycoproteins that are 
a vital component in the responses of the adaptive immune system towards invading 
pathogens. The membrane bound glycoproteins are subdivided into two different 
classes termed MHC class I and II (MHCI and MHCII) molecules, exhibiting distinct 
subunit compositions and tissue expression patterns. MHCI and MHCII molecules 
originate from one gene locus, share high levels of polymorphism and similar spatial 
structure (Neefjes et al., 2011). Furthermore, both MHC classes bind and present 
pathogen-derived peptide fragments and antigens from self-proteins on the cell 
surface. A MHC-complex is made up of either a MHCI or II molecule and a pathogen 
derived peptide. Together, these components constitute a ligand that is intended to 
be recognised by the antigen receptors of CD8+ and CD4+ T-cell subsets and as 
consequence of this, to induce T-cell proliferation and to activate the T-cell’s distinct 
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effector function. MHC class I molecules are present on the surfaces of all nucleated 
cells and most highly expressed on cells of the hematopoietic lineage. In contrast, 
the expression of MHC class II proteins is restricted to a comparatively small subset 
of professional antigen-presenting cells (APCs) such as monocytes/macrophages, 
dendritic cells and B-cells. Moreover, in humans MHCII expression was also 
observed to be expressed on activated T-cells and epithelial cells of the thymus 
(TECs) that are critical in the generation of CD4+ T-cells. MHCII expression is also 
known to be induced in a couple of other cell types such as fibroblasts, epithelial 
cell and keratinocytes by IFN-γ stimulation (Pober et al., 1983; Glimcher and Kara, 
1992; Pattenden et al., 2002). The MHCI molecules consist of two peptide chains, 
a polymorphic heavy α-chain which is non-covalently bound to a non-polymorphic 
smaller light chain called β2-microglobulin (B2M). The whole MHCI complex is 
subdivided into four domains. Three of which make up the heavy α-chain (α1-3) and 
the fourth is contributed by B2M. Only the α-chain) exhibits a transmembrane 
domain (α3) and thus anchors the whole MHCI complex in the cytoplasma 
membrane. The other α-chain domains, 1 and 2 together form the peptide-binding 
groove which includes the major differences between the different polymorphic 
MHCI α-chains. Peptides bound by MHCI molecules usually consist of 8 to 10 aa 
and are accommodated deeply within the peptide binding cleft which is closed at its 
ends by conserved tyrosine residues (Matsumura et al., 1992; Bouvier et al., 1994; 
Zacharias and Springer, 1994). The bound peptide within the groove stabilises the 
complex. Without a peptide ligand MHCI proteins are stabilised by ER chaperons 
like calreticulin, ERP57, PDI and tapasin. In humans, the heavy α-chain is encoded 
by three polymorphic genes named HLA-A, HLA-B and HLA-C located on 
chromosome 6p21 whereas the light chain (B2M) coding gene is situated on 
chromosome 5q (MHC sequencing consortium,1999; Roberts et al., 2006). HLA-A 
and -B usually exhibit higher expression levels compared to HLA-C which is 
sparsely expressed as it is (post-) transcriptionally controlled by microRNAs 
(Neefjes and Ploegh, 1988; Kulkarni et al., 2011). MHCII is categorised in 3 classical 
and 2 non-classical molecules that are encoded by genes located in the same gene 
locus as MHCI genes. Classical MHCII molecules that are responsible for antigen-
presentation, are encoded by the three polymorphic HLA-DR, HLA-DQ and HLA-DP 
genes from which HLA-DR is the most highly expressed in humans (Cresswell, 
1994; Landsverk et al., 2009). The expression of classical, non-classical MHCII and 
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several associated genes like CD74, stands under the coordinated control of a 
master transcriptional regulator the “class II major histocompatibility complex 
transactivator” (CIITA). In general, CIITA regulates the maturation dependent 
permanent expression of genes implicated in antigen presentation (Steimle et al., 
1993; Wright et al., 2006). The activity of this MCHII transactivator in turn, is 
controlled by post-translational modifications such as phosphorylation and 
monoubiquitylation and other elements predominantly found to be active in cells 
belonging to the immune system. Structurally, a MHCII molecule is a heterodimer 
composed of two membrane anchored peptide chains, termed α and β, each 
consisting of two domains α 1, 2 and β 1, 2. In MHCII molecules the peptide binding 
groove, which encompasses the major polymorphism sites, is formed by aas of the 
two different peptide chains, α1 and β1. The MHCII peptide binding groove exhibits 
open ends. Therefore, the N-and C-terminal tails of a bound peptide-antigen are not 
buried within the MHCII molecules as their MHCI counterparts and accommodated 
peptides have a length of 13 to 25 residues (Wieczorek et al., 2017). Whether a 
peptide is suitable to be accommodated in the binding groove of MHCI and MHCII 
molecules is determined by the correct length and particular aa-residues at certain 
sequence positions (p), p2 or p5/6 of MHCI peptides and p1, 4, 6 and 9 of MHCII 
peptides. These aa-residues do not have to be identical but related in structure and 
characteristics. They occupy defined pockets in the MHC molecules and anchor the 
peptide antigen to the MHC backbone. Thus, these aa-residues are called anchor 
residues. The 2 non-classical MHCII molecules called HLA-DM, HLA-DO and the 
invariant chain (li), also known as CD74 (located on chr.5q32) are required as 
accessory proteins in the proper loading of MHCII molecules with peptides.  
HLA-DM is not present at the cell surface and does not bind antigenic-peptides itself. 
Instead, it catalyses the dissociation of the CLIP peptide, which is generated by the 
degradation of CD74, from the peptide binding groove of MHCII molecules. 
Furthermore, HLA-DM binds to and stabilises the peptide-free MHCII state.  
HLA-DM also acts as peptide editor and selects for antigenic-peptides that bind 
stably to MHCII molecules by promoting the dissociation of inappropriate peptides. 
The other non-classical MHCII molecule HLA-DO was found to be expressed in 
thymic epithelial cells, dendritic cells and B-cells (Liljedhal et al., 1996; Douek and 
Altmann, 1997). HLA-DO is as HLA-DM not present on the cell surface and seems 
not to bind antigens. It functions as HLA-DM negative regulator by associating with 
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HLA-DM and thereby inhibiting its catalytic peptide exchange activity. The HLA-DO 
inhibitor function was proven by the transfection of HLA-DO lacking but HLA-DM/-
DR3 and li endogenously expressing cells with cDNA constructs coding for HLA-
DO. This resulted in higher amounts of MHCII molecules still associated with li, a 
decreased number of antigenic peptide loaded MHCII complexes and thus reduced 
antigen presentation to T-cell clones (van Ham et al., 1997). MHCI and II exhibit 
different pathways of antigen processing to achieve surface antigen-peptide 
presentation to the immune system (a schematic overview of both pathways is 
depicted in Figure 11.). MHCI surface complexes of nucleated cells present 
antigenic peptide fragments originating from intracellular i.e. cytosolic and nuclear 
localised proteins which are degraded by 26S proteasomes. A large share (30% to 
70%) of intracellular proteins is degraded ensuing translational synthesis just prior 
to the formation of operational proteins due to failures in transcriptional or 
translational processes. These degradation products are called defective ribosomal 
products (DRiPS) and explain why for instance viral proteins are presented on cell 
surfaces and recognised by T-cells in only a few hours after the infection (influenza 
virus antigens in ~ 90 minutes) independent from the natural half-life of a certain 
protein (Khan et al., 2001). The proteasomally generated peptide fragments of 8 to 
16 aa length are translocated by the transporter associated with antigen 
presentation (TAP) into the endoplasmic reticulum (ER) where MHCI molecules are 
waiting for peptides (Parcej and Tampe, 2010). The MHCI molecules in the ER are 
folded by the chaperon tapasin which can also function as peptide editor  
in the same manner as HLA-DM in MHCII antigen loading. The ER transporter TAP 
also serves as platform for the binding of several tapasin proteins (Wearsch and 
Cresswell., 2008). Two more proteins, the chaperons calreticulin and ERp57 
participate in the folding and stabilisation of MHCI molecules in the ER. Together, 
these ER-located chaperons form the so called peptide-loading complex (PLC) 
which facilitates the loading of peptides onto MHCI molecules and is released when 
peptide loading is accomplished. Before peptide fragments can be loaded by the 
PLC onto MHCI molceules, some of them first have to undergo N-terminal trimming 
by the ER aminopeptidases ERAP1 and ERAP2 in humans or the ER 
aminopeptidase associated with antigen processing (ERAAP) in mice (Serwold et 
al., 2002; Saveanu et al., 2005; Saric et al., 2002). ERAAP is known to shorten 
peptides down to minimally 8 aa (Schubert et al., 2000). In case these N-terminally 
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processed peptides do not bind a MHCI molecule, they are transported back into 
the cytosol by ER associated protein degradation (ERAD). In the cytosol, these 
peptides are eliminated by cytosolic aminopeptidases like the thimet oligopeptidase 
(TOP), the tripeptidyl peptidase II (TPPII) or the proteasome. Some peptides 
however, reenter the ER by TAP mediated transport and search again for a suitable 
MHCI molecule (Roelse et al., 1994; Koopmann et al., 2000). Successfully peptide 
loaded MHCI complexes are allowed to leave the ER. Consequently, the MHCI 
complexes detach from the ER and are subsequently mediated by the Golgi 
apparatus transported to the cytoplasma membrane to display their peptide antigens 
to CD8+ cytotoxic T-cells. This CD8+ T-cell subset kills cells presenting foreign 
antigens derived from intracellular pathogens or altered self-peptides for instance 
from mutated cancerous proteins. This process constitutes an important defense 
mechanism of the immune system in order to prevent the spread of infection and 
cancer. The already mentioned TCR coreceptor CD8 is a disulfide-inked 
heterodimer composed of an α- and β-chain. Additionally to the TCR, CD8 interacts 
with the MHCI molecule on a nucleated cell. In particular, CD8 binds to a conserved 
site in the α3-domain and also residues in the α2-domain of MHCI.                          
These additional interactions stabilise the conjunction between the MHCI bearing 
cell and the T-cell and are thus essential for generating an effective immune 
response directed against the presented antigen and its origin. MHCI complexes 
present on the cell surface are quite stable and targeted for degradation by MARCH 
family proteins from which MARCH4 and 9 were described to regulate MHCI half-
life by ubitquitylation (Bartee et al., 2004). This protein modification catalyses the 
internalisation and subsequent lysosomal degradation of MHCI molecules.  
MHCII molecules are mainly expressed by professional APCs and were shown to 
assemble in the ER. In this organell, MHCII proteins also associate with the trimeric 
CD74 chaperon. Each of the three CD74 subunits binds to a single MHCII 
heterodimer. Since a stretch of the CD74 protein lies within the peptide binding 
groove of MHCII, CD74 prevents premature binding of antigenic peptide fragments 
to the cleft. For this reason, Bodmer et al. (1994) were able to show that in CD74 
deficient mice, the fraction of endogenous-derived peptide fragments presented by 
MHCII is increased. Ensuing, the formed MHCII heterodimer translocates in a CD74 
guided fashion, through the Golgi directly or by taking a detour via plasma 
membrane to a late endosomal compartment termed MHC class II compartment 
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(MIIC). Here, CD74 is digested in several serial steps by acid proteases such as the 
cysteine proteases cathepsin-S and-L (Hsing and Rudensky, 2005). The proteases 
leave a remaining short class II-associated li peptide (CLIP) which is still bound in 
the MHCII peptide binding cleft. Afterwards, the chaperon HLA-DM facilitates the 
exchange of CLIP for a suitable antigenic peptide fragment destined to be 
accommodated in the MHCII peptide binding groove in order to form a stable MHCII 
complex (as described earlier in more detail). HLA-DM also prevents aggregation 
and degradation of MHCII molecules before they bind their respective antigenic 
peptide (Kropshofer et al., 1996). MHCII molecules that do not bind a peptide after 
the release of CLIP are not stable within the low-pH MHCII environment upon the 
fusion with lysosomes and are thus degraded. In contrast to MHCI, MHCII molecules 
bind peptides derived from proteins that originate from exogenous sources and are 
degraded in the endosomal pathway upon their internalisation. Once MHCII 
molecules bound an appropriate peptide fragment, they are released from the MIIC 
and transported in vesicles to the plasma membrane where they can present their 
peptide antigen to CD4+ T-cells. The release of peptide loaded MHCII containing 
vesicles from the MIIC was found to be dependent from several factors such as 
kinases, GTPases, cholesterol and cytosolic pH. The activation of the CD4+ T-cell 
population by this MHCII dependent mechanism is important for the coordination 
and regulation of effector cells. CD4 is a monomeric protein that comprises 4 Ig-like 
domains (D1-D4). CD4 binds MHCII molecules displayed on the cell surface of a 
professional APC at a hydrophobic cleft between the α2 and β2 domain by the lateral 
site of the D1 domain. The simultaneous binding of the MHCII complex to the TCR 
and its CD4 co-receptor present on the T-cell surface enhances the signal triggered 
within the T-cell and furthermore, increases the T-cell’s sensitivity towards the 
presented antigenic-peptide. Alike MHCI, MHCII molecules are quite stable 
complexes that do not degenerate on the cell surface and exhibit cell type 
dependent half-lives. Similarly to MHCI also MHCII molecules can be ubiquitinated  
by MARCH proteins, in particular MARCH1, thereby being targeted for endocytosis 
and proteasomal degradation (de Gassart, A. et al., 2008). Thibodeau et al. (2008) 
demonstrate the direct interaction of MHCII and MARCH1 proteins by 
immunoprecipitation experiments. MARCH1 expression was found to be strongly 
induced by IL-10 in human primary monocytes. Furthermore, siRNA mediated 
MARCH1 knockdown was observed to abrogate the IL-10 mediated down regulation 
Introduction 
 
57 
 
of surface MHCII levels in primary monocytes. Together, these experiments explain 
the mechanism behind the interfering impact of IL-10 on MHCII antigen 
presentation. It is also assumed that MHCII molecules are just degraded in usual 
lysosomal proteolysis. As already described earlier, MHCI complexes display 
antigenic peptides from intracellular sources whereas MHCII complexes present 
peptide fragments originating from extracellular proteins. However, this attribution 
of peptide sources to MHCI and II molecules is not static and it is therefore possible 
that cells can present antigens derived from extracellular origins on MHCI 
molecules. Furthermore, also endogenous antigenic protein fragments can be 
presented by MHCII complexes in case there were generated by autophagy under 
certain conditions. This link between MHCI and MHCII antigen presentation is 
termed antigen cross presentation. One purpose why endogenous proteins are 
exclusively presented by MHCI molecules is that healthy cells that have absorbed 
proteins of viral or tumorous origin derived from diseased cells in the close proximity 
do not get killed by CD8+ cytotoxic T-cells. On the other hand, naive CD8+ cytotoxic 
T-cells have to be activated by professional APCs before they can execute their 
lethal effector function. In case endogenous proteins would be exclusively restricted 
to be displayed on the surface of professional APCs by MHCI complexes, 
intracellular pathogens for instance that do not infect professional APCs, impair the 
endogenous antigen presentation or when a neoplasm does not originate from 
APCs, the only way to activate naïve CD8+ cytotoxic T-cells by APCs is to present 
exogenous-derived antigens on MHCI molecules (Kurts et al., 2010).  
Regarding B-cell malignancies, a loss of MHCI and MHCII expression was generally 
found to be associated with poor survival outcome and a more aggressive clinical 
behaviour of the neoplasms under CHOP or R-CHOP treatment (Guy et al., 1986; 
Moller et al., 1986; Riemersma et al., 2000; Booman et al., 2008; Momburg et al., 
1987; Amiot et al., 1998, Wilkinson et al., 2012). In the context of DLBCL 
pathogenesis and prognosis, decreased MHCII expression for example of HLA-
DRA surface expression was found to be associated with less tumor infiltrating CD8+ 
T-cells and reduced patient survival, indicating impaired immunosurveillance 
(Rimsza et al., 2004). In addition, Rimsza et al., 2007 demonstrated that  
the expression of classical MHCII, non-classical MHCII and CD74 correlates  
with the expression of CIITA in DLBCL. In line with this, Cycon et al. (2009) found 
the expression of MHCII genes in the GCB DLBCL cell lines SU-DHL-4 and SU-
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DHL-6 to be coordinately reduced and the extent of their expression was correlated 
with CIITA expression. The group found varying MHCII levels when they 
investigated the surface MHCII expression of several DLBCL model cell lines. They 
report that the ABC DLBCL cell line OCI-LY10 does not exhibit any HLA-DR and 
HLA-DQ surface protein levels due to homozygous deletions found in the MHCII 
locus. Furthermore, they also describe a dyscoordinated downregulation of the 
MCHII β-chain in the ABC DLBCL cell line OCI-LY3 resulting in dramatically 
decreased surface MHCII levels. An IHC-based study conducted by Rimsza et al. 
(2007), comprising 97 paraffin embedded tissue samples from MACOP-B regimen 
treated DLBCL patients revealed a loss of HLA-DR expression in 37% of 
investigated cases. MHCII gene expression loss was also reported to be common 
in rare cases of DLBCL arising in immune privileged sites such as eyes, brain, testes 
or ovary. It was shown that this type of DLBCL exhibits a loss of MHCII gene 
expression in more than 50% of cases in which the primary tumor was found in brain 
or testis. It is also described that the loss of MHCII expression was often 
accompanied by the homo- or heterozygous deletion of the MHCII locus in the 
above mentioned immune-privileged DLBCL cases. Whereas in 5% other DLBCL 
the loss of MHCII expression was not accompanied with abnormalities within the 
chr. 6p MHC gene locus (Riemersma et al., 2000; Jordanova et al., 2002). 
Moreover, the DLBCL subtype PMBL was also reported to exhibit a loss of MHCII 
proteins frequently. Furthermore, PMBLs showed significantly lower average 
expression of all individual MHCII genes except for CD74 compared to the GCB-
DLBCL subtype whereas not to the ABC DLBCL subtype. This difference could 
probably be explained by the fact that GCB- and ABC DLBCL react differently to IL-
4 exposure. IL-4 is known to encompass the MHCII genes as target genes. If this 
difference is also true for in vivo behaviour of DLBCL, this could be a reason for 
higher MHCII gene expression in GCB DLBCL. 
In addition, also poor patient survival in PMBL cases was found to be correlated with 
decreased MHCII expression levels. Wilkinson et al., 2012 investigated the 
relationship between the loss of MHCII and the B-cell differentiation state as the 
plasmacytic differentiation of non-cancerous B-cells is known to be linked to the loss 
of MHCII surface expression. Accordingly, MHCII gene expression fluctuates within 
B-cell differentiation. Thus, MHCII gene expression is absent in pro-B-cell 
populations but is highly present in mature B-cells and further maturation to plasma 
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cells abolishes MHCII expression by the down regulation of the transcriptional 
regulator CIITA (Benoist et al., 1990). Indeed, the Wilkinson group was able to show 
that GCB exhibit significantly higher MHCII levels than the ABC DLBCL subtype. In 
accordance with this, they also revealed a negative correlation between the mRNA 
levels and the protein expression of MHCII (HLA-DR) molecules and classical 
plasmacytic markers such as MUM1, BLIMP1 and XBP1s. (For further review see 
Neefjes et al., 2011) 
 
 
 
Figure 11. Schematic illustration of the basic events in the (a) MHCI and the (b) MHCII 
antigen presentation pathway. (a) The MHCI pathway begins with the generation of peptide 
fragments by the proteasome from cytosolic or nuclear proteins. These antigenic peptides are then 
translocated via the ABC transporter TAP into the ER. In the ER lumen MHCI proteins are loaded 
with suitable peptides. The resulting MHCI-peptide complexes are subsequently released from the 
ER. Through passing the Golgi apparatus they get to the cytoplasma membrane where they present 
their peptide cargo to the antigen receptor of CD8+ cytotoxic T-cells. In case, a MHCI molecule does 
not bind a peptide in the ER it is transported back into the cytosol where it is degraded or 
alternatively, enters again via TAP the ER in order to find an appropriate MHCI molecule to bind. 
(b) The α-and β-chain of MHCII molecules is assembled in the ER of a professional APC. The 
trimeric invariant chain (li; CD74) then binds to three MHCII molecules in order to prevent 
premature peptide binding and to target the MHCII complex to be transported to the late endosomal 
compartment MIIC. This occurs either in a direct manner or via a detour to the cytoplasma 
membrane. In the MIIC the invariant chain is serially degraded by proteases. Also peptide fragments 
derived from endocytosed proteins from extracellular sources are generated here. The remaining 
fragment of the invariant chain which is called CLIP still binds the peptide-binding groove until it is 
exchanged for an appropriate antigenic-peptide. This exchange occurs in assistance with the auxiliary 
non-classical MHCII molecule and chaperon HLA-DM. Ensuing, antigen loaded MHCII molecules 
are transported to the cytoplasma membrane where they display their respective antigen to the TCR 
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of a CD4+ T-cell. Abbreviations: APC, antigen presenting cell; TAP, transporter associated with 
antigen presentation; ER, endoplasmic reticulum ERAD, ER-associated protein degradation; TCR, 
T-cell receptor; β2m, β2-microglobulin; MIIC, MHC class II compartment; CLIP, class II-associated 
li peptide. Figure adapted from Neefjes et al., 2011. 
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2. Material and Methods 
2.1 Materials 
2.1.1 Providers 
Providers  
Abcam Abcam plc, Cambridge, U.K. 
Agilent   Agilent Technologies GmbH, Böblingen, Germany 
Ambion  Life Technologies GmbH, Darmstadt, Germany 
AppliChem Applichem GmbH, Darmstadt, Germany 
BD BD Biosciences, Heidelberg, Germany 
BioLegend BioLegend, San Diego, U.S.A. 
Biorad Bio-Rad, Hercules, U.S.A 
Cayman Chemical Biomol GmbH, Hamburg, Germany 
Cell Signaling New England Biolabs, Inc., Ipswich, U.S.A. 
Corning Corning, Inc., Tewksbury, U.S.A. 
Eppendorf Eppendorf AG, Hamburg, Germany 
Eurofins MWG GmbH Ebersberg, Germany 
GE Healthcare   GE Healthcare Lifesciences, Dornstadt, Germany 
Genaxxon Genaxxon Bioscience GmbH, Ulm, Germany 
Gibco Gibco/Invitrogen Cell Culture, Carlsbad, U.S.A. 
Gilson Gilson, Inc. Middleton, WI,USA 
IBA IBA GmbH, Göttingen, Germany 
Immunotools ImmunoTools GmbH, Friesoythe, Germany 
Invitrogen Life Technologies GmbH, Darmstadt, Germany 
KapaBiosystems KapaBiosystems, Wilmington, Massachusetts U.S.A. 
Macherey-Nagel Macherey-Nagel GmbH & Co. KG, Düren, Germany 
Merck  Merck KGaA, Darmstadt, Germany 
NEB New England Biolabs, Inc., Ipswich, U.S.A. 
PAA PAA Laboratories GmbH, Cölbe, Germany 
PEQLAB  PEQLAB Biotechnologie GmbH, Erlangen, Germany 
Pineda  Pineda – Antikörper service, Berlin, Germany 
Promega Promega Corp., Madison, U.S.A. 
Qiagen  Qiagen GmbH, Hilden, Germany 
Roche  Roche GmbH, Basel, Switzerland 
Roth Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Santa Cruz Santa Cruz Biotechnology, Santa Cruz, U.S.A. 
Selleckchem Selleckchem, Munich, Germany 
Sigma Sigma Aldrich, Buchs, Switzerland 
Tecan Tecan Group, Ltd., Crailsheim, Germany 
Thermo  Thermo Fisher Scientific, Karlsruhe, Germany  
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TPP Techno Plastic Products AG Trasadingen, Switzerland 
VWR  VWR International GmbH, Darmstadt, Germany 
 
2.1.2 Chemical reagents 
Reagent Provider 
2% Bis-acrylamide   AppliChem 
2-propanol Merck 
2x HeBS pH 7.5  Self made 
40% Acrylamide   AppliChem 
50 mM MgSO4  Invitrogen 
Ammonium peroxodisulphate (APS) Roth 
Ampicillin Sigma 
Bradford  Biorad 
Bromphenol blue Biorad 
BSA PAA 
CaCl2  Merck 
CHX Sigma 
cOmplete™, Mini, EDTA-free 
Protease Inhibitor Cocktail Tablets 
Roche 
 
Cyclosporin A Merck 
Dithiothreitol (DTT) Roth 
DMEM  Sigma 
DMSO  Sigma 
dNTPs  Thermo Scientific 
DPBS Thermo 
EDTA Roth 
FCS PAA 
FK506 Selleckchem 
GenAgarose LE   Genaxxon 
Glacial acetic acid AppliChem 
Glycerol  AppliChem 
Glycine  AppliChem 
HEPES  AppliChem 
IMDM Sigma 
Ionomycin Sigma 
Isopropanol Merck 
Kanamycin Sigma 
KCl Sigma 
LB-agar  Roth 
LB-medium Roth 
L-glutamine, 200 mM Sigma 
Luminol enhancer solution Promega 
MgCl2 AppliChem 
Na3VO4  AppliChem 
Na4P2O7 AppliChem 
NaCl AppliChem 
NaF AppliChem 
NaN3 AppliChem 
Nonfat dried milk powder Applichem 
Nonidet P-40 (NP-40) Applichem 
nuclease-free water Ambion 
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Orange G Applichem 
PBS (1x) PAA 
Penicillin, 10000 units/ml Sigma 
Peroxide solution Promega 
Plasmocin Invitrogen 
PMA   Sigma 
Polysorbat 20/Tween 20 Merck 
RPMI 
Triton-x-100  
Sigma 
Merck 
Sodium dodecyl sulphate (SDS) Merck 
Streptomycin Sigma 
Sucrose Merck 
SYBR ™ safe DNA gel stain Invitrogen 
Tetramethylethylenediamine 
(TEMED)  
Roth 
Tris base AppliChem 
β-mercaptoethanol AppliChem 
 
2.1.2 Commonly used Buffers and Solutions and their 
composition 
Buffer / Solution Compounds 
Cell lysis  
Lysis buffer 1% triton X-100 150 mM NaCl 
 
 
50 mM tris, pH 7,4 
Lysis buffer 1% triton X-100 complete 10 ml lysis buffer 
 1% triton X-100 
 50 mM NaF 
 10 mM Na4P2O7 
 10 mM Na3VO4 
 1 tablet protease inhibitor 
Agarose gel electrophoresis  
50x TAE buffer  242.2 g tris in 600 ml H2O 
  57.1 ml glacial acetic acid 
  100 ml 0,5 M EDTA, pH 8 
  ad 1 l H2O 
5x DNA Sample Buffer  30 % (v/v) glycerol 
  0.2 % (w/v) orange G   
SDS – Polyacrylamide gel 
electrophoresis  
 
10% acrylamide for resolving gel 125 ml 40% acrylamide 
49 ml 2% bis-acrylamide 
 125 ml 1.5 M tris-HCl, pH 8.8 
 ad 500 ml H2O 
 
25% acrylamide for resolving gel 312 ml 40% acrylamide  
 17 ml 2% bis-acrylamide 
 125 ml 1,5 M tris-HCl, pH 8.8 
 ad 500 ml H2O 
 
10x migration buffer 60.6 g tris 
 288 g glycine 
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Sample buffer for SDS-PAGE 
20 g SDS 
ad 2 l H2O 
 
7,5 ml 1 M tris, pH 7.4 
2.4 g SDS 
12 mg bromphenol blue 
30% glycerol 
4 ml 14.3 M β-mercaptoethanol 
ad 100 ml H2O 
adjust to pH 6.8 with HCl 
  
2X urea sample buffer:  
 
 
 
50mM Tris HCl pH 6.8 
1.6% SDS 
7% glycerol 
8M urea 
4% β-mercaptoethanol 
0.016% bromophenol blue 
 
Stacking gel 31.25 ml 40% acrylamide 
 16.25 ml 2% bis-acrylamide 
 
 
 
31.25 ml 1M tris-HCl, pH 6.8 
ad 250 ml H2O 
Western Blot  
10x blot buffer 238 g glycine 
50 g tris 
 
1x blot buffer 1 l 10x blot buffer 
1.7 l methanol 
 
 
Western wash buffer:  
1x PBS/T 
7.3 l H2O 
 
 
1 l 10x PBS 
 50 ml tween 
9 l H2O 
Blocking solutions: 
5% milk / PBS/T 
 
25 g nonfat dried milk powder 
 
 
5% BSA / PBS/T 
 
 
Ponceau Rouge  
 
 
ECL 
ad 500 ml PBS/T 
 
25 g BSA 
ad 500 ml PBS/T 
 
10 g Ponceau  
15 ml trichloroacetic acid  
150 g sulfosalicylic acid 
ad 500 ml H2O  
1:1 luminol enhancer solution : peroxide solution 
Cell fractionation  
Buffer C 10 mM HEPES, pH 7.9 
1.5 mM MgCl2 
 300 mM sucrose 
0,25% / 0.5% NP-40 
10 mM KCl 
 0,5 mM DTT added at the last minute 
complete protease inhibitor 
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Buffer N 20 mM HEPES pH 7.9 
100 mM NaCl 
0,2 mM EDTA 
20% (v/v) glycerol 
100 mM KCl 
0,5 mM DTT added at the last minute 
complete protease inhibitor 
Cell stimulation  
PMA/Ionomycin (P/I) 10 ng/ml PMA, 1 µM ionomycin in DMSO 
PMA 10 ng/mL in DMSO 
Ionomycin PMA 1 µM ionomycin in DMSO 
  
 
2.1.3 Pharmacological inhibitors 
Inhibitor Description  Provider 
CyclosporinA Calcineurin inhibitor in complex with the 
immunophilins CyclophilinA. 
 
Merck 
FK506 (Tacrolimus) Macrolidlacton calcineurin inhibitor in 
complex with the immunophilins FKBP12. 
 
Selleckchem 
JAK-1 inhibitor  Reversible, cell permeable, ATP –
competitive Inhibitor witch a IC50 of 15nM. 
Soluble in DMSO (5 mg/ml) 
 
Calbiochem 
 
p38 MAPK inhibitor 
(SC204157) 
 
Potent p38 MAPK inhibitor with a C50 = 35 
nM; soluble in DMSO (25 mg/ml). 
Santa Cruz 
Sotrastaurin (STN) 
Synonym: AEB071 
Potent and selective panPKC-inhibitor. 
Mostly for PCK θ with a Ki of 0, 22 nM. 
PKCβ1 Ki: 0, 64 nM. Inactive to PKCζ. 
Soluble in DMSO at 25°C: (87 mg/ml). 
 
Selleckchem 
Sulfosuccinimidyl Oleate 
(SSO) 
Irreversible CD36 inhibitor which does not 
permeate the cytoplasma membrane. 
 
CaymanChemical 
Chemical 
z-LVSR-fmk 
  
2.1.4 Enzymes 
Tetrapeptide; MALT1 inhibitor. Based on 
“LVSR85” sequence in the MALT1 substrate 
RelB. 
 
Margot Thomé 
Designation Description Provider 
Pfu DNA polymerase, 
recombinant 
Highly thermostable DNA 
polymerase from Pyrococcus 
furiosus 
Agilent 
Platinum™ Pfx DNA 
polymerase 
 
Higher fidelity than Pfu. Thermo 
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Hot start polymerase. 
Provided in inactive state due 
to antibody binding. 
Restriction endonucleases Cuts DNA strands at enzyme 
specific palindromic 
recognition sequences 
Thermo, NEB 
T4 DNA Ligase  
 
Joins DNA fragments by the 
formation of phosphodiester 
bonds between blunt and 
cohesive end DNA termini  
Thermo, NEB 
FastAP Thermosensitive Alkaline 
Phosphatase. Catalysis the 
release of 5’ and 3’ 
phosphates from DNA, RNA, 
nucleotides and from proteins. 
Thermo 
 
2.1.5 Media and buffers for cell culturing 
Medium/Buffer Compounds/Preparation 
DMEM Before usage media from providers were 
supplemented with 100 U/ml penicillin, 100 µg/ml 
streptomycin, 2,5 µg/ml plasmocyin and either 
10% or 20% FCS 
IMDM 
RPMI 
Cell wash buffer  1x PBS 
FACS Buffer 1x PBS; 2% (v/v) FCS. 
Freezing buffer  20 % (v/v) DMSO in FCS 
 
2.1.6 Media for bacterial culturing 
Medium Compounds/Preparation 
LB-agar 4 % (w/v) LB-agar diluted with ddH20; autoclave 
and cool to 60°C; pour plates and store them at 
4°C 
LB-selection agar suppl. with ampicillin 4 % (w/v) LB-agar diluted with ddH20; autoclave 
and cool to 60°C subsequently add 100 µg/ml 
ampicillin; pour plates and store them at 4°C 
LB-selection agar suppl. with 
kanamycin 
4 % (w/v) LB-agar diluted with ddH20; autoclave 
and cool to 60°C subsequently add 50 µg/ml 
ampicillin; pour plates and store them at 4°C 
LB-medium 2 % (w/v) LB-medium; autoclave; store at  4°C 
LB-selection medium suppl. with 
ampicillin 
2 % (w/v) LB-medium; autoclave; cool down  to                  
~ 60°C; add 100 µg/ml ampicillin and store at  4°C 
LB-selection medium suppl. with 
kanamycin 
 
 
 
 
 
2 % (w/v) LB-medium; autoclave; cool down to                    
~ 60°C; add 50 µg/ml kanamycin and store at  4°C 
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2.1.7 Kits  
Product Application                        Provider                          
RNeasy Mini Kit Isolation of RNA Qiagen   
 
QuantiTect Reverse 
Transcription Kit  
2-step-reaction, gDNA digestion and 
cDNA synthesis 
Qiagen  
 
GeneJET Plasmid Miniprep 
Kit 
Isolation of plasmid DNA Thermo 
ScientificTM  
 
GeneJET Gel Extraction Kit Purification of DNA from agarose gel Thermo 
ScientificTM  
 
GeneJET PCR Purification 
Kit 
 
Purification of DNA-fragments generated 
by PCR 
Thermo 
ScientificTM  
 
NucleoBond Xtra Maxi Kit Large-scale isolation of plasmid DNA Macherey-Nagel 
Dual-Luciferase® Reporter 
Assay System 
  
Genetic reporter system to investigate 
eukaryotic gene expression and cellular 
physiology 
Promega 
eBioscience™ Human IL-2 
ELISA Ready-SET-Go!™ Kit 
Detection of IL-2 in the supernatant of 
human cells 
Thermo 
ScientificTM  
 
eBioscience™ Human IL-6 
ELISA Ready-SET-Go!™ Kit 
Detection of IL-6 in the supernatant of 
human cells 
Thermo 
ScientificTM  
 
eBioscience™ Human IL-10 
ELISA Ready-SET-Go!™ Kit 
Detection of IL-10 in the supernatant of 
human cells 
Thermo 
ScientificTM  
 
KAPA SYBR® FAST qPCR 
Master Mix (2X) Kit 
Ready-to use cocktail to conduct qRT-
PCR assays. Comprises: 2X master mix 
with integrated antibody-mediated hot 
start polymerase, SYBR Green I 
fluorescent dye, MgCl2 , dNTPs, and 
stabilizers 
KapaBiosystems 
CellTiter 96® AQueous One 
Solution Cell Proliferation 
Assay 
Colorimetric method to determine the 
portion of viable cells 
Promega 
LEGENDScreen™ 
Lyophilized Antibody Array 
Human PE Kit 
Kit containing 361 PE-conjugated 
lyophilised antibodies directed against 
human cell surface markers and 
corresponding isotype controls. 
BioLegend® 
 
2.2 Biological material 
2.2.1. Size markers for DNA and proteins  
Product Provider 
O´GeneRuler 1 kb Plus DNA ladder, ready-to-use Thermo Scientific 
O’GeneRuler 100 bp Plus DNA Ladder, ready-to-use Thermo Scientific 
Spectra Multicolour Broad Range Protein Ladder Thermo Scientific 
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2.2.2. Antibodies 
According to the manufacturer’s instructions antibodies were dissolved in respective 
dilutions either in 1xTBS/T supplemented with 5% (w/v) nonfat dried milk powder or 
1xTBS/T supplemented with 5% (w/v) BSA. Additionally, NaN3 in a dilution of 1:250 
was added to prevent spoilage of Milk or BSA. The prepared dilutions were used 
several times and stored at 4°C or -20°C dependent on the antibody. Secondary 
antibodies were prepared freshly prior to use and dissolved 1:10.000 in 1xTBS/T 
supplemented with 5% (w/v) nonfat dried milk powder. 
 
Protein 
 
Mol. Weight Species Provider Catalogue 
number 
Primary antibodies 
A 20 (59A426) 90 kDa 
 
mouse 
monoclonal 
Santa Cruz 
 
sc-52910 
 
Bcl10 (H-197) 33 kDa 
 
rabbit 
polyconal 
Santa Cruz 
 
sc-5611 
 
BCL-XL 
 
30kDa 
 
rabbit 
monoclonal 
Cell Signaling 
 
2764 
 
CYLD (D1A10) 
 
108 kDa 
 
monoclonal 
rabbit 
Cell Signaling 
 
#8462 
 
ERK 2 (C14) 
 
42kDa 
 
rabbit 
polyclonal 
Santa Cruz 
 
sc-154 
 
Flag (M2)  
 
1 kDa mouse 
monoclonal 
 
Sigma 
 
F1804 
 
GAPDH (A3) 
 
37 kDa 
 
mouse 
monoclonal 
Santa Cruz 
 
sc-137179 
 
IkB-α (L35A5) 
 
39 kDa 
 
mouse 
monoclonal 
Cell Signaling 
 
#4814 
 
IκBNS 
 
35 kDa &  
70 kDa 
rabbit 
polyclonal 
abcam 
 
ab182633 
IκBNS p35/p70 
 
35 kDa & 70 kDa rabbit 
polyclonal 
Pineda Self-made 
against aa 105-
120 and aa  
IκBNS p70 
 
70 kDa rabbit 
polyclonal 
Pineda Self-made 
against aa 215-
231 
Lamin A/C 
 
28 kDa 
 
rabbit 
polyclonal 
Cell Signaling 
 
#2032 
 
MALT1 
 
90 kDa 
 
rabbit 
polyclonal 
Cell Signaling 
 
#2494 
 
NFAT c1 (7A6) 110 kDa 
 
mouse 
monoclonal 
Santa Cruz 
 
sc-7294 
 
p-BLNK (Y96) 
 
68 kDa rabbit 
polyclonal 
Cell Signaling 
 
3601 
 
Phospho-IkBα 
(Ser32/36) 
40 kDa 
 
mouse 
monoclonal 
Cell Signaling 
 
#9246 
 
Phospho-Stat3 
(Thy705) (D3A7) 
79, 86 kDa 
 
rabbit 
polyclonal 
Cell Signaling 
 
#9145 
 
Phospho-Tyrosine 
 
total protein mouse 
monoclonal 
Cell Signaling 
 
#9411 
 
ß-Tubulin (H-235) 
 
55 kDa 
 
rabbit 
polyclonal 
Santa Cruz 
 
sc-9104 
 
Stat3 (124H6) 
 
79, 86 kDa 
 
mouse 
monoclonal 
Cell Signaling 
 
#9139 
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StrepMAB-Classic 
 
1,1 kDa mouse 
monoclonal 
Iba 
 
2-1507-001  
Syk (Tyr526)  
 
70 kDa rabbit 
polyclonal 
 
Cell Signaling 
 
#2704 
 
Flow 
cytometry 
antibodies 
Mol. weight Colour Provider Catalogue 
number 
CD36 
  
53 kDa FITC ImmunoTools 21270363 
 
CD90 
 
18 kDa FITC affymetrix 
eBioscience 
 
11-0909 
 
CD108 
 
75 kDa FITC ImmunoTools 
 
21271083 
 
CD274 
 
33 kDa APC affymetrix 
eBioscience 
 
17-5983 
 
HLA-DR 29 kDA FITC ImmunoTools 21278993 
secondary 
antibodies 
Description  Provider  
anti-mouse IgG HRP conjugated 
secondary 
antibody 
 Promega W4021 
anti-rabbit IgG HRP conjugated 
secondary 
antibody 
 Promega W4011 
 
2.2.3 Oligonucleotides  
All applied oligonucleotides were purchased from Sigma. 
2.2.3.1 RNAi mediated gene expression knockdown:  
Designation  Sequence  5’ - 3’ 
shRNAs designed for IκBNS knockdown 
shRNA1 Sense: 
Antisense:   
GCC AGG AGA TCA AGA GCA ACA 
CCC GTG GGC CTT CAT GTT G 
shRNA2 Sense: 
Antisense:   
CAA CAT GAA GGC CCA CGG G 
CCC GTG GGC CTT CAT GTT G 
shRNA3 Sense: 
Antisense:   
CTG CGC AAC CTG GAG AAT G 
CAT TCT CCA GGT TGC GCA G 
shRNA4 Sense: 
Antisense:   
CAG CTG TTG AAG AGG AGC C 
GGC TCC TCT TCA ACA GCT G 
shRNA5 Sense: 
Antisense:   
GGG GAC TCC CAG GCC TGT G 
CAC AGG CCT GGG AGT CCC C 
shRNA6 Sense: 
Antisense:   
CCC CAG GGC ATG GAG GCT G 
CAG CCT CCA TGC CCT GGG G 
shRNA7 Sense: 
Antisense:   
CTG AGC ATC ACT CAA GCT C 
GAG CTT GAG TGA TGC TCA G 
shRNA8 Sense: 
Antisense:   
GCA AAC CCA TGA TAAT GTA 
TAC ATT ATC ATG GGT TTG C 
shRNA9 Sense: 
Antisense:   
CGG CAT ATG CTG CGG CTG A 
TCA GCC GCA GCA TAT GCC G 
shRNA10 Sense: 
Antisense:   
ACA TGA AGG CCC ACG GGA A 
TTC CCG TGG GCC TTC ATG T 
shRNA11 Sense: 
Antisense:   
ACT GAG ATC TTT CGG GTT C 
GAA CCC GAA AGA TCT CAG T 
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siRNA pools Provider 
IκBNS:   SMARTpool: ON-TARGET plus NFKBID siRNA Dharmacon™, GE Healthcare 
MALT1: SMARTpool: ON-TARGETplus MALT1 siRNA Dharmacon™, GE Healthcare 
Control:  ON-TARGETplus Non-targeting Pool Dharmacon™, GE Healthcare 
2.2.3.2 Oligonucleotides used in Crispr/Cas9 mediated gene 
expression knockout 
Target gene  gRNA sequence 5’ - 3’ 
Nfkbid fwd: 
rev: 
GCT CAC GAA TGT CAA GAC GC 
GTT TAA AAA CTC GCG GGT ACC GG 
2.2.3.3 Oligonucleotide primers applied in qRT-PCR experiments 
Template 
mRNA 
 Sequence  5’ - 3’ Length (bp) Tm°C 
CD36 fwd: 
rev:   
GGC TG TGA CCG GAA CTG TG 
AGG TCT CCA ACT GGC ATT AGA A 
19 
22 
62,9 
60,8 
CD90 fwd: 
rev:   
ATC GCT CTC CTG CTA ACA GTC 
CTC GTA CTG GAT GGG TGA ACT 
21 
21 
61,3 
60,9 
CD274 fwd: 
rev:   
TGG CAT TTG CTG AAC GCA TTT 
TGC AGC CAG GTC TAA TTG TTT T 
21 
22 
62,0 
60,4 
ACADM fwd: 
rev:   
ACA GGG GTT CAG ACT GCT ATT 
TCC TCC GTT GGT TAT CCA CAT 
21 
21 
60,5 
60,6 
ACADVL fwd: 
rev:   
ACA GAT CAG GTG TTC CCA TAC C 
CTT GGC GGG ATC GTT CAC TT 
22 
20 
61,2 
62,5 
HADHA fwd: 
rev:   
ATA TGC CGC AAT TTT ACA GGG T 
ACC TGC AAT AAA GCA GCC TGG 
22 
21 
60,4 
63,0 
IκBNS fwd: 
rev:   
GTG TAC CGG CGT CTT GAC ATT 
GTG AGG CCC TCG AAG TCT CT 
21 
20 
62,7 
62,8 
SDHA fwd: 
rev:   
CAA ACA GGA ACC CGA GGT TTT 
CAG CTT GGT AAC ACA TGC TGT AT 
21 
23 
60,7 
60,9 
2.2.3.4 Oligonucleotide primers used for sequencing of plasmids 
Sequencing Primer  Sequence  5’ - 3’ 
BGH Reverse TAG AAG GCA CAG TCG AGG 
EF-1α Forward TCA AGC CTC AGA CAG TGG TTC 
GLprimer2 CTT TAT GTT TTT GGC GTC TTC CA 
SP6 ATT TAG GTG ACA CTA TAG 
T7 TAA TAC GAC TCA CTA TAG GG  
2.2.4 Bacterial strains 
Product  Provider 
NEB 5-alpha competent E.coli  NEB 
One Shot™ Stbl3™ Chemically Competent E. coli Thermo  
2.2.5 Continuous human cell lines 
Cell Line 
Lymphoma   
(Sub-)Type Medium 
% Supplemented 
FCS 
DLBCLs     
BJAB GCB RPMI 10 
SU-DHL-4 GCB RPMI 10 
SU-DHL-6 GCB RPMI 10 
OCI-LY1 GCB IMDM 10 
OCI-LY7 GCB IMDM 10 
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OCI-LY19 GCB IMDM 10 
HBL-1 ABC RPMI 20 
U2932 ABC RPMI 20 
TMD8 ABC RPMI 20 
OCI-LY3 ABC RPMI 20 
OCI-LY10 ABC IMDM 20 
MCLs    
Granta 519 MCL DMEM 10 
Z138 MCL RPMI 10 
Rec-1 MCL RPMI 10 
Jeko-1 MCL RPMI 10 
JVM2 MCL RPMI 10 
UPN1 MCL RPMI 10 
Others    
Jurkat 
 
 
Adult T-cell 
Leukemia/ 
Lymphoma (ATLL) 
RPMI 
 
 10 
Raji Burkitt's Lymphoma RPMI 10 
Ramos Burkitt's Lymphoma RPMI 20 
HEK293T 
Human embryonic 
kidney 293 cells DMEM 10 
2.2.6 Plasmids 
   
Plasmid 
Backbone/ 
Description Resistance Source 
Transient Expression Plasmids 
FLAG-RelA pCR3  Amp Margot Thomé 
FLAG-NFKBID pCR3 Amp This study 
STREP-NFKBID pCR3  Amp This study 
V5-NFKBID Iso3 pCR3 Amp This study 
FLAG-DN-IkBa pCR3  Amp This study 
VSV-MALT1 - Amp Margot Thomé  
VSV-Bcl10 - Amp This study 
StrepHA-MyD88 L265P (aa13-296) - Amp Oliver Wolz 
StrepHA-MyD88 wt (aa13-296) - Amp Oliver Wolz 
HA-CARMA1 WT pTO_HA Amp Georg Lenz 
HA-CARMA1 Mutant2 (L244P) pTO_HA Amp Georg Lenz 
HA-CARMA1 Mutant3 (G116S) pTO_HA Amp Georg Lenz 
NFATc1  pcDNA3 Amp Georg Lenz 
pSUPER empty Intermediate vector for 
cloning shRNAs into 
pLVTHM or pAB286.1 
(Rueda et al., 2007) 
Amp Margot Thomé; 
OligoEngine 
Retroviral expression constructs 
V5-BIRC3 WT pRetro_PG Amp Georg Lenz 
V5-BIRC3 S441Stop pRetro_PG Amp Georg Lenz 
Lentiviral expression constructs 
V5-NFKBID Iso3 pRDI_292 Amp, Puro This study 
FLAG-NFKBID  pRDI_292 Amp, Puro This study 
FLAG-a-fos pRDI_292 Amp, Puro This study 
pLVTHM IRES GFP coupled 
shRNA expression 
Amp Addgene 
#12247 
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pLVTHM IκBNS shRNA1 and 8 IRES GFP coupled 
expression of 
shRNAs targeting 
IκBNS mRNA 
Amp  
pAB286.1 Lentiviral 
expression of 
shRNA 
Amp Margot Thomé 
pAB286.1 IκBNS shRNA1 to 11 Lentiviral 
expression of 
shRNA1 to 11 
targeting IκBNS 
mRNA 
Amp  
lentiCRISPRv2 Empty Crispr/Cas9 
vector 
Amp Addgene 
#52961 
lentiCRISPRv2 gRNA IκBNS Comprises 
specifically 
designed gRNA to 
knock out IkBNS by 
Crispr/Cas9 
Amp This study 
Helper plasmids to generate lenti-viral particles  
pCMV-VSV-G CMV promoter-
driven expression of 
VSV-G envelope  
Amp Addgene #8454 
psPAX2 
 
2nd generation 
lentiviral packaging 
plasmid.  
Amp Addgene 
#12259 
Luciferase reporter plasmids 
Human IκBNS promoter in pGL3-basic Construct of the 
human IκBNS 
promoter for testing 
its activity in 
response to 
transcription factor 
is luciferase assay. 
Amp Promega 
pRL-TK Renilla Luciferase Control 
Reporter Vector 
 
Transcription 
efficacy 
normalisation in 
luciferase assay. 
 
Amp Promega 
2.3 Additional materials 
Material Provider 
Filter Paper for Western Blotting Thermo 
Nitrocellulose membrane, protran BA 83, whatman GE Healthcare 
Ultra Cruz autoradiography film, blue  Santa Cruz 
Tissue Culture Test Plates (6, 12, 24, 48 - well) 
Tissue Culture Flask 500 ml 
Cell Culture Flask 20 ml, 250 ml, 550 ml 
CELLSTAR® 96 well plates flat bottom, round bottom 
LightCycler® 480 Multiwell Plates 96, 384, white 
Centrifuge tubes 15ml, 50 ml 
TPP 
TPP 
Greiner 
Greiner 
Roche 
VWR 
Corning® large volume centrifuge tube, 500 ml 
VWR® Culture Tubes, Plastic, with Dual-Position Cap 
Sigma 
VWR 
VWR® PCR 8-Well Tube Strips; PCR Tubes and Caps VWR 
Safe-Lock Tubes, 1.5 ml;2,0 ml Eppendorf Quality™ Eppendorf 
Pipetman Classic Pipettes P20, P200 and P1000 Gilson, Inc. Middleton, WI ,USA 
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2.3.1 Devices used for conducting experiments 
Device Provider 
DMI6000 Microscope Leica 
Light Cycler 480 II Roche 
LSRII FACS Device BD 
Nanodrop 1000 Peqlab 
Tecan Infinite M200 Tecan 
Film processor for western blot films Agfa 
Gene Pulser Xcell™ Electroporation Systems Biorad 
Gene Pulser®/MicroPulser™ Electroporation 
Cuvettes, 0.4 cm gap 
Biorad 
PerfectBlue™ gel system Twin ExW S Peqlab 
Trans-Blot® Cell BioRad 
2.4 Methods 
2.4.1 Experimental procedures in molecular biology 
2.4.1.1 Isolation of whole cell RNA 
Whole cell RNA was isolated using the Qiagen RNA mini Kit according to the 
manufacturer’s instructions from frozen or freshly harvested supernatant-free 
GCB/ABC DLBCL cell line derived pellets. RNA was eluted in the final step from the 
column by using 35 µl nuclease free water. Until usage, isolated RNA was stored at 
-80°C. 
2.4.1.2 Determination of nucleic acid concentrations and purity 
DNA and RNA concentrations and purity was determined photometrically using the 
Nanodrop 1000 device as per manufacturer's protocols. 
2.4.1.3 Reverse transcription of RNA  
The QuantiTect Reverse Transcription Kit was used according to the manufacturer’s 
instructions to reverse-transcribed 500 ng of isolated RNA (3.4.1.3) into cDNA in a 
final volume of 10 µl. 
2.4.1.4 Quantitative RT-PCR 
Quantitative RT-PCR was conducted in a LightCycler 480II. cDNA was diluted with 
H20 to 50ng/µl. Per reaction 7,5 ng of cDNA was applied. When using a 96/384 well 
plate 15 µl/7,5µl of the KAPA Master mix (H20, KAPA SYBR® FAST qPCR Master 
Mix (2X) Kit, resolight, fwd/rev primers) plus 5 µl/2,5µl cDNA was used per well. 
Primer pairs were diluted 1:10 in H20. mRNA levels were analysed by applying the 
following primer pairs: CD36 fwd/rev; CD90 fwd/rev; CD274 fwd/rev; ACADM 
fwd/rev; HADHA fwd/rev; ACADVL fwd/rev; IκBNS fwd/rev; SDHA fwd/rev. SDHA 
mRNA levels were determined in order to be used as house-keeping reference gene 
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in all qPCR analysis. Primer sequences as listed in 3.2.3.3 were obtained from the 
“PrimerBank - PCR Primers for Gene Expression Detection and Quantification 
database” (https://pga.mgh.harvard.edu/primerbank/). Relative Quantification of the 
reverse transcribed RNA was conducted using the ∆∆CP method: 
∆CP = CP target gene – CP reference gene (here: SDHA) 
∆∆CP = ∆CP treatment – ∆CP control (solvent control) 
Ratio = 2–∆∆CP 
 
2.4.1.5 RNAseq analysis 
For IκBNS knock-down, HBL-1 cells were lentivirally transduced with the empty 
pAB286.1 vector as control and pAB286.1 comprising IκBNS shRNA1. After 4 days 
of puromycin selection, cells were harvested and whole cell RNA was isolated as 
described in 3.4.1.1. RNA samples were sent to the group of Prof. Dr. med. Georg 
Lenz, Medizinische Klinik A – Hämatologie und Onkologie, UK Münster who 
conducted the RNAseq and subsequent analysis. For the characterisation of the 
second IκBNS isoform, deep sequencing analysis was performed in collaboration 
with the “Institut für Humangenetik”, Münster 
2.4.1.6 Digesting DNA strands with restriction endonucleases 
In subcloning ,standard restriction endonuclease digestions were performed in a 
total volume of 20 µl including 2-3 µg of target or/insert comprising vector that were 
digested with corresponding restriction enzymes and buffers as to the 
manufacturer’s instructions. Restriction enzymes were obtained from Thermo or 
NEB. 1,5 µl of FastAP was used to dephosphorylate DNA-ends in order to prevent 
self-ligation of vectors upon single enzyme digestion. Enzymatic digestion of vector 
DNA was incubated for 1 h at 37°C.  
2.4.1.7 Agarose gel electrophoresis 
Un-/Digested dsDNA originating from vectors or PCR-products was analysed by 
size separation using agarose gel electrophoresis. To this end, 1-2% (w/v) of 
GenAgarose LE was dissolved in 1xTAE buffer using a microwave. Subsequently, 
4 µl SYBR Safe was added to the liquid agarose which was poured into a sealed 
gel casting frame and cooled down at RT in order to solidify. Before loading into 
agarose-gel pockets, DNA samples were mixed with 5x sample buffer. 
Electrophoresis was performed in 1xTAE buffer at 90-120V. As DNA molecular 
weight standards served the DNA ladders O´GeneRuler 1 kb Plus DNA ladder or 
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the O’GeneRuler 100 bp Plus DNA Ladder. Separated DNA fragments were 
visualised by an LED transilluminator, exciting the dsDNA intercalating SYBR Safe. 
2.4.1.8 Extraction of DNA fragments from agarose 
Desired DNA fragments were cut out from the agarose and purified from the gel 
using the GeneJET Gel Extraction Kit according to the manufacturer’s instructions. 
The final DNA column elution step was performed with 40 µl ddH2O. 
2.4.1.9 Ligation 
Ligation of appropriate cut and purified vectors and inserts was performed using the 
T4 Ligase. For this purpose 5 µl Insert, 3 µl vector and 1 µl each of T4 DNA Ligase 
and T4 DNA Ligase buffer were mixed and incubated at RT for at least 1h.  
2.4.1.10 Transformation of competent E.coli bacteria 
For transformation of non-viral expression vectors, NEB 5-alpha competent E.coli 
were used for transformation whereas for the transformation of viral expression 
vectors One Shot™ Stbl3™ Chemically Competent E. coli were used. Until usage, 
bacterial strains were stored at -80°C. For transformation they were thawed on ice 
and incubated for 20 – 30 minutes with 1 - 2,5 µl of the ligation reaction or 200 ng 
of plasmid. Subsequently, bacteria were heat-shocked at 42°C for 30 sec in case of 
NEB 5-alpha and for 45 sec. in case of Stbl3™ bacteria. Following 1 min on ice the 
bacteria were transformed with an ampicillin resistance bearing vector, were plated 
out immediately on selective agar plates and incubated over night at 37°C. Bacteria 
transformed with a kanamycin resistance bearing vector were incubated after heat 
shock with 200 µl of SOC-outgrowth medium and incubated for 1h at 37°C.  
Ensuing, bacteria were plated out on selective agar plates and incubated overnight. 
2.4.1.11 Analytical plasmid preparation 
On selection agar grown single bacterial colonies were picked with an autoclaved 
pipet tip. Subsequently, picked colonies sticking to pipet tips were transferred into  
3 ml of selective LB- medium and incubated over night at 37°C and shaking (140 
rpm). The next day, plasmid preparation from grown bacterial suspensions was 
conducted using the GeneJET Plasmid Miniprep Kit following the manufacturer’s 
instructions. Plasmid DNA was eluted from the column with 40 µl of elution buffer. 
In turn to validate if the isolated plasmids actually contain the desired insert, 15 µl 
of each isolated plasmid was digested with the appropriate restriction enzyme. 
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Ensuing, digested samples were analysed by agarose gel electrophoresis for the 
presence of the insert of interest. 
2.4.1.12 Sequencing 
In order to be certain that a distinct plasmid comprises the exact sequence of interest 
or in case of undirected cloning the insert in the correct orientation, 50-100 ng of a 
plasmid in 15 µl dH2O were sent for sequencing to Eurofins MWG Operon. 
Depending on the vector and the availability of oligonucleotide primers provided by 
Eurofins, sequencing samples were additionally mixed with 10 nM of oligonucleotide 
primers in 2µl dH2O resulting in a total volume of 17 µl. 
2.4.1.13 Preparative plasmid isolation 
NEB 5-alpha competent E.coli or One Shot™ Stbl3™ Chemically Competent E. coli 
were transformed with freshly isolated and via sequencing validated plasmid 
constructs. A single bacteria colony or a small amount of a frozen bacteria glycerol 
stock was picked by a pipette tip and transferred to 200 ml of LB-medium 
supplemented with the appropriate selection antibiotic and incubated over night at 
37°C and shaking (140 rpm). For optimal growth, 3 ml pre-bacterial cultures from 
glycerol stocks were set up and incubated over day at 37°C and shaking (140 rpm). 
In the evening pre-cultures were inoculated in 200 ml of selective LB-medium and 
incubated over night at 37°C and shaking (140 rpm). The next day, plasmid DNA 
was prepared using the NucleoBond Xtra Maxi Kit for high-copy plasmids as per 
manufacturer's instructions. Deviating from that 100 – 250 µl ddH20 were used to 
resolve the DNA pellet. Finally, the plasmid DNA concentration was adjusted to  
1 µg/µl. Plasmid DNA solutions were stored at -20°C. 
For long-time storage of back-up bacterial cultures bearing generated plasmid 
constructs, bacterial glycerol stocks were prepared. For this purpose, 500 µl of the 
overnight culture was added to 20% of glycerol and 30% of LB-medium. Bacterial 
glycerol stocks were stored at -80°C.  
2.4.1.14 Polymerase chain reaction (PCR) 
PCR was conducted in order to introduce restriction endonuclease recognition sites 
flanking the DNA sequences of inserts or to change start and stop codons. PCR 
reactions were performed using the Pfu DNA polymerase or the Platinum™ Pfx DNA 
polymerase according to the manufacturer’s instructions. In a standard PCR 
reaction, 200 ng of template was used in a total volume of 50 µl.  
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2.4.1.15 Cloning of PCR fragments 
Using the Pfx DNA Polymerase generates blunt end DNA fragments. Primers can 
be designed to yield PCR generated amplicons that are flanked by palindromic 
sequenced serving as restriction endonuclease recognition sites. The digested ends 
of the PCR fragment facilitates a ligation in an appropriately digested target vector. 
Subsequently to a PCR, the total reaction volume of 50 µl was analysed via agarose 
gel electrophoresis (3.4.1.7). The DNA fragment with the correct size was cut out of 
the gel and purified using the GeneJet gel extraction kit and eluted in 50 µl. 40 µl of 
the PCR product was taken to be subjected to restriction with the appropriate 
endonuclease digestion and afterwards purified again. In parallel, appropriate target 
vectors were digested with the same endonucleases and purified. Finally, the 
digested PCR fragment could be ligated with the appropriate cut target vector 
(3.4.1.9). 
2.4.1.16 Generation of shRNA expressing vectors  
shRNA sequences targeting IkBNS mRNA (3.2.3.1) were modified with flanking 
adaptor sequences to bear BglII and HindII target sites and in order to generate a 
64-mer that constitutes the final duplex form with the 3’UU overhang, typical for 
siRNA: 
5’-gatcccc-target sequence sense-ttcaagaga- target sequence antisense-ttttta-3’ 
5’-agcttaaaaa- target sequence sense-tctcttgaa- target sequence antisense-ggg-3’ 
 
The designed forward and reverse 64-mers were annealed and digested by BglII 
and HindII. The pSuper backbone is digested by BglII and HindII, as well. The 
digested pSUPER backbone and the annealed and digested insert can then be 
ligated as described in 3.4.1.9  
For subcloning of the shRNA sequence into the lentiviral expression vector 
pAB286.1, pSUPER and the target vector were digested by BamHI and SalI 
followed by ligation. 
For subcloning into the pLVTHM vector, pSUPER and the target vector had to be 
digested by EcoRI and ClaI, followed by ligation. 
3.4.1.17 Generation of CRISPR/Cas9 expressing vectors 
In order to clone the target gRNA sequence into the lentiCRISPRv2 backbone,  
two 25-mer oligonucleotides had to be generated in the following form (N designates 
any DNA nucleotide): 
  Materials and Methods 
 
 
78 
 
5‘-caccgNNNNNNNNNNNNNNNNNNNN-3‘ 
3‘-cNNNNNNNNNNNNNNNNNNNNcAAA-5‘ 
 
The gRNA sequence replacing “N” in order to target the NFkBID gene are listed 
under 3.2.3.2 Lentiviral backbone digestion, oligo-annealing and gRNA cloning into 
the digested vector were conducted according to the “Target Guide Sequence 
Cloning Protocol” established by the Zhang lab. 
2.4.1.18 Luciferase IkBNS promoter reporter generation 
The putative IkBNS promoter sequence with flanking restriction endonuclease 
recognition sites was chemically synthesized by Invitrogen GeneArt Gene 
Synthesis. Upon delivery, the received bacterial stab was cultured and the plasmid 
containing the synthesized promoter sequence was isolated. Subsequently, the 
IkBNS promoter sequence was cut out of its backbone and subcloned into the pGL3-
basic luciferase reporter plasmid using XhoI and NheI. With the generation of this 
plasmid construct the IkBNS promoter activity could be investigated under different 
conditions by the Dual luciferase reporter assay (3.4.2.8). 
2.4.2 Experimental procedures in cell biology 
2.4.2.1 Determination of cell concentrations 
Cell concentrations were determined by using Neubauer Chamber slides according 
to the manufacturer’s instructions. 
2.4.2.2 Cryoconservation of cells 
106 - 107 cells per mL were dissolved in 1,5 ml freezing buffer in cyroconservation 
tubes. Subsequently, cells were inverted several times and stored for a couple of 
days in Mr. Frosty™ freezing containers at -80°C. For long time storage, cells were 
stored in liquid nitrogen. 
2.4.2.3 Thawing of cells 
In liquid nitrogen frozen cells were thawed in a 37°C water bath and subsequently 
transferred into 50 ml of the cell line corresponding medium with the purpose to 
dilute the cell toxic DMSO. Cells were pelleted by centrifugation at 300 g for 4 min.  
The supernatant was decanted and cells were resuspended in 15 ml of the 
respective cell culture medium (3.1.5).  
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2.4.2.4 Culture of lymphoma cells 
All cell lines used (3.2.5) were cultured in a humidified atmosphere under standard 
conditions comprising 5 % CO2, 20 % O2 and a temperature of 37°C. 
The GCB DLBCL cell lines BJBAB, SU-DHL-4, SU-DHL-6 were cultured using 
RPMI supplemented with Plasmocin, 100 U/ml penicillin/ 100 µg/ml streptomycin 
and 10% FCS. OCI-LY1, OCI-LY7, OCI-LY19 were cultured using IMDM 
supplemented with 2,5 µg Plasmocin, Pen/Strep and 10% FCS. The ABC DBLCL 
cell lines HBL-1, TMD8, U2932, OCI-LY3 were cultured using RPMI supplemented 
with 2,5 µg/ml Plasmocin, 100 U/ml penicillin/ 100 µg/ml streptomycin and 20% FCS. 
OCI-LY10 was cultured using IMDM supplemented with 2,5 µg/ml Plasmocin, 100 
U/ml penicillin/ 100 µg/ml streptomycin and 20% FCS. MCL cell lines Z138, Rec-1, 
Jeko-1, JVM2, UPN1 were cultured using RPMI supplemented 2,5 µg/ml Plasmocin, 
100 U/ml penicillin/ 100 µg/ml streptomycin and 20% FCS except for Granta519 
which was cultured using DMEM supplemented with Plasmocin, Pen/Strep and 10% 
FCS. The Burkitt’s lymphoma cell lines Raji and Ramos were cultured using 
RPMI supplemented 2,5 µg/ml Plasmocin, 100 U/ml penicillin/ 100 µg/ml 
streptomycin 10% and 20% FCS, respectively. The Adult T-cell Leukemia/ 
Lymphoma (ATLL) cell line Jurkat was cultured using RPMI supplemented 2,5 
µg/ml Plasmocin, 100 U/ml penicillin/ 100 µg/ml streptomycin and 10% FCS. 
HEK293T cells were cultured using DMEM supplemented with Plasmocin, 100 U/ml 
penicillin/ 100 µg/ml streptomycin and 10% FCS. Cells were kindly provided by Prof. 
Dr. Falko Fend, University of Tuebingen, Germany; Prof. Dr. Georg Lenz University 
of Münster, Germany and Prof. Dr. Margot Thomé Université de Lausanne, 
Switzerland. 
2.4.2.5 Transfection of DNA by calcium phosphate precipitation 
24 h prior to transfection, confluent HEK293T cells were splitted 1:10 with 
supplemented DMEM. In case adherent cells grown in 6-well plates were 
transfected, 125 µl nuclease free water was mixed with 12,5 µl of 2,5 M CaCl2. For 
10 cm culture dishes 500 µl nuclease free water and 50 µl of 2,5 M CaCl2 were 
mixed. To this mixture, the respective plasmid DNA was added. Subsequently, 125 
µl (6-well plate) or 500 µl (10 cm dish) of 2x HeBs (pH7,05) was added dropwisely 
to this mixture under vortexing followed by an incubation time of 10 min at room 
temperature. Ensuing, this mixture was added in small drops to the cells. The media 
of the transfected cells was exchanged 16 h later. 24 h - 48 h after transfection, cells 
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were harvested and lysed for usage in downstream methods such as western blot 
and luciferase assay.  
2.4.2.6 Lentiviral transduction of DNA 
HEK293T cells were seeded in 10 cm plates. 24h later HEK293T cells were 
transfected using calcium phosphate precipitation with the lentiviral helper plasmids 
pCMV-VSV-G (3 µg per sample) and psPAX2 (6,5 µg per sample) and an 
appropriate lentiviral expression vector (10 µg per sample). Another 24 h later, 
medium was sucked off the 10 cm plates and substituted by 6ml the appropriate 
target cell medium. 96 h after transfection, virus containing HEK293T supernatant 
of one plate (6 ml) was given to 2x106 target cells in 6 ml medium by syringe driven 
filtration (0,45 µM). 48h after infection, medium was exchanged for puromycin 
containing selection medium. At least 48 h after exposure to selection medium, 
remaining antibiotic resistant cells can be harvested and checked for proper 
expression of the protein of interest by western blot. 
2.4.2.7 Transfection of DNA by electroporation 
Suspension cells were transfected by electroporation. Per sample, 6 to 10 million 
cells were pelleted and washed in DPBS supplemented with Ca2+/Mg2+. 
Subsequently, the cells resuspended in 350 µl DPBS. Ensuing, up to 30 µg plasmid 
DNA was added. Samples were then incubated for 15 min and then transferred to 
a 4 mm electroporation cuvette. Electroporation pulsing was conducted by BioRad 
Gene Pulser using the exponential protocol at 220-230 V, 950 µF and infinite 
resistance in cuvettes with 4 mm gap size. After pulsing, 1 ml of RPMI medium 
without supplements was added to the cells in the 4 mm cuvette. By using a transfer 
pipette, cells were transferred preferably without cellular debris to pre-warmed 
cell line corresponding culture medium. 24 h - 48h after transfection, cells were 
harvested and lysed for usage in downstream methods such as western blot or 
luciferase assay. 
2.4.2.8 Dual luciferase reporter assay 
For conducting the dual luciferase reporter assay, adherent HEK293T cells in 6 well 
plates were additionally transfected to the plasmids of interest with 0,125 µg of 
pGL3-basic comprising the putative human NFkBID promoter which was cloned 
upstream of a firefly luciferase coding gene and 0,0125 µg of a TK-Renilla 
expressing vector. Transfection was conducted using the calcium phosphate 
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precipitation method. 24 h – 48 h after transfection medium was sucked off the wells. 
Subsequently, cells were lysed using the provided 1x passive lysis buffer and 
incubated for half an hour under agitation. Ensuing, 5 µl of cell lysate was added to 
50 µl of luciferase substrate in a FACS tube. By using a photometer, luminescence 
intensity of the expressed firefly luciferase was measured. After that, 50 µl stop and 
glow solution was added to the mixture and then the luminescence value for TK-
Renilla was measured. The constitutive expression of TK-renilla and the resulting 
luminescence value was determined as efficacy control for transfection and thus for 
the normalization of samples in order to compare them equitably independent from 
different transfection efficacies. As negative control served a sample containing only 
the promoter to be investigated and the TK-renilla encoding plasmid. Samples were 
transfected as either duplicates or triplicates. 
2.4.2.9 MTS Assay 
In order to determine the number of viable cells upon the treatment of DBCL cells 
with calcineurin inhibitors, the colorimetric based MTS assay was performed using 
the Promega CellTiter 96® Aqueous One Solution Cell Proliferation Assay. The 
assay was conducted in 96-well plates according to the manufacturer’s instructions 
with 1-2,5 x 105 cells. Absorbance at 490 nm was measured using the Tecan Infinite 
M200. As background values served wells filled with equal amounts of the 
corresponding medium. Samples were applied as triplicates to the 96 well plate 
each containing 1-2,5 x 105 untreated or treated cells dependent from the 
experiment. 
2.4.2.10 Generation of protein lysates for Western Blot 
For lysis, suspension cells were centrifuged down at 500g for 4 min. Subsequently, 
supernatant was discarded and cells washed with 1x PBS and transferred to a 1,5 
ml reaction tube. The supernatant of adherent cells was discarded and cells were 
detached from culture plate with 1 ml of 1x PBS and transferred to a 1,5 ml reaction 
tube. After centrifugation, PBS was aspired and depending on the cell pellet double 
the volume of ice-cold Tris-NaCl lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, and 
1% Triton X-100) complemented with inhibitors of proteases (cOmplete™, Mini, 
EDTA-free Protease Inhibitor Cocktail Tablet) and phosphatases (50 mM NaF, 10 
mM Na4P2O7, and 10 mM NaVO4) was added. After vortexing, cells dissolved in 
lysis buffer were incubated for 15 min of ice, interrupted by occasional vortexing. 
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Subsequent to incubation, cell debris was removed by centrifugation for 10 min at 
14.000 g and 4°C. The cleared postnuclear cell lysate was finally transferred to 
another 1,5 ml reaction tube and stored at -20°C. The remaining cell debris was 
discarded.  
3.4.2.11 Protein quantification 
Protein concentration of cell lysates was determined calorimetrically using the Bio-
Rad Protein Assay Dye Reagent Concentrate. The Concentrate was diluted 1:5 in 
a volume of 1 ml ddH20 in 1,5 ml reaction tubes. In this dilution 0,5 µl of cell lysate 
was pipetted and the total volume was transferred into a cuvette. Protein 
concentration of lysate sample duplicates was finally determined using a photometer 
measuring absorbance at 595 nm. 
2.4.2.12 Fractionation of cytosolic and nuclear proteins 
10 to 20 million cells of the GCB DLBCL cell line BJAB and the ABC DLBCL cell 
lines U2932 and HBL-1 were harvested and washed once with ice-cold 1x PBS and 
centrifuge for 5 min at 300g at 4°C. The reductant DTT and a protease inhibitor was 
added to Buffer C before the resuspension of cells with 3-to 4-fold the volume of the 
cell pellet. After short vortexing cells were incubated in Buffer C on ice for 5 minutes. 
The cytosolic fraction and the nuclei were then separated by centrifugation at 9000 
rpm for 45 sec. Subsequently, the generated supernatant i.e. the cytosolic fraction 
was now transferred to a fresh 1,5 ml reaction tube. The remaining pellet was then 
washed twice for 10 sec. with Buffer C. In order to crack the nuclei, dependent on 
pellet size two times the volume of Buffer N was added and the reaction tubes were 
frozen in liquid nitrogen and thawed in a 37°C water bath for 9 cycles. Subsequently, 
the samples were sonicated for 10 seconds. Ensuing, the cellular debris was 
separated from the nuclear fraction by centrifugation at 14.000g for 10 min. The 
supernatant i.e. the nuclear fraction was transferred to a new 1,5 ml reaction tube. 
To examine the subcellular distribution of the protein of interest and to verify the 
purity of fractions, samples were then separated by SDS-PAGE and analysed by 
immunoblotting. 
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2.4.2.13 Stimulation of cells 
Cells were centrifuged down at 500g for 4 min in 15 ml falcons. The supernatant 
was discarded and cells were resuspended in 1-4 ml of corresponding 
supplemented cell medium. Cells were then incubated for 15 min in a pre-warmed 
water bath at 37°C. Finally, B- or T-cells were stimulated with either a mixture of 
PMA (10 ng/ml) and Ionomycin (1 µM) (P/I; 1:1000), PMA (10 ng/ml; 1:500) or 
Ionomycin (1 µM; 1:200) for different periods of time. As stimulation control, DMSO 
was applied in the same dilution as the cell stimuli. 
2.4.2.14 Cycloheximide treatment of ABC DLBCL cell lines 
To investigate the protein half-life of IkBNS isoforms, the ABC DLBCL cell lines 
HBL-1 and OCI-LY3 were treated with the protein biosynthesis inhibitor 
cycloheximide (CHX). Cells were harvested an resuspended in 3 ml RPMI medium 
supplemented with 20% FCS in 15 ml tubes. Tubes were then incubated for 15 min 
in a 37°C water bath. Subsequently, CHX was added to the cells to a final 
concentration of 20 µg/ml for 1, 2, 4 or 6h at 37°C. After that, cells were harvested 
and protein lysates were generated that were separated by SDS PAGE and 
analysed by western blot. 
 
3.4.2.15 Stable isotope labeling by/with amino acids in cell culture  
300 ml of densely grown HBL-1 were centrifuged down at 500g for 4 min. Cells were 
then resuspended in equal portions of 150 ml in light growth medium (RPMI 20% 
FCS) containing normal amino acids, medium heavy amino acids containing growth 
medium (RPMI 20% FCS), containing amino-acids labeled with non-radioactive 
isotopes and growth medium comprising amino acids labeled with stable heavy 
isotopes. Cells were splitted every other day and harvested after 12 days of 
incubation in corresponding medium. Five hours prior harvesting CsA (2,5 µM) and 
FK506 (5 µM) were added to differentially labeled cells that were previously 
resuspended in 50 ml of corresponding fresh SILAC medium. Subsequent to 
harvesting, cells were resuspended in lysis buffer provided by the Quantitative 
Proteomics & Proteome Center Tuebingen. Cells in lysates were stored at -20°C 
until given to MS analyses in order to assess calcineurin inhibition dependent 
changes in the phosphoproteom in the ABC DLBCL cell line 
HBL-1. 
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2.4.3 Immunobiological methods 
2.4.3.1 Staining of lymphoma cell surface markers and analysis 
by FACS  
Lymphoma surface marker expression was quantified by FACS analysis using an 
LSRII device. For this purpose, 4 ml of GCB and ABC DLBCL cell suspensions were 
harvested in FACS tubes by centrifugation at 500g for 4 min. Medium supernatant 
was discarded. Cells were subsequently washed with 4 ml of 1x PBS and 
resuspended in 200 µl FACS Buffer (1x PBS; 2% FCS) containing fluorochrome-
conjugated anti-CD36, CD90, CD108, CD274 or HLA-DR in a dilution of 1:50 each. 
As control served the staining of cells line with appropriate fluorochrome-labelled 
isotype control antibodies. Following an incubation time of 30 minutes in the dark, 
cells were centrifuged at 500g for 4 min, supernatant was discarded and cells were 
washed once using 4 ml of FACS Buffer. Finally, cells were resuspended in 200 µl 
FACS of Buffer and subjected to FACS analysis. 
2.4.3.2 Legend screen™ 
The BioLegend® LEGENDScreen™ Lyophilized Antibody Array Human PE Kit was 
conducted following the standard operating procedures provided by the 
manufacturer using the GCB DLBCL cell lines BJAB, SU-DHL-4 and SU-DHL-6 and 
the ABC DLBCL cell lines HBL-1, TMD8, U2932, and OCI-LY3. 
2.4.3.3 ELISA  
In order to detect the amounts of Jurkat secreted interleukin-2 and ABC DLBCL 
secreted interleukin-6 and -10 the eBioscience™ Human IL-2, IL-6 and IL-10 ELISA 
Ready-SET-Go!™ Kits were used. The respective interleukin containing 
supernatants of control samples and differently treated cell lines were harvested as 
triplicates and transferred into 1,5 ml reaction tubes that were subsequently stored 
at -80°C until usage. When conducting an ELISA, samples were initially thawed on 
ice. Samples were applied as duplicates to the 96-well pre-coated ELISA plate. The 
following ELISA was performed according to the manufacturer’s instructions. 
Deviating from that, as controls served cell line corresponding media without 
supplements. 
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2.4.3.4 Sodium dodecylsulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
Proteins in generated cell lysates (3.4.2.10) were size separated using the 
denaturing sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS‐
PAGE). The appropriate volume of lysate corresponding to the desired amount of 
protein was mixed with reducing 3x SDS sample loading buffer or 2x urea sample 
buffer. This mixture was subsequently boiled for 10 min at 95°C to denature the 
proteins. Afterwards, samples were loaded into polyacrylamide gels (acrylamide 
percentage depends on the size of the protein of interest), that were handcasted 
using the Peqlab PerfectBlue™ gel system Twin ExW S. As molecular weight 
standard, the Spectra Multicolour Broad Range protein ladder was additionally 
loaded. Samples were electrophoretically separated according to their size in the 
Peqlab PerfectBlue™ gel system chamber filled with 1x migration buffer. Initially, 80 
V were applied. As soon as the samples ran out of the pockets of the stacking gel, 
SDS-PAGE was continued applying 120 V until the loading front ran out of the 
resolving gel. 
2.4.3.5 Immunoblotting 
Subsequent to the size dependent separation of lysate proteins by SDS-PAGE, 
proteins were transferred to a nitrocellulose membrane by tank blotting for 90 min 
at 100 V using the BioRad Trans-Blot® Cell filled with 1x blotting buffer. Optionally, 
in order to check regular protein transfer on membranes could be incubated for 
some minutes in Ponceau Rouge which could washed away using dH2O. Hereafter, 
nitrocellulose membranes were incubated for 30 to 60 min in blocking solutions 
under shaking. Depending on the later applied primary antibody blocking solutions 
either contained 5% milk powder or 5% BSA dissolved in 1xTBS/T. After blocking, 
the primary antibody (3.2.2) either dissolved in 25 ml 5% milk powder/ 1xTBS/T or 
25 ml 5% BSA/1xTBS/T was added to the membrane and incubated over night or 
longer at 4°C under shaking. The next day, membranes were washed three times 
for 5 minutes with 1xTBS/T. Ensuing, membranes were incubated for 2-4h in 
immunoblotting secondary antibody solution comprising HRP-coupled IgG 
secondary antibodies in a dilution of 1:10.000 depending on the primary antibody 
either from mouse or rabbit (3.2.2) After secondary antibody incubation, membranes 
were washed three times for 5 minutes with 1xTBS/T. Subsequently, ECL solution 
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was applied and specific protein bands were finally detected by exposing the 
nitrocellulose membranes to Ultra Cruz Blue autoradiography films. 
For reprobing of membranes with another primary antibody, membranes were 
washed three times for 5 minutes with 1xTBS/T and blocked again for 30-60 min 
depending on the primary antibody with either 5% milk / PBS/T or 5% BSA / PBS/T. 
Additionally, 100 µl NaN3 was added to the blocking solution to eliminate remaining 
HRP activity from the previous detection. Subsequent to blocking, another primary 
antibody was given to the membrane and incubated at least over night at 4°C. 
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3. Results 
3.1 IκBNS regulation in lymphocytes 
In turn to investigate how IκBNS expression is regulated in lymphocytes and 
moreover which transcription factor families (TF-families) might be implicated in this 
regulation we made use of a model T-cell line. 
To figure out whether the AP-1 family or NF-κB could be the driving factors of IκBNS 
expression we lentivirally transduced the T-cell line Jurkat with either A-Fos,                       
an inhibitory AP-1 construct preventing the binding of other AP-1 family members to 
DNA in a competitive manner (Olive et al., 1997) or with a FLAG-tagged,  
non-phosphorylatable dominant negative IκBa (DN-IκBa). Both TF-families are well 
known to positively regulate IL-2 secretion upon T-cell activation (Hoyos et al, 1989, 
Jain et al., 1995; Juilland et al., 2016). Therefore, we stimulated Jurkat cells for 16 
h with P/I, a mixture of PMA (phorbol-12-myristate-13-acetate), activating PKC, and 
Ionomycin an ionophore produced by Streptomyces conglobatus, which is leading 
to raising intracellular Ca2+ levels. Subsequently, IL-2 was measured in the 
supernatants of the differently transduced Jurkat cells (Figure 12.a). In comparison 
to control cells, A-Fos and DN-IkBa transduced cells secreted considerably less IL-
2 upon P/I stimulation, indicating the proper functionality of A-Fos and DN-IκBa. To 
further validate the functionality of the Flag-tagged DN-IκBa in B-lymphocytes and 
to see a putative effect on IκBNS induction, we lentivirally transduced the GCB-
DLBCL cell line BJAB with the NFκB inhibitor. As a DN-IκBa functionality control, 
we blotted against A20, a negative regulator and target of NF-κB (Compagno et al., 
2009). A20 expression was clearly diminished upon stimulation in DN-IκBa 
transduced cells compared to control cells (Figure 12.b). Expression of DN-IκBa 
was confirmed by staining against the FLAG-tag. Upon 16 h of P/I stimulation we 
did not observe any difference between IκBNS levels in control cells and DN-IκBa 
transduced BJAB cells (Figure 12.b), suggesting NF-κB not to be essential for 
IκBNS induction and expression maintenance. 
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Figure 12. Proving functionality of A-Fos and DN-IκBα. (a) IL-2 ELISA made from 
supernatants of non-stimulated or P/I treated Jurkat cells that were lentivirally transduced with either 
a FLAG-tagged expression construct for A-Fos, DN-IκBα or an empty vector as control. (b) 
Immunoblot analysis of IκBNS, A20, FLAG expression levels in BJAB cells transduced with a 
FLAG-tagged expression construct for DN-IκBα or an empty vector as control. Cells were treated 
with P/I for 16 h or with solvent alone as control (a, b) GAPDH served as an indicator for equal 
loading.  
 
To narrow down which TF-families are responsible for IκBNS expression, we again 
lentivirally transduced BJAB B-cells and Jurkat T-cells cells with either an empty 
control vector, A-Fos or DN-IκBa and the combination of A-Fos and DN-IκBa to 
exclude a redundancy of AP-1 and NF-κB TF-family members (Figure 13.a,b; 14a, 
b). Expression of the dominant negative inhibitors was validated by using an anti-
FLAG antibody. The activation of B- and T-cells was confirmed by blotting against 
CYLD, a deubiquitinase and negative regulator of NF-κB (Brummelkamp et al., 
2003). Upon B- and T-cells activation CYLD is cleaved C-terminally by MALT1 in a 
40 kDa and 70 kDa fragment (Figure 13.a, b; 14a, b) and is therefore an indicator 
of B- and T-cell activation. To the different viral backgrounds of BJABs we 
additionally applied a p38-inhibitor and Cyclosporin A (CsA) (Figure 13.a, b, 14.a, 
b), an inhibitor of the phosphatase calcineurin and thus of the NFAT-family of TFs, 
as well. CsA was originally isolated from fungus Tolypocladium inflatum and is today 
an essential, commonly used immunosuppressive drug. Since IκBNS is not 
expressed in BJAB under steady state conditions, cells were initially pre-incubated 
for 20 minutes with the previously mentioned inhibitors and afterwards stimulated 
with P/I for the indicated periods of time to induce IκBNS expression. IκBNS was 
clearly detectable after 1 h of P/I stimulation. The IκBNS expression level reached 
its peak at 3 h and declined after 4 h of P/I mediated stimulation under all conditions. 
BJAB expressing A-Fos, DN-IκBa alone or the combination thereof did not show 
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any changes in their IκBNS induction behaviour upon P/I stimulation compared to 
the control (Figure 13.a). This finding is in line with the result of Figure 12.b which 
showed that NF-kB inhibition alone does not have an influence on proper IκBNS 
induction. When we treated the cells additionally to the expression of the dominant 
negative inhibitors with a p38-inhibitor we saw slightly diminished levels of IκBNS 
induction upon P/I treatment. This is most likely due to toxic side effects of this 
inhibitor. In contrast, when we added Cyclosporin A, IκBNS induction was 
tremendously hampered upon stimulation in all differently transduced cells 
compared to non-treated cells (Figure 13.b). Notably, the combined treatment with 
the NFAT-inhibitor Cyclosporin A and the expression of the NF-κB-inhibitor (DN-
IκBa) led to the strongest impairment of IκBNS induction upon P/I stimulation. To 
further elucidate how IκBNS induction is regulated in lymphocytes we conducted the 
same experiment with Jurkat T-cells (Figure 14.a, b). To confirm the effect of CsA 
seen in Figure 13.b we also tested FK506 (tacrolimus), another calcineurin inhibitor, 
that is commonly used in immunosuppressive therapies. FK506 is a macrolid 
lactone originally produced by Streptomyces tsukubaensis and exerts its 
mechanism of action basically in the same manner as Cyclosporin A does (Haddad 
et al., 2006; Bonner and Boulianne, 2017). Using this second calcineurin inhibitory 
compound made it possible for us to exclude putative unspecific CsA effects and to 
further validate the observations previously made in BJAB. As in BJAB B-cells, 
Jurkat T-cells obviously expressed IκBNS 1 h upon P/I mediated stimulation, 
reached its peak at ~ 3 h but remained at the same expression level at 4 h, 
regardless the expression of the empty control vector, A-Fos, DN-IκBa or the 
combination of both. Moreover, the eventual expression levels of IκBNS were 
neither altered under AP-1, NF-κB inhibitory nor the combination thereof compared 
to empty control (Figure 14.a). However, as soon as we gave in the calcineurin 
inhibitors CsA or FK506, IκBNS induction was remarkably affected compared to 
non-treated controls. For FK506 treated samples, this effect was even more 
pronounced (Figure 14.b). Noteworthy, in Jurkat T-cells the strongest negative effect 
on IκBNS induction did not occur under the combination of CsA treatment and DN-
IκBa expression compared to CsA only treated cells. The same applies to Jurkat 
cells, in which we combined calcineurin inhibition by FK506 and NF-κB inhibition 
(Figure 14.a, b). Hence, the induction of IκBNS in T-cells could be slightly 
differentially regulated as in B-cells. 
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Figure 13. Investigating the TF-family dependency of IκBNS induction and expression 
maintenance in B-cells. Analysis of IκBNS protein expression by western blot in lysates of BJAB 
cells lentivirally transduced with either an empty control vector (Control), an expression construct 
for Flag-tagged A-Fos, DN-IκBα or the combination of thereof upon P/I stimulation for the indicated 
times. Cells were pre-incubated with p38 inhibitor or Cylcosporin A (2,5 µM)  for 20 min ahead of 
P/I stimulation. FLAG-tag expression was assessed to validate expression of A-Fos and DN-IκBa. 
Proper B-cell stimulation by P/I was verified by determining CYLD cleavage. In a+b blotting for 
GAPDH served as a loading control. 
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Figure 14. Investigating the TF-family dependency of IκBNS induction and expression 
maintenance in T-cells. Immunoblot analysis of IκBNS protein expression in lysates of Jurkat 
cells lentivirally transduced with either an empty control vector (Control), an expression construct 
for Flag-tagged A-Fos, DN-IκBα or the combination of thereof upon P/I stimulation for the indicated 
times. Cells were pre-incubated with calcineurin inhibitors Cylcosporin A (2,5 µM) or FK506 (5 
µM) for 20 min ahead of P/I stimulation. FLAG-tag expression was assessed to validate expression 
of A-Fos and DN-IκBa. Proper T-cell stimulation by P/I was verified by determining CYLD 
cleavage. In a+b blotting for GAPDH served as a loading control. 
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To substantiate our previous findings of IκBNS regulation and to exclude unspecific 
CsA effects in B-lymphocytes as well, we also tested FK506 in BJAB. Cells were 
pre-treated with solvent only or with either one of the calcineurin inhibitors CsA or 
FK506 just before P/I mediated cell stimulation for the indicated times (Figure 15.a).  
Under solvent only (control) conditions IκBNS protein levels could be appreciably 
determined by western blot analysis after 1 h, raised at its highest level after 3 h and 
remained at the same level after 4 h of P/I stimulation. However, in CsA or FK506 
pre-treated BJAB IκBNS induction was unambiguously impeded (Figure 15.a). 
Collectively, these findings show that the indirect inhibition of NFAT by using 
calcineurin inhibitors CsA and FK506 lead to impaired IκBNS induction in both  
B-and T-lymphocytes. Moreover, when the NF-κB pathway is additionally blocked 
by a dominant negative approach this inhibitory effect is, at least in B-cells the 
strongest among all tested conditions. Taken together, the results suggest a 
synergistic role for NF-κB and NFAT TF-family members for the induction and 
maintenance of IκBNS in B-and T-lymphocytes. 
So far, the effect of CsA or FK506 was only tested upon P/I meditated cell 
stimulation. Due to this, we wanted to assess next the effect of NFAT-inhibition by 
CsA and FK506 also on high steady state expression level of IκBNS. As we describe 
in chapter 4.2 in more detail, we noticed that ABC DBLCL cell lines express high 
levels of IκBNS under steady state conditions. Therefore, we treated the ABC 
DLBCL B-lymphocyte cell lines HBL-1 and U2932 for two days with CsA and 
examined the effect on IκBNS protein levels (Figure 4.b). CsA treatment clearly 
decreased the IκBNS levels in both cells lines compared to solvent controls (Co) 
even after one day of application and was also lasting at the same extend on day 
two (Figure 15.b). These findings are in accordance with the previously gained data 
and therefore strengthen the assumption that NFAT is likely to be important for the 
induction of IκBNS upon cell stimulation (Figure 13.a, b; Figure 14.a, b; Figure 15.a). 
Furthermore, as found in HBL-1 and U2932 (Figure 15.b) NFAT is also important 
for the maintenance of high level steady state IκBNS levels in ABC DLBCL. 
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Figure 15. NFAT requirement for induction of IκBNS upon P/I stimulation and 
maintenance of high level steady state IκBNS protein levels in B-lymphocytes analysed 
by western blotting. (a) The GCB-DLBCL cell line BJAB was preincubated for 20 min with either 
solvent control (DMSO), CsA (2,5 µM) or FK506 (5 µM) and subsequently stimulated with P/I for 
the indicated times. (b) HBL-1 and U2932 ABC DLBCL lines were treated for 1 or 2 days with 
DMSO (Co) or CsA (2,5 µM). Blots were incubated with the indicated antibodies. GAPDH was 
blotted to show equal loading of samples in (a, b). 
 
Owing the fact that we have observed the strongest impairment of IκBNS induction 
upon P/I mediated B-cell stimulation when combining an NFAT inhibitor and an NF-
κB inhibitor (Figure 13.b) we now ask ourselves what would be the outcome of 
single-treatment with either PMA or Ionomycin on IκBNS up-regulation compared to 
their combined treatment. PMA mimics diacylglycerol and therefore activates PKC 
and adjoining downstream pathways. Amongst others, NF-κB and AP-1 (Staudt and 
Young, 2013) but due to lacking Ca2+ mobilisation, NFAT is not activated hereby.  
In contrast, treating the cells only with Ionomycin gives rise to elevating intracellular 
Ca2+ levels that lead in turn to the activation of calcineurin and eventual nuclear 
translocation and activation of NFAT (Steinbach et al., 2007) but not NF-κB. In this 
manner we were able to distinguish between the effects of NFAT and NF-κB activity 
alone, compared to their synergistic impact on the induction of IκBNS (Figure 16.). 
PMA treatment of BJAB cells alone obviously led to IκBNS up regulation albeit very 
weak compared to P/I stimulation. After 1 h IκBNS expression was already 
detectable in western blot, reached its highest level at 3 h and was on the edge to 
decline after 4h of stimulation upon PMA treatment. Thereby, only IκBNS p70 was 
detectable most likely due to the anyway higher expression levels than IκBNS p35. 
However, the treatment of BJAB cells with Ionomycin alone did not lead to any 
detectable IκBNS (Figure 16.).  
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Taking into account the previously gained findings, this result was further approving 
the assumption that NF-κB and NFAT play a synergistic role to fully induce IκBNS 
expression levels as we could observe them upon stimulation in B- and 
T-lymphocytes and as well as under high steady state expression levels in 
representative ABC-DLBCLs. In detail, NF-κB alone is able of inducing only very 
little amounts of IκBNS whereas NFAT alone does not exhibit the capability to 
induce IκBNS at all (Figure 16.). 
 
Figure 16. Distinguishing the inductive capabilities of NF-κB and NFAT solely and in 
synergy to up regulate IκBNS in BJAB B-lymphocytes analysed by immunoblotting.                            
Cells were treated with either PMA, Ionomycin or their mixture for the indicated times. Protein 
levels, stimulation of B-cells and equal loading were determined with the indicated antibodies.  
 
So far, all evidences suggested that NF-κB and NFAT together were the main 
drivers of proper Nfκbid gene induction and expression maintenance in  
B-lymphocytes. Thus, we had a closer look at the Nfκbid gene structure. CHIP data, 
published in the UCSC Genome Browser (http://genome.ucsc.edu) revealed a 
putative Nfκbid promoter region in intron one of the Nfκbid gene (Figure 17.a; framed 
in red; Figure 17.b nucleotide sequence of this chromosome stretch) with putative 
binding sites for NF-κB family members and NFATc1. Moreover, when we analysed 
the nucleotide sequence as shown in Figure 17.b for potential transcription factor 
binding sites by using a prediction tool, we actually found potential NF-κB (Figure 
17., depicted in yellow and red) and NFAT (Figure 17., depicted in blue) binding 
sites. 
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Figure 17. Putative promoter sequence of the Nfκbid gene. (a) CHIP-Seq data for different 
NF-κB family members and NFATc1 in the region of the Nfκbid gene on chromosome 19q13.12 in 
multiple cell lines. Framed in red: the sequence in intron one of the Nfκbid gene containing potential 
transcription factor binding sites as indicated by several peaks (b) Nucleotide sequence of the 
sequence framed in red in (a) which is covering the stretch of putative binding sites for NF-κB family 
members and NFATc1 in intron one of the Nfκbid gene. Depicted in 5’3’ direction. Highlighted 
in blue: potential NFAT binding site; in yellow and red: potential NFκB binding sites. 
 
To investigate this Nfκbid promoter sequence further, we cloned the whole 
sequence as depicted in Figure 17.b upstream of a firefly luciferase encoding gene 
located in a reporter construct, with which we then transfected HEK293T cells. By 
measuring the activity of this firefly luciferase reporter, we had the tool to test for 
factors that would potentially activate the putative Nfκbid promoter (Figure 18. a, b).                                              
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When we added RelA as a potent NF-κB activator alone in a low amount (of plasmid 
DNA) we were able to induce the promoter up to ~ 7,5 fold compared to an empty 
vector control. However, when we applied the same amount of RelA and additionally 
treated the HEK293T cells 3 h before harvesting with Ionomycin we could double 
the promoter activity up to ~ 15,5 fold. The same was true of higher amounts of RelA 
leading to a luciferase activity that could be more than doubled by incubating the 
cells with Ionomycin (Figure 18.a). To figure out whether the promoter activity could 
be reduced by using a DN-IκBa approach, we also co-transfected steady amounts 
of RelA and two different amounts of DN-IκBa. This NF-κB inhibitory approach 
reduced promoter activity in a dose dependent manner down to the empty control 
background level. So far, it remains an open question why the lentiviral approach 
(Figure 13.a) in which DN-IκBa was expressed solely did not lead to a reduction of 
IκBNS levels. A possible reason for this could be that multiple pathways were 
switched on after the inhibition of classical NF-κB signaling by DN-IκBa that either 
substitute NF-κB activity or exert a redundant function like the related alternative 
NF-κB signaling on the IκBNS promoter. Conceivable as well is that the lentivirally 
transduced DN-IκBa inhibited NF-κB not completely resulting in low levels of NF-κB 
sufficient to induce IκBNS. 
In the next step we wanted to explore the direct effect of an NFAT-transcription 
family member (NFATc1) on Nfκbid promoter activity (Figure 18.b). We co-
transfected again RelA that led to a clear dose dependent induction of the Nfκbid 
promoter activity. Since the treatment of B-lymphocytes with Ionomycin only, did not 
induce any IκBNS expression (Figure 16.) we also co-transfected NFATc1.  
As anticipated, NFATc1 did not activate the IκBNS promoter. Moreover, we then 
also co-transfected NFATc1 additionally to RelA. This combination however, led to 
an even better induction of the luciferase activity compared to RelA alone. Taken 
together, the collected data suggest that the induction and expression of IκBNS is 
indeed driven by NF-κB and NFAT, acting in a synergetic manner. NF-κB and NFAT 
alone however, are only capable of inducing very low levels of IκBNS (NF-κB) or 
even unable to induce IκBNS (NFAT). 
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cell stimulation (Hachmann et al., 2015; Rebeaud et al., 2008; Coornaert et al., 
2008). As part of the CBM complex, MALT1 is a pivotal upstream-modulator of  
NF-κB activity (Lucas et al., 2001; Thome et al., 2010). Sotrastaurin (AEB071, 
Novartis) on the other hand is a pan-PKC inhibitor, thus blocking the activation of 
PKCβ (B-cell specific isoform) in the context of B-cell stimulation by e.g. proximal 
antigen-receptor engagement or artificially by PMA. PKCβ phosphorylates 
CARMA1, which is part of the CBM complex, essential for NF-κB activity (Shinohara 
et al., 2005; Sommer et al., 2005). Treatment of BJAB with LVSR or Sotrastaurin 
under concomitant P/I stimulation completely abolished IκBNS induction (Figure 
19.a). To further verify the important role of NFκB signaling on IκBNS expression 
not only under stimulating conditions, we next conducted an siRNA mediated 
approach to knock-down MALT-1 levels in HBL-1 B-lymphocytes cells that 
constitutively express high levels of IκBNS (Figure 19.b). As a consequence of this, 
IκBNS protein levels were drastically reduced but not completely vanished 
compared to scramble control. This is most likely based on to the incomplete siRNA-
block of detectable MALT1 expression, other unknown factors leading to NFκB 
signaling in HBL-1 and also the fact that IκBNS expression is according to our data 
a result of the interplay of NFκB and NFAT (Figure 12.-18.). Collectively these 
results fortify an important role for NFκB signaling in IκBNS induction upon P/I 
mediated stimulation and under high level steady state expression conditions. 
 
Figure 19. Determining IκBNS expression upon (a) direct pharmacological inhibition 
or (b) siRNA mediated knock-down of NFκB signaling up-stream elements MALT1 
and PKC under P/I mediated B-cell stimulation in (a) BJAB or (b) under high level 
steady-state conditions in HBL-1 cells (b) by western blotting. (a) BJAB cells were pre-
treated for 20 min with either DMSO as solvent cont
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or the pan-PKC inhibitor Sotrastaurin (10 µM) and were subsequently stimulated by P/I for the 
indicated time points. Thereafter, cell lysates were analysed for IκBNS levels. A not specific band 
(n.s.) served as loading control. (b) HBL-1 cells expressing IκBNS under steady state conditions 
were electroporated with scramble as a control or siRNA targeting MALT1. Following cell 
lysis 48 h post-electroporation lysates were analysed for IκBNS levels and as a control for efficient 
siRNA mediated knockdown for the presence of MALT1. GAPDH served as a loading control. 
 
To gain further and more detailed insights into the mechanisms of IκBNS regulation 
in B-lymphocytes we next had a closer look at another signaling pathway that could 
be implicated in this context. As IκBNS is a member of the atypical IκB-family and 
from these the murine IκBNS protein sequence is known to share its highest 
similarity with the murine IκBζ (43%) (their human counterparts 26 %) in this 
subgroup of nuclear NF-κB inhibitors (Fiorini et al., 2002), we presumed it to be 
highly likely that IκBζ and IκBNS could also share some aspects in regard to their 
regulation in B-lymphocytes. Nogai et al, 2013 found only very low levels of IκB-ζ 
mRNA expression in multiple myeloma and classical Hodgkin lymphoma compared 
to ABC DLBCL cell lines, even though their survival also depends on the activity of 
the NF-κB signaling network. Therefore, Krappmann comments on this finding that 
NF-κB activation could not be solely responsible for high IκB-ζ levels as observed 
in ABC DLBCL cell lines (Daniel Krappmann, Comment on Nogai et al, page 2242; 
Blood, 2013). It was reported that not only NF-κB is able to induce IκB-ζ but also the 
activation of STAT3 by JAK1 phosphorylation due to a pivotal autocrine feedback 
loop of IL- 6 and IL-10 in ABC DLBCLs (Lam et al., 2008; Okamoto et al., 2010; 
Okuma et al., 2013). This link between IκB-ζ that also positively regulates IL-6/-10 
secretion and STAT3 phosphorylation suggests a positive feed-back loop that is 
supporting the malicious excessive IL-6/-10 production and NF-κB hyperactivity in 
ABC DLBCL. So far however, it was not shown, whether JAK1 inhibition would 
directly influence IκB-ζ (Daniel Krappmann, Comment on Nogai et al, page 2242; 
Blood, 2013). Taking everything into account, we were therefore interested to see if 
there would be an observable effect of JAK1 inhibition on steady state IκBNS 
expression levels in the ABC DLBCL cell line OCI-LY3 (Figure 20.). OCI-LY3 cells 
were incubated with the JAK1 inhibitor up to 6h. At all times indicated we could not 
observe any changes in IκBNS levels compared to solvent control or amongst 
treatment time points. The JAK1 inhibitor worked properly due to the complete 
disappearance of active phosphorylated STAT3 (Figure 20.). Taken together, the 
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expression of IκBNS seems to be independent from the JAK/STAT signaling 
pathway despite its relation to IκB-ζ. 
 
 
 
Figure 20. Revealing potential links between IκBNS expression and the JAK/STAT 
signaling pathway in the ABC cell line OCI-LY3 by western blot analysis. IκBNS 
expression levels were assessed at the indicated time points upon treatment with 5 µM of JAK1 
inhibitor. Blotting for p-Stat3 levels served as proof of functionality of the JAK1 inhibitor. Loading 
of equal amounts of proteins was controlled by blotting for GAPDH. 
 
Another yet in the literature undescribed aspect of IκBNS regulation in  
B-lymphocytes is concerning the half-life of the protein and whether there is a 
difference between IκBNS p35 and IκBNS p70. To investigate this, we took two ABC 
DLBCL cell lines that express high levels of IκBNS under state conditions. HBL-1 
and OCI-LY3 cells were incubated for the indicated times in the presence of the 
antibiotic cycloheximide, an inhibitor of protein translation from Streptomyces 
griseus. IκBNS levels did not alter still within the sample with the longest incubation 
of cycloheximide for 6h in both cell lines. Thereby, we could not observe any 
difference between IκBNS p35 and IκBNS p70. For controlling the proper function 
of cycloheximide we were blotting against IκBα, which is known to have a rather 
short half-life (Fagerlund et al., 2015). IκBα clearly diminished over time in OCI-LY3 
cells, and was almost completely vanished at 6 h of cycloheximide treatment. 
Surprisingly, in HBL-1 cells however, IκBα levels just began to decline at 6h of 
applying cycloheximide. Thus, IκBα seems to have a longer half-life in HBL-1 cells 
compared to OCI-LY3 cells. In summary, it can be stated that IκBNS has a rather 
long half-life of more than 6h in the ABC DLBCL cell lines HBL-1 and OCI-LY3. 
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Figure 21. Determining the half-life of IκBNS in HBL-1 and OCI-LY3 cells under 
steady state conditions for the indicated time periods by the treatment with the protein 
synthesis inhibitor cycloheximide. IκBNS levels in lysates of HBL-1 and OCI-LY3 cells upon 
cycloheximide treatment were determined by western blot to estimate half-life of IκBNS and to see 
possible differences between IκBNS p35 and IκBNS p70 in this respect. Functionality of translation 
blockage by cycloheximide was assessed by blotting against IκBα. Tubulin levels were determined 
to check for evenly-loaded amounts of protein.  
 
3.2 Role of IκBNS in ABC DLBCL 
Gene expression profiling of the clinically heterogeneous DLBCL revealed three 
distinct subgroups of DLBCL (Alizadeh et al., 2000). This eventually led to their 
molecular classification into GCB/ABC DLBCL and PMBL. Those subtypes are 
highly different in their prognosis and their response to therapeutic approaches.                     
Moreover, in 2001 Davis et al. unveiled the constitutive activity of the NF-κB pathway 
as a hallmark of ABC DLBCL. Furthermore, they also showed the dependency of 
this subtype on hyperactive NF-κB signaling by using a NF-κB super-repressive 
form of IκBα which was toxic for ABC DLBCL but not for GCB DLBCL. Since IκB-ζ, 
which like IκBNS belongs to the family of the atypical nuclear NF-κB inhibitors, was 
reported to be overexpressed in ABC DLBCL but not in GCB DLBCL (Nogai et al., 
2013) and we previously found IκBNS induction and expression maintenance to be 
regulated by NF-κB, (chapter 3.1) we were interested in whether this expression 
pattern would be also hold true for IκBNS. 
For this purpose, we screened a selection of GCB and ABC DLBCL model cell lines 
for their expression of IκBNS (Figure 22., 23a). Initially, we used a commercially 
available antibody to assess IκBNS protein levels (Figure 11.). In this panel we also 
included several representative mantle cell lymphoma (MCL) lines (Figure 22.).             
We chose this aggressive B-cell cancer type because MCL were shown to have 
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either chronic active BCR-driven classical NF-κB signaling (Jeko-1, Rec-1)  like ABC 
DLBCL or NIK (MAP3K14) depended alternative NF-κB signaling (Granta-519, 
JVM2, Z-138) (Rahal et al., 2014). To estimate the size of IκBNS on a SDS-PAGE 
we also involved two lysates of HEK293T cells in the western blot, an empty control 
and a sample in which we overexpressed a FLAG-tagged IκBNS p35 (Figure 22.). 
Indeed, when we compared the IκBNS expression pattern of GCB and ABC DLBCL 
cell lines, IκBNS was exclusively expressed in ABC DLBCL cell lines, just as IκB-ζ, 
shown in Nogai et al., 2013. The MCL cell lines showed a rather mixed pattern of 
IκBNS expression, most likely depending on whether the classical or alternative NF-
κB signaling pathway was predominantly activated, indicating that IκBNS is mainly 
induced by classical NF-κB signaling. In this experiment (Figure 22.) we also noticed 
a consistently with IκBNS p35 upcoming band running at approximately 70 kDa, 
labelled as IκBNS p70. We presumed it either to be an IκBNS p35 homodimer, 
posttranslational modification of IκBNS p35 or another IκBNS isoform. This issue 
will be further investigated in chapter 4.4. 
 
 
Figure 22. Determining IκBNS expression levels in GCB, ABC DLBCL and MCL by 
western blot analysis. Samples from HEK293T cells, either transfected with an empty vector or 
with a FLAG-IκBNS p35 construct served as a negative and positive control. 
 
As the IκBNS antibody we used so far, displays plenty of unspecific bands (Figure 
22.), we decided to generate an anti-IκBNS antibody ourselves. We used this self-
made antibody to repeat the experiment depicted in Figure 22., comprising mostly 
the same GCB and ABC DLBCL model cell lines (Figure 23.a). This time were not 
only interested to assess IκBNS protein levels but IκBNS mRNA levels, as well 
(Figure 23.b). Using the self-made antibody confirmed IκBNS to be solely expressed 
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in ABC DLBCL compared to GCB DLBCL cell lines. An empty and a FLAG-tagged 
IκBNS overexpressing HEK293T sample served again as specificity controls to 
estimate at which size IκBNS p35 has on a SDS-PAGE. Also detected by the 
antibody was the IκBNS p70 band, which only appears when IκBNS p35 is detected, 
as well. As B-cell activation markers, we stained against CYLD and BCL-10.  
BCL-10 is like CYLD a substrate of MALT1 and part of the CBM complex, thus 
important for an appropriate NF-κB response upon B- and T-cell receptor 
engagement (Rebeaud et al., 2008; Ruland et al., 2003). As expected, only DLBCL 
of the ABC subtype exhibit MALT1 substrate cleavage of CYLD and BCL-10. The 
assessment of IκBNS mRNA levels reflects the protein levels (Figure 23.a, b). 
Relative to GCB DLBCL cell lines ABC DLBCL cell lines express abundant amounts 
of IκBNS mRNA (Figure 23.b), indicating that increased mRNA levels are translated 
into protein expression. 
 
 
 
Figure 23. Assessment of IκBNS mRNA and protein levels in GCB and ABC DLBCL 
model cell lines. (a) IκBNS mRNA levels were determined by qPCR and normalized against the 
IκBNS expression level of the GCB DLBCL cell line BJAB. Bars represent means ± standard 
deviation. (b) IκBNS protein levels were detected by immunoblot using a self-made antibody. 
Lysates from HEK293T cells that were either transfected with an empty vector or with a FLAG-
IκBNS p35 expression construct served as a negative and positive control. Blotting against CYLD 
and BCL-10 indicates B-cell activation status. GAPDH served as a loading control. 
 
In summary, the atypical nuclear IκB IκBNS is expressed exclusively in the NF-κB 
signaling dependent ABC subtype of DLBCL what is reflected on both, the mRNA 
and protein level. Moreover, also MCL model cell lines that mainly exhibit chronic 
activation of BCR-driven classical NF-κB signaling express IκBNS. Furthermore, we 
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found a second correlating, presumably specific p70 IκBNS band additionally to 
IκBNS p35 that could represent a dimer, a posttranslational modification of IκBNS 
p35 modified or an unknown IκBNS isoform (further investigated in chapter 4.4). 
Taken together, these results underscore the regulation of IκBNS induction and 
expression maintenance by classical NF-κB signaling in the context of oncogenic 
signaling in DLBCL and MCL. 
In order to shed some more light on IκBNS regulation within the framework of 
frequent mutations leading to oncogenic NF-κB pathway signaling in ABC DLBCLs, 
we next made us again of the already established NFκBID promoter sequence 
cloned into a luciferase reporter construct (Figure 17.). A number of different somatic 
mutations in positive and negative NF-κB regulator proteins have been found to 
contribute to chronically active NF-κB signaling in ABC DLBCLs including e.g. 
MYD88 and CARMA1/CARD11 (Lenz et al., 2008; Kato et al., 2009; Davis et al., 
2010; Ngo et al., 2011;). Thus, we co-transfected several well-known proteins 
afflicted in ABC DLBCL in their wild type and representative mutant variants together 
with our luciferase reporter construct in HEK293T cells (Figure 24.a). NFκBID 
promoter activity was clearly induced by RelA and blocked upon adding DN-IκBa, 
reproducing results gained earlier (Figure 18.a, b). However, when we co-
transfected NF-κB signaling regulatory proteins affected in ABC DLBCL in their wild-
type version, mutant version or combinations of different mutants like they also 
occur in ABC DLBCL, luciferase activity was only slightly increased (Figure 24.a). 
This result suggests, that NF-κB upstream elements alone (wild type or mutant), that 
positively regulate the classical NF-κB pathway in ABC DLBCL, have only a minor 
impact on IκBNS induction. This is most likely due to the missing synergistic IκBNS 
inducible effect of Ca2+ mediated NFAT signaling in HEK293T cells under steady 
state conditions. 
So far we were just examining if wild-type or mutant upstream elements of the 
classical NF-κB pathway like CBM complex members or MYD88 would induce the 
NFκBID promoter luciferase reporter. But also a BIRC3 missense mutation was 
recently described for the first time in DLBCL (Hatem et al., 2016). For these 
reasons, we were next investigating if also elements that are implicated in 
alternative NF-κB signaling would be capable of inducing or repressing the NFκBID 
promoter. For this purpose, we used a wild-type and a mutant variant of BIRC3 
which is a key regulatory component of the non-canonical NF-κB pathway.  
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BIRC3 interacts with BIRC2 and TRAF2/3 in regulatory complex to down regulate 
NIK by constitutive ubiquitin-dependent degradation. NIK supports the transition of 
the cytosolic p100 precursor into the active p52, thereby activating alternative  
NF-κB signaling (Zarnegar et al., 2008; Zarnegar BJ et al.,2008; Vallabhapurapu et 
al., 2008.). Rahal et al. showed in 2014 that roughly 10% of MCL patient samples 
they collected, carry mutations in BIRC3 leading to genetically deregulated 
alternative NF-κB signaling. They revealed amongst others, two frequent mutants 
namely BIRC3S441* and BIRC3C560S. They found those mutants to be less efficient in 
destabilizing NIK and to be affected to prevent p52 maturation. Moreover, they also 
showed BIRC3S441* and BIRC3C560S expression in a GCB DLBCL cell line to elevate 
p52 levels, thereby increasing alternative NF-κB signaling. Obviously, BIRC3S441* 
and BIRC3C560S lost their ability to suppress alternative NF-κB signaling. For this 
reason we were interested to examine what effect wild-type and the BIRC3S441* 
mutant would have on NFκBID promoter activity. When we co-transfected wild-type 
BIRC3, NFκBID promoter activity negligibly increased for yet unknown reasons. 
Albeit, when we co-transfected the non-sense mutation BIRC3S441* we observed a 
weak but dose-dependent increase in luciferase activity (Figure 24.b). That implies 
that IκBNS can also be induced by the alternative NF-κB pathway. Together, the 
results obtained from the experiments depicted in Figure 24.a, b indicate that IκBNS 
expression can be induced by both classical and alternative NF-κB signaling. In 
particular, the IκBNS promoter was also inducible, although weakly, by upstream 
wild-type but also mutant elements of classical NF-κB signaling regulation 
commonly found in the context of ABC DLBCL somatic mutation patterns. Also a 
typical negative regulator of the non-canonical NF-κB pathway that lost its 
suppressive function by a missense mutation, found in MCL and recently reported 
to be also found mutated in DLBCL, slightly induced IκBNS promoter activity. 
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Figure 24. Examining the inducible abilities of classical and alternative NF-κB wild-
type and in the context of ABC DLBCL pathogenesis commonly mutated NF-κB 
upstream elements on NFκBID promoter activity by luciferase assay. (a) Co-transfection 
of wild type and mutant variants commonly found somatically altered in the context of ABC DLBCL 
mutagenesis. RelA co-transfection and the inhibition of its induced NFκBID promoter activity by 
DN-IκBα served as a specificity control of induction (b) Co-transfection of the wild-type BIRC3 
negative regulator of alternative NF-κB signaling and the loss of function variant missense mutated 
BIRC3S441*. (a, b) Triangles indicate increasing amounts of plasmid DNA co-transfected to a 
constant amount of NFκBID promoter luciferase construct. RLU means Relative Luciferase Units 
Bars represent means ± standard deviation. 
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To strengthen the previous findings that were obtained based on the analysis of 
NFκBID promoter activity we subsequently wanted to figure out what would be the 
result of CARMA1L244P and CARMA1G116S overexpression in a GCB DLBCL (without 
constitutive NF-kB signaling) on the actual IκBNS protein expression (Figure 25.).                                    
Thus, we electroporated BJAB cells with either an empty vector as control, wild-type 
CARMA1 or the missense base substitution carrying mutant proteins CARMA1L244P 
and CARMA1G116S. These CARMA1 variants are both mutated in their coiled-coil 
domains and were discovered in the ABC DLBCL cell line OCI-LY3 (harbours a 
CARMA1L244P mutation) and in an ABC DLBCL biopsy (CARMA1G116S) (Lenz et al., 
2008; Snow et al., 2012). Both mutants were shown to generate high levels of 
constitutive active NF-κB signaling without any extrinsic stimuli and introduction in 
BJAB resulted in the induction of NF-κB target genes (Lenz et al., 2008). Since our 
previous results suggest that IκBNS is also a NF-κB target gene, we assumed 
IκBNS to be induced also on the protein level upon introduction of CARMA1L244P and 
CARMA1G116S in BJAB cells. Indeed, the overexpression of CARMA1L244P or 
CARMA1G116S in BJAB led to a clear induction of IκBNS p35/p70 proteins in a 
comparable degree (Figure 25.). Moreover, also BJAB cells expressing wild-type 
CARMA1 showed a weak induction of IκBNS p35/p70 but considerably less 
pronounced compared to the mutant CARMA1 variants (Figure 25.) most likely due 
to its potent NF-kB activating properties. 
Taken together, the weak induction of IκBNS p35/p70 protein levels upon 
introduction of ABC DLBCL derived CARMA1 mutants into the GCB DLBCL cell line 
BJAB is in line with the weak induction of the IκBNS promoter reporter upon co-
transfection with common mutant ABC DLBCL NF-κB regulators (Figure 24.a). 
Additionally, this result validates IκBNS as NF-κB target gene and constitutive NF-
κB signaling in ABC DLBCL to drive IκBNS expression. The only weak induction 
also indicates that NF-κB is capable of inducing IκBNS expression on its own but 
for full induction and high protein levels as seen in ABC DLBCL, it might require the 
synergistic signaling of NF-κB together with NFAT. 
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Figure 25. CARMA1 mutants induce the expression of IκBNS in the GCB DLBCL cell 
line BJAB as revealed by Western Blot analysis. Cells were either electroporated with an 
empty vector as control, wild-type CARMA1 or the missense base substitution carrying mutant 
proteins CARMA1L244P or CARMA1G116S. 
 
To further elucidate the role of IκBNS and how important its steady state expression 
is for ABC DLBCL we now tried a shRNA mediated knock down approach targeting 
IκBNS. Therefore, we initially designed and screened for functional shRNA 
sequences (Figure 26.). For this, we lentivirally transduced BJAB cells, a cell line 
model of the GCB DLBCL subtype with constructs expressing the distinct shRNAs 
and assessed the suppressive abilities of the different shRNAs on IκBNS protein 
levels upon P/I mediated induction of IκBNS. Out of 11 different possible shRNA 
sequences we identified two suitable shRNA sequences (#1 and #8) that were 
sufficiently able to decrease IκBNS expression levels after 4 h of P/I stimulation 
compared to controls (Figure 26.). 
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Figure 26. Screening for functional shRNA sequences to knock down IκBNS levels.                                  
BJAB cells were lentivirally transduced with shRNA sequences (#1 - #11) targeting IκBNS mRNA. 
Upon selection of shRNA expressing cells by puromycin cells were stimulated with P/I for 4 h to 
induce IκBNS expression. Suitable shRNA sequences should markedly diminish induced IκBNS 
protein levels induced by 4 h of P/I stimulation compared to stimulated controls. Two shRNAs #1 
and #8 were identified to sufficiently decrease IκBNS on the protein level. Weak and strong 
exposures are shown to evaluate down regulations of IκBNS p35 and p70 due to differences in 
expression levels. Tubulin served as a loading control. 
 
With IκBNS shRNA #1 and #8 we now had the appropriate tool to test the effect of 
IκBNS knock down on DLBCL. To this end, we lentivirally transduced DLBCL of the 
ABC and GCB subtype with the identified functional shRNAs (#1 and #8) targeting 
IκBNS. shRNA expression was coupled to the expression of GFP by an IRES-
element, so that GFP served as a read-out for the survival rate of shRNA #1 and #8 
expressing cells over the course of time.  
IκBNS knock down by the two independent shRNAs #1 and #8 clearly induced 
toxicity in the group of IκBNS positive ABC DLBCL cell lines (HBL-1, TMD8, U2932,                    
SU-DHL-2) after some days in case of shRNA #1 and after roughly one week for 
shRNA #8 after transduction (Figure 27.). This obvious time difference could be 
explained by the different efficiencies of both shRNAs to knock down IκBNS (Figure 
26.). For instance the growth rate of TMD8 declined over the course of time down 
to 30% 17 days after transduction transduced with shRNA #1 and to less than 20% 
23 days after transduction with shRNA #8. In contrast, the shRNAs did not affect the 
growth of the GCB DLBCL group (HT, SU-DHL-4, SU-DHL-6, OCI-LY1, OCI-LY7) 
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which exhibited little or no IκBNS mRNA levels and displayed no detectable IκBNS 
on the protein level, as well (Figure 22.; 23.a, b). This result suggests a selectively 
toxic effect of the IκBNS knock down to ABC DLBCL and furthermore an addiction 
of ABC DLBCL to the expression of IκBNS, indicating an essential role for growth. 
 
 
Figure 27. Investigating the effect on survival of IκBNS knock down mediated by two 
independent shRNAs. Cells of the GCB and ABC subgroup of DLBCL were lentivirally 
transduced by either shRNA #1 (upper panel) or # panel8 (lower) mediating the knockdown of 
IκBNS. shRNA expression was coupled to the expression of GFP by an IRES element. GFP served 
as a read out for the rate of living transduced cells in % of day 0 fraction over the course of time 
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measured by flow cytometry. Survival rates were assessed for 17 days after transduction for shRNA 
#1 and for 23 days after transduction for shRNA #8  
 
As demonstrated, IκBNS knock down is exclusively toxic to the ABC subgroup of 
DLBCL (Figure 27.). We now addressed the question whether what would be the 
outcome of the vice-versa experiment, meaning the overexpression of IκBNS p35 
in GCB and ABC DLBCL cell lines for a longer period of time. Thus, we lentivirally 
transduced a GCB cell line (BJAB) and two ABC cell lines (HBL-1 and U2932) with 
a GFP-tagged IκBNS p35. GFP served as the read out for the rate of living 
transduced cells over the next 14 days of measurement. As depicted in Figure 28., 
the overexpression of IκBNS p35 did not affect the growth of GCB and ABC DLBCL 
cell lines over a time frame of two weeks. Taken together, the overexpression of 
IκBNS p35 has neither a noticeable positive effect on the survival of IκBNS negative 
cells (BJAB) nor a negative effect on IκBNS positive ABC DLBCL cell lines (HBL-
1,U2932) and vice versa, 14 days after IκBNS p35 transduction. This suggests, 
IκBNS p35 overexpression alone does not confer a survival advantage over non-
transduced GFP- cells. Furthermore, the high steady levels of IκBNS in ABC DLBCL 
does not seem to be vulnerable to a further increase in IκBNS p35 protein 
expression since no toxic effects on survival were observed.  
In summary, IκBNS knockdown is selectively toxic to ABC DLBCL cell lines whereas 
the overexpression of IκBNS p35 does not affect the survival of both the GCB and 
the ABC subtype of DLBCL neither in a positive nor in negative manner in the time 
span of several weeks.  
 
Figure 28. Impact of IκBNS p35 overexpression on the survival of GCB and ABC 
DLBCL cell lines. The IκBNS negative cell line BJAB (GCB DLBCL) and IκBNS positive cell 
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lines HBL-1, U2932 (both ABC DLBCL) were lentivirally transfected with a GFP-tagged IκBNS 
p35 expression construct. GFP expression served as a read out for the rate of living IκBNS p35 
transduced cells in % of day 0 fraction measured by flow cytometry over a period of 14 days. 
 
To substantiate the clinical importance of this study and to reaffirm the finding that 
IκBNS is expressed exclusively in the ABC but not in the GCB subtype of DLBCL 
also in a clinical context, we analysed patient samples from both DLBCL subtypes 
for the relative mRNA expression of IκBNS. Indeed, also clinical samples derived 
from GCB and ABC DLBCL patients show the same IκBNS mRNA expression 
pattern as the investigated DLBCL model cell lines (Figure 29.). Also in these patient 
derived samples IκBNS mRNA is significantly higher expressed in ABC DLBCL 
samples compared to GCB DLBCL samples confirming the results shown in Figure 
23.b. The high background of IκBNS mRNA levels in both DLBCL subtypes is most 
likely due to infiltrating activated T-cells expressing high levels of IκBNS mRNA.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Comparison of relative NFκBID mRNA expression levels determined by 
qPCR in patient samples derived from DLBCL of the GCB and ABC subtype.                            
NFκBID mRNA expression is depicted relative to the housekeeping gene ACTB coding for Actin 
Beta. Analysis was performed on 19 patient samples (n=19) for each DLBCL subtype. Each dot 
represents one patient sample. Shown is the standard error of the mean. The difference between the 
two groups was statistically significant with **p < 0, 05 (unpaired, two-tailed t-test). The experiment 
was performed in collaboration with Dr. Irina Bonzheim. 
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3.3 Role of calcineurin in DLBCL 
As demonstrated earlier in this study, the induction of IκBNS expression upon 
stimulation of GCB DLBCL by P/I and the maintenance of IκBNS expression under 
steady state conditions in ABC DLBCL needs both, classical NF-κB signaling and 
NFAT signaling, together acting in a synergistic manner. Thus, we have also shown 
that it is possible to decrease IκBNS expression by applying the phosphatase 
calcineurin inhibitors Cyclosporin A (CsA) and FK506. This effect, we assume is 
most likely the consequence of NFAT signaling blockage by CsA and FK506. CsA 
and FK506 mediated calcineurin inhibition, prevents the cytosolic NFAT to be 
dephosphorylated. Thus, also its consecutive translocation in the nucleus is blocked 
where it would otherwise, cooperatively with other partners such as NF-κB direct 
transcriptional control over a multitude of target genes including IκBNS (Figure 
15.a,b; 16. a,b; 17.a,b) (Fu et al. 2006; Pham et al. 2005; Steinbach et al., 2007; 
Gachet and Ghysdael, 2009). Due to this dependency of IκBNS expression to active 
NFAT signaling and because IκBNS was highly expressed in all investigated ABC 
DLBCL, we were interested to figure out the activation status of the calcium 
signaling responsive NFAT member NFATc1 in the DLBCL cell lines (Figure 30.). 
Therefore, we treated cells from the GCB subtype (BJAB, HT, SU-DHL-4) and the 
ABC subtype (HBL-1, TMD8, OCI-LY10, OCI-LY3, SU-DHL-2, U2932, RIVA) of 
DLBCL for 2 h with CsA and compared afterwards lysates from CsA treated cells 
with untreated cells in regard to their NFATc1 protein expression. Undoubtedly, all 
tested cell lines except for SU-DHL-4 exhibit active dephosphorylated NFATc1 
species. Those hyperphosphorylated active NFATc1 isoforms could be identified by 
an obvious upward shift of NFATc1 bands to higher molecular weights on the blot, 
upon CsA treatment (Figure 30.). Notable were also the highly different NFATc1 
expression levels amongst the DLBCL cell lines (Figure 30.). 
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Figure 30. Assessment of NFATc1 phosphorylation and expression levels in DLBCL of 
the GCB and ABC subtype by western blot. Each cell line was either treated with solvent 
control (Ctrl) or 2,5 µM CsA for 2 h prior to lysis. Different NFATc1 blot exposures (long exp., mid 
exp., short exp.) are shown due to the different NFATc1 expression levels of the investigated 
DLBCL. Blotting for Tubulin served as loading control amongst untreated and CsA treated samples. 
 
As shown in Figure 30., it turned out that NFAT signaling was active in all GCB                     
and all ABC DLBCL cell lines tested except SU-DHL-4. In Figure 27., we have 
proven that the direct knock down of IκBNS by two independent shRNAs was toxic 
to all ABC DLBCL we tested but not to GCB DLBCL cell lines. We now asked 
ourselves what would be the impact on ABC and GCB DLBCL growth of indirect 
IκBNS protein expression knock down as shown in Figure 15.a,b by CsA and FK506 
mediated inhibition of NFAT signaling. For this, we treated GCB (SU-DHL-4, BJAB, 
HT) and ABC (HBL-1, TMD8, OCI-LY3, U2932, RIVA, SU-DHL-2, OCI-LY10) 
DLBCL with either two different concentrations of CsA or FK506 (Figure 31.) and 
measured their growth by MTS assay on day six of calcineurin inhibitor treatment. 
Inhibitors were once reapplied on day two. In detail, the GCB DLBCL group (SU-
DHL4, BJAB, HT) was completely unaffected by CsA or FK506 inhibitor treatment. 
However, some members of the ABC DLBCL group namely HBL-1 and TMD8 were 
severely impaired in their proliferation capabilities by the application of both 
inhibitors and concentrations. For instance, at the higher CsA or FK506 inhibitor 
concentration those cell lines show a reduction of growth up to 80 % or 60% 
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compared to respective solvent controls. Furthermore, U2932, RIVA, SU-DHL-2 and 
OCI-LY10 represent a group of ABC DLBCL that were clearly impeded in their 
proliferation by both inhibitors concentrations of CsA and FK506 but were less 
vulnerable than HBL-1 and TMD8. On the contrary, OCI-LY3 was the only ABC 
DLBCL cell line that entirely tolerated CsA and FK506 treatment. 
Figure 31. Indicated GCB and ABC DLBCL cell lines show different growth 
behaviours upon treatment with calcineurin inhibitors CsA and FK506. Cells were 
treated with either solvent as control (a, b) or two different concentrations of (a) CsA (2, 5 µM or 5 
µM) and (b) FK506 (5 µM or 10 µM), respectively. Inhibitors were applied on day 0 and 2 of the 
experiment. Cell proliferation was determined on day 6 of inhibitor treatment by MTS assay. Bars 
represent means from 3 independent replicates ± standard deviation. 
 
In order to exclude unspecific toxic side effects mediated by CsA and FK506                     
at µM concentrations and to validate our findings concluded from the results 
depicted in Figure 31. we selected four ABC DLBCL cell lines to test at lower CsA 
and FK506 inhibitor concentrations (Figure 32.). To this end, we decided to 
comprise one or more ABC DLBCL cell line representative of each distinct inhibitor 
susceptibility group. The most sensitive HBL-1 and TMD8, the intermediate 
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sensitive SU-DHL-2 and the resistant OCI-LY3 ABC DLBCL cell line. Treating the 
selected ABC DLBCL with considerably lower concentrations of CsA (250 nM and 
500 nM) or FK506 (500 nM and 1000 nM) reproduced the results gained from higher 
concentrations (Figure. 31) albeit less pronounced (Figure 32.). Cell growth was 
again measured by MTS assay on day 6 of treatment. Cells were retreated with 
inhibitors on day 2, as well. HBL-1 and TMD8 were again the cell lines the most 
susceptible to inhibitor treatment whereas OCI-LY3 was also here not affected by 
inhibitor treatment. SU-DHL-2 however, that previously showed intermediate 
sensitivity to calcineurin inhibition seemed to be unimpressed by lower CsA and 
FK506 concentrations (Figure 32.). The less pronounced impairing effects on growth 
of HBL-1 and TMD8 cells and the unsuceptibility of SU-DHL-2 to CsA and FK 
treatment at lower concentrations can be attributed most likely to the short time span 
of treatment.  
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Figure 32. GCB and ABC DLBCL cell lines show different growth behaviours upon 
treatment with calcineurin inhibitors CsA and FK506 also at lower compound 
concentrations. Indicated cell lines were treated with either solvent as control (a, b) or two 
different concentrations of (a) CsA (250 nM or 500 nM) and (b) FK506 (500 nM or 1000 nM), 
respectively. Inhibitors were applied on day 0 and 2 of the experiment. Cell proliferation was 
determined on day 6 of inhibitor treatment by MTS assay. Bars represent means from 3 independent 
replicates ± standard deviation. 
 
In summary, these results suggest calcineurin inhibition to be exclusively toxic to 
some ABC DLBCL cell lines at both, high and low inhibitor concentrations indicating 
calcineurin activity to be essential for the growth of certain ABC DLBCL cell lines. 
Hereby, we can differentiate between highly sensitive, intermediate sensitive and 
resistant ABC DLBCL cell lines in regard to calcineurin inhibition by CsA and FK506. 
In contrast, all tested cell lines of the GCB subtype of DLBCL were not prone to 
calcineurin inhibition, at all. Moreover, due to the usage of two independent 
calcineurin inhibitors these impairing effects on cell growth are highly likely to be 
specific. Besides this, the observed effects on cell growth could be independent from 
NFAT signaling that is blocked upon calcineurin inhibition, since NFAT is active in 
all investigated ABC DLBCLs. Taken together, taking into consideration all previous 
mentioned points the different outcomes of the ABC DLBCL growth upon calcineurin 
inhibition could be the result of a yet unknown calcineurin substrate that positively 
regulates pivotal chronic active BCR-driven classical NF-κB signaling of ABC 
DLBCL in its dephosphorylated state but loses this ability when calcineurin 
dependent dephosphorylation is blocked. Furthermore, the given circumstance of 
CsA/FK506 less or insensitive ABC DLBCL cell lines could be dependent from the 
distinct mutation patterns harboured by the ABC DLBCL cell lines, since the highly 
sensitive cell lines HBL-1 and TMD8 share mutations in the same protein CD79B  
quite upstream in BCR signaling (Davis et al., 2010). The toxic effect of calcineurin 
inhibition could be overridden by different common NF-κB positive regulating 
mutations that can be found in CsA and FK506 intermediate and insensitive ABC 
DLBCL downstream of this putative substrate. Such mutations in intermediate or 
non-sensitive cell lines include mutant CARMA1 and mutant/biallelic truncating 
mutation of A20 in SU-DHL-2 (Naylor et al., 2011, Ma et al., 2015); TAK1 mutation 
and A20 hemizygous deletion in U2932 (Fontan et al., 2012; Ma et al., 2015); mutant 
CARMAL244P  and hemizygous A20 deletion in OCI-LY3 (Lenz et al., 2008; Naylor et 
al., 2011; Ma et al., 2015), possibly explaining the growth behaviour of those cell 
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lines. Upon obtaining the results shown in Figure 31. and 32. the question emerged 
what the general reason could be that leads to impaired growth of ABC DLBCL cell 
lines as result of CsA and FK506 treatment. As already described earlier, ABC 
DLBCL are addicted to classical NF-κB signaling. But moreover, this chronically 
active NF-κB signaling also induces the induction and subsequent secretion of the 
B-cell pro-proliferative cytokines IL-6 and IL-10 (Kishimoto, 2005; Moore et al., 
2001). An autocrine/paracrine feedback loop of those cytokines then activates IL-6 
and IL-10 receptor associated JAK kinases which subsequently phosphorylate 
STAT3. This phosphorylated STAT3 (p-STAT3) transcription factor accumulates in 
the nucleus and initiates target gene transcription, such as STAT3 itself, establishing 
a positive auto regulatory loop (Narimatsu et al., 2001). Therefore, ABC DLBCL that 
exhibit high NF-κB activity show also high IL-6 and IL-10 secretion in turn leading to 
elevated STAT3 and p-STAT3 levels (Lam et al., 2008). In addition to that, IL-6 and 
IL-10 secreting ABC DLBCL cell lines were killed by the inhibition of STAT3 
signaling alone and combining JAK-1 and NF-κB inhibition actually led to synergistic 
toxicity, indicating ABC DLBCL to be addicted not only to NF-κB signaling alone but 
also to the mentioned autocrine/paracrine cytokine signalling loop consisting of IL-
6 and IL-10 (Lam et al., 2008). For these reasons, we were interested to see whether 
p-STAT3 levels and therefore also the associated pivotal IL-6 and IL-10 secretion 
of ABC DLBCL would be affected in ABC DLBCL exposed to calcineurin inhibitors. 
To test this, we treated a GCB DLBCL cell line (BJAB) and four ABC DLBCL (HBL-
1, TMD8, SU-DHL-2, RIVA) cell lines that were sensitive to calcineurin inhibition as 
shown in Figure 31.a,b; 32.a,b with 2,5 µM of CsA or FK506 for one or two days, 
respectively. Calcineurin inhibitors worked properly in all cell lines, indicated by the 
shift of NFATc1 bands (Figure 33.a-e). Indeed, when we treated the cells with either 
CsA or FK506 we observed clearly decreased p-STAT3 levels in all ABC DLBCL 
cell lines (Figure 33.b-e) just after one day of treatment, whereas STAT3 levels 
remained the same. Noteworthy, the CsA and FK506 highly sensitive cell lines HBL-
1 and TMD8 and the intermediate sensitive cell line RIVA showed the most 
pronounced reduction in p-STAT3 when treated with the inhibitors. SU-DHL-2 cells 
that were shown to be intermediate sensitive for higher concentrations (Figure 31.a, 
b) and insensitive for lower concentrations of calcineurin inhibitors accordingly 
showed only a small decrease of p-STAT3 levels for CsA treatment and little, if any 
reduced p-STAT3 levels when treated with FK506 even after two days of treatment. 
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In comparison, the calcineurin inhibitor insensitive GCB DLBCL cell line BJAB was 
if, at most, only marginally affected in p-STAT3 levels. Also STAT3 levels remained 
the same upon treatment (Figure 33.a). We also included two well-known NF-κB 
targets, the antiapoptotic BCL-XL (Chen et al, 2000; Lee et al, 1999) and the  
NF-κB negative regulator A20 (Krikos et al, 1992) in our experiment to check 
whether NF-κB signaling in DLBCL would be affected. This was seemingly not the 
case for all DLBCL cell lines tested (Figure 33.a-e).  
 
 
Figure 33. Assessing the impact of calcineurin inhibition of CsA and FK506 treatment 
on signaling in GCB and ABC DLBCL cell lines (a- e). Protein expression levels in GCB 
(BJAB) and ABC DLBCL (HBL-1, TMD8, SU-DHL-2, RIVA) cell lines was determined by western 
blot using the indicated antibodies. Cells were either treated with solvent control or calcineurin 
inhibitors CsA (2,5 µM) / FK506 (5 µM) for one or two days. Blotting against NFATc1 served as 
functionality control for CsA and FK506. In figure panels (a, b, c, e) blotting for tubulin served as a 
loading control, whereas in (d) a non-specific band indicates equal loading. 
 
In turn to verify that the sensitivity of ABC DLBCL towards calcineurin inhibitors  
(Figure 31.a, b; 32.a, b) correlates with the extend of p-STAT3 level reduction upon 
CsA and FK506 application, we treated the highly sensitive ABC DLBCL cell line  
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HBL-1 (Figure 34.a, c) and the fully insensitive ABC DLBCL cell line OCI-LY3 with 
dilution series of CsA for 2 days and compared consequent p-STAT3 levels to 
untreated cells. We did this in a dilution series to learn whether the reductive effect 
on p-STAT3 levels is CsA dose dependent. As presumed, with increasing 
concentrations of CsA we observed reciprocally decreasing levels of p-STAT3 
(Figure 34.a, b), indicating a CsA dose dependent effect. On the contrary, OCI-LY3 
cells treated with a CsA dilution series did not show any changes in their p-STAT3 
levels at all concentrations applied (Figure 34.b). Again, STAT3 expression 
remained at the same level in HBL-1 and was not altered in OCI-LY3 cells under all 
conditions, as well (Figure 34.a, b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Verifying the decline of p-STAT3 levels in a dose-dependent manner as a 
result of a CsA dilution series treatment by western blotting. (a, b). Lysates were analysed 
by western blotting with anti NFATc1, anti-STAT3, anti p-STAT3, and anti-BCL-10 antibodies. 
Results 
 
121 
 
Cells were treated with solvent control or CsA applied at the indicated concentrations. In (a, b) a 
non-specific band served as a loading control. Equal loading in (b) is indicated by BCL-10. 
 
In summary it can be said, therefore, that the different sensitivities of GCB and ABC 
DLBCL in respect of their growth towards the treatment with increasing 
concentrations of calcineurin inhibitors CsA and FK506 correlates with their 
observed reciprocal decrease in STAT3 phosphorylation as a consequence of CsA 
and FK506 application. Mentionable, this effect was dose-dependent at least for the 
investigated CsA treatment. Unphosphorylated STAT3 levels however, stayed the 
same at all times. Since we found lowering p-STAT3 levels upon CsA and FK506 
treatment in only certain ABC DLBCL cell lines e.g. HBL-1 and TMD8  we supposed 
the secreted amounts of IL-6 and IL-10 (that bind their corresponding receptors 
distal from JAK1 mediated STAT3 phosphorylation) of solely those cell lines also to 
be reduced. On the other hand, we did not expect the secretion of IL-6 and IL-10 of 
OCI-LY3 cells to be reduced as result of CsA and FK506 treatment as p-STAT3 
levels were not declined. Hence, we treated calcineurin inhibitor treatment highly 
sensitive ABC DLBCL cell lines HBL-1 and TMD8 and the unresponsive OCI-LY3 
cell line with either a solvent as control or CsA and FK506 in a dilution series for two 
days and subsequently assessed relative IL-6 and IL-10 secretion levels in 
the supernatants.  
In fact, we were able to reveal that secretion of both Interleukins, IL-6 and IL-10 by 
HBL-1 and TMD8 cells were clearly decreased when treating them for two days with 
calcineurin inhibitors (Figure 35.a, b). This was even the case for very low levels of     
40 nM for CsA and 160 nM for FK506, respectively. Those cell line were also shown 
to have markedly lowered p-STAT3 levels when they were exposed to calcineurin 
inhibitors (Figure 33.b, c; 34.a). In contrast, the IL-6 and IL-10 secretion of OCI-LY3 
cells was completely unaffected by calcineurin inhibitors (Figure 35.a, b) what is in 
agree with stable p-STAT3 levels upon CsA/FK506 treatment. Furthermore, already 
low CsA or FK506 concentrations had a strong impairing effect on IL-6 and IL-10 
secretion. Moreover, higher compound doses did not improve the interleukin 
secretion inhibitory effect (Figure 35.a, b). Worth mentioning as well is the fact that  
IL-10 secretion is slightly more hampered compared to IL-6 secretion by usage of 
both calcineurin inhibitors (Figure 35.a, b).  
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Figure 35. Determination of IL-6 and IL-10 levels in the supernatants of ABC DLBCL 
cell lines HBL-1, TMD8 and OCI-LY3 upon two days treatment of CsA and FK506 in 
dilution series. Cells were either treated with DMSO as solvent control, or the calcineurin 
inhibitors CsA and FK506 at the indicated concentrations. After two days of exposure, 
supernatants of cells were collected and subsequently measured for their levels of IL-6 and 
IL-10 by ELISA. Bars represent means from 3 independent replicates ± standard deviation. 
 
To substantiate the finding of decreasing IL-6 and IL-10 secretion of ABC DLBCL 
cell lines that exhibit diminished p-STAT3 levels upon calcineurin inhibitor treatment 
the next experiment was performed including the CsA/FK506 resistant cell line 
SU-DHL-2 (at low concentrations; Figure 32.a,b). Cells were again subjected to CsA 
or FK506 treatment for two days before assessing IL-6 and IL-10 levels in their 
supernatants. As it was expected, IL-6 and IL-10 secretion upon inhibitor treatment 
was tremendously hampered in in samples derived from HBL-1 and TMD8 cells 
whereas the supernatants collected from OCI-LY3 and SU-DHL-2 showed 
unchanged (in case of CsA) or inconsiderably less (in case of FK506) IL-6 and  
IL-10 secretion (Figure 36.a, b). This finding correlates well with both, the 
remarkable decrease of p-STAT3 levels in HBL-1 and TMD8, the unaltered levels 
of p-STAT3 in OCI-LY3 and finally the only slightly decreased p-STAT3 levels in 
SU-DHL-2 when applying CsA or FK506 (Figure 33.b, c, d; Figure 34.a-c). 
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Figure 36. IL-6 and IL-10 secretion assessment of calcineurin inhibitor sensitive and 
insensitive ABC DLBCL cell lines treated with 300 nM CsA. (a, b). Cells were treated 
with DMSO as solvent control or a sole concentration of CsA (300 nM) for two days. 
Subsequently supernatants were taken to measure IL-6 and IL-10 levels by ELISA. Bars 
represent means from 3 independent replicates ± standard deviation. 
 
Taken together, the demonstrated results suggest that the different growth 
outcomes of ABC DLBCL upon treatment with calcineurin inhibitors correlate with 
distinct secretion levels of the pro-proliferative interleukins IL-6 and IL-10, which act 
in a survival promoting autocrine/paracrine feedback loop, the cells are addicted to. 
These varying interleukin secretion properties are reflected by diverging amounts of 
p-STAT3. In summary, this means the higher the sensitivity towards calcineurin 
inhibitors of DLBCL with respect to their growth, the lower are secreted IL-6 / IL-10 
levels as well as p-STAT3 levels. As already stated earlier, NFAT activity is shared 
by all ABC DLBCL tested and moreover all of them express high levels of IκBNS, 
as well. In addition to that, when we considered differences between the ABC 
DLBCL cell lines we concluded that they mainly differ, as previously mentioned, in 
exhibiting distinct mutant patterns. In this regard, we noticed that cell lines that were 
impaired the most by calcineurin inhibitor treatment in their ability to secrete IL-6 
and IL-10, thus also affected severely in respect to proliferation, were mutated in the 
BCR associated signaling protein CD79. Taking this into account, we addressed the 
question what the molecular mechanism could be behind this selective toxicity. A 
recently published paper by Dutta and colleagues gave us an indication for a 
possible explanation. In their study they were investigating primary human CD4+  
T-cells and Jurkat T-cells. From their results they draw the conclusion that 
calcineurin is recruited to the TCR signaling complex, where it positively regulates 
the tyrosine kinase LCK by removing an inhibitory phosphorylation which is normally 
induced by TCR activation. Moreover, when they inhibited calcineurin activity by 
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different approaches such as the pharmacological inhibition by CsA or FK506 or 
siRNA mediated knock down, they observed increased TCR-mediated LCK 
inhibitory phosphorylation, impaired phosphorylation of ZAP-70 and various 
alterations of phosphorylation events in related TCR-proximal pathways. The T-cell 
and B-cell antigen receptor pathways share a multitude of common elements and 
other similarities such as the association of the antigen receptor to invariant ITAM 
bearing accessory proteins, the recruitment of Src-family kinases to the receptor 
complex, the involvement of proteins sharing strong sequence homologies such as 
BLNK and SLP-76 and the eventual activation of proximal signaling pathways 
converging in the activation of NF-κB, NFAT and AP-1 TF-families. These 
homologies are the reason why we thought that calcineurin could be not only 
implicated in TCR-signaling but also in BCR-signaling events by dephosphorylation 
of a yet unknown substrate as already earlier mentioned. This in turn would lead to 
positive regulatory effect on downstream BCR signaling. When we transferred this 
thought in the context of ABC DLBCL signaling it was justified to hypothesise that 
only CD79 mutated ABC DLBCL cells were vulnerable to CsA/FK506 mediated 
calcineurin inhibition because the more proximally mutated cell lines could override 
the loss of the positive regulation of BCR signaling upon calcineurin inhibition.  
To unveil this putative new calcineurin substrate whose dephosphorylation indirectly 
or directly leads to an enhanced BCR downstream signaling we performed a SILAC 
with subsequent phosphoproteom analysis by mass spectrometry (MS). For this, we 
treated HBL-1 cells for 5 h with either CsA or FK506 after being subjected to medium 
containing amino acids with differentially heavy isotopes. The frequency of 
phosphorylated peptides in calcineurin inhibitor treated samples was then compared 
to the abundance of the corresponding phosphorylation in peptides from the solvent 
treated control. SILAC revealed, that indeed proteins that are implicated in BCR-
proximal signaling are present in a more phosphorylated state like CD79A and 
CD79B or in a less phosphorylated state as the adaptor protein BLNK (Table 1.). 
This result indicates that calcineurin could be indeed recruited to BCR downstream 
signaling where it dephosphorylates (a) certain substrate(s) leading directly or 
indirectly to a promotion of further BCR signaling events. As a specificity control for 
this SILAC experiment serves the finding of BCL-10 that is accordingly to our result 
roughly two times more phosphorylated at serine 138 (S138) when calcineurin is 
inhibited by either CsA or FK506. BCL-10 S138 is known to be an IKK2 
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phosphorylation target site and was identified by Zeng et al. (2007) as a T-cell 
receptor activation-induced phosphorylation site that is implicated in the induction 
of BCL-10 ubiquitination and subsequent degradation. Zeng et al. demonstrate that 
the prevention of BCL-10 phosphorylation at S138 inhibits T-cell activation induced 
BCL-10 ubiquitination and degradation and also causes sustained NF-κB signaling 
and enhanced IL-2 production. Palkowitsch et al. (2011) revealed calcineurin to 
constitutively interact with the CBM complex in T-cells and moreover CsA/FK506 
inhibition and siRNA mediated knock-down of calcineurin led to increased levels of 
phosphorylated BCL-10, reduced CBM complex formation and consequently 
decreased NF-κB activity. Furthermore, based on their results, Palkowitsch et al.  
suggest BCL-10 S138 to be a calcineurin dephosphorylation site. In accordance 
with the Zeng study, Palkowitsch et al. suggest that the calcineurin mediated  
BCL-10 dephosphorylation at S138 is thus linked to a positive regulation of CBM 
complex assembly and therefore to antigen receptor induced NF-κB signaling, as 
well. Moreover, our results also revealed BCLAF1 as a new direct putative 
calcineurin substrate or at least indirectly regulated by calcineurin. According to the 
SILAC analysis BCLAF1 frequently appeared to be more phosphorylated upon 
calcineurin inhibition at several known and unknown putative phosphorylation sites 
(Table 1). So far, there is nothing known about the already noted phosphorylation 
sites, neither their function nor whether they have a positive or negative effect on 
BCLAF1 function. BCLAF1 fulfils diverse functions. It is known as inducer of 
apoptosis, autophagic cell death in myeloma cells and as repressor of transcription 
(Kasof et al., 1999; Liu et al., 2007; Lamy et al., 2013) and was moreover it was 
found as a target of NF-kB (Kong et al., 2011; Shao et al., 2016). Taken together, 
this result suggests an actual role of calcineurin in modifying BCR downstream 
signaling as we found BCR signaling elements under the top hits of peptides with 
altered phosphorylation rates by phosphoproteom analysis. Putative substrates 
thereby could be directly due to more phosphorylation CD79 or indirectly due to less 
phosphorylation BLNK. Since the inhibition of calcineurin impairs the growth of 
certain ABC DLBCL we have to assume a positively regulating role of calcineurin in 
BCR signaling. We found CD79B phosphorylation altered at serine 221 in close 
proximity to the CD79B amino terminal ITAM (aa185 - aa213) when calcineurin was 
inhibited. This suggests that the common heterozygous HBL-1 and TMD8 amino 
acid substitutions Y196F and Y196H, located in the middle of the CD79B ITAM, 
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could somehow enhance the negative effect of calcineurin inhibition on BCR 
downstream signaling compared to wild-type CD79B Y196. Moreover, MS based 
phosphoproteom analysis of isotope labelled samples also revealed CD79A to be 
more phosphorylated at multiple sites upon calcineurin inhibition. Those sites are 
situated closely to the CD79A ITAM except for S197 what lies in the middle of the 
CD79A ITAM. As OCI-LY10 exhibits a heterozygous deletion of aa191- aa208 
affecting parts of the CD79A ITAM also this mutation could slightly strengthen the 
adverse effect on BCR downstream signaling upon inhibition of calcineurin causing 
their intermediate sensitivity towards calcineurin inhibition. This link between 
CD79A/B mutations in ABC DLBCL that somehow alter the outcome  
of calcineurin inhibition on BCR downstream signaling and calcineurin 
dephosphorylation sites in CD79A/B could also explain why the interleukin secretion 
and growth of wild-type cell lines such as GCB DLBCL or some ABC DLBCL are 
only minimally or not impaired by calcineurin inhibition. 
 
In order to have an overview of the general changes in the patterns of 
phosphorylated tyrosines upon calcineurin inhibition we next stimulated the cell line 
Ramos for different time periods with anti-IgM antibodies with or without pre-
incubation of CsA and had then a closer look at phosphorylated tyrosine residues 
by western blotting (Figure 37.). As GCB DLBCL are known to be stimulated by anti-
IgM only very difficult we used the Burkitt lymphoma cell line Ramos for this 
experiment. Moreover, Burkitt lymphoma usually do not harbour mutations in BCR 
proximal CD79 signaling, just as GCB DLBCL. ITAMs are common for associated 
signaling chains of immunoreceptors such as CD79A / CD79B of the BCR and are 
phosphorylated at two invariant tyrosines upon activation of the corresponding 
immunoreceptor and critical for the intracellular signal generation by e.g. upon 
antigen engagement (Niemann and Wiestner, 2013). As tyrosine phosphorylation 
(p-tyrosine) is a common feature in BCR mediated signaling in B-cells, it is possible 
to recognise changes in the phosphorylation of ITAM tyrosines by using anti-p-
tyrosine antibodies in western blotting. 
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Protein aa Position Peptide with STY 
phosphorylation 
probabilities 
Ratio M/L 
normalised 
by protein  
CsA treatment 
Ratio H/L 
normal-
ised by 
protein 
FK506 
treatment  
      
CD79A S 197 LGLDAGDEY(0.001) 
EDENLY(0.079)EGLNLDD
CS(0.609)MY(0.188) 
EDIS(0.123)R 
1,85 3,78 
 Y 210 GLQGT(0.002)Y(0.998)QV
GS(1)LNIGDVQLEKP 
1,74 2,09 
 S 215 GLQGT(0.002)Y(0.998)QV
GS(1)LNIGDVQLEKP 
1,30 1,27 
 T 209 GLQGT(0.748)Y(0.016)QV
GS(0.236)LNIGDVQLEKP 
1,25 1,05 
CD79B S 221 WS(1)VGEHPGQE 1,94 1,58 
BLNK S 129 SSQRHS(1)PPFSK 0,89 0,85 
 S 213 S(1)PPPAAPSPLPR 0,74 0,76 
 S 409 NHQHS(1)PLVLIDSQ 
NNTK 
0,66 0,67 
 S 270 QEAVQS(1)PVFPPAQK 0,43 0,46 
BCL-10 S 138 SNS(1)DESNFSEK 1,74 2,09 
BCLAF1 S 196 DTFEHDPSES(1)IDEFNK 2,21 2,72 
 S 523 S(0.921)T(0.085)FREE  
S(0. 994)PLR 
2,10 2,72 
 S 395 QKFNDS(1)EGDDTEE        
TEDYR 
1,40 1,24 
 S 387 AEGEWEDQEALDYFS(1) 
DKES(1)GK 
1,37 1,57 
 S 383 AEGEWEDQEALDYFS 
(1)DK 
1,33 1,23 
 S 295 YS(0.965)PS(0.035)QNS(1
)PIHHIPS(0.791)RRS(0.20
9)PAK 
1,29 1,38 
 S 529 STFREES(1)PLRIK 1,23 1,04 
 
Table 1. Peptides and their corresponding proteins that prevail in a more or less 
phosphorylated state upon CsA or FK506 treatment. “aa” for amino acid designates the 
abbreviation for a certain amino acid in its one letter code. “Position” means the amino acid’s spot 
in the protein. “Peptide with STY phosphorylation probabilities” depicts the found peptide with 
the assigned probabilities of phosphorylation of the amino acids serine (S) threonine (T) or tyrosine 
(Y). “Ratio M/L” or “H/L” normalised by protein represents the frequency of a certain 
phosphorylated peptide with medium heavy (M) or heavy (H) labelled isotopes in the CsA or FK506 
treated sample divided by the frequency of this phosphorylated peptide labelled with normal, light 
isotopes (L) under untreated control conditions. 
 
From the results obtained from this approach, we concluded no major changes in 
tyrosine phosphorylation patterns upon BCR signaling activation of Ramos cells in 
the presence of CsA compared to control conditions (Figure 37.). Anti-IgM 
stimulation itself was successful because unstimulated cells showed considerably 
fewer and less intensive p-tyrosine bands (Figure 37.). From this result it can be 
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claimed that upon BCR-mediated B-cell stimulation under calcineurin repressive 
conditions, tyrosine phosphorylation patterns are not appreciably changed, at least 
in B-cells deriving from Burkitt’s Lymphoma. In summary, calcineurin seems to 
convey its positive influence on BCR signaling not indirectly by altering the 
phosphorylation of tyrosines as there was no obvious change in BCR upstream 
signaling p-tyrosine patterns. This conclusion is at least true for the Burkitt’s 
Lymphoma cell line Ramos and cannot be handled as general and can be therefore 
different for DLBCL which show other mutation patterns. 
 
 
 
Figure 37. Detection of p-tyrosine residues by western blot in lysates from the Burkitt 
lymphoma cell line Ramos upon anti-IgM mediated BCR stimulation in the presence 
or absence of CsA. Ramos cells were either pre-incubated for 20 min with solvent as control or 3 
µM CsA prior to 15 µg/ml anti-IgM mediated BCR stimulation for the indicated periods of time. 
Weak and strong exposure of p-tyrosine blots are shown to better assess the effects of calcineurin 
inhibition on tyrosine phosphorylation due to the difference in band thickness. 
 
Following this, to further elucidate the potential influence of calcineurin on BCR 
proximal signaling we investigated the phosphorylation of additional proteins 
implicated in BCR signaling. The Ashwell lab recently published in the previously 
mentioned study by Dutta et al., which they found the activating Y493 within the 
activation loop of the tyrosine kinase domain of Zap-70 to be less phosphorylated 
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subsequently to the loss of calcineurin activity that was achieved by different 
approaches (Dutta et al., 2017). Since ZAP-70 is specifically expressed in T-cells 
and plays a role in TCR signaling we were thus interested in the BCR signal 
transduction analogous and structurally similar protein SYK (Chu et al.,1998). Alike 
ZAP-70, SYK is a protein tyrosine kinase and activated by the phosphorylation of 
Y525 and Y526 in the activation loop of its kinase domain. These site are therefore 
crucial for the proper function of SYK (Zhang et al., 2000). For this reason, Y493 of 
ZAP-70 and SYK Y525 and Y526 can be regarded equally in their respective 
function in the context of TCR and BCR signaling. Furthermore, Dutta et al. also 
showed that the phosphorylation of the ZAP-70 ensuing downstream signaling 
molecule SLP-76 at Y145, which facilitates the binding to ITK (Bunnell et al., 2000) 
was diminished by the CsA and FK506 mediated inhibition of calcineurin in T-cells. 
Due to that finding, we were also here interested in the B-cell homologous adaptor 
protein which is called BLNK or SLP-65. BLNK follows directly to SYK in the signal 
transduction chain. It is phosphorylated by SYK among others at Y96 which serves 
similar to p-Y145 of SLP-76 as docking site for signaling molecules as for instance 
PLCγ (Kurosaki and Tsukada, 2000; Ishiai et al., 1999). Consequently, also the 
phosphorylation sites Y145 from SLP-76 and Y96 from BLNK at are homologous in 
their function as ZAP-70 Y493 and SYK Y525 / Y526. For these reasons and 
because there were no commercially available antibodies against the 
phosphorylation sites we unveiled by SILAC for BLNK and CD79A/B as well, we 
examined the phosphorylation sites Y526 from SYK and Y96 from BLNK that are 
both important for BCR downstream signaling in a bit more detail (Figure 38.).  
For this purpose, we treated calcineurin sensitive ABC DLBCL cell lines TMD8 and 
HBL-1 with CsA or FK506 for 2, 5 and 5 and were keen to see if p-SYKY526 or  
p-BLNKY96 levels would change when calcineurin is inhibited. As control for CsA and 
FK506 function, we blotted once more against NFATc1. Both inhibitors worked 
regularly as indicated by NFATc1 shift. We did not recognise any changes in SYK 
and BLNK phosphorylation in neither CsA/FK605 insensitive nor sensitive cell lines 
(Figure 38.). Notably there were no detectable p-BLNKY96 levels emanating from 
TMD8. In summary, the alterations of TCR signaling phosphorylation events upon 
calcineurin inhibition found by Dutta et al seem to be not true for the corresponding 
molecules and phosphorylation sites of BCR signal transduction, we investigated. 
This in turn suggests, a completely different mechanism or other phosphorylation 
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events in the same or other proteins to be the reason behind the calcineurin 
inhibition caused effects on B-cell signaling and their final impact on interleukin 
secretion and proliferation of certain ABC DLBCL. Hence, it is likely that calcineurin 
acts differently in BCR signaling compared to the mechanisms that were shown for 
the phosphatase in primary CD4+ and Jurkat TCR downstream signaling by the 
Aswhell lab. As these mechanisms seem to differ, it is therefore not unlikely that the 
calcineurin mediated positive effect on BCR signaling is caused by the direct and 
indirect dephosphorylation of the newly by SILAC identified putative calcineurin 
affected amino acids in CD79A and/or CD79B or the indirect phosphorylation of 
BLNK at one or multiple sites (Table 1.), which are consequently less 
phosphorylated when calcineurin activity is blocked. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38. Revealing the effects of calcineurin inhibition on BCR downstream 
phosphorylation events in CsA and FK506 sensitive cell lines. (a, b). As indicated lysates 
derived from TMD8, HBL-1 were analysed for protein levels of NFATc1, p-SYKY526 and p-BLNKY96 
by western blotting. Cells were treated with either a solvent as control (0 h), or for 2, 5 and 5 h with 
CsA (2, 5 µM) / FK506 (5µM). A non-specific band approves the equal loading of samples.  
 
3.4 Expression of IκBNS isoforms in B and T-cell 
lymphoma cell lines 
Western blot based analysis of IκBNS expression levels in a panel of ABC DLBCL 
cell lines and the P/I mediated stimulation of the GCB DLBCL cell line BJAB and 
Jurkat T-cells revealed a constantly with the predicted 35 kDa IκBNS signal 
correlated emerging band with a size of approximately 70 kDa. Furthermore, this 70 
kDa signal always appeared to be stronger compared to the IκBNS p35 one. In turn 
to investigate if the 70 kDa protein is indeed another IκBNS specific gene product, 
we tried different IκBNS specific knock down or knock out approaches (Figure 39.a-
d). For this purpose, we lentivirally transduced the GCB DLBCL cell line BJAB with 
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either an empty vector or a construct expressing shRNA #1 and subsequently 
selected for shRNA expressing BJAB cells. Because BJAB do not express IκBNS 
under steady state conditions we induced IκBNS expression in both cell populations 
by P/I mediated stimulation for different time periods (Figure 39.a). To figure out 
whether the experimental outcome would be the same for T-cells, we conducted the 
former described experiment with Jurkat cells, as well (Figure 39.b). Additionally, 
we also tried siRNA mediated IκBNS knock down under steady state IκBNS 
expression in the ABC DLBCL cell line HBL-1 (Figure 39.c). Moreover, we designed 
a CRISPR/Cas9 guide RNA (gRNA) for specific genomic knock out of IκBNS.  Since 
the GCB DLBCL cell line BJAB does not depend on IκBNS expression under steady 
state conditions, we lentivirally transduced BJAB cells with the CRISPR/Cas9 
construct comprising the gRNA targeting the genomic NFκBID sequence.  
For validation of CRISPR/Cas9 caused IκBNS knock out BJAB cells were stimulated 
by P/I for several time periods to induce IκBNS gene expression (Figure 39.d). P/I 
treated BJAB samples that were CRISPR/Cas9 transduced were then compared to 
stimulated empty vector transduced BJAB samples. In case the unknown 70 kDa 
protein should be indeed another IκBNS as well, the 70 kDa signal should vanish 
concomitantly with the p35 IκBNS band in all mentioned IκBNS knock down and 
knock out attempts. All cells transduced with an empty vector as a control, P/I 
treatment induced both, the IκBNS p35 and p70 signal in the expected ratio, 
regardless of B- or T-cell origin (Figure 39.a-d). Indeed, the shRNA and siRNA 
mediated knock down of IκBNS (Figure 39.a, b, c) and the CRISPR/Cas9 conducted 
knock out (Figure 39.d) of IκBNS which all targeted originally the p35 protein also 
affected the appearance of the 70 kDa band in the same manner as for p35 (Figure 
39.a-d). Furthermore, also this result was true for both, the shRNA knock down of 
IκBNS in B- and T-cells. The correlation between the p35 and the p70 band could 
be monitored very nicely in the siRNA mediated knock down approach on steady 
state levels of IκBNS in HBL-1. Here, the strength of both, the p35 and p70 signal 
simultaneously and gradually increased when the siRNA mediated knock down of 
IκBNS ceased over time (Figure 39.c). Blotting against the MALT1 substrate CYLD 
served as control for B- and T-cell stimulation. Taken together, these results suggest 
that in addition to the already known IκBNS p35, there actually exists another IκBNS 
protein that could constitute for instance a posttranslationally modified IκBNS, an 
IκBNS homodimer or a different IκBNS isoform with a size of approximately 70 kDa, 
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afterwards designated as IκBNS p70. As our self-made antibody recognised IκBNS 
p70 and the shRNA, we applied, also targeted this IκBNS p70, both IκBNS proteins 
must share at least those stretches of amino acid sequences that are recognised by 
the antibody and the shRNA sequence. Since the CRISPR/Cas9 knock out 
approach that was designed with the ambition to target IκBNS p35 also led to the 
disappearance of the IκBNS p70 signal in immunoblot further indicates that both, 
the p35 and p70 IκBNS protein are indeed NFκBID gene products and are supposed 
to originate from the same gene locus in B- and T-cells. 
 
 
Figure 39. shRNA and siRNA mediated IκBNS knock down and CRISPR/Cas9 caused 
IκBNS knock out approach to elucidate whether the emerging p70 signal is a IκBNS 
specific band. (a) BJAB GCB DLBCL cells or (b) Jurkat T-cells were lentivirally transduced with 
either an empty vector as control or a construct expressing shRNA#1. Subsequent to puromycin 
selection, cells were stimulated with P/I for the indicated time periods. Induced IκBNS expression 
levels under empty vector and shRNA#1 expressing vector conditions were determined by Western 
Blotting. (c) HBL-1 cells were electroporated at 240 V with either a mixture of unspecific siRNA 
sequences as control or 300 pmol of siRNA targeting IκBNS. Lysates of HBL-1 cells electroporated 
with either control or siRNA targeting IκBNS were analysed by Western Blot for IκBNS p35 and 
p70 knock down for the indicated days following electroporation. Weak and strong exposure of 
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IκBNS p70 is shown due to different expression levels of IκBNS p35 and p70. (d) BJAB cells were 
lentivirally transduced with either a CRISPR/Cas9 encoding vector without gRNA (empty vector) as 
control or a construct bearing a gRNA sequence targeting the genomic sequence of NFκBID leading 
to a knock out. To verify the successful knock out of IκBNS p35 and p70 upon puromycin selection, 
levels of P/I induced IκBNS p35 and p70 in control cells and IκBNS knock out cells were compared 
by western blot analysis. In (a, b and d) CYLD cleavage validated cell activation by P/I. In all figure 
panels (a-d) Tubulin served as loading control. 
Next, we wanted to shed some more light on the induction mechanisms of IκBNS 
p35 and p70. Since the stimulation of B-cells by their antigen receptor is more 
difficult to achieve compared to T-cells we decided to investigate this issue in a T-
cell lymphoma model cell line. The acute T-cell leukemia derived cell line Jurkat 
showed the same stimulation behaviour in the up regulation and shRNA mediated 
knock down of IκBNS p35 and p70 as BJAB GCB DLBCL (Figure 39.a, b). For this 
reason, we chose the Jurkat T-cell line as model to investigate IκBNS up regulation. 
To study whether different fashions of T-cell activation would also result in diverse 
induction manners of whole IκBNS levels or in differences between the expression 
patterns of IκBNS p35 and p70 we stimulated Jurkat cells with either cross-linked 
stimulating monoclonal antibodies against the T-cell activation molecules CD3 and 
CD28 or P/I for different time periods. Subsequently IκBNS p35 and p70 expression 
was assessed by western blot. Anti-CD3/CD28 antibodies activate T-cells in a way 
that partly mimics physiological stimulation by antigen-presenting cells, whereas cell 
stimulation mediated by P/I acts more proximally in TCR signaling by inducing PKC 
activity and increasing Ca2+ mobilisation. Both stimuli led to the induction of high 
IκBNS p35 and p70 expression levels in the familiar ratios after 180 min of 
administration (Figure 40. a, b). Noteworthy, both the p35 and the p70 IκBNS signal 
appear as a lower strong and upper weak double band, indicating the existence of 
further modified IκBNS proteins. The only small distinction between the different 
kinds of T-cell stimulation regarding IκBNS induction was the non-long lasting T-cell 
stimulation intensity and as a consequence of this the earlier decline of IκBNS p35 
and p70 levels after 360 min when cells were activated by anti-CD3/CD28 
antibodies compared to P/I stimulated T-cells. This effect is caused most likely due 
to the fact that P/I seemed to stronger stimulate the cells in general and over a 
longer time frame in this experiment indicated by the higher portions of cleaved 
CYLD p40 of P/I stimulated cells compared to CYLD p40 levels in anti-CD3/CD28 
stimulated cells. Furthermore, from this outcome we can draw the conclusion that 
there are neither noteworthy differences between whole IκBNS levels nor 
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observable changes in the ratios of p35 and p70 expression levels caused by the 
two fashions of T-cell stimulation. In summary, this result suggests that both IκBNS 
gene products, the p35 and p70 protein are also induced when T-cell receptors 
engage their antigens reflected by the physiological TCR activation by anti-
CD3/CD28 antibodies. Taken together, we can state that T-cell stimulation is a 
potent functional inducer of IκBNS p35 and p70 expression. 
          
 
Figure 40. Investigating the potential differences of anti-CD3/CD28 antibody and P/I 
mediated T-cell stimulation on IκBNS p35 and p70 expression. (a) Jurkat T-cells were 
treated with 10 µg/µl cross-linked anti-CD3/CD28 antibodies or (b) P/I for the indicated periods of 
time. Lysates were analysed for IκBNS and CYLD expression levels by immunoblot. (a, b) CYLD 
cleavage by MALT1 reflects the antibody and P/I mediated activation of Jurkat T-cells. Tubulin 
served as an indicator for equal loading of samples. 
 
Thanks to the previously conducted experiments we now had several lines of 
evidence that the p70 signal is indeed another additional IκBNS protein sharing 
amino acid sequence stretches with the predicted IκBNS p35. Moreover, by applying 
the CRISPR/Cas9 method, we proved that the two proteins arise from the same 
gene locus in human B-cells. Both IκBNS proteins were already observed in mouse 
conventional T-cells by Schuster et al. in 2012 and in mouse embryonic fibroblasts 
by Jeltsch et al. in 2014, as well. Schuster et al. also assumed p35 and p70 to 
emanate from a sole gene locus as stimulated mouse Nfkbid-deficient cells show 
no p70. Additionally, Jeltsch et al. claim IκBNS to produce specific signals at 35 and 
70 kDa. However, the two of them did not show evidence that the 70 kDa signal 
arises indeed from another distinct IκBNS protein in mouse cells. Nevertheless, so 
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far, we did not know what exactly the additional IκBNS protein with a size of 
approximately 70 kDa was indeed. We speculated if the IκBNS p70 could be a 
second IκBNS isoform, a postranslationally modified p35 or a p35 homodimer. The 
latter possibility was the most obvious for us as the IκBNS protein of so far unknown 
genesis exhibits exactly double the size (70 kDa) of the predicted IκBNS with 35 
kDa. For that reason, we next tried to figure out if the IκBNS p70 is just a seemingly 
SDS-stable homodimer of IκBNS p35. To this end, we tried different approaches to 
crack the putative IκBNS p70 homodimer in lysates derived from steady state IκBNS 
expressing cell lines OCI-LY3, HBL-1 and Rec1 by different modifications of our 
sample buffer (Figure 41.a,b). Kolodziejski et al. suggested to increase the 
concentration of protein reducing agents to destruct dimers. From this we 
considered combining 2-ME that is already included in our sample buffer with the 
other commonly used reductant DTT (Figure 41.a). Moreover, we also applied 
another strongly reductive sampler buffer (2x urea buffer) to lysates comprising  
8 M urea plus either 8% of SDS or 6 M guanidine hydrochloride (Figure 41.b). We 
decided to include 8% SDS and 6 M guanidine hydrochloride concentrations 
according to Kolodziejski et al., 2003. All listed compounds are either strongly 
reductive agents such as 2-ME and DTT or strong protein denaturants like urea, 
SDS and guanidine hydrochloride (Wingfield, 2016) that should disrupt the putative 
IκBNS dimers of 70 kDa into two 35 kDa IκBNS monomers. As depicted in Figure 
41.a, b, none of the different reductive and denaturising conditions successfully led 
to the disruption of the presumable 70 kDa homodimer. This is indicated by stable 
amounts of IκBNS p70 and no further increase in the amount of putative IκBNS p35 
monomers (Figure 41.a) in comparison to sample buffer controls (sample buffer with 
2-ME). HEK293T lysates derived from cells transfected with an empty vector or a 
FLAG-tagged IκBNS p35 expressing construct were included in Figure 41. to 
estimate the size at which IκBNS p35 runs on a SDS-gel. Taken together, this result 
suggests that IκBNS p70 is not an IκBNS p35 homodimer and favours instead the 
hypothesis of a further, larger IκBNS isoform or postranslationally modified IκBNS 
p35.  
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Figure 41. Pursuing the question whether IκBNS p70 is a SDS stable IκBNS p35 
homodimer. (a) Lysates from OCI-LY3 cells expressing steady state levels of IκBNS p35 and p70 
were treated with either our commonly used sample buffer or a modified variant containing 100 mM 
DTT. Expression levels of IκBNS were then assessed by western blotting (b) Western blot analysis 
of lysates from OCI-LY3, HBL-1 and Rec1 cells expressing steady state IκBNS p35 and p70 levels 
were exposed either to the commonly used sample buffer as control or 2 x Urea Buffer comprising 
either 8% SDS or 6 M of guanidine hydrochloride to disrupt the presumable 70 kDa IκBNS p35 
homodimer. 
 
To further elucidate if IκBNS p70 is indeed no dimer and no postranslationally 
modified p35, as well, we next overexpressed a FLAG-tagged IκBNS p35 in the ABC 
DLBCL cell line HBL-1 by lentiviral transduction. Both, IκBNS p35 and p70 are 
already expressed at high levels under steady state conditions in HBL-1 cells. The 
FLAG-tagged IκBNS p35 exhibits a slightly higher molecular mass than the 
endogenously expressed IκBNS p35. We assumed that in case the IκBNS p70 
would be a homodimer, made up of two IκBNS p35 or a postranslationally modified 
IκBNS p35 then the artificially introduced FLAG-tagged IκBNS p35 should also exist 
either as a FLAG-tagged p70 IκBNS dimer or postranslationally modified FLAG-
tagged p70 IκBNS. Due to the FLAG-tag these IκBNS p70 versions would then have 
a slightly higher molecular weight compared to their endogenously expressed 
counterparts and would therefore run higher on a SDS-gel, so that they could be 
easily distinguished from each other. Thus, the existence of those FLAG-tagged p70 
IκBNS versions would strengthen the p35 dimer and posttranslational modification 
hypothesis. However, the outcome of this experiment as depicted in Figure 42. 
rejects the dimer and posttranslational modification thesis since the described 
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additional FLAG-tagged p70 IκBNS signals do not appear. In summary, we excluded 
the IκBNS p70 protein to be an IκBNS p35 homodimer by different disruption 
approaches (Figure 41.a,b). This result was approved by the overexpression of a 
FLAG-tagged IκBNS p35 in HBL-1 cells that did not lead to the generation of  
a FLAG-tagged IκBNS p70 that could easily be distinguished from the endogenous 
counterparts in immunoblot due to the slightly increased molecular weight. 
Moreover, the absence of those FLAG-tagged IκBNS p70 variants also proofs that 
IκBNS p70 is not just a posttranslationally modified IκBNS p35. Taken together, the 
obtained results suggest that the IκBNS p70 is most likely a further second, discrete 
IκBNS isoform originating from the same gene locus as IκBNS p35. 
                                     
 
Figure 42. Exploring whether IκBNS p70 is an IκBNS p35 derived homodimer or a 
postrans-lationally modified IκBNS p35. The steady state endogenous IκBNS p35 and p70 
expressing ABC DLBCL cell line HBL-1 was lentivirally transduced with either an empty vector as 
control or a FLAG-tagged IκBNS p35 expressing vector. HBL-1 lysates were analysed for IκBNS 
levels by western blotting. Due to the FLAG-tag, the lentivirally transduced IκBNS p35 exhibits a 
minimally higher size therefore running at slightly higher molecular weight on the western blot 
compared to endogenous IκBNS p35. As no FLAG-tagged IκBNS p70 band emerges upon 
expression of FLAG-tagged IκBNS p35 the theory of an IκBNS p70 consisting of two IκBNS p35 
and an IκBNS p70 that is a posttranslationally modified IκBNS p35 was ruled out. Weak and strong 
exposures of blots are shown for a better impression of the different expression levels of IκBNS p35 
and p70. 
 
Since previous experiments strongly indicate IκBNS p70 to be a second distinct 
IκBNS isoform originating from the same gene locus as IκBNS p35, we next had a 
closer look at the transcribed NFκBID mRNA. In fact, deep sequencing conducted 
with samples from the ABC DLBCL cell line HBL-1, revealed that only one IκBNS 
mRNA is expressed. Furthermore, with the help of an ORF prediction tool, we found 
a second open reading frame consisting of 1716 nucleotides coding for a protein 
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comprising 572 aa with a resulting predicted molecular weight of 61 kDa, suggesting 
the expression of a second isoform (Figure 43.; IκBNS p70). This molecular weight 
was a bit less than expected, as we assumed a molecular weight of approximately 
70 kDa due to the IκBNS p70 signal. In order to prove the presence of the predicted 
IκBNS isoform in B-cells  
 
 
Figure 43. Schematic illustration of the IκBNS p35 and p70 isoform. The human IκBNS 
p35 consists of 313 aa and includes 6 ankyrin repeats (ANK; shaded in grey), important for protein-
protein interactions. IκBNS p70 comprises 572 aa and exhibits an additional 259 aa N-terminal 
unstructured portion of unknown function (shaded in grey), and shares the complete IκBNS p35 
sequence. The predicted molecular weight of IκBNS p35 is 33,5 kDa whereas IκBNS p70 is predicted 
to have a molecular weight of 61,1 kDa. aa, amino acid; NH2, N-terminus; COOH, C-terminus. 
 
In turn to examine this newly established isoform (Figure 43.; IκBNS p70) in more 
detail, we cloned a vector encoding the potential new IκBNS p70 isoform and 
conducted multiple experiments with this. First of all, we wanted to figure out at 
which size the presumable IκBNS p70 would actually run on a SDS gel compared 
to the endogenous IκBNS p70 counterpart to have a clue whether our sequence 
could be indeed identical to the endogenous one found in ABC DLBCL as well as in 
in GCB DLBCL and Jurkat T-cells upon P/I mediated stimulation. To this end, we 
transfected HEK293T cells with either an empty vector as control or with vector 
constructs expressing STREP-tagged IκBNS p35 or p70. In order to compare these 
STREP-tagged proteins with the size of endogenously expressed IκBNS p35 and 
p70 proteins we included several samples from ABC DLBCL cell lines (HBL-1, 
TMD8, OCI-LY3 and RIVA) in the experiment showing high endogenous expression 
levels of IκBNS p35 and p70. In contrast to that we also implicated multiple samples 
deriving from GCB DLBCL cell lines (SU-DHL-4, SU-DHL-6 and OCI-LY1) that are 
known to us to express no IκBNS. As shown in Figure 44.a, STREP-tagged IκBNS 
p35 was properly expressed in HEK293T and showed as expected a slightly higher 
molecular weight than the endogenous protein. Furthermore, western blot analysis 
also clearly revealed that the STREP-tagged IκBNS p70 expressed in HEK293T  
de facto exhibits a slightly higher molecular weight in the blot than the actual 
predicted size of 62 kDa including STREP-tag. This size was comparable with the 
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endogenous IκBNS p70 from ABC DLBCL (Figure 44.a). Moreover, the expression 
of the STREP-tagged IκBNS p70 led to the formation of several bands that were 
lying close to each other, resembling the band pattern observable in ABC DLBCL 
samples (Figure 44.a). Noteworthy as well, the expression of IκBNS p35 and p70 
expressed in HEK293T cells closely resembled the pattern of IκBNS p35 and p70 
endogenously expressed by ABC DLBCL. For these reasons, the IκBNS p70 protein 
sequence we found is likely to be same as the endogenous IκBNS p70 amino acid 
sequence found under steady state conditions in ABC DLBCL cell lines and upon 
stimulation of GCB DLBCL.  
The following experiment we conducted to analyse what influence the ectopic 
expression of IκBNS p35 and p70 would have on endogenous IκBNS p35 and 70 
levels that were induced by P/I mediated T-cell stimulation (Figure 44.b). In addition 
to that, we wanted to know, whether the expression of the IκBNS p70 isoform in  
T-cells would look the same as in HEK293T cells. For this purpose, we lentivirally 
transduced Jurkat T-cells with either an empty vector or plasmid constructs 
expressing either FLAG-tagged IκBNS p35 or the V5-tagged IκBNS p70 isoform. 
Once the successfully transduced cells were selected by puromycin treatment 
Jurkat T-cells were stimulated by P/I to induce endogenous levels of IκBNS p35  
and p70. Samples were subsequently analysed for IκBNS expression by 
immunoblotting. Both IκBNS isoforms that were lentivirally transduced expressed 
well in Jurkat cells (Figure 44.b). As already observed in samples coming from 
HEK293T cells, the expression of lentivirally transduced V5-tagged IκBNS isoform 
p70 exhibits just a marginally higher size than the endogenously expressed IκBNS 
p70 caused by the V5-tag. For the same reason, also the FLAG-tagged IκBNS p35 
shows a slightly increased molecular weight compared to its physiological 
correspondent. In this way it was possible to clearly distinguish between 
endogenous and lentivirally transduced IκBNS isoforms. Compared to the P/I 
induced IκBNS p35 and p70 levels of Jurkat cells transduced with an empty vector 
both, the expression of the FLAG-and V5-tagged lentivirally transduced IκBNS p35 
and p70 isoforms resulted in remarkably decreased levels of endogenous IκBNS 
p35 and p70 that were induced by 4 h of cell stimulation by P/I (Figure 44.b). 
Noteworthy, the level of cell stimulation was equal amongst the samples, indicated 
by the amount of cleaved CYLD. This result suggests that IκBNS p35 and p70 act 
in a negative (auto inhibitory) feedback loop to restrict and down regulate their own 
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expression. By pull-down experiments in TCR transgenic thymocytes, IκBNS was 
shown to bind NFκB family members such as nuclear p50, p65, RelB and c-Rel. 
Moreover, IκBNS binds to transcriptional inactive p50 homodimer on the IL-6 
promoter (Hirotani et al., 2006). In IκBNS deficient macrophages Kuwata et al. 
observed in 2006, the extended binding of the RelA/p50 heterodimer to the IL-6 
promoter, indicating that IκBNS is able to act as a transcriptional repressor. Thus, it 
would be conceivable that this negative feedback loop could be conducted by the 
binding of IκBNS to NF-κB components such as a transcriptional inactive p50 
homodimers, thereby preventing subsequent DNA binding of other active NF-κB and 
NFAT members to the NFκBID promoter. Also imaginable would be that IκBNS 
shortens the resting time of active RelA/p50 heterodimers by removing them from 
the NFκBID promoter. Taken together, these results suggest that the IκBNS p70 
amino acid sequence we revealed is indeed equivalent to the endogenous IκBNS 
p70 protein sequence from B- and T-cells under steady state and P/I mediated 
induced IκBNS expression conditions. Furthermore, both IκBNS isoforms seem to 
work in a negative (auto inhibitory) feedback loop to limit and down modulate a 
surplus of IκBNS expression levels.  
 
 
Figure 44. Expression of the revealed IκBNS p70 protein in comparison to steady state 
endogenous IκBNS p70 in ABC DLBCL cell lines and P/I induced IκBNS p70 in Jurkat 
T-cells. (a) HEK293T cells were transfected either with an empty vector as control or a vector 
expressing IκBNS p35 or p70. Lysates from indicated GCB and ABC DLBCL cell lines were 
analysed for IκBNS p35 and p70 expression in comparison to IκBNS p35 and p70 overexpressed in 
HEK293T cells. GAPDH served as a loading control especially for samples from GCB DLBCL cell 
lines that do not express IκBNS (b) Jurkat T-cells were lentivirally transduced either with an empty 
vector as control or one of the two IκBNS isoforms (FLAG-tagged p35 or V5-tagged p70) and 
stimulated for 4 h with P/I to induce endogenous IκBNS expression.  CYLD cleavage was determined 
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to indicate T-cell stimulation by P/I. A not specific band (n.s.) served as indicator for equal loading 
of samples. 
 
To further substantiate that the IκBNS p70 isoform sequence we established is really 
the one that can be found endogenously in DLBCL, we generated an IκBNS p70 
isoform specific antibody that binds an antigen in the N-terminal portion unique for 
IκBNS p70. Thus, this antibody should not detect the shorter IκBNS p35 isoform.                   
In order to test the anti-IκBNS p70 antibody, we stimulated the GCB DLBCL cell line 
BJAB for different periods of time with P/I what would cause the induction of both                    
IκBNS isoforms. By western blot analysis we compared the IκBNS antibody 
recognising both isoforms (Figure 45. upper panel) with the antibody detecting 
exclusively the larger p70 IκBNS isoform. Indeed, the p70 isoform specific antibody 
detected a protein strongly appearing after 180 min of P/I mediated cell stimulation 
with the expected size of approximately 70 kDa. Unfortunately, this presumably 
specific IκBNS p70 signal was partly overlaid with another unspecific band.  
Thus, it was not possible for us to make further statements about the recognition 
capacities of the self-made anti-IκBNS p70 antibody and the pattern of bands 
specific for IκBNS p70. Moreover, the anti-IκBNS p70 antibody did not detect any 
IκBNS p35 isoform at all (Figure 45. middle panel) as it was the case for the anti-
p35/p70 antibody (Figure 45. upper panel) that recognised an IκBNS p35 specific 
band in samples from BJAB cells that were stimulated with P/I for 180, 240 and 360 
minutes. BJAB stimulation by P/I was confirmed by assessing the cleavage of the 
MALT1 substrates BCL-10 and CYLD. In summary, this result strengthens the 
assumption that the endogenous IκBNS p70 isoform is indeed identical with our 
IκBNS p70 aa-sequence as the antibody recognises an antigen located in the N-
terminal portion that is unique for the IκBNS p70 isoform. 
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Figure 45. Testing the self-made anti-IκBNS p70 antibody for 
its detection capabilities for the larger IκBNS p70 isoform in 
comparison to the anti-IκBNS p35 and p70 antibody. 
BJAB cells (GCB DLBCL) were stimulated by P/I for 0, 15, 240 
and 360 min to induce endogenous IκBNS expression. Lysates 
were analysed for IκBNS expression with the anti-IκBNS p35 and 
p70 antibody (upper panel) and the anti-IκBNS p70 specific 
antibody (middle panel). Blotting against the MALT1 substrates 
BCL-10 and CYLD served as B-cell activation marker. An 
unspecific band (n.s.) indicates the equal loading of samples. 
 
 
 
 
 
 
 
 
 
 
Since we expect different IκBNS isoforms not only to have mutual tasks and 
properties but also isoform specific and unique purposes and characteristics, we 
were next interested in the existence of differences between the IκBNS p35 and p70 
isoform. Schuster et al. claimed in 2012 that in immunoblotting IκBNS appears within 
the first   4 h of P/I mediated stimulation of conventional mouse T-cells as a 35 kDa 
protein in the cytoplasm and as two 70 kDa IκBNS proteins in the nucleus. Moreover, 
Fiorini et al., found that IκBNS (most likely the p35 isoform) was selectively found in 
the nuclear fraction of thymocytes derived from mice treated 2 h with VSV8. 
Furthermore, they expressed an N-terminally eGFP-tagged IκBNS p35 in HeLa cells 
that was predominantly localised to the nucleus.  
In turn to see where IκBNS p35 and p70 localise and if the isoforms would indeed 
differ in their spatial distribution also in B-cells we conducted cell fractionations with 
BJAB cells (GCB DLBCL) that were treated for 1 and 3 h with P/I to induce IκBNS 
(Figure 46.a) and with U2932 and HBL-1 (ABC DLBCL) cells, both expressing 
IκBNS under steady state conditions (Figure 46.b). Lamin A/C was considered as 
nuclear marker whereas ERK2 constituted the cytoplasmic marker protein. Western 
blot analysis showed that under inductive IκBNS expression conditions in BJAB cells 
the IκBNS p70 isoform emerges first in the nuclear fraction after 1 h of P/I stimulation 
whereas IκBNS p35 is not detectable in both, the cytoplasmic and nuclear fraction 
at that time point. After 3 h of P/I mediated B-cell stimulation both isoforms appear 
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in the cytosolic fraction in rather low but equal amounts. This is in contrast to the 
nuclear fraction where both isoforms were clearly enriched compared to the 
cytoplasmic fraction whereby IκBNS p70 was now obviously more abundant than 
the smaller IκBNS p35 isoform (Figure 46.a). The fractionation of ABC DLBCL cell 
lines expressing steady state IκBNS levels revealed that  there is clearly more 
IκBNS p35 and p70 in the nucleus than in the cytoplasm (Figure 46.b). Thereby, the 
ratios of protein amounts between IκBNS p35 and p70 apparently remained the 
same no matter in which cellular compartment.  
Taken together, from these results we draw the conclusion that there exists no 
cytoplasmic or nuclear specific IκBNS isoform. Furthermore, upon IκBNS 
expression induction by P/I, IκBNS p70 clearly appears first in the nucleus whereas 
IκBNS p35 is not present neither in the cytoplasm nor the nucleus. This could be 
caused simply by the fact that IκBNS p70 is generally higher expressed than IκBNS 
p35. Thus the smaller isoform is also expressed but in such little amounts that is not 
detectable by immunoblotting. Moreover, in general it can be said, that both isoforms 
are more abundant in the nucleus than in the cytoplasm after the induction by P/I 
and under steady state conditions, as well. Mentionable, the ratio of protein levels 
between IκBNS p35 and p70 always remains the same with only one exception. 
After 3 h of P/I stimulation the ratio between the levels of IκBNS p35 and p70 is 
equal in the cytoplasmic fraction and p70 is strikingly more abundant in the nuclear 
fraction than p35. This fact could be explained by different nuclear shuttling 
behaviours of the IκBNS isoforms. The larger isoform IκBNS p70 could probably 
bear a nuclear localisation sequence (NLS) in its unique N-terminal portion and 
could be therefore retained in the nucleus in contrast to IκBNS p35 for which no NLS 
was found so far. According to the cytoplasmic and nuclear marker,  
cell fractionations worked properly in all samples. 
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Figure 46. Fractionation of P/I stimulated one GCB DLBCL and two ABC DLBCL cell 
lines under steady state conditions to assess potential differences between the spatial 
distribution of IκBNS p35 and IκBNS p70. (a) The GCB DLBCL cell line BJAB was 
stimulated with P/I for 0, 1 and 3 h to induce IκBNS p35 and IκBNS p70 expression. Subsequently, 
cells were fractionated into cytoplasmic and nuclear moieties. (b) The ABC DLBCL cell lines U2932 
and HBL-1 cells were harvested under steady state conditions. Afterwards, cytoplasmic and nuclear 
fractions were prepared. (a, b) Expression levels of IκBNS p35 and IκBNS p70, Lamin A/C and 
ERK2 were determined by immunoblotting. In both panels Lamin A/C detection served as a marker 
for the purity of the nuclear fraction whereas ERK2 levels indicate the purity of the cytoplasmic 
fraction. An unspecific band (n.s.) served as loading control. 
 
3.5 Regulation of HLA-DR expression by IκBNS 
IκBNS belongs to the group of atypical, nuclear residing NF-κB inhibitors.                           
The members of this protein family were shown to contribute considerably to the 
modulation of NF-κB mediated transcription in immune cells. They accomplish this               
task by their capability to negatively or positively regulate the transcriptional activity 
of target genes together with DNA-associated NF-kB transcription factors (reviewed 
in Annemann et al., 2016). For this reason, we were interested which genes and in 
which direction these affected genes would be regulated by an IκBNS knockdown 
in ABC DLBCL. For this purpose, we conducted an inducible shRNA #1 mediated 
IκBNS knock down in HBL-1 cells for 96 h that was followed by an RNA-Seq. The 
approach revealed multiple MHC class II (MHCII) genes and moreover genes 
encoding accessory proteins that are needed for MHCII-restricted antigen 
presentation like CD74 (also known as invariant chain or Li) or Human Leucocyte 
Antigen-DM (HLA-DM) (LeibundGut-Landmann et al., 2004) among the top hits of 
genes that were negatively regulated by IκBNS (Table 2.). MHCII molecule 
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expression is restricted to the surface of professional antigen presenting cells such 
as B-cells and is crucial for presenting peptide antigens derived from extracellular 
pathogens to the TCR of CD4+ T-cells. This MHCII:peptide complex engagement by 
the TCR in turn induces the activation and proliferation of the respective T-cell and 
is therefore pivotal for an antigen-specific response of the adaptive immune system. 
Moreover, MHC class II molecules are not only important for mounting an adaptive 
immune response directed against pathogens but also for the recognition of 
peptides specific for tumorigenic cells by tumor-specific T-cells. This feature 
indicates the important role of MHCII in immune surveillance (Wilkinson et al., 2012). 
The human MHCII protein family is subdivided into the classical MHCII (HLA-DP, 
-DQ, and –DR), the non-classical (HLA-DM and –DO) and the invariant chain 
molecules. Unlike their classical counterparts, non-classical MHCII are not located 
at the cell surface and do not present antigens. Instead, they regulate and promote 
the loading of peptide antigens to classical MHCII molecules (Alfonso and Karlsson 
2000; Ting and Trowsdale, 2002; Reith and Mach., 2001; LeibundGut-Landmann et 
al., 2004; Wilkinson et al., 2009). Remarkably, also the class II major 
histocompatibility complex transactivator “CIITA” which is the essential master 
transcriptional regulator of the entire MHC class II genes and several associated 
genes like the membrane glycoprotein Li, was positively affected by IκBNS silencing  
(Table 2.). CIITA governs whether and in what extend MHC II proteins are 
expressed. Therefore, CIITA is expressed in MHCII positive professional antigen 
presenting cells such as B-cells, macrophages and DCs (Reith and Mach., 2001; 
LeibundGut-Landmann et al., 2004). 
Based on the results we obtained by RNA-Seq., we were next interested to further 
examine the impact of IκBNS expression on MHC class II protein expression in 
DLBCL. As B-cells are professional antigen presenting cells, they usually express 
MHCII on the cell surface. Thus, we also expected to find MHC class II molecules 
on the surface of DLBCL cell lines. RNA-Seq. revealed the HLA-DRB1 gene which 
encodes the beta subunit of the HLA-DR isoform to be the most affected MHC class 
II gene by shRNA mediated IκBNS knockdown. In addition to that HLA-DR is known 
to be the highest expressed isoform in human (Landsverk et al., 2009). Accordingly, 
we decided to investigate this particular classical MHCII isoform on the surface of 
DLBCL cell lines in our experiments.  
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Gene Fold change P-value 
 LAG3;CD223 1,60 1,24E-17 
HLA-DRB1 1,51 9,37E-27 
ferritin heavy chain 1 1,44 2,46E-15 
2'-5'-oligoadenylate synthetase 3 1,44 8,77E-11 
CD52 1,42 8,85E-15 
MX dynamin like GTPase 1 1,41 7,87E-11 
HLA-DRA1 1,40 1,67E-24 
Janus kinase 3  1,40 5,42E-17 
HLA-DQA 1,39 2,97E-11 
TNF alpha induced protein 2  1,39 1,14E-08 
protein tyrosine phosphatase, non-receptor type 7 1,38 1,74E-13 
transmembrane protein 160 1,38 3,69E-08 
CD74 (invariant chain) 1,37 9,59E-41 
BCL2 interacting killer  1,36 3,66E-08 
heat shock protein family B (small) member 1 1,35 1,20E-08 
MIR663A host gene 1,35 6,40E-08 
fibromodulin  1,34 6,34E-10 
parvin gamma 1,34 4,44E-07 
HLA-DRB 1,34 2,11E-07 
surfactant protein B 1,33 5,02E-09 
class II major histocompatibility complex 
transactivator (CIITA) 
1,22 3,77E-07 
NFKB inhibitor delta (IκBNS) 0,76 3,29E-11 
   
Table 2. Genes that were revealed by RNA-Seq. to be upregulated upon 96 h of 
inducible shRNA mediated IκBNS knock down in samples from the steady state IκBNS 
expressing ABC DLBCL cell line HBL-1. “Gene” designates the name of the gene found to 
exhibit an altered transcriptional activity upon IκBNS knock down; “Fold change” means the extent 
of the transcriptional activity change compared to the control; Highlighted in bold are genes that 
belong to MHC class II gene family.  
 
Partial IκBNS knock-down can be easily achieved in a relative short time span by 
treating ABC DLBCL cell lines with the calcineurin inhibitors CsA and FK506.  
For this reason, we subjected the calcineurin inhibitor sensitive cell line HBL-1 and 
the insensitive cell line OCI-LY3 to a dilution series of CsA. After an incubation of 
two days we determined the amount of HLA-DR molecules displayed on the cell 
surface by flow cytometry. Indeed, the CsA mediated knock down of IκBNS led to 
an increase of HLA-DR proteins residing on cell surface of approximately 30 % for 
HBL-1 and more than 50% for OCI-LY3 cells in comparison to the untreated control 
(Figure 47.). This effect is dose dependent as there was an observable tendency of 
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elevating HLA-DR surface levels accompanied by increasing CsA concentrations. 
The highest HLA-DR surface levels could be therefore achieved in both cell lines 
with the highest applied concentration of CsA. In summary, these results indicate, 
that the partial IκBNS knock down caused by the pharmacological inhibition of 
calcineurin and resulting NFATc1 activity blockage is leading to the enhanced 
presentation of HLA-DR molecules on the cell surface of ABC DLBCL cell lines. 
Notably, this effect seems to be independent from whether the cell line is calcineurin 
inhibitor sensitive or not. 
 
Figure 47. Measurement of HLA-DR surface levels on HBL-1 and OCI-LY3 cells (ABC 
DLBCL) upon two days of CsA mediated knock down of IκBNS. (a) HBL-1 and (b) OCI-
LY3 cells were treated with solvent as control or the indicated concentrations of CsA for two days 
prior to flow cytometry analysis of HLA-DR surface levels. (a, b) Depicted is the mean fluorescence 
intensity (MFI) of HLA-DR+ cells normalised to solvent treated cells (control). 
 
Since we wanted to confirm the previously observed effect (Figure 47.),                              
we consequently treated another ABC DLBCL with both available calcineurin 
inhibitors (CsA and FK506). Thus, we incubated TMD8 cells that also exhibit high 
expression levels of IκBNS with dilutions series of both inhibitors for two days and 
subsequently assessed HLA-DR surface levels by flow cytometry. The impact of 
CsA mediated IκBNS knock down on HLA-DR levels that we had already observed 
for HBL-1 and OCI-LY3 cells could clearly be reproduced for HLA-DR surface levels 
of TMD8 cells treated with CsA or FK506 (Figure 48.). Furthermore, the effect of 
raising HLA-DR surface levels going along with increasing concentrations of CsA 
was this time clearly dose dependent. It was possible to increase HLA-DR surface 
levels more than 3-fold compared to solvent control by treating TMD8 cells with 
5 µM CsA (Figure 48.a). FK506 treatment of TMD8 cells clearly induced the 
elevation of HLA-DR surface levels, as well. Noteworthy, the mentioned dose 
dependent effect we have seen for CsA treatment was also present here, as the 
highest HLA-DR surface levels could be measured at the highest amounts of FK506 
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(Figure 48.b), but not that impressive as for CsA treatment of TMD8. Here, 
calcineurin inhibition by FK506 led to an HLA-DR surface expression up to 1,5 fold 
compared with the solvent control. In summary, the CsA and Fk506 mediated knock 
down of IκBNS in ABC DLBCL leads to clearly enhanced HLA-DR surface levels in 
a dose dependent manner. 
 
Figure 48. Assessment of HLA-DR surface levels upon treatment of TMD8 cells (ABC 
DLBCL) with dilutions series of the calcineurin inhibitors CsA and FK506 to knock 
down IκBNS expression. Cells were treated with solvent as control or (a) the indicated 
concentrations of CsA or (b) for two days ahead of flow cytometry analysis of HLA-DR surface 
levels. (a, b) Depicted is the mean fluorescence intensity (MFI) of HLA-DR+ cells normalised to 
solvent treated cells (control). 
 
To demonstrate that IκBNS itself directly causes the changes of HLA-DR surface 
levels on B-cells we overexpressed both IκBNS isoforms (FLAG-tagged p35 and 
V5-tagged p70) in B-cell lines that show high HLA-DR and no steady state IκBNS 
expression. RNA-Seq. revealed IκBNS as a negative regulator of HLA-DR. 
Therefore, the knock down of IκBNS by calcineurin inhibitors led to increased HLA-
DR surface levels on ABC DLBCL cell lines (Figure 47. and 48.). For this reason, 
we expected diminished HLA-DR surface levels on B-cells overexpressing the 
IκBNS isoforms p35 and p70. In order to figure this out, we lentivirally transduced 
the GCB DLBCL cell line BJAB and the Burkitt’s lymphoma cell line RAJI with either 
an empty vector as control or vectors coding for IκBNS p35 or p70 (Figure 49.a, b). 
Upon puromycin selection of successfully transduced cells, we measured HLA-DR 
surface levels of BJAB and RAJI cells that were properly expressing IκBNS p35 or 
p70 one week after lentiviral transduction (Figure 49.a, b). As assumed, BJAB and 
RAJI cells expressing IκBNS p35 or p70, showed indeed clearly diminished HLA-
DR surface levels (Figure 49.a, b) compared to the empty vector transduced cells. 
In detail, HLA-DR surface levels were lowered up to roughly 30% for BJAB and 40% 
for RAJI cells by the expression of IκBNS p35, whereas the expression of IκBNS 
p70 caused a reduction of HLA-DR surface levels by approximately 40% on BJAB 
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and slightly more than 40% on RAJI cells (Figure 49.a, b). In summary, the 
overexpression of IκBNS p35 and p70 in B-cells deriving from GCB DLBCL and 
Burkitt’s lymphoma origin caused a clear reduction of HLA-DR surface levels. 
Thereby was the extent of reduction independent from the overexpressed isoform 
albeit the effect was minimally more pronounced in cells expressing IκBNS p70. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49. Determining HLA-DR surface levels of BJAB (GCB DLBCL) and RAJI (Burkitt’s 
lymphoma) B-cells expressing IκBNS isoforms p35 and p70. (a, b) BJAB and RAJI cells were 
lentivirally transduced with an empty vector as control or vectors expressing a FLAG-tagged IκBNS p35 
or a V5-tagged IκBNS p70. After puromycin mediated selection of successfully transduced cells, HLA-
DR surface levels were determined by flow cytometry. (a, b left) Depicted is the mean fluorescence 
intensity (MFI) of HLA-DR+ cells normalised to solvent treated cells (control). (a ,b right) On the day of 
flow cytometry measurement, cells were harvested and lysates were analysed by western blotting to assess 
IκBNS p35 and p70 expression. GAPDH served as control for equal loading of samples. 
 
Taken together, this result approves that IκBNS is indeed a negative regulator of 
MHC class II genes e.g. from HLA-DR indicated by the change of surface levels on 
B-cells. Hence, the IκBNS knock down by pharmacological calcineurin inhibitors in 
naturally IκBNS expressing ABC DLBCL cell lines causes the elevation of HLA-DR 
surface levels. Whereas, the overexpression of one IκBNS isoform (either p35 or 
p70) in B-cells exhibiting no steady state IκBNS expression is sufficient to 
remarkably diminish HLA-DR surface display 
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3.6 CD Marker screen of GCB and ABC DLBCL 
DLBCL represent a heterogeneous group of lymphoid malignancies in regard to 
clinical presentation and morphological aspects. Due to this there was an obvious 
need for having methods and algorithms that would help to stratify patients into 
distinct groups regarding prognosis and prediction to therapy response.  
An advanced approach in this respect was the classification of DLBCL according to 
gene expression profiling into three main molecular subtypes (GCB, ABC, PMBL) 
that exhibit different survival outcomes (Alizadeh et al.,200). But so far GEP is quite 
expensive, requires time for analysing huge amounts of data and is not available for 
a broad range of laboratories. Therefore, intensive efforts have been made during 
the last years to reveal reliable biological markers and to establish simpler, more 
broadly available clinical tools and methods that would provide improvements in risk 
stratification and in the development of new, more specific therapies. One such quite 
well validated and still commonly used tool is the so called International prognostic 
index (IPI) established in 1993 by the International Non-Hodgkin's Lymphoma 
Prognostic Factors Project. IPI remains the most robust predictive tool for DLBCL 
also after the introduction of the monoclonal anti-CD20 antibody rituximab 
complementing the conventional CHOP therapy, now R-CHOP (Vaidya and Witzig, 
2014). However, this index is based on five clinical risk factors found in DLBCL that 
are quite subjective and a substantial amount of patients rated as “low” or 
“intermediate risk” by IPI show therapeutic failure (Linderoth et al., 2003). Several 
groups describe the usage of immunohistochemical profiling as a promising method 
to identify outcome predictors and deduced algorithms that are moreover relatively 
easy to apply and appropriate for daily routine in clinical laboratories. One of these 
immunohistochemical (IHC) approaches was proposed by Hans et al. in 2004. They 
suggested an algorithm including CD10, BCL6 and MUM1 as specific markers to 
distinguish between DLBCL subtypes and achieved a concordance of 80% with 
GEP classification (Hans et al., 2004). Furthermore, this immunostaining based 
Hans’ algorithm was improved in 2009 by Choi et al. using GCET1, CD10, BCL6, 
MUM1, and FOXP1 as biological markers for DLBCL subclassification and 
facilitating risk stratification. Although the used markers and the deduced algorithms 
described in literature for class prediction were quite similar, the results were 
inconsistent regarding accuracy of significant prognostic value. Considering the 
previously described points, there is still an obvious need for reliable, specific 
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biomarkers that are capable to differentiate DLBCL into GCB and ABC subgroups, 
predict the response to R-CHOP therapy and present targets for new antibody 
treatments. Among the potential candidates meeting these demands are cell surface 
molecules from which the majority is listed in the cluster of differentiation (CD) index. 
This is demonstrated for instance by the fact that CD10 was already used to 
differentiate between GCB and ABC DLBCL by several algorithms 
(Hans et al., 2004; Choi et al., 2009) and that CD20 serves as the target for the 
monoclonal Rituximab in the standard treatment of DLBCL and many other 
Non-Hodgkin-Lymphoma.  
In order to reveal CD-markers that could serve as suitable biomarkers on GCB and 
ABC DLBCL, we performed an antibody based screen assessing the expression 
levels  of 360 cell surface markers of three GCB (BJAB, SU-DHL-4, SU-DHL-6) and  
three ABC (HBL-1, TMD8, U2932) DLBCL cell lines. The CD-marker screen 
revealed that, there are indeed noticeable differences in the expression of multiple 
cell surface molecules between GCB and ABC DLBCL as depicted in Figure 50.a. 
Several of these markers can be regarded as indicators for the validity of the assay. 
IgM-BCR for instance is predominantly expressed by ABC DLBCL whereas GCB 
DLBCL usually exhibit an Ig class switch recombination (CSR) to IgG-BCR (Young 
et al., 2015). Indeed, high surface IgM was also observed on ABC DLBCL in the 
conducted screen whereas absent on GCB DLBCL cell lines (Figure 50.a). The ABC 
DLBCL characterising aberrant CSR causing high IgM-BCR is based on the finding 
of deletions in the switch µ (Sµ) region of the IgH gene by Lenz et al. (2007), which 
interfere with CSR. The group assumed that the high and persistent expression of 
AID in ABC DLBCL contributes in the formation of these high frequent Sµ deletions 
mutations leading to functionally impaired CSR. Moreover, also the common reliable 
GCB phenotype predictive marker, the 100 kDa neutral membrane metallo-
endopeptidase CD10 which is implicated in the deactivation of numerous 
biologically active peptides (Dogan et al., 2000; Ohshima et al., 2001; Sezaki et al., 
2003), was confirmed by our screen to be expressed primarily in the comprised GCB 
DLBCL cell lines (Figure 50. a). In general, CD10 is an antigen found on the surface 
of lymphoid precursor cells and B lymphoid cells arising from the germinal centre 
origin (McCluggage et al., 2001). Furthermore, GEP revealed CD10 mRNA 
expression to be strongly associated with the GCB subtype of DLBCL (Ohshima et 
al., 2001). On this basis CD10 positivity of cells was therefore demonstrated and 
  Results 
 
 
152 
 
defined by several IHC based decision algorithms as the primary defining criterion 
for GCB classification e.g. the earlier described Hans’ algorithm, an altered Hans’ 
algorithm suggested by Muris et al. in 2006 or in a predictive IHC algorithm that 
classifies DLBCL in regard to the clinical prognosis into poor intermediate and good 
proposed by more by Anderson et al. in 2009.  
 
 
Figure 50. Surface marker screen determining 360 distinct molecules with GCB and 
ABC DLBCL. (a) Top hits of surface markers that were differentially or (b) equally expressed on 
the included cell lines of the GCB (BJAB, SU-DHL-4 and SUD-DHL-6) and ABC (HBL-1, TMD8 
and U2932) subtype of DLBCL. (c) Illustration of the expression distribution of the selected surface 
markers CD36, CD90 and CD274 on the included GCB and ABC DLBCL cell lines. (d) Fractions 
of CD36+, CD90+ and CD274+ of the indicated DLBCL cell lines. (a-d) Depicted are the fractions of 
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PE+ cells in %. The LEGENDScreen™ assay was conducted according to the manufacturer’s 
instructions. 
 
According to the CD marker screen results we selected three surface proteins that 
were differentially expressed between GCB and ABC DLBCL for further, more 
detailed investigations (Figure 50.a). We decided to choose CD90 as particular GCB 
and two membrane proteins namely CD36 and CD274 as ABC DLBCL specific 
surface markers (Figure 50.a, c, d).  
Since we were interested to confirm the expression pattern of CD36, CD90 and 
CD274 in DLBCL we recapitulated the assessment of those molecules on a broader 
range of GCB (BJAB, SU-DHL-4, SU-DHL-6, OCI-Ly1, OCI-Ly7 and OCI-Ly19) and 
ABC DLBCL (HBL-1, TMD8, U2932, OCI-Ly3 and OCI-Ly10) on both, the surface 
protein expression and the mRNA level (Figure 51.a-d). CD36 was indeed 
exclusively expressed at different fractions on all ABC DLBCL we investigated 
(Figure 51.a). Whereas on the mRNA levels also the GCB cell line OCI-Ly1 and 
OCI-L19 exhibit little presence of CD36 mRNA (Figure 51.b). The supposed GCB 
DLBCL marker CD90 was in fact expressed only on cell lines classified as the GCB 
subtype of DLBCL although not all of those cell lines were positive for CD90 (BJAB, 
OCI-Ly1, and OCI-Ly7) (Figure 51.c). This CD90 surface expression pattern is quite 
well reflected by CD90 mRNA levels. Only the GCB cell lines that also showed 
surface CD90 protein expression namely SU-DHL-4, SU-DHL-6 and OCI-Ly19 
exhibit CD90 mRNA levels, remarkably in the same proportionality (Figure 51.d). 
Also the presumable specific ABC DLBCL indicator CD274 was as revealed by the 
CD marker screen actually expressed solely on DLBCL cell lines belonging to the 
ABC subtype. Here, the fractions of CD274+ cells were quite different. Two cell lines 
ABC cell lines (U2932, OCI-LY3) did not show CD274 surface expression whereas 
TMD8 and OCI-Ly10 are characterised by considerable high fractions of CD274+ 
cells (Figure 51.e). The CD274 mRNA levels also demonstrate a clear preference 
of CD274 expression by ABC DLBCL. All investigated ABC DLBCL cell lines 
express CD274 mRNA at different levels (Figure 51.f). Noteworthy, TMD8 which 
exhibits the highest fraction of CD274+ cells also shows the highest CD274 mRNA 
expression among the ABC DLBCL cell lines tested. Remarkably, also the GCB cell 
line OCI-Ly1 shows slight expression of CD274 mRNA what is not reflected on the 
protein level.  
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Taken together, the results obtained by the surface molecule screen could be 
well reproduced by our array of GCB and DLBCL cell lines. Thereby, the 
protein expression extent of chosen surface markers correlated quite well with 
mRNA levels. 
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Figure 51. Assessment of surface protein and mRNA levels of selected surface markers 
specific for GCB and ABC DLBCL. (a, c , e) Fractions of (a) CD36 (c) CD90 and (e) CD274 
positive cells of the indicated GCB and ABC DLBCL cell lines were determined by flow cytometry. 
(b, d, f) Relative (b) CD36, (d) CD90 and (f) CD274 mRNA expression levels of indicated DLBCL 
cell lines of the GCB and ABC subtype. mRNA levels were assessed by qPCR and analysed using 
the ΔΔCT method. In (b) and (f) the GCB DLBCL cell line SU-DHL-6 and in (d) the ABC cell line 
U2932 served as a reference for relative mRNA expression levels of the respective surface marker 
gene. 
 
Next we were interested in functional aspects of the revealed DLBCL subtype 
specific surface markers in the context of DLBCL pathomechanisms. Many solid 
tumors exhibit an altered FA metabolism as well as increased utilisation of lipids via 
β-oxidation to gain energy. Multiple FA pathways were found to be constitutively 
activated in DLBCL and moreover cell survival seems to be strongly dependent on 
lipid metabolism (Dashnamoorthy et al., 2014). As earlier described, CD36 signaling 
coordinates the cellular fat metabolism by numerous functions. Recently, Samovski 
et al. unveiled a direct link between CD36 and β-oxidation in muscle cells. 
CD36 regulates the activation of the AMP-activated protein kinase (AMPK), a 
cellular metabolic and redox sensor. AMPK is activated upon energy deprivation 
and consequently inhibits energy-intensive metabolic pathways whereas on the 
other hand it concomitantly upregulates nutrient uptake and catabolic reactions. 
Thus, AMPK induces the recruitment of CD36 to the cytoplasma membrane and 
upregulates β-oxidation. CD36 inhibits AMPK under basal conditions. Whereas FA 
induced CD36 signaling promotes the activation of AMPK in turn leading to the 
increased activity of β-oxidation and the recruitment of more CD36 to the plasma 
membrane ending up in a feed forward cycle (Samovski et al., 2015). CD36 gene 
expression is regulated by the peroxisome proliferator-activated receptor γ 
(PPARγ), liver X receptor (LXR), and pregnane X receptor (PXR) (Tontonoz et al., 
1998). Activating ligands of the transcription factor PPARγ are oxidized 
phospholipids which are also abundant within the oxLDL particle that is bound and 
transported into the cell by CD36 (Silverstein et al., 2010). Therefore, CD36 
reinforces its own transcription by taking up lipoproteins such as oxLDL. CD36 
binding and uptake of FA and oxLDL and subsequent intracellular signaling can be 
irreversibly blocked by the membrane-impermeable N-hydroxysuccinimidyl (NHS) 
esters of long chain FA (Harmon and Abumrad, 1993; Pepino et al., 2014). NHS 
esters of long-chain FA, were originally used to label and cross link proteins by their 
ability to covalently bind to the amino group of lysine side chains (Kuda et al., 2013; 
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Kalkhof and Sinz, 2008). The most commonly used CD36 inhibitor is sulfo-N-
succinimidyl oleate (SSO), an oleate ester shown to efficiently inhibit CD36-
mediated FA uptake and signaling in various cell types by binding to the lysine164, 
a residue lying within a predicted binding site for FA and oxLDL (Coort et al., 2002; 
Kuda et al.,2011, 2013).  
Since ABC DLBCL cell lines show high CD36 mRNA and surface protein levels 
compared to GCB DLBCL cell lines, we next examined whether ABC DLBCL would 
as a consequence of this also exhibit higher β-oxidation activity. Thus also elevated 
mRNA levels of key β-oxidation enzymes in comparison to GCB DLBCL cell lines.                              
To this end, we investigated the mRNA levels from genes coding for essential                           
key-enzymes of β-oxidation in GCB (BJAB, SU-DHL-4, SU-DHL-6, OCI-Ly1, OCI-
Ly7 and OCI-Ly19) and ABC (HBL-1, TMD8, U2932, OCI-Ly3 and OCI-Ly10) 
DLBCL cell lines (Figure 52.a). The ACADM gene codes for the medium-chain acyl-
CoA dehydrogenase (MCAD) required for the metabolisation of medium chain fatty 
acids consisting of 4 to 12 carbonatoms (Bartlett and Eaton, 2004). The very long-
chain acyl-CoA dehydrogenase (VLCAD) is encoded by the ACADVL gene. VCLAD 
catalyses the initial step of β-oxidation of long-chain fatty acids comprising 14 to 20 
carbonatoms (Leslie et al 2009). The HADHA gene encodes the hydroxyacyl-CoA 
dehydrogenase α-subunit which is part of an enzyme complex called mitochondrial 
trifunctional protein. This complex contains three distinct enzymes and is essential 
for the metabolisation of long-chain fatty acids with chain lengths between 12 to 18 
carbonatoms (Choi et al., 2007). Though ABC DLBCL show higher levels of CD36 
mRNA and surface protein levels than GCB DLBCL cell lines, the mRNA levels of 
the selected β-oxidation key enzymes amongst the different DLBCL subtypes were 
comparable for all genes tested (Figure 52.a). This result indicates that the 
expression of genes regulating β-oxidation is not affected by the different degrees 
of CD36 expression in DLBCL. 
In turn to investigate the importance of CD36 in respect of its FA and oxLDL uptaking 
properties and its resulting potential influence on β-oxidation activity in DLBCL in 
more detail we treated the GCB cell line SU-DHL-6, which showed only minimal 
CD36 mRNA levels and two ABC (HBL-1 and TMD8) DLBCL cell lines with the 
irreversible CD36 inhibitor SSO at different concentrations. Subsequently, we 
assessed the mRNA levels of ACADM, HADHA, ACADVL and CD36. As depicted 
in Figure 52.b, c, d the inhibition of CD36 by SSO had no remarkable effect on 
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neither the mRNA levels of the β-oxidation key enzyme coding genes nor the mRNA 
levels of CD36 itself. This was also independent from GCB and ABC subtype. 
Noticeable exceptions seem to be mRNA expression levels of ACADVL and CD36 
in SU-DHL-6 cells treated with 250 µM SSO that exhibit a two fold increase 
compared to solvent control. In summary, these results indicate that although CD36 
is substantially more expressed in the ABC subtype of DLBCL on both the mRNA 
and the surface protein level, β-oxidation is not affected by this obvious difference. 
This result also suggests that the level of β-oxidation activity is comparable between 
DLBCL subtypes. Additionally, from the treatment of GCB and ABC DLBCL cell lines 
with an irreversible CD36 inhibitor we can conclude that there is no impact on neither 
β-oxidation nor CD36 mRNA levels when CD36 FA and oxLDL uptake and 
associated (FA and oxLDL initiated) signaling is blocked. Taken together, this result 
suggests that CD36 might be a valid biomarker to differentiate between GCB and 
the more aggressive ABC DLBCL. However, CD36 seems not to be appropriate as 
a putative therapy target since CD36 blockage had no impact on the expression of 
genes coding for proteins regulating the activity of the vital β-oxidation which was 
found to be comparable between the GCB and ABC subtype of DLBCL. 
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Figure 52. Determining mRNA expression levels of genes coding for β-oxidation key 
enzymes and CD36 in GCB and ABC DLBCL under steady state conditions and CD36 
inhibition by SSO. a) Relative mRNA expression of ACAVDM, HADHA and ACADVL coding 
for β-oxidation key enzymes were assessed by qPCR in samples from the indicated GCB and ABC 
DLBCL cell lines and analysed using the ΔCT method. (b-d) The GCB cell line (b) SU-DHL-6 and 
two ABC DLBCL cell lines (c) HBL-1, (d) TMD8 were treated either with solvent as control or the 
indicated concentrations of the irreversible CD36 inhibitor SSO for 1 h. Subsequently, cells were 
harvested, RNA was isolated and reversely transcribed into cDNA. By qPCR mRNA levels from 
ACAVDM, HADHA, ACADVL and CD36 were assessed and analysed using the ΔΔCT method. 
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4. Discussion 
4.1 Significance of DLBCL research 
DLBCL are a highly heterogeneous and aggressive B-cell Non-Hodgkin-Lymphoma 
malignancy. The molecular era of disease characterisation led to steady advances 
in the development of disease tailored treatment approaches. This includes the 
establishment of biologicals such as target-directed monoclonal antibodies e.g. 
rituximab and small molecule drugs e.g. Ibrutinib that are designed to interfere with 
the effector functions of proteins in key positions of vital signal transduction 
pathways. These new therapies considerably improved patient overall survival (Link 
and Friedberg, 2008; Lenz et al., 2008). 
In the context of DLBCL treatment, the addition of the anti-CD20 monoclonal 
antibody rituximab based immunotherapy to the established first-line 
chemotherapeutics based standard chemotherapy regimen CHOP in 2002, 
remarkably improved complete remissions by 15 to 20%. Despite the success of 
rituximab, when having a closer look at the distinct survival rates of the  
DLBCL molecular subtypes there is still a proportion of patients with advanced 
DLBCL disease stages who do not response to R-CHOP therapy or exhibit relapsed 
or refractory DLBCL in the aftermath of R-CHOP immuno- chemotherapy. In 
particular, patients suffering from the more favourable GCB subtype still exhibit a 3-
year progression free survival (PFS) rate of 74% and a 3-year overall survival (OS) 
rate of approximately 80% upon R-CHOP treatment. Moreover, patients affected by 
the most aggressive DLBCL and thus less favourable ABC subtype which is often 
resistant to standard chemotherapies show a worse 3-year PFS rate of 40% and  
3-year OS rate of approximately 45% following R-CHOP therapy. (Lenz et al., 2008; 
Young et al., 2015). Therefore, there is an obvious need for identifying new 
molecular targets and the further development of corresponding, more efficient 
novel agents in order to improve clinical outcome and prolong patient survival 
suffering from this hematopoietic cancer type, especially the adverse ABC subtype. 
To achieve this aim, understanding the underlying molecular pathological 
mechanisms characterising (ABC) DLBCL lymphomagenesis is of critical 
importance.  
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During the last years, investigation of ABC DLBCL by gene expression profiling 
revealed constitutive active canonical NF-κB signaling. By transduction of an IκBα 
super repressor and dominant negative forms of IKKβ as well as the application of 
IKKβ small molecule inhibitors the ABC DLBCL subtype was unveiled to be addicted 
to this chronically active NF-kB signaling that emerged to be the major hallmark of 
this lymphoma entity and a major criterion to distinguish the ABC from the GCB 
DLBCL subtype (Davis et al., 2001).The aberrant NF-kB signaling was found to be 
caused by various genetic abnormalities present in different NF-κB activity 
modulating signal elements constituting key drivers of this oncogenic signaling (e.g. 
CD79A/B; CARMA1, MYD88 or A20) (Davis et al., 2001; Ngo et al., 2006; Lenz et 
al., 2008, Compagno et al., 2009, Kato et al., 2009; Davis et al., 2010; Ngo et al., 
2011). However, little is known about the role of typical and especially atypical IκBs 
like IκBNS concerning the oncogenic NF-κB signaling in ABC DLBCL. IκB protein 
family members are known to be implicated in negative and positive regulation of 
the NF-κB signaling network and consequently NF-κB target gene transcription. Due 
to this, investigating their function and importance in contributing to the oncogenic 
molecular signaling pathways present DLBCL is of great interest. A deeper and 
more comprehensive knowledge about the regulation and role of the atypical NF-κB 
inhibitor IκBNS in the context of the complex oncogenic DLBCL pathogenesis is a 
promising research issue in order to provide a basis for the development of future 
therapeutic agents. 
4.2 The expression of IκBNS in DLBCL subtypes 
Within the present study, we showed that in contrast to the GCB DLBCL subtype 
cell lines the atypical, nuclear IκB family protein IκBNS was constitutively expressed 
in all tested model cell lines of the ABC DLBCL subtype cell lines as proven by the 
assessment of mRNA and protein levels. The distribution of IκBNS expression 
according to DLBCL subtypes was confirmed at least on the mRNA level determined 
in 19 patient derived samples for each DLBCL subtype. Unfortunately, the 
background of this measurement was relatively high, most likely due to activated  
T-cells in the inflammatory tumor environment that also express IκBNS. Based on 
these findings, we suggest that the expression of IκBNS could be a further 
biomarker in order to classify the GCB and ABC DLBCL subtypes on the molecular 
level. This would help to improve stratifying patients into different risk groups and 
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thus survival prediction and to choose the most suitable therapy strategy. As already 
mentioned, DLBCL tumor surrounding cells like activated T-cells should also 
express IκBNS, as indicated by P/I and anti-CD3/28 mediated stimulation of Jurkat 
T-cells in this study. Thus, in case IκBNS would be applied as ABC DLBCL 
biomarker in immunohistochemistry, there would be an obvious need to increase 
the recognition specificity in order to clearly identify IκBNS expression that belongs 
to the B-cell derived tumor and to exclude IκBNS derived signals from cells present 
in the tumor environment. For this reason, we suggest that IκBNS staining of DLBCL 
tumor tissue should be correlated with other already well-established B-cell (e.g. 
CD20) and DLBCL markers that would in the first line identify DLBCL cells and 
second the distinct DLBCL subtype. For this purpose, IκBNS staining could be 
implemented in already established immunostaining based algorithms such as the 
Hans’ algorithm (Hans et al., 2004) that defines the ABC DLBCL type as CD10-, 
BCL6- , and MUM+ or an algorithm proposed by Choi et al (2009) that includes 
GCET1, CD10, BCL6, MUM1, and FOXP1 as staining markers for DLBCL and to 
distinguish subtypes. According to Choi et al., their proposed immunohistochemistry 
staining based algorithm has a concordance of 93% with gene expression profiling 
of DLBCL. 
4.3 The mutual transcriptional regulation of IκBNS 
by NF-κB and NFAT 
In addition to the NF-κB signaling addicted ABC DLBCL cell lines, IκBNS expression 
was also detected in several sotrastaurin (STN)/Ibrutinib sensitive, BCR-driven 
canonical NF-κB signaling exhibiting MCL cell lines and one STN/Ibrutinib 
insensitive MCL cell line that displays activation of the non-canonical NF-κB 
signaling (Rahal et al., 2014). In additional B- and T-cell lymphoma/leukemia model 
cell lines representing GCB DLBCLs, Burkitt’s lymphoma and T-ALL we were able 
to induce IκBNS expression by the application of P/I or PMA alone albeit in a quite 
less extent within one hour. Furthermore, also TCR stimulation of a T-ALL cell line 
triggered the induction of IκBNS expression. The interference with NF-κB upstream 
signaling by LVSR and STN application under simultaneous cell stimulation by P/I 
completely abolished the induction of IκBNS expression. Moreover, siRNA mediated 
knock down of MALT1 in an ABC DLBCL cell line resulted in diminished IκBNS 
expression levels. Together, these results suggest that IκBNS is a target gene of 
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canonical NF-κB signaling in a couple of different lymphoma malignancies. The 
hypothesis of IκBNS expression to be controlled through NF-κB signaling in ABC 
DLBCL was further strengthened by the induction of its expression on the protein 
level by CARMA1 mutants found in roughly 10% of ABC DLBCL patient samples to 
activate the classical NF-κB pathway. Moreover, a putative IκBNS promoter 
sequence within intron one of the NFκBID gene, bearing NF-κB and NFAT 
recognition sites was discovered by the analysis of published CHIP-datasets. This 
promoter sequence showed transcriptional activity when RelA and canonical wild-
type NF-κB, mutated upstream elements e.g. MALT1/BCL-10, CARMA1, MYD88 
and combinations thereof, how they are commonly found in the context of oncogenic 
ABC DLBCL signaling, were added. Furthermore, also the noncanonical NF-κB 
signaling element BIRC3 in its wild-type and a MCL-derived mutant version induced 
promoter activity. These findings substantiated the hypothesis of IκBNS 
transcriptional regulation by canonical and noncanonical NF-κB signaling. Further 
studies of this IκBNS promoter sequence by CHIP and EMSA experiments should 
validate its capacity to bind NF-κB subunits. 
Interestingly, the combination of the NF-κB subunit RelA with Ionomycin was able 
to induce IκBNS promoter activity more than twice as much as RelA alone. 
Ionomycin treatment alone however, was not able to induce IκBNS promoter activity. 
Thus, as anticipated, the addition of NFATc1 did not result in induction of the IκBNS 
promoter. On the contrary, similarly to the combination with Ionomycin, RelA in 
combination with NFATc1 caused a strong induction of IκBNS promoter activity 
compared to RelA alone. Our results therefore indicate that IκBNS transcription is 
driven by NF-κB signaling in synergy with Ca2+-NFAT signaling as already indicated 
by the finding of NF-κB and NFAT sites within the IκBNS promoter sequence. 
Notably, each transcription factor family on its own was able to induce low IκBNS 
protein levels. Combined expression however, induced strong IκBNS promoter 
activity consistent with strong induction of IκBNS protein expression in GCB DLBCL 
cell lines stimulated by P/I. 
The assumption that besides NF-kB also NFAT signaling is involved in IκBNS 
expression regulation was further substantiated by the treatment of constitutively 
IκBNS expressing ABC DLBCL cells for several days with calcineurin-NFAT 
signaling inhibitors what led to clearly diminished IκBNS protein levels. Furthermore, 
also the induction of IκBNS by P/I was obviously impeded by pre-treatment of cells 
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with calcineurin inhibitors. Moreover, lentiviral mediated expression of a dominant 
negative IκBα in combination with the application of CsA or FK506 had a clear 
impairing effect on P/I mediated induction of IκBNS expression in a T-ALL and a 
GCB DLBCL cell line. Notably, this effect was more pronounced than in cells in 
which either NF-kB or NFAT was inhibited. Thus, our findings suggest that high 
IκBNS levels as seen constitutively in ABC DLBCL or upon P/I induction in GCB 
DLBCL cell lines require the transcriptional activity of both, the NF-kB and NFAT 
transcription factor family.  
In accordance with the previously described results, the treatment with the 
calcineurin inhibitor CsA revealed that except for the GCB DLBCL cell line  
SU-DHL-4, NFATc1 was found dephosphorylated in all investigated GCB and ABC 
DLBCL cell lines, indicating a transcriptionally active NFATc1 state. Notably,  
in consistence with this finding, nuclear localised and dephosphorylated NFATc1 
and dephosphorylated NFATc2 were also reported to be observed in samples 
obtained from DLBCL patients (Fu et al., 2006; Medyouf et al., 2007). Furthermore, 
in line with our calcineurin inhibitor results, NFAT activity was shown to be 
calcineurin-dependent in cell lines derived from DLBCL and T-ALL patients, as their 
treatment resulted in the suppression of NFAT activation. In addition, NFATc1 
activity in DLBCL was also indicated by an immunohistological evaluation of almost 
300 lymphoma samples conducted by Marafioti et al. (2005) that revealed NFATc1 
to be overexpressed in most lymphoid neoplasms. This overexpression could be at 
least in some ABC DLBCL cell lines the result of a genomic amplification affecting 
a 1,9 Mb region of chromosome 18q that includes the NFATc1 gene.  
This amplification was found in 5% of ABC DLBCL and could cause a gene dosage 
based overexpression of NFATc1 (Lenz et al., 2008; Müller et al., 2010). Marafioti 
et al. (2005) observed NFATc1 to exhibit a nuclear localisation in 30% of DLBCL 
and 70% of Burkitt’s lymphoma samples, indicating in vivo activity of the NFAT 
pathway in those malignancies what is in accordance with our DLBCL cell line model 
results. In general, the expression of NFATc1 across the investigated DLBCL cell 
line panel in this study was highly variable and expression levels did not correlate 
with any particular lymphoma subgroup. Additionally, the sensitivity of DLBCL cell 
lines towards CsA seems to be independent of NFAT protein expression levels as 
both, the ABC DLBCL cell lines OCI-LY3 and SU-DHL-2 show very low NFATc1 
levels but differ clearly in the sensitivity towards CsA treatment. Thus, the results 
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indicate that NFAT is of importance for both DLBCL subtypes. Furthermore, blotting 
against NFATc1 in samples derived from an array of GCB and ABC DLBCL cell lines 
also revealed three broad NFATc1 specific bands for each cell line. The close bands 
of each of the three band clusters are most likely different NFATc1 phosphorylation 
states, whereas the three main bands assumingly represent the different A, B and 
C NFATc1 isoforms. Considering the predicted NFATc1 isoform sizes, the lowest 
band represents most likely the NFAT c1/A α (716 aa) and β (703 aa) isoforms, the 
middle band the NFATc1/B α (825aa) and β (812aa) variants and the upper band 
the NFATc1/C α (943 aa) and β (930aa) isoforms (uniprot.org.; Entry O95644 
(NFAC1_HUMAN)). 
 
Why is NFATc1 dephosphorylated in GCB DLBCL cell lines? 
NFATc1 activity in GCB DLBCL cell lines stands in contradiction to the finding that 
cells show up regulation and constitutively active NFATc1 signaling as a result of 
activated BCR signaling which can be triggered either by antigen engagement or 
aberrantly by acquired somatic mutations. Activated BCR signaling leads to the 
generation of IP3, causing the mobilisation of intracellular Ca2+ which in turn initiates 
the influx of extracellular Ca2+ resulting in the activation of calcium dependent 
signaling such as NFAT (Le Roy et al., 2012; Young et al., 2015). This suggests that 
NFATc1 activity in GCB DLBCL could be regulated by a mechanism other than BCR 
signaling. GCB DLBCL were unveiled to be insensitive against targeted knock-down 
of BCR components such as the mIg light and heavy chain and the associated 
signaling chains CD79A and B. Also the RNAi mediated knock-down of BCR 
downstream signaling elements such as SYK, BLNK, BTK, PLCγ2, PKCβ, CARD11 
and the pharmacological inhibition of BTK by Ibrutinib, PKCβ by STN, MALT1 by z-
VRPR-fmk and IKK by e.g. MLN120B were found to be selectively toxic to ABC 
DLBCL that do not harbour a CARD11 mutation, but not to GCB DLBCL. (Ngo et 
al., 2006; Lam et al., 2005; Hailfinger et al., 2009; Davis et al., 2010). Furthermore, 
this lymphoma subtype does not exhibit common mutations in elements of the BCR 
signaling cascade. Based on these result, it could be concluded that in contrast to 
ABC DLBCL, GCB DLBCL do not rely on active BCR and integrated downstream 
signaling pathways such as NF-kB for survival (Davis et al., 2001). The chronically 
active BCR signaling of ABC DLBCL encompasses the activation of the PI3K 
pathway which is a hallmark of multiple cancer types as it is important for cell 
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survival, growth and proliferation by for instance linking BCR signaling to the 
prosurvival NF-kB pathway (Pfeifer et al., 2013). Furthermore, the constitutive PI3K 
activity was found to be vital for two ABC DLBCL cell lines harbouring CD79B 
mutations (Kloo et al., 2011). However, albeit GCB DLBCL do not exhibit chronic 
active BCR signaling, Chen et al. (2013) revealed that also a subset of GCB DLBCL 
depend on SYK mediated activation of the PI3K/AKT pathway. In line with the 
previous, the GCB DLBCL subtype maintains normal BCR expression but exhibits 
higher relative SYK expression, contributing to the activation of the PI3K/AKT 
pathway (Srinivasan et al., 2009; Kenkre et al., 2012; Chen et al., 2013).  
In accordance with this, GCB DLBCL were also reported to show mutations in the 
PI3K/AKT pathway negative regulatory phosphatase PTEN, genetic deletions on 
chr.10q23 comprising the PTEN locus and amplifications of the mIR17-192 micro 
RNA cluster that result in the inactivation of PTEN in more than 55% of cases and 
only in 14% of ABC DLBCL (Lenz et al., 2008; Xiao et al., 2008; Song et al., 2012; 
Chen et al., 2013; Pfeifer et al., 2013). Moreover, Pfeifer et al. (2013) revealed an 
addiction of PTEN deficient GCB DLBCL cell lines to PI3K/AKT signaling by 
reexpressing functional PTEN. An investigation of the BCR on the surface of ABC 
and GCB DLBCL cells revealed that that in contrast to ABC, the GCB DLBCL 
subtype does not show BCR low diffusion clusters, as they are known for antigen-
dependent stimulation of B-cells (Davis et al., 2010). The parallels of ABC DLBCL 
BCR signaling to antigen-stimulated active signaling in benign B-cells led to the 
assumption that the chronic active BCR signaling of ABC DLBCL may be driven by 
auto-antigens. These could be derived from various sources or even as reported in 
CLL, the ABC DLBCL BCR recognises its self, thereby acting as its own antigen 
ligand that triggers the intracellular signaling cascade. Considering these facts, 
it was suggested that the essential PI3K activity in GCB DLBCL cell lines is triggered 
by so called tonic BCR signaling, which is antigen-independent in contrast to the 
(auto)-antigen-dependent chronically active BCR signaling observed in ABC 
DLBCL. Tonic BCR signaling delivers antigen-independent “low level” survival 
signaling leading to low baseline NF-κB activity as it was shown in SU-DHL-4, 
SU-DHL-6 cells and enables long term survival of resting B-cells, independent from 
CARD11. (Gauld et al., 2002, Kraus et al., 2004; Monroe, 2004; Srinivasan et al., 
2009; Rossi et al., 2013; Chen et al., 2013). Taking into account the above illustrated 
mechanism of GCB DLBCL BCR signaling it would be conceivable that the activity 
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of NFATc1 in the GCB DLBCL cell lines investigated by this study is based on 
antigen-independent tonic BCR signaling which could lead next to a low baseline 
NF-κB activity also to a base-line NFAT activity as revealed in BJAB and HT cells. 
Why SU-DHL-4 cells exhibit only very weakly or no dephosphorylated NFATc1 albeit 
they were shown to have base-line NF-κB activity remains unresolved and could be 
an issue for further investigation. 
Whereas the GCB cell lines were entirely resistant, the inhibition of NFAT signaling 
by calcineurin inhibitors did not affect growth behaviour of all comprised ABC 
DLBCL cell lines in the same manner. Even though NFAT was seemingly active in 
all model cell lines and all of them expressed high IκBNS levels. Thus, calcineurin 
inhibition seemed to be selectively toxic and we could distinguish ABC DLBCL cell 
lines responding insensitively, medium sensitively and highly sensitively to 
calcineurin inhibitor treatment. In order to reveal the underlying reason why ABC 
DLBCL cell lines exhibit altered growth behaviour upon calcineurin inhibitor 
treatment, we found a clear correlation between increasing concentrations of 
calcineurin inhibitors and the reduced secretion of the survival promoting and pro-
proliferative interleukins IL-6 and IL-10 and corresponding STAT3 phosphorylation 
levels. ABC DLBCL were described by earlier studies to be addicted to an 
autocrine/paracrine positive feedback loop including IL-6 and IL-10, that is driven by 
NF-κB signaling and interleukin receptor downstream STAT3 phosphorylation 
(Moore et al., 2001; Kishimoto et al., 2005; Lam et al., 2008). Furthermore, we 
excluded some well known NF-κB signaling targets to be affected by calcineurin 
inhibitor treatment by testing the expression levels and revealed a dose-dependent 
negative effect of CsA mediated calcineurin inhibition on STAT3 phosphorylation, 
indicating that only a subset of NF-κB targets such as IL-6 and IL-10 are affected by 
calcineurin inhibition (Libermann and Baltimore, 1990; Xu and Shu, 2002). The 
described impact of pharmacological calcineurin inhibition on ABC DLBCL growth 
was thus most pronounced in inhibitor highly sensitive cell lines that exhibited the 
strongest decrease in p-STAT3 levels and IL-6 and IL-10 amounts. Whereas no 
change in secreted interleukin levels and STAT3 phosphorylation was observed in 
calcineurin inhibitor insensitive ABC DLBCL cell lines. A recently published work 
proposed a model in which calcineurin is recruited to the TCR and acts there as 
positive modulator of TCR downstream signaling by removing an inhibitory TCR 
activation induced phosphorylation (Dutta et al., 2017). As TCR and BCR signaling 
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show many similarities we propose calcineurin to be involved in BCR signaling, as 
well. We therefore speculate that calcineurin participates in BCR signaling positive 
regulation in ABC DLBCL that leads to enhanced NF-κB and NFAT signaling. Either 
this occurs indirectly by removing an inhibitory phosphorylation from an unknown 
substrate which in turn, in its active state, positively regulates BCR downstream 
signaling or directly by dephosphorylation of substrates in the BCR signaling chain.  
 
4.4 Calcineurin as positive regulator of BCR 
signaling 
In order to find the assumed putative calcineurin substrate(s) in BCR signaling,            
we conducted a phosphoproteom analysis by SILAC with subsequent MS with 
samples derived from CsA or FK506 treated ABC DLBCL HBL-1 cells. Indeed, 
phosphoproteom analysis identified a couple of putative new substrates that are 
involved BCR signaling. The fact that the found possible direct and indirect 
calcineurin substrates were far upstream in BCR-signaling would explain why CD79 
mutated ABC DLBCL cell lines were worst affected by calcineurin inhibitor 
treatment. Thus, it would be conceivable that NF-kB activating mutations of more 
downstream signaling elements such as CARMA1, TAK1 or A20 just compensate 
or mitigate the loss of the calcineurin mediated positive effect on BCR signaling as 
consequence of CsA or FK506 mediated calcineurin inhibition. This downstream 
mutation overwriting mechanism eventually leads to unaltered or only slightly 
declined NF-κB signaling and thus to an only minor impact on IL-6 and IL-10 
secretion of cells bearing such mutations such as OCI-LY3 or SU-DHL-2. This in 
turn would explain the more insensitive effect on the growth of those cell lines when 
treated with calcineurin inhibitors.  
Several putative calcineurin dependent dephosphorylation sites namely S197, 
T209, Y210, S215 in CD79A and S221 in CD79B were found hyperphosphorylated 
by phosphoproteom analysis in HBL-1 samples that were treated by the calcineurin 
inhibitors CsA and FK506. Except for S197, all putative calcineurin substrate sites 
found in CD79A are located C-terminally from the CD79A ITAM sequence (aa 185 
- aa 202) which plays a central role in transmembrane signal transduction. Essential 
for the functionality of the CD79A ITAM are two tyrosine-residues Y188 and Y199. 
In the context of ABC DLBCL biology, Davis et al. (2010) found by sequencing that 
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2,9% of patient derived biopsies had a mutation affecting CD79A. The ABC DLBCL 
cell line OCI-LY10 for instance, exhibits a heterozygous CD79A splice donor site 
mutation leading to a deletion of 18 aa, eradicating almost the whole ITAM 
sequence. Remarkably, over 90% of the OCI-LY-10 CD79A mRNA derived from the 
mutated allele. Under resting conditions, the BCR is suggested to be already 
associated with a preformed transducer complex as a prerequisite for BCR 
signaling, including kinases, phosphatases and diverse adaptor proteins (Wienands 
et al., 1996). In particular, Clark et al. (1992) conclude from their results that the 
cytoplasmic domains of CD79 associate with the src-family tyrosine kinases LYN 
and FYN, the PI3K and one or more serine/threonine (S/T) kinases, putative 
antagonists of calcineurin. 
Upon ligand binding of the IgM, a member of the src family protein-tyrosine kinase 
family, predominantly LYN initially catalyses, the phosphorylation of the first  
N-terminal ITAM tyrosine of CD79A and CD79B (see Figure 53.). Noteworthy, the 
ITAM tyrosines of CD79B are less efficiently phosphorylated than the corresponding 
CD79A tyrosines. This N-terminal p-tyrosine provides a docking site for the  
C-terminal SYK SH2-domain. SYK is described to be a vital component in BCR 
signaling and was shown by mouse knock out models to be indispensable for the 
majority of BCR signaling mediated responses to antigen binding (Takata et al., 
1994; Turner et al., 1995; Cheng et al., 1995; Cornall et al., 2000). A structural NMR 
based study conducted by Gaul et al., 2000, suggests that the preference of LYN 
towards the first ITAM tyrosine is based on the interaction of LYN with a glutamate 
residue three positions C-terminally and a glycine residue two aa N-terminally from 
the acceptor tyrosine (see Figure 53.). In order to generate proper signal 
transduction by CD79A however, asymmetrical ITAM phosphorylation is insufficient. 
Therefore, the phosphorylation of both ITAM tyrosines is required. Most likely, SYK 
itself exerts this second ITAM phosphorylation at Y199 (Rolli et al., 2002). Only then 
an interaction of the CD79A ITAM with the SYK tandem-arranged pair of SH2 
domains is possible and leads to SYK activation and further signal propagation. 
Long lasting SYK activity is needed by NFAT to remain active for more than one 
hour after the triggering of the BCR (Oh et al., 2007), indicating the importance of 
CD79 signaling for IκBNS expression. Not only CD79A and B ITAM tyrosine 
residues become phosphorylated upon BCR ligand binding but also several serine 
and threonine residues (Clark et al., 1992; Van Noesel et al., 1990; Leprince et al., 
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1992). Serine/threonine residue phosphorylation was observed in the cytoplasmic 
portions of various receptors and conferred either negative or positive influence on 
downstream signal transduction (Mufson, 1997; Lim and Cao, 1999; Li et al., 1999). 
Hence, Müller et al. (2000) were keen to figure out which impact the S/T residues in 
the cytoplasmic tail of CD79A (aa 166-aa 226) would have on BCR signaling.  
For this purpose, they mutated two serines and the threonine of the CD79A 
cytoplasmic domain (see Figure 53.) to non-phosphorylatable alanines and a valine, 
respectively. Among the mutated residues were also our putative CD79A calcineurin 
dephosphorylation sites S197 and T209. By testing the signaling function of this 
unphosphorylatable CD79A they revealed that the phosphorylated S/T residues of 
CD79A negatively regulate BLNK and ITAM tyrosine phosphorylation. In particular, 
they observed a stronger and more prolonged ITAM tyrosine phosphorylation of the 
S/T unphosphorylatable CD79A compared to the S/T phosphorylatable wild-type 
CD79A. This finding indicates that CD79A S/T kinases negatively modulate BCR 
signaling output. This is in accordance with our assumption that the S/T 
phosphatase calcineurin seems to positively regulate BCR signaling for instance by 
removing CD79A ITAM signaling hampering phosphorylations on S197, T209 and 
S215 as unveiled by SILAC/MS. This would establish calcineurin as an antagonist 
of the CD79A S/T kinases that negatively regulate CD79 proximal signaling. 
Moreover, Müller et al. also investigated the impact of the unphosphorylatable 
CD79A variant on the phosphorylation of both CD79A ITAM tyrosines, Y188 and 
Y199, from which the phosphorylation of the former is more pronounced. To analyse 
this, they substituted either one of ITAM tyrosines or both tyrosines with 
phenylalanines with and without an additional unphosphorylatable CD79A 
background. This experimental setting unveiled that the mutation of the N-terminal 
CD79A ITAM tyrosine (Y188F) leads to an only weakly phosphorylated second C-
terminal ITAM tyrosine in the context of a S/T phosphorylatable CD79A cytoplasmic 
tail. In contrast to that, a mutated N-terminal ITAM tyrosine in an S/T 
unphosphorylatable CD79A background results in an increase of the 
phosphorylation of the second ITAM tyrosine. On the other hand, the mutation of 
the C-terminal ITAM tyrosine (Y199F) in both CD79A backgrounds did not 
remarkably alter CD79A phosphorylation. From these outcomes the authors 
concluded that the phosphorylation of S/T residues in the cytoplasmic CD79A 
portion mainly regulates the phosphorylation of the C-terminal CD79A ITAM tyrosine 
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(Y199). This is also implicated as well by the fact that Y199 is situated in the 
proximity to three flanking serine residues (S197 and S203 and S215) and one 
threonine residue (T209). All of them except for S203 were found to be 
hyperphosphorylated in our SILAC/MS based phosphoproteom analysis conducted 
with samples derived from a calcineurin inhibitor treated ABC DLBCL cell line. 
Noteworthy, the binding of the second C-terminal ITAM tyrosine to SYK is stronger 
than that of the C-terminal SYK SH2 domain to the first N-terminal ITAM tyrosine 
(Fütterer et al., 1998). Considering the depicted facts, it’s reasonable to assume that 
the balance between phosphorylation and dephosphorylation of CD79 by 
associated so far unidentified kinases and phosphatases of the putative calcineurin 
target sites S197, T209 and S215 in the cytoplasmic portion possibly modulates the 
binding of SYK to CD79A and thus further signal transduction as well. In this 
proposed model, phosphorylation of the S/T residues impedes proper high-affinity 
SYK CD79 binding and further signaling, establishing a negative feedback loop. 
Whereas dephosphorylation of distinct aa-residues in the cytoplasmic portion by e.g. 
the S/T phosophatase calcineurin promotes the phosphorylation of the ITAM 
tyrosines followed by high-affinity binding of both SYK SH2 domains and proximal 
BCR signaling. The same mechanism we propose for CD79B.  
 
Why does calcineurin modulate upstream BCR signaling? 
Considering our obtained results in the context of the depicted literature it is 
conceivable that under BCR unligated conditions, the cytoplasmic portions of 
CD79A and B are constitutively phosphorylated by S/T kinases at the introduced 
serine and threonine residues in order to prevent premature or non-specific 
activation of proximal BCR signaling. Furthermore, upon ligand binding the delicate 
balance between phosphorylated and unphosphorylated S/T residues in the CD79 
cytoplasmic portion could represent a fine-tuning mechanism for the extent of BCR 
proximal signal propagation in order to adapt to external stimuli and to respond in 
adequate degree. Thus, when calcineurin is pharmacologically inhibited by the 
application of CsA or FK506, the phosphorylated CD79A/B state is predominant and 
BCR signal propagation to downstream pathways such as NF-κB, NFAT and AP-1 
is dampened or completely ceased. Unless downstream activating mutations in 
proteins like CARMA1 as found in the CsA/FK506 insensitive cell line OCI-LY3 
override this effect. Accordingly, the constitutive expression of NF-κB and NFAT 
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target genes such as IκBNS and IL-6 and IL-10 in ABC DLBCL in which calcineurin 
is constitutively active as indicated by dephosphorylated NFATc1, would be 
negatively affected by calcineurin inhibition, as well in turn leading to reduced growth 
and survival as seen in this study. Notably, this theory would be in line with the 
finding that T-cells that express an unphosphorylatable CD79A exhibit constitutive 
NFAT and thus calcineurin activity, as well (Müller et al., 2000).  
In contrast, it is also imaginable that under non-stimulated conditions, the CD79A 
and B cytoplasmic tails are kept in an S/T unphosphorylated state with the 
participation of calcineurin and other phosphatases and become gradually or at 
once phosphorylated instantly or after a certain time upon BCR engagement. Thus, 
in case calcineurin is inhibited just prior to and during BCR stimulation, CD79A 
would be hyperphosphorylated at all time and signal propagation would be blocked 
as ITAM tyrosines were not efficiently phosphorylated by src kinases as LYN.  
How the phosphorylated S/T residues in CD79A and B inhibit ITAM tyrosine 
phosphorylation by src kinases however remains elusive. Hypothetically, the 
phosphorylated serines and threonines could depict sites for protein-protein 
interactions providing binding platforms for proteins that consequently interfere with 
LYN and SYK binding and thus with further signal transduction, a mechanism that 
was already observed several times in other receptors (Yaffe and Cantley, 1999; 
Bünemann and Hosey, 1999; Levine, 1999). Another possibility is that the 
phosphorylated S/T residues just represent a steric hindrance for the binding of 
proximal signal transducers such as SYK and BLNK and thus disrupt the signaling 
cascade.  
Contrary to its positive impact on BCR proximal signaling, the cytoplasmic ITAM 
bearing part of CD79A was also found to encompass a function in BCR signal 
inhibition. This was concluded from mouse B-cells, expressing a truncated CD79A 
molecule lacking a large part of the endoplasmic tail thus including only 21 instead 
of 61 aa and lacking the ITAM sequence. These murine B-cells were hyperactive 
and could be stimulated easier by BCR cross-linking and additionally show 
constitutive BCR signaling. (Kraus et al.1999, Torres et al., 1996; Torres and Hafen, 
1999).  
This resembles the ABC DLBCL cell line OCI-LY10 which lacks aa 191 to aa 208, 
affecting a large stretch of the ITAM of CD79A including the second ITAM tyrosine 
and the putative calcineurin site S197 and just flanks T209, another putative 
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calcineurin target site found by the phosphoproteom analysis. Taking into account 
the findings from Müller et al. (2000) and the B-cells bearing truncated CD79A, this 
deletion could cause enhanced and sustained BCR signaling, consequently leading 
to NF-kB and NFAT signaling as the inhibitory function of p-S197 is missing, 
conferring a positive modulation similar to calcineurin by S197 dephosphorylation. 
SYK would then nevertheless be able to bind the CD79A N-terminal phosphorylated 
tyrosine albeit in a lower affinity and promote downstream signaling. Alike CD79A, 
CD79B also contains two ITAM tyrosines that upon src kinase mediated 
phosphorylation recruit and bind SYK (Rowley et al., 1995). Likewise in CD79A the 
second ITAM tyrosine of CD79B is surrounded by several S/T residues.  
As already mentioned earlier, the phosphoproteom analysis in HBL-1 also unveiled 
with S221 a putative calcineurin dephosphorylation site in CD79B in close proximity 
to the second ITAM tyrosine. Assuming that the theory of downstream signaling 
inhibitory S/T residues also applies for CD79B, the dephosphorylation of S221 by 
calcineurin could also result in enhanced CD79B ITAM tyrosine phosphorylation and 
lead to SYK recruitment and consequently to positive modulation of BCR signaling. 
Interestingly, the ABC DLBCL cell lines HBL-1 and TMD8 used in this study, harbour 
a heterozygous missense mutation leading to the substitution of the first CD79B 
ITAM tyrosine to a phenylalanine (HBL1-1: Y196F) or histidine (TMD8: Y196H), 
respectively, preventing their phosphorylation. However, though heterozygous, over 
90% of total CD79B mRNA in HBL-1 was originating from the mutant allele 
according to Davis et al. (2010). The replacement of the BCR proximal signaling 
essential first CD79B ITAM tyrosine was found by Davis et al (2010) to occur in 18% 
of patient derived samples. The group also found that this substitution of the first 
CD79B ITAM tyrosine led to elevated BCR surface levels and decreased LYN 
kinase activity. In accordance with this, also GCB DLBCLs that were reconstituted 
with common ABC DLBCL CD79 A or B mutants were observed to have higher 
surface Ig levels than wild-type controls. Moreover, also ABC DLBCL that were 
transduced with mutant CD79B expressed increased BCR amounts in their surface 
compared to wild-type bearing controls. Furthermore, murine B-cells that bear 
mutations in CD79A or CD79B ITAM tyrosines were shown to exhibit increased 
surface BCR levels due to inhibited receptor clathrin-dependent endocytosis.  
The increased number of BCR on the cell surface leads to the amplification of BCR 
signaling which calcineurin activity could even further enhance by 
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dephosphorylating S221 of CD79B and thus promote the phosphorylation of the 
second C-terminal ITAM tyrosine (Y207) providing a docking site for SYK. The CD79 
ITAMs are also needed for the controlled termination of BCR signaling as they 
mediate receptor internalisation. Notably, murine B-cells that harbour CD79A/B 
ITAM impairing mutations were observed to response more sensitive to antigen 
encounter (Gazumyan et al., 2006; Kraus et al., 1999; Torres et al., 1999). A study 
by Busman-Sahay (2013) who established a model system including both CD79 
subunits, showed that the N-terminal CD79B ITAM tyrosine (Y196) is the only ITAM 
tyrosine needed for internalisation. In addition to that, they also unveiled that the 
CD79A cytoplasmic portion is required to activate CD79B’s ability to trigger BCR 
receptor endocytosis. Thus, deletion mutations of CD79A as found in OCI-LY10 
could interfere as well with proper BCR internalisation. 
LYN is a further factor, needed for BCR internalisation that is as already mentioned 
above, less active in CD79B membrane-proximal ITAM tyrosine mutated cells  
(Ma et al., 2001; Niiro and Clark., 2002). LYN holds a dual role within BCR signaling 
since it promotes signaling by phosphorylating CD79 ITAM tyrosines but is also 
capable of attenuating BCR signaling by phosphorylating CD22 ITIMs leading to the 
recruitment of the protein tyrosine phosphatase SHP-1 (refer to: chapter BCR 
signaling). Conclusively, the mutation of the HBL-1 and TMD8 N-terminal ITAM 
tyrosine (Y196), the partial deletion of the CD79A ITAM as seen in OCI-LY10 cells 
or the deletion of the CD79A cytoplasmic portion would therefore result in declined 
LYN kinase activity mediated increased BCR surface presence, as a consequence 
of impaired endocytosis, promoting chronically active BCR signaling.  
The mutation of the first N-terminal CD79A ITAM tyrosine to phenylalanine by Müller 
et al. led to decreased phosphorylation of the second ITAM tyrosine in an otherwise 
S/T phosphorylatable CD79A cytoplasmic tail. However, in a non-phosphorylatable 
CD79A background, mimicking the dephosphorylated state as sustained by S/T 
phosphatases such as calcineurin, Y188F mutation resulted in enhanced 
phosphorylation of the second C-terminal ITAM tyrosine (Y199). Transferring these 
observations to CD79B in the context of HBL-1 and TMD8 mutations, this would 
mean that CD79B bearing the somatically acquired Y196H or Y196F mutations 
would exhibit higher phosphorylation of the second ITAM tyrosine (Y207) 
assumingly mediated by a src family kinase in a S/T dephosphorylated background 
sustained by calcineurin enzymatic activity resulting in positive modulation of 
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chronic BCR signaling in ABC DLBCL. However, as soon as the phosphate activity 
of calcineurin is blocked by CsA or FK506, S221 would not be kept in its 
phosphorylated state anymore and as a consequence of this, the second ITAM 
tyrosine Y207 would be phosphorylated only weakly. This would lead to an 
attenuating impact on the binding of SYK and consequently BCR signaling 
transduction. CD79B does not harbour non-ITAM tyrosines that are crucial for 
binding BLNK. Consequently, only CD79A is able to recruit BLNK to the BCR 
signaling complex upon ligand binding, though both CD79 subunits can bind SYK 
by phosphorylated ITAM tyrosines (Rowley et al., 1995). However, the CD79B 
subunit exhibits only weak ITAM tyrosine phosphorylation (Clark et al., 1992; 
Flaswinkel and Reth, 1994). Furthermore, CD79A and CD79B induce different kinds 
of calcium signaling. Only CD79A induces transmembrane Ca2+ influx and a long-
lasting single shot release of intracellular Ca2+ stores. Whereas CD79B induced 
emptying of intracellular Ca2+ stores is described to be brief and oscillatory (Choquet 
et al., 1993), indicating that CD79B alone does not have the competency to initiate 
proper primary BCR downstream signaling on its own. Luisiri et al. (1996) found that 
CD79B is able to enhance the tyrosine phosphorylation of CD79A by more than          
10-fold associated with a reduction of the stimulation threshold for tyrosine              
kinase activation. Therefore, CD79B seems rather to regulate CD79A tyrosine 
phosphorylation and thus the signaling transducing capability of CD79A instead of 
inducing primary BCR-signaling itself. Considering the CD79B ITAM tyrosine 
phosphorylation promoting influence on CD79A, calcineurin phosphatase inhibition 
that leads to an increased CD79B S221 phosphorylation and assumingly to the 
inhibition of ITAM tyrosines phosphorylation and thus to the prevention of SYK 
binding to CD79B could therefore also interfere with the ability of CD79B to 
positively regulate CD79A ITAM tyrosine phosphorylation and thus to negatively 
regulate the proximal BCR signaling cascade. 
Phosphoproteom analysis also revealed the CD79A non ITAM residue Y210 to be 
hyperphosphorylated under calcineurin inhibitory conditions in the ABC DLBCL cell 
line HBL-1. Kabak et al. (2002) all showed the corresponding ITAM flanking murine 
residue Y204 to be required, in its phosphorylated state, for the recruitment and 
direct binding to the linker protein BLNK by its SH2 domain. They also conclude 
from their findings that the murine Y176 (human Y182), which was not found to be 
phosphorylated, contributing to a functional coupling of BLNK to CD79A by a 
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phosphorylation independent mechanism. They suppose that this contribution to 
BLNK binding is achieved by the spatial orientation of BLNK to the kinase domain 
of SYK. The binding of BLNK to CD79A by phosphorylated Y210 brings BLNK into  
proximity of the CD79A ITAM tyrosine bound SYK. Consequently, SYK is capable  
of phosphorylating BLNK tyrosines that serve as binding partners for SH2 domains 
of different signaling proteins that integrate multiple downstream signaling 
pathways. In this manner, SYK activation is linked to downstream pathways. 
Moreover, Kabak et al. (2002) report that tyrosine-to-phenylalanine mutation of 
Y204 (corresponding to the human Y210) and to a lesser extent Y176 
(corresponding to the human Y182) led to a reduction of BLNK phosphorylation and 
subsequent BLNK dependent pathways like JNK activation. Furthermore, CD79A 
Y176 and Y204 (human: Y182 and Y210) mutation and the consequent inability of 
BLNK to bind CD79A cannot be compensated by CD79B as it does not harbour any 
tyrosine residues outside of the ITAM in its cytoplasmic domain (Müller et al., 2000). 
The enhanced phosphorylation of the CD79A Y210 upon CsA and FK506 treatment 
of HBL-1 and the subsequent BLNK binding and SYK dependent phosphorylation 
assumingly results in the maintenance of BCR downstream signaling as suggested 
by Kabak and colleagues. This contradicts the proposed role of the S/T phosphatase 
as a positive modulator of BCR signaling. Moreover, it stands also in opposition to 
the suggestion of Kabak et al. that SYK recruitment by phosphorylated CD79A ITAM 
tyrosines is a prerequisite for the phosphorylation of Y204 (human Y210). On the 
other hand, Müller et al. (2000) assume based on their findings that the rapid 
phosphorylation of BLNK does not need prior ITAM phosphorylation and suggest 
that the phosphorylation of S/T residues in CD79A negatively regulates BLNK and 
ITAM phosphorylation. One possible explanation for this calcineurin inhibition 
induced Y210 hyperphosphorylation could be a mechanism in which after a certain 
time of calcineurin inhibition that leads to a negative impact on BCR-signaling by the 
above described mechanism, Y210 is phosphorylated e.g. by a certain src-kinase 
establishing some kind of bypass in order to maintain BCR signaling. This signaling 
is supposed to be of a small magnitude as BCR signaling addicted ABC DLBCL that 
do not harbour CD79 proximal BCR signaling or NF-kB and NFAT activating genetic 
alterations such as the mutation of CARD11 or the deletion of A20, respectively are 
impaired in growth. Moreover, as observed by the treatment of ABC DLBCL cell 
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lines with calcineurin inhibitors, the expression of mutual NF-kB and NFAT target 
genes such as IκBNS become clearly reduced. 
Furthermore, also the scaffold protein BLNK was affected by the inhibition of 
calcineurin S/T phosphatase activity. The BLNK aa-residues S129; S213; S409 and 
S270 were found to be hypophosphorylated as a consequence of pharmacological 
calcineurin phosphatase activity inhibition by CsA and FK506. As calcineurin is a 
phosphatase, this hypophosphorylation has to be a secondary effect, assumingly 
caused by a kinase that is positively regulated by calcineurin. This result also 
suggests that these serine residues participate in positive regulation of BCR 
downstream signaling when they are phosphorylated. Their actual function(s) 
however remains elusive and should be an issue of future studies e.g. by assessing 
the effects on downstream signaling by replacing the serine residues through 
unphosphorylatable or phosphomimicking residues. 
However, it also conceivable that the CD79A Y210 residue that was phosphorylated 
in the proposed bypass mechanism under calcineurin inhibition is bound by BLNK 
which is subsequently relieved of inhibitory phosphorylations by the activity of an 
unknown S/T phosphatase at S129; S213; S409 and S270, which are to the best of 
our knowledge undescribed in literature. Inhibition of those phosphorylations in turn 
would lead to an aberrant BLNK function because SYK does not phosphorylate the 
tyrosine residues that serve as binding platform for signaling elements. SYK would 
not be active due to the lacking phosphorylations of the CD79A/B ITAM tyrosines to 
which it normally binds and subsequently gets activated. 
According to the conducted phosphoproteom analysis, also the BCL-10 residue 
S138 was affected by calcineurin inhibition as it was found to be present in a hyper-
phosphorylated state, indicating that this particular phosphorylated BCL-10 serine 
residue is a substrate of calcineurin S/T phosphatase activity. This finding is in line 
with a study conducted by Palkowitsch et al. (2011). They report that calcium influx 
is essential for proper CBM complex formation as the calcium dependent 
catalytically active calcineurin subunit CnA in stimulated Jurkat T-cells and in vitro 
was found to positively affect the formation of the CBM complex by the 
dephosphorylation of BCL-10. Thus, they suggest that the calcium signaling 
dependent S/T phosphatase calcineurin is implicated in the assembly of the CBM 
complex. As the formation of the CBM complex is a prerequisite for NF-κB activity 
the calcineurin dependent BCL-10 dephosphorylation also positively regulates TCR 
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induced activity of NF-κB signaling. Also Zeng et al. (2007) conclude from their 
experiments that T-cell activation induces BCL-10 phosphorylation. BCL-10 S138 
and the surrounding serine residues S134, S136, S141 and S144 in the 
serine/threonine rich C-terminal BCL-10 domain that contains about 20% S/T 
residues are known to be IKKβ targets (Wegener et al., 2006).                                            
Their phosphorylation by IKKβ was found to interfere with T-cell activation as it leads 
to a change in the structure of the MALT1-BCL-10 dimer that is present in the 
cytoplasm of unstimulated cells, resulting in the attenuation of CBM complex 
assembly when cells are stimulated (Wegener et al., 2006). Thus IKKβ acts also 
upstream of IκB phosphorylation by phosphorylating BCL-10 and is in this fashion 
able to negatively and positively regulate antigen receptor induced NF-kB activity, 
establishing a negative feedback mechanism by the phosphorylation of BCL-10 at 
S138. In accordance with this, studies conducted by Scharschmidt et al. (2004) and 
Hu et al. (2006) describe an ubiquitin mediated degradation of BCL-10 that is 
induced by T-cell activation. Palkowitsch and colleagues found that calcineurin acts 
as IKKβ antagonist since they observed calcineurin to reverse the IKKβ mediated 
BCL-10 hyperphosphorylation. Especially the phosphorylation of S138 is associated 
with a signal-induced degradation of BCL-10. Zeng et al. (2007) mutated S138 to 
an alanine and observed an impaired T-cell activation-induced phosphorylation 
of BCL-10, prevented activation-induced BCL-10 ubiquitination and thus a 
delayed BCL-10 degradation. Consequently, the replacement of serine 138 to an 
unphosphorylatable alanine results also in prolonged NF-κB signaling and 
consistent with that an increased IL-2 secretion. In consistency with this, the 
mutation of these BCL-10 serines by Wegener et al (2006) was also found to result 
in enhanced expression of the NF-kB target genes IL-2 and TNF-α upon activation 
of primary T-cells. These finding is in accordance with the revealed reduced 
expression of the NF-κB targets IL-6 and IL-10 in calcineurin inhibitor sensitive ABC 
DLBCL cell lines in this study. In summary, Zeng and colleagues conclude from 
these findings that the phosphorylation at the BCL-10 S138 is the trigger for  
BCL-10 ubiquitination and subsequent degradation upon cell activation. 
Furthermore, the phosphorylation of BCL-10 at S138 was found to negatively 
regulate the NF-κB pathway and subsequent IL-2 production, assumingly in order 
to properly terminate T-cell activation. By co-immunoprecipitation Palkowitsch et al. 
revealed that CnA obviously interacts constitutively with the CBM complex 
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components MALT1 and CARMA1. Moreover, they also demonstrate that the 
pharmacological calcineurin inhibitors (CsA and FK506) and in a weaker extent the 
siRNA mediated knockdown of CnA interferes with P/I or anti-CD3/28-induced CBM 
complex assembly in T-cells. This was indicated by a reduction of BCL-10-CARMA1 
interaction. Moreover, Zeng et al. confirmed the impairing effect of the 
unphosphorylatable BCL-10 S138A mutation on cell activation-induced degradation 
of BCL-10, they had observed in Jurkat T-cells as well as in primary murine splenic  
B-cells. Due to this and because B-cells share many similarities with T-cell antigen-
receptor signaling it is justified to transfer the results obtained by Zeng and 
Palkowitsch into the context of ABC DLBCL signaling. Thus we suggest, that the 
chronically active BCR and Ca2+ signaling induced calcineurin constitutively 
dephosphorylates BCL-10 at S138. This in turn results in a promotion of CBM 
complex formation and an inhibition of ubiquitin mediated BCL-10 degradation. This 
means that the inhibition of calcineurin by CsA or FK506 BCL-10 results in BCL-10 
hyperphosphorylation at S138, assumingly mediated by IKKβ. This in turn leads  
to enhanced BCL-10 ubiquitination followed by BCL-10 degradation.  
The downregulation of BCL-10 has a negative regulatory effect on NF-κB signaling 
resulting in diminished transcriptional induction of respective NF-κB target genes 
such as IκBNS as well as IL-6 and IL-10. As a consequence of the proposed 
mechanism, especially ABC DLBCL cell lines like HBL-1 and TMD8 that do not 
harbour CBM complex formation promoting or CBM downstream NF-κB signaling 
activating mutations could therefore be very sensitive towards the treatment with 
pharmacological inhibitors of calcineurin.  
Taken together, there exist several elements at different positions in antigen 
receptor signaling on which calcineurin S/T phosphatase activity could exert its 
positive regulatory influence on the signaling cascade. The different mutation 
pattern of ABC DLBCL are suggested to influence the consequences of calcineurin 
inhibition. Only ABC DLBCL cell lines harbouring signaling transduction activating 
mutations downstream of calcineurin engagement in proximal BCR signaling are 
supposed to compensate or mitigate the loss of calcineurin positive modulation and 
are thus less to non-sensitive towards CsA and FK506 treatment. 
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Figure 53. CD79A and B amino-acid sequences. (a, b) In bold: the CD79A/B cytoplasmic 
portions. Underlined: the CD79A/B ITAM sequences. ITAM regions were revealed to be affected 
by somatically acquired mutations in 2,9% of GCB DLBCLs and 21,1% of ABC DLBCL. 
Highlighted in red: ITAM tyrosines which are important in their phosphorylated state for SYK 
binding at the sequence positions (a) Y188 and Y199 in CD79A and (b) Y196 and Y207 in CD79B. 
The CD79B N-terminal ITAM tyrosine (Y196) was found to be substituted by multiple amino acids 
due to point mutations in 18% of ABC DLBCL as for instance in HBL-1 (Y196F) and TMD8 
(Y196H) model cell lines. The ABC DLBCL cell line model OCI-LY10 has a heterozygous splice 
donor site mutation that leads to the deletion of 18 aa affecting the majority of the ITAM sequence. 
Highlighted in yellow: S/T/Y residues found hyperphosphorylated by phosphoproteom analysis upon 
CsA and FK506 treatment of HBL-1 cells. For further information see continuous text. Amino-acid 
sequences taken from uniprot.org: Entry name: CD79A_HUMAN; Entry P11912; Entry name: 
CD79B_HUMAN; Entry: P40259. 
 
4.5 Characterisation of two IκBNS isoforms  
RNAi mediated knockdown and the application of the CRISPR/Cas9 technique both, 
originally designed to target IκBNS p35, revealed the presence of a second IκBNS 
isoform sharing the respective target sequences and originating from the same gene 
locus. The new isoform was observed to be expressed always along with the IκBNS 
p35 protein in all tested cell lines and exhibits a size of approximately 70 kDa in 
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SDS-PAGE. Consequently, protein levels were affected by both gene expression 
editing techniques. This new IκBNS p70 isoform was observed to exhibit an 
endogenous expression level more than twice as high as IκBNS p35 under 
constitutive expression in ABC DLBCL and P/I and anti-CD3/28 triggered 
expression in GCB DLBCL, Burkitt’s lymphoma and T-ALL cell lines. On the other 
hand, IκBNS p70 showed the same characteristics as IκBNS p35 regarding 
expression levels and subcellular distribution upon P/I mediated cell stimulation in 
GCB DLBCL cell lines and under constitutive expression in ABC DLBCL. The 
treatment of ABC DLBCL cell lines with cycloheximide revealed no difference 
between half-lifes of both IκBNS isoforms. 
The 70 kDa IκBNS specific signal was already described by earlier studies in murine 
cells and was assumed to emanate from one gene locus but was suggested to be 
generated by a posttranslational modification (Schuster et al., 2012; Jeltsch et al., 
2014). Deep sequencing comprising ABC DLBCL samples revealed that there exists 
only one Nfκbid mRNA that should be therefore the origin of both, the IκBNS p35 
and p70 signal. Indeed, the usage of an ORF prediction tool applied on the Nfκbid 
mRNA sequence, unveiled the existence of a second ORF that was validated to be 
the origin of the IκBNS p70 protein. According to this analysis, IκBNS p70 is protein 
made up of 572 aa with a predicted molecular weight of 61 kDa. In particular, the 
newly established IκBNS p70 aa sequence includes the whole IκBNS p35 
sequence, bearing six ankyrin repeats important for protein-protein interactions. 
Further, it exhibits an additional 259 aa counting unstructured N-terminal tail of so 
far unknown function. With this putative IκBNS p70 aa-sequence, we generated an 
expression construct comprising the above described aa-sequence and expressed 
it transiently in HEK293T and over a longer period of time, lentivirally mediated in 
Jurkat T-cells. By comparing the introduced IκBNS p70 with the endogenously 
expressed IκBNS p70 of ABC cell lines and the P/I induced IκBNS p70 of Jurkat 
T-cells by immunoblotting, we observed that the 61 kDa predicted sequence actually 
exhibits the same size and band pattern as the endogenous counterpart, indicating 
the validity of our IκBNS p70. The multiple bands that were observed to be specific 
for both IκBNS isoforms could constitute post translationally modified versions of the 
IκBNS p70 isoform of so far unknown function. The lentiviral expression of both 
isoforms in Jurkat T-cells revealed as well an autoinhibitory feedback loop of IκBNS. 
The expression of the endogenous IκBNS p35 and p70 isoform was remarkably 
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diminished upon P/I mediated cell stimulation under simultaneous lentiviral 
overexpression of IκBNS p35 and p70. This assumed autoinhibitory feedback loop 
is likely made to prevent a surplus of IκBNS expression what would also result in a 
dysregulation of putative IκBNS controlled target genes. 
In order to further validate the existence of the predicted IκBNS p70, we generated 
an antibody against aa 215- aa 231 of the IκBNS p70 sequence, an epitope located 
within the additional N-terminal tail. By application of this antibody in immunoblotting 
we were indeed able to detect an upcoming band of approximately 70 kDa by P/I 
mediated stimulation of BJAB cells. As expected, the IκBNS p35 isoform was not 
detectable with this IκBNS p70 specific antibody. Unfortunately, the seemingly 
IκBNS specific 70 kDa band was partly covered by an unspecific band. 
The difference in the protein sequences of the distinct IκBNS isoforms should have 
an impact on protein structure and function, as well. However, we could not assign 
any structure to the additional N-terminal portion of IκBNS p70 and thus no obvious 
function. It is conceivable that this unstructured region could represent some kind of 
autoinhibitory peptide domain that covers ankyrin repeats, keeping IκBNS p70 in an 
inactive state. Due to steric reasons, this would prevent interactions with unknown 
interaction partners and Rel family proteins IκBNS was shown to interact with (Fiorini 
et al., 2002; Hirotani et al., 2005; Schuster et al., 2012). However, by an unknown 
mechanism assumingly a phosphorylation event, the autoinhibitory portion could 
alter its spatial orientation and its autoinhibitory property could be abrogated and  
IκBNS p70 could become additionally to its smaller isoform active as transcriptional 
regulator. This mechanism would introduce a new layer of IκBNS controlled target 
gene regulation. Another possibility is that the additional N-terminal portion of the 
IκBNS p70 isoform comprises a yet unrecognised TAD. A comparable issue is 
known for the three described IκBζ splicing variants IκBζ (S, L and D) (Kitamura et 
al., 2000; Haruta et al., 2001; Ito et al., 2004). Whereas IκBζ(S) and IκBζ(L) are 
known to contain a TAD, IκBζ(D) misses such a domain. Regarding IκBζ, this 
difference between the isoforms became functionally obvious in an experiment in 
which a retroviral mediated expression of IκBζ (S) and (L) but not IκBζ(D) in a mouse 
fibroblast cell line resulted in increased IL-6 production (Motoyama et al., 2005). The 
presence of a TAD in the IκBNS p70 N-terminus would establish a dual system 
consisting of a putative transcriptional negative regulator namely IκBNS p35 that 
lacks a TAD and IκBNS p70 that possesses a TAD as transcriptional positive 
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regulator. Consequently, this would mean a fine tuning mechanism for IκBNS 
controlled target genes. Therefore, future experiments should shed light on the 
function of the of the additional N-terminal portion of IκBNS p70. For instance by 
targeted knockdown of only one isoform in ABC DLBCL or conducting GAL4 fusion 
protein reporter assays with the 259 aa IκBNS p70 N-terminal tail. 
 
4.6 IκBNS is essential for ABC DLBCL survival and 
might promote immune escape of ABC DLBCL 
by regulating MHCII surface expression 
The importance of constitutive IκBNS expression for ABC DLBCL biology was 
demonstrated by the induction of toxicity selectively in ABC DLBCL cell lines by 
shRNA mediated knock-down of IκBNS within one week. In contrast, 
overexpression of IκBNS p35 did neither impair nor confer a growth advantage to 
neither GCB nor ABC DLBCL cell lines. This indicates that putative targets genes 
controlled by IκBNS are critical for ABC DLBCL survival and a further increase of 
the IκBNS p35 protein amount in ABC DLBCL does not affect cell growth. In 
summary, our results suggest that IκBNS is a crucial mediator of canonical NF-κB 
activity in the NF-κB signaling addicted ABC subtype of DLBCL. As IκBNS 
expression seems to be vital for ABC DLBCL survival, IκBNS could represent a 
promising suitable molecular target in the therapy of ABC DLBCL. Since IκBNS does 
not exhibit enzyme activity, a negative impact on its functionality should rather 
interfere with its function as transcriptional inducer and repressor. This could be 
achieved by designing small peptides/molecules mimicking the binding sites from 
NF-κB interaction partners of IκBNS. In this manner, IκBNS would not be able 
anymore to associate with NF-κB subunits and as a consequence of this not having 
transcriptional control neither positively nor negatively over its target genes.  
shRNA mediated knock-down of IκBNS in the ABC DLBCL cell line HBL-1 followed 
by RNAseq revealed several genes encoding classical MHCII molecules such as 
HLA-DRA1, HLA-DRB, HLA-DRB1,HLA-DQA, the invariant chain (CD74) and also 
the class II major histocompatibility complex transactivator “CIITA” which represents 
the essential master regulator of MHCII expression to be negatively regulated IκBNS 
target genes. The treatment of HBL-1, OCI-LY3 and TMD8 cells with calcineurin 
inhibitors, which was known to us to cause IκBNS knock-down, actually resulted in 
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a calcineurin inhibitor dose dependent increase of HLA-DR surface presentation as 
previously indicated by RNAseq results. To substantiate that IκBNS has indeed a 
direct negative regulating impact on HLA-DR surface levels, both IκBNS isoforms 
were lentivirally expressed in the GCB DLBCL cell line BJAB and the Burkitt’s 
lymphoma cell line RAJI that do not express endogenous IκBNS. Indeed, as 
expected, the overexpression of IκBNS p35 or p70 in the mentioned B-cell lines 
caused a clear reduction of HLA-DR surface expression at a comparable, 
suggesting that IκBNS is indeed a MHCII negative regulator. This finding is from 
interest in respect of possible DLBCL treatment options. Clinical studies with DLBCL 
patients conducted by Rimsza et al. in 2007 show that low levels of MHC class II 
HLA-DR molecules on DLBCL are associated with a remarkable poor survival 
outcome of patients. This association is most likely based on the finding that 
decreased levels or also even the loss of MHCII on DLBCL cells causes an impaired 
tumor-infiltrating T-cell response and as consequence of this a compromised 
immunosurveillance of the tumorigenic cells (List et al., 1993; Rimsza et al., 2004; 
Roberts et al., 2006; Kendrick et al., 2017). Efficient and sustained anti-tumor 
response in the priming and effector phase needs the assistance from CD4+ T-cells 
that recognise MHCII molecules displayed on the surface of professional APCs such 
as B-cells (Toes et al., 1998; Ossendrop et al., 2000). Accordingly, the loss of MHCII  
is commonly observed in oncogenic diseases and represents a mechanism with 
which malignant cells are capable of editing the immune system to their advantage 
by preventing their detection and subsequent elimination. This mechanism is also 
called “immune escape” (Khong et al., 2002; Dunn et al., 2002; Beatty and Gladney 
2015). Furthermore, our RNAseq results are consistent with the finding of Rimsza 
et al. (2006) that show that the expression of classical and non-classical MHCII 
molecules as well as CD74 in DLBCL is associated with the expression of CIITA. 
This non-DNA-binding MHCII expression master transcriptional factor was found in 
this study by RNAseq to be increased upon IκBNS knock down in HBL-1 cells. Thus, 
it can be assumed that IκBNS is a negative regulator of CIITA function. Further 
experiments should therefore investigate the interaction between IκBNS and the 
transcriptional regulation of the CIITA encoding gene MHC2TA and moreover the 
“CIITA enhanceosome complex” that serves as CIITA docking platform and thus 
regulates CIITA target gene transcription. MHC2TA transcription is controlled by 
four distinct not-coregulated promoters (pI to IV). In B-cells transcription of MHC2TA 
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was found to be initiated from pIII (LeibundGut-Landmann et al., 2004). As GCB 
DLBCL cell lines were found during this study not to express IκBNS, the finding by 
Wilkinson et al. (2012) that in general MHCII expression of GCB DLBCL is 
significantly higher than in ABC DLBCL is in accordance with our results. This could 
be one reason why the ABC DLBCL subtype exhibits a more aggressive clinical 
course and decreased patient survival than the GCB subtype. Remarkably reduced 
MHCII surface levels were for instance observed by Cycon et al. (2009) in OCI-LY3 
cells that were caused by a dyscoordinated downregulation of the MHCII β-chain for 
an unknown reason. However, they are also other reasons that are clearly 
independent from IκBNS expression why some ABC DLBCL do express reduced or 
not express MHCII molecules. Cycon et al. (2009) found that the ABC DLBCL cell 
line OCI-LY10 harbours a homozygous deletion in the MHCII locus and thus the cell 
line has no detectable HLA-DR and HLA-DQ expression. According to our results, 
it can be said that the low levels of MHCII molecules on the surface of ABC DLBCL, 
that are characterised by adverse survival under treatment is caused by a steady 
state expression of IκBNS that conveys a clear survival advantage over GCB 
DLBCL in respect of immune evasion. Taking into account the previously mentioned 
facts and that we have shown that artificial IκBNS p35 and p70 overexpression in  
B-cell lines causes decreased HLA-DR surface levels, it is valid to claim that one 
reason why ABC DLBCL cell lines were selected to express high levels of 
endogenous IκBNS p35 and p70 could be its capability to repress HLA-DR surface 
levels by a so far unknown mechanism. This in turn leads to decreased 
immunogenicity of the cells and therefore augmented immune escape and thus 
survival of ABC DLBCL.  
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4.7 Calcineurin inhibitor administration as 
additional therapeutic option to R-CHOP in the 
treatment of ABC DLBCL 
Considering the findings regarding the impact of calcineurin inhibitor treatment on 
certain ABC DLBCLs in this study, the inhibition of calcineurin seems to hold a not 
negligible therapeutic potential in the treatment of ABC DLBCL. The calcineurin 
inhibitors CsA and FK506 are commonly used as potent immunosuppressive 
especially in preventing transplant rejection and in the therapy of autoimmune 
diseases. CsA and FK506 mediated calcineurin inhibition was found by this study 
to clearly impair the growth of ABC DLBCL with a certain mutation pattern.  
This growth impairing effect was revealed to be caused by reduced NFAT and 
NF-kB signaling the consequently resulted in decreased secretion levels of the pro-
proliferative IL-6 and IL-10 and reduced IκBNS expression. For this reason, 
we suppose that calcineurin inhibitor treatment could be suitable for ABC DLBCL 
that harbour mutations which are upstream of MALT1. CsA or FK506 treatment 
could thus be applied prior to the R-CHOP regimen in order to weaken the cells by 
interfering with the BCR antigen-receptor signaling cascade and Ca2+/NFAT 
signaling. This interference in turn results in a reduction of the aberrant pro-
proliferative and anti-apoptotic NF-kB signaling in ABC DLBCL. As a consequence 
of this, also the expression of (mutual) NF-kB and NFAT target genes such as the 
vital IκBNS would be affected by this R-CHOP complementary pre-treatment. 
Moreover, calcineurin inhibitor treatment of ABC DLBCL cell lines study was found 
by this study to lead to increased surface expression of MHCII molecules most likely 
by the down-regulation of IκBNS. The MHCII down regulating impact of IκBNS could 
be exploited as well by a R-CHOP complementary pre-treatment of ABC DLBCL 
with calcineurin inhibitory compounds. Increased MHCII surface levels would 
enhance the immunogenicity of the ABC DLBCL cells in turn leading to a better 
immunosurveillance and finally a more effective anti-tumor immune response. 
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4.8 IκBNS and its relative IκBζ 
According to our results, constitutive IκBNS expression represents an intrinsic 
advantage for ABC DLBCL tumor survival as its shRNA mediated knock down led 
to the induction of toxicity in ABC DLBCL. We elucidated one possible mechanism 
why IκBNS expression is a survival advantage for ABC DLBCL. We showed IκBNS 
expression to negatively regulate MHCII surface presentation assumingly leading to 
reduced immunosurveillance of the oncogenic cell. But is this mechanism the only 
reason why ABC DLBCL were selected to express IκBNS steady state levels? 
The human atypical IκB proteins IκBNS and its relative IκBζ share a sequence 
similarity of 26% (their murine counterparts 43%) and were shown to share 
characteristics regarding effector functions in several cell types and also in respect 
of their regulation and role in the pathogenesis of the ABC subtype of DLBCL.  
Both IκBs were revealed to be upregulated by constitutive NF-κB signaling and thus 
to be overexpressed in the ABC DLBCL subtype. Furthermore, the shRNA mediated 
downregulation of IκBNS and IκBζ had a toxic effect on ABC DLBCL cell lines 
indicating that the target genes under their transcriptional control are critical for the 
survival of ABC DLBCL (This study; Nogai et al., 2013). Moreover, as found by 
Nogai et al. (2013) shRNA mediated knock-down of IκBζ downregulates the 
expression of IL-6 and IL-10 in ABC DLBCL cell lines. An investigation of IκBζ 
lacking B-cells by Hanihara et al., 2013 revealed that IκBζ is essential for the 
induction of several genes such as IL-10 upon BCR or TLR stimulation. In addition 
to that, IκBζ was described by several studies to positively regulate IL-6 in various 
cell types. In human monocytes for instance, the expression of IL-6 depends on the 
binding of p50/IκBζ heterodimers to its promoter. This finding could be confirmed by 
monocytes that exhibit higher IκBζ expression than monocyte-derived macrophages 
as their IL-6 expression reflected the distinct IκBζ expression levels (Seshadri et al., 
2009). Furthermore, in murine macrophages, IκBζ/p50/p50 complexes bind to the 
IL-6 locus and increase transcription when the cells were stimulated with TLR 
ligands and IL-1 (Yamamoto, 2004; Eto, 2003). In consistence with this, 
overexpression of IκBζ leads to increased IL-6 expression, whereas a lack of IκBζ 
results in reduced IL-6 expression (Yamamoto et al., 2004; Kitamura et al., 2000). 
Additionally, IκBζ regulates IL-12p40 expression by binding to its promoter and in 
line with this, IκBζ deficient cells were observed to express less IL-12p40 
(Yamamoto et al., 2004; Kayama et al., 2008). Moreover, also IκBζ-defective 
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conventional DCs were shown to express less LPS-induced IL-6 (Okamoto et al., 
2010). Also IκBNS was shown to be involved in the regulation of IL-6, IL-10 and 
IL12p40. IκBNS is described to be crucial for the expression of IL-6 and  
IL-12p40 in bone marrow derived DCs (Kuwata et al., 2006). However, in 
macrophages and DCs lacking IκBNS, LPS induced a prolonged and increased IL-
6 and IL-12p40 expression. This suggested that IκBNS is a negative regulator of 
LPS induced IL-6 and IL-12p40 expression in macrophages. It was supposed that 
an IκBNS/p50 complex is needed to end IL-6 expression (Hirotani et al., 2005; 
Kuwata et al., 2006). Annemann et al, (2015) observed a reduced secretion of  
IL-10 in IκBNS deficient TH17 cells. They revealed IκBNS to bind to the IL-10 gene 
locus in stimulated TH17 cells and found decreased expression of IL-10 in IκBNS 
lacking TH17 cells, indicating IL-10 to be a direct positively regulated target of IκBNS 
in this T-cell subset. This means that IκBζ and IκBNS share the regulation of certain 
target genes such as IL-6, IL-10 and IL-12p40. Furthermore, both atypical IκBs 
seem to have an essential positive regulator function on IFN-γ gene expression. 
Mature CD4+ T-cells deficient for IκBNS for example show reduced IFN-γ 
expression upon anti-CD3/28 antibody mediated TCR stimulation (Touma et al., 
2007). Furthermore, decreased IFN-γ production was also observed by IκBNS 
knock-out lymphocytes and CD8+ T-cells derived from lymph nodes (Touma et al., 
2007). IκBζ was like IκBNS found to be indispensable for IFN-γ production by NK 
cells. In this respect, IκBζ was shown to be induced by IL-12 or IL-18 stimulation of 
NK cells and subsequently recruited to the IFN-γ gene promoter region (Miyake et 
al., 2010). In accordance with the previous, IκBζ was found to associated with the 
IFN-γ promoter in a complex including p50/p65 (Kannan et al., 2011). IκBζ deficient 
mice were observed to exhibit impaired TH17 development resulting in resistance 
to experimental autoimmune encephalomyelitis (EAE) when they were immunised 
with the myelin oligodendrocyte glycoprotein (MOG)-peptide (Okamoto et al., 2010). 
Also a mouse model lacking IκBNS expression was found to be more resistant to 
EAE induction (Kobayashi et al., 2014). In addition, IκBζ and IκBNS deficient mice 
exhibit a deregulated humoral immune response as indicated by markedly reduced 
IgM and IgG3 serum levels (Touma et al., 2011; Arnold et al., 2012; Hanihara et al., 
2013). In case of IκBNS deficiency this could be illustrated in the production of less 
antigen-specific antibodies against influenza viruses. Moreover, B-cells from IκBNS 
deficient mice also exhibit a defective IgG3 class switch (Touma et al., 2011). 
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Both atypical NF-kB inhibitors were also reported by several studies to be implicated 
in TH17 development and proliferation whereby IκBζ seems to play more important 
role than IκBNS. Mice deficient for IκBNS showed a clearly reduced number of IL-
17+ T-cells under C.rodentium infection, induced EAE and colitis. Furthermore, 
TH17-cells lacking IκBNS exhibited impaired expression of IL-10, IL-17A, IL-17F 
and GM-CSF (Annemann et al., 2015; Kobayashi et al., 2014). Notably, also GM-
CSF mRNA expression of LPS stimulated peritoneal macrophages was found to be 
dependent from IκBζ (Yamamoto et al., 2004). Also described is a defective TH17-
related RORγt and CCR6 expression in CD4+ IκBNS-deficient cells what could 
represent a possible explanation for the above mentioned cytokine secretion defect. 
The direct transcriptional control of IκBNS over the TH17 characteristic interleukin 
IL-17A could be excluded by Kobayashi et al. (2014). According to Okamoto et al. 
(2010), IκBζ seems to play a crucial regulatory role in TH17 development by 
cooperating with ROR nuclear receptors. In more detail, in contrast to IκBNS, IκBζ 
could be unveiled to bind in a RORγt and RORα-dependent manner to the IL17A 
promoter and was suggested to positively regulate IL17A expression by the 
increased binding of transcriptional co-activators (Okamoto et al., 2010). 
In consistence with that, IκBζ knock-out TH17 cells show decreased mRNA levels 
of IL17A and other TH17-related genes like IL-21, IL-22 and IL-23r. As a 
consequence of this TH17 phenotype promoting impact of IκBζ, corresponding IκBζ 
knock-out mice are completely resistant to EAE due to the lack of IL-17 producing 
TH17 cell (Okamoto et al., 2010).  
As depicted above, IκBζ and IκBNS seem to share multiple functional similarities 
and to have partially redundant roles in different cellular processes. Therefore, it is 
conceivable that the found steady state expression of IκBNS in ABC DLBCL as it 
was already shown for IκBζ shown by Nogai et al. (2013) also represents an intrinsic 
advantage for ABC DLBCL cells for several reasons that led to the selective 
pressure to express IκBNS. These reasons are assumingly at least partially 
redundant for IκBζ. First, IκBNS in ABC DLBCL could directly control, as IκBζ, the 
expression of IL-6 and IL-10 and thus sustain the autocrine/paracrine pro-
proliferative cytokine signaling loop. Second, IκBζ was suggested by Nogai and 
colleagues to play a central role in the regulation of NF-κB target genes and thus to 
be required for proper functionality of the NF-κB signaling network in ABC DLBCL. 
The same function could be true for IκBNS, which could partially regulate the same 
Discussion 
 
189 
 
NF-κB target genes as IκBζ does in ABC DLBCL. However, the knock-down of 
IκBNS induced toxicity in all IκBNS and IκBζ expressing ABC DLBCL cell lines 
tested. This experimental outcome is similar to the result of an IκBζ knock-down 
experiment conducted by Nogai et al. (2013). This suggests that the observed toxic 
effects that were induced by the individual knock-down of both atypical IκBs are 
based on non-redundant functions of IκBNS and IκBζ that cannot be mutually 
adopted.  
4.9 Seeking new surface markers and molecular 
targets for classifying and combat DLBCL  
We were conducting the LEGENDScreen™ assay with 3 cell lines of the GCB 
DLBCL subtype (BJAB, SU-DHL-4, SU-DHL-6) and 3 cell lines classified as ABC 
DLBCL (HBL-1, TMD8, U2932) with the intention to reveal new biomarkers which 
could be useful to differentiate between the GCB and ABC DLBCL subtypes and 
moreover that could be potentially exploited as molecular targets in future DLBCL 
treatment approaches. The screen unveiled surface markers that were expressed 
on both DLBCL subtypes and also markers that were mainly or even exclusively 
expressed by only one, the GCB or the ABC DLBCL subtype. 
Understandably, among the surface markers that were mutually expressed by 
the GCB and the ABC DLBCL subtype cell lines, the screen unveiled plenty of 
surface molecules that are known to be generally expressed on the surface of 
B-cells and are thus also shared by both DLBCL entities such as the pan B-cell 
marker CD20 and CD79B. 
CD20 is a non-glycosylated surface protein of 33-37 kDa that is expressed in B-cell 
development from the early pre-B to the stage of mature B-cells and is down 
regulated during the transition to plasma blasts (Cragg et al., 2005; Rehnberg et al., 
2009). CD20 can be found in approximately 95% of B-cell lymphoma, is not present 
on precursor B-cells or stem cells and at low levels on plasma cells (Cragg et al., 
2005; (Boye, Elter and Engert, 2003). It was found to localise with MHCII and the 
BCR ahead to antigen engagement (Cragg et al., 2005). It is the target of several 
antibodies in the therapy of CD20+ B-cell Non-Hodgkin Lymphoma and autoimmune 
disorders (Boye, Elter and Engert, 2003; Randall, 2016). The functionality of CD20 
is not yet understood but in respect of cancer treatment it contributes to complement 
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and effector-cell mediated lysis, apoptosis induction and interferes with calcium 
influx (Boye, Elter and Engert, 2003).  
CD79B and CD79A make up the heterodimer CD79 and together with the surface 
Ig it forms the BCR-complex, the characteristic feature of B-cells (Chu and Arber 
2001; Naeim et al., 2013). It is crucial for the transport of mIg to the cell surface and 
the propagation of proximal BCR signaling (Torres et al., 2008). Thus, CD79 is 
already expressed in prior to Ig heavy chain rearrangement and also CD20 in the 
course of B-cell maturation. It is therefore a convenient pan-B-cell marker to e.g. 
classify leukemia and hence to identify B-cell neoplasms such as DLBCL, as well. 
From the CD markers that were revealed to be differentially distributed between the 
GCB and ABC DLBCL subtypes, we chose CD90 which was revealed to be 
exclusively expressed by GCB DLBCL cell lines and CD36 as well as CD274 that 
were both found to be associated with the ABC DLBCL subtype for more detailed 
investigations. 
CD90 which is also called Thy-1 is a 25-37 kDa GPI-anchored membrane protein 
lacking an intracellular domain. The core protein exhibits 25 kDa, whereas the fully            
N-glycosylated protein displayed on the cell surface comprises 37 kDa (Pont, 1987; 
Kumar et al., 2016). With a carbohydrate content of up to 30% of its molecular mass 
it is one of the most heavily glycosylated proteins (Pont, 1987). Thy-1 exerts tasks 
in cell-cell and cell-matrix interactions, apoptosis, migration, fibrosis (Rege and 
Hagood, 2006) and was recently found to be implicated in several kinds of neoplasia 
were it has a binary role in tumor facilitation and containment dependent on the 
cancer type (Kumar et al., 2016). Moreover, Thy-1 expression was found in the 
highly invasive cancer cell microenvironment in prostate and pancreatic cancer, 
determining their aggressive and metastatic abilities (Pascal et al., 2011; Zhu et al., 
2014). This is from importance since the altered tumor stroma plays in general a 
considerable role in cancer progression and metastasis (Barron and Rowley, 2012; 
Ungefroren et al., 2011). Furthermore, Thy-1 is also discussed as cancer stem cell 
(CSC) marker candidate as Thy-1 was revealed to be co-expressed with other CSC 
markers and CD90+ cells were isolated from various tumor types such as breast 
cancer (Lobba et al., 2012). These CD90+ cells showed the characteristic traits of 
CSCs in regard to spheroid forming abilities, proliferation, differentiation, metastatic 
properties and the capability to grow as tumor xenograft in mice (Shaikh et al., 
2016). Interestingly, in line with our results, Thy-1 was also identified at high 
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expression levels by Ishiura et al. (2010) in B-cell lymphoma cell lines such as BJAB 
(GCB DLBCL). The treatment of those cell lines with an anti-Thy-1 antibody 
revealed an inhibitory effect on proliferation contributed partially by apoptosis and 
necrosis. The antibody caused caspase activation and additional down regulation 
of anti-apoptotic BCL-2 family members. This proliferation inhibitory effect that was 
observed by Ishiura et al. seemed to be even stronger than that facilitated by 
rituximab. As we found CD90 to be highly expressed by the GCB subtype of DLBCL 
treatment with bi-specific anti-CD20/CD90 antibodies could be therefore indeed a 
promising approach in the therapy of GCB DLBCL. 
CD36 (alternative names: FAT, GPIV, GPIIIb, PAS IV) is an 88 kDa integral 
membrane glycoprotein and member of the scavenger receptor family of pattern 
recognition receptors (Silverstein and Febbraio, 2009; Danilova et al., 2013; Park, 
2014).CD36 is made up of two transmembrane domains, two short intracytoplasmic 
domains containing both termini, lacking known intracellular signaling domains and 
a larger extracellular extensively glycosylated domain (Febbraio et al., 2001; Park, 
2014). CD36 is expressed on numerous cells types like monocytes, macrophages, 
dendritic cells, microvascular endothelial cells, adipocytes and platelets (Pepino et 
al., 2014). It is known to interact with other membrane receptors like integrins, TLRs 
and tetraspanins. (Miao et al., 2001; Akira, 2003 Lawler et al., 2012). CD36 binds a 
multitude of different ligands at different binding sites such as thrombospondin-1, 
oxidized phospholipids, DAG, cholesterol, native lipoproteins (HDL, LDL and VLDL), 
oxidized lipoproteins (oxLDL and oxHDL) and long-chain fatty acids (Lawler et al., 
2012; Park 2014; Pepin et al., 2014). Concerning functionality, CD36 plays among 
others a role in fat metabolism as it acts as a high affinity fatty acid translocase 
(FAT) by binding long chain free fatty acids (FA) and transporting them into the cell, 
thereby providing an energy source for β-oxidation (Harmon et al., 1993; Glatz et 
al., 2010; Abumrad and Davidson, 2012; Park 2014). Moreover, CD36 is also 
reported to be implicated in FA metabolism related issues including fat taste 
perception, fat uptake and absorption and FA exploitation by muscle and adipose 
tissues (Glatz et al., 2010; Abumrad and Davidson, 2012; Pepino et al., 2014). 
Despite the negligible intracellular presence and lacking a common intracellular 
signaling domain, CD36 was reported to have diverse downstream ligand-
dependent signaling pathways (Moore et al., 2002; Chen et al., 2008; Silverstein 
and Febbraio, 2009). It interacts for example directly with src-kinases like FYN, LYN 
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and YES (Huang et al., 1991). This for instance occurs in macrophages upon 
engagement of oxLDL leading to LYN phosphorylation and the subsequent 
activation of downstream signaling molecules. Amongst them are e.g. JNK1 & 2 
which in turn facilitate oxLDL inward transport (Silverstein and Febbraio, 2009; Park, 
2014). Moreover, CD36 downstream signaling also comprises the activation of NF-
κB (Janabi et al., 2000). This was concluded from the finding that macrophages from 
CD36 deficient patients exhibit attenuated NF-κB activity and decreased secretion 
of IL-1β and TNF-α (Yamashita et al., 2007). Patients suffering from a CD36 
deficiency show high incidences of cardiomyopathy, hyperlipidemia and insulin 
resistance (Yamashita et al., 2007). Furthermore, it functions as endogenous 
angiogenesis negative regulator of microvascular endothelial cells (Dawson et al., 
1997). This is achieved by inhibiting proangiogenic signals inducing proliferation and 
tube formation, generating instead signals leading to apoptosis by activating 
caspase 3 and the secretion of FasL and TNF-α (Jiménez et al., 2000). Furthermore, 
CD36 activation that was mediated by an N-terminal recombinant thrombospondin-
2 fragment was recently shown to inhibit growth and metastasis of breast cancer by 
endothelial cell apoptosis (Koch et al., 2011). Thus, CD36 is also considered to play 
an important role in tumor growth and other processes that involve 
neovascularisation. Regarding B-cell malignancies, CD36 was revealed to be 
transcriptionally regulated by Oct-2, a commonly known B-cell differentiation 
regulator (Corcoran et al., 1993; Pfisterer et al., 1997). Additionally, the expression 
of CD36 in chronic B-cell lymphoproliferative diseases was linked to metastasis 
(Rutella et al., 1997). In B-CLLs CD36 is described as an indicator for tumor cell 
dissemination (Rutella et al., 1999). In respect of DLBCL context, CD36 was 
described to be a predictor for the non-GCB DLBCL subtype (Danilova et al., 2013). 
This result is in line with the results of our CD-marker screen that revealed CD36 to 
be selectively expressed in ABC DLBCL on both the mRNA as well as the protein 
level. Moreover, the overexpression of CD36 was reported as a protective factor, 
since it improved overall and progression-free survival in DLBCL patients under R-
CHOP therapy (Danilova et al., 2013).  
A study by Kobayashi et al. (2003), reports that CD36 together with Integrin β1 was 
overexpressed in most cases of CD5+ DLBCL, a unique de novo DLBCL subtype 
that has been identified based on CD5 expression. As demonstrated by genome 
profiling and immunohistochemistry, the majority of CD5+ DLBCL belongs to the 
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ABC DLBCL subgroup. This is in accordance with our finding of CD36 to be 
specifically expressed in ABC DLBCL. This CD5+ DLBCL entity accounts for 5-10% 
of all DLBCL cases and exhibits an aggressive disease course and thus a poorer 
prognosis (Jain et al., 2013). Whereas Integrin β1 was exclusively expressed on 
lymphoma cells, CD36 was overexpressed only on vascular endothelia cells from 
CD5+ DLBCL (Kobayashi et al., 2003). Therefore, the authors assumed an 
interaction between the Integrin β1 bearing lymphoma cells and the CD36 
expressing endothelial cells residing in the CD5+ DLBCL tumor, also because both 
proteins were shown to interact with each other by Thorne et al. in 2000. Considering 
the previously described findings and conclusions from literature and our 
observation that CD36 seems to be selectively expressed in the ABC subtype of 
DLBCL, CD36 could indeed represent a promising surface molecule to identify ABC 
DLBCL cells and could also be a target molecule of future ABC DLBCL therapy 
approaches. However, the blockage of CD36 by SSO in this study did not affect 
mRNA expression levels of GCB and ABC DLBCL encoding enzymes implicated in 
the regulation of β-oxidation. This suggests that CD36 is not an essential element 
in the lipid metabolism of DLBCL and is therefore at least in this regard not a 
promising target molecule in the treatment of ABC DLBCL. Additionally, it could 
serve as prognostic marker to predict therapy response and survival outcome of 
DLBCL patients, as well.  
CD274 (PD-1L; B7-H1) is a 33 kDa immunomodulatory glycoprotein mainly 
expressed on the cell surface of antigen-presenting cells like activated T-cells, 
natural killer (NK), T-cells, B-cells, DCs, and macrophages (Agata et al.1996; 
Andorsky et al., 2011; Krempski et al., 2011; Fang et al., 2017). It is also common 
on a broad range of solid tumors including breast, lung, colon, melanoma, liver, 
thymus or head (Konishi et al., 2004; Keir et al., 2008). In B-cell malignancies, 
however PD-L1 and its cognate inhibitory receptor PD-1 are rarely expressed 
(Brown et al., 2003; Andorsky et al., 2011). PD-L1 was also found to be expressed 
on selected DLBCL and on non-cancerous cells infiltrating the tumor such as 
macrophages (Chen et al., 2013; Georgiou et al., 2016). In addition to that, the 
number of DLBCL tumor infiltrating PD-1+ lymphocytes correlates with favourable 
overall survival (Muenst et al., 2010; Ahearne et al., 2014). This finding however 
contradicts the suppressing role of PD-1 in immune response. Fang et al. (2017) 
assume that the correlation between the increase of PD-1+ lymphocytes and 
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beneficial outcome might reflect previous active immune response. Moreover, 
PD-1L is also reported to be expressed on several primary T-cell lymphoma like 
anaplastic large T-cell lymphoma (Brown et al., 2003). Engagement of PD-1L with 
PD-1, which is expressed on the surface of activated T-cells, transmits a negative 
regulatory signal leading to the inhibition of cell cycle progression and cytokine 
production of activated T-cells transforming them into the reversible “T-cell 
exhaustion” phenotype (Freeman et al., 2000). As PD-L1 inhibits local antitumor 
T-cell responses by this mechanism, the expression of PD-L1 is strongly connected 
to tumor progression and poor outcome in many types of cancers (Kim et al., 2013; 
Kiyasu et al., 2015). Thus, the expression of PD-1L by tumor cells or APCs 
neighbouring the tumor constitutes an important factor for various cancers to 
achieve immune evasion (Iwai et al., 2002; Chen et al., 2013; Akbay et al., 2013; 
Georgiou et al., 2016). Dong et al. showed in 2002 that melanoma cells of mice 
expressing PD-1L avoid immune system mediated elimination by inhibiting the 
activation of tumor specific T-cells or even promote apoptosis of tumor specific T-
cells. In consistence with this, the treatment of mice with anti-PD-1L-antibodies 
(Hirano et al., 2005) and PD-1 knockout mice that were treated with tumor cells mice 
showed enhanced anti-tumor responses indicated by cytotoxicity and cytokine 
secretion (Iwai et al., 2002 and 2005). Hence, PD-1L blockage is able to augment 
immunotherapies. Consequently, therapies targeting PD1 and PD-1L approved to 
be from clinical efficacy in patients with different types of solid cancers, and 
Hodgkin/Non-Hodgkin lymphoma (Topalian et al., 2012; Bachy et al., 2014; Ansell 
et al., 2015). Moreover, the utility of this therapy approach is further underscored by 
the recent promising treatment of lymphoid malignancies including DLBCL using the 
anti-PD-1 receptor antibody nivolumab (Lesokhin et al., 2016; Ansell et al., 2015). 
A further remarkable example in this regard is the therapy approach with anti PD-
1/PD-1L antibodies of the so far immunotherapy non-responsive NSCLC which led 
to an enhanced anti-tumor immune response and therefore markedly improved 
clinical therapeutic effects (Gettinger et al., 2016). The antibody based therapy 
targeting the PD-1/PD-1L axis was also found to enhance the proliferation of tumor-
derived T-cells and supported the activation of NKT cells (Chu et al., 2009). 
Moreover, the extent of PD-1L expression is associated with treatment response in 
several tumor subsets (Brahmer et al., 2012; Topalian et al., 2012). In accordance 
with our CD-marker screen Chen et al. reported in 2013 that the investigation of 61 
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DLBCL cases, amongst them 27 ABC DLBCL cases, for PD-1L expression revealed 
the association between the ABC subtype and PD-1L expression as statistically 
significant. Moreover, also Kiyasu et al. found in a retrospective study of 1253 
patient DLBCL biopsies that PD-1L expression was significantly associated with the 
non-GCB subtype, EBV positivity and hence poor prognosis. They also report that 
patients with PD-1L+ DLBCL exhibit an inferior overall survival compared to cases 
with PD-L1- DLBCL. A statistical tendency of PD-1L expression to be linked to ABC 
DLBCL was also observed by Kwiecinska et al. in 2016. This correlation between  
PD-1L expression and the ABC DLBCL subtype was also observed by Andorsky et 
al. in 2011. This group also described that the blockage of PD-1L in DLBCL by 
antagonising antibodies results in increased activation of nearby T-cells. Overall,  
PD-1L could be thus considered as a potential reliable biomarker of the aggressive 
ABC subtype of DLBCL and the associated adverse clinical prognosis. Moreover,  
PD-1L could also constitute a promising therapy target in antibody based 
immunotherapy of PD-1L+ DLBCL in order to reduce immune escape capabilities of 
this lymphoma type. 
 
4.10 Summary: The pivotal role of calcineurin and 
IκBNS in ABC DLBCL biology 
In summary, we propose a model in which calcineurin and IκBNS play an essential 
role in the survival and immune evasion of ABC DLBCL, exhibiting chronically  
active BCR signaling due to somatically acquired mutations upstream of CARD11. 
BCR signaling leads by the increase of intracellular calcium levels to the activation 
of calcineurin which in turn has versatile tasks. It dephosphorylates NFAT which in 
turn migrates to the nucleus where it positively regulates together with NF-kB the 
expression of IκBNS p35 and p70. Constitutive IκBNS p35 and p70 results in 
reduced MHCII molecule surface expression levels, assumingly by modulating 
CIITA expression or transcriptional activity on target genes probably resulting in 
enhanced immune escape. Furthermore, as revealed by phosphoproteom analysis 
and supported by literature (Müller et al., 2000; Palkowitsch et al., 2011; Zeng et al., 
2007), most notably a reported comparable mechanism unveiled in TCR signaling 
(Dutta et al., 2017), the S/T phosphate activity of calcineurin seems to act as a 
positive regulator of BCR signaling. Calcineurin accomplishes this as indicated by 
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phosphoproteom analysis by the dephosphorylation of several putative BCR 
proximal signaling elements such as CD79A/B, BLNK or BCL-10. The positive 
impact of calcineurin activity on BCR signaling consequently leads to the 
enhancement of the prosurvival and anti-apoptotic NF-kB and NFAT signaling 
networks and hence to the maintenance of the vital IL-6 and IL-10 
autocrine/paracrine positive feedback loop as well as to a further reinforcement of 
IκBNS expression. Together, these findings suggest that a deeper investigation of 
the calcineurin and IκBNS function in the context of aberrant NF-kB signaling in ABC 
DLBCL seems to be a promising issue in order to lay the foundation for future 
therapy approaches. For an overview see Figure 54. 
 
Figure 54. Illustrative overview of the proposed model in which calcineurin acts at 
different positions as BCR signaling positive regulator and promotes the expression of 
IκBNS by activating and enhancing NFAT and NF-kB signaling in ABC DLBCL. 
IκBNS p35 and p70 were found to be under the mutual transcriptional control of NFAT and NF-kB. 
IκBNS p35 and p70 expression leads to reduced MHCII surface expression in B-cells most likely by 
interfering with the expression or transcriptional activity of CIITA and thus could contribute to 
immune escape of ABC DLBCL and was moreover found to be essential for ABC DLBCL survival. 
Cyclosporin A and FK506 are structurally unrelated inhibitors of calcineurin phosphatase activity. 
Yellow dashed arrows: Ca2+ signaling; Green dashed arrows: direct effects of calcineurin activity; 
Red dashed arrows: IκBNS p35 and p70 caused effects; Blue dashed arrows: IL-6 and IL-10 
autocrine/paracrine cytokine signaling; Black dashed arrows: BCR and NF-kB signaling. 
Abbreviations: BCR, B-cell receptor; S/T, Serine/Threonine; BLNK, B-cell linker protein; NFAT, 
Nuclear Factor of activated T-cells; CARD11, Caspase recruitment domain-containing protein 11 
;MALT1, Mucosa-associated lymphoid tissue lymphoma translocation protein 1; BCL-10, B-cell 
lymphoma/leukemia 10; JAK1, Janus kinase 1; STAT3; Signal transducer and activator of 
transcription 3; CRAC, Calcium release-activated channels; MHCII major histocompatibility 
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complex; CIITA class II, major histocompatibility complex, transactivator; ER, endoplasmic 
reticulum; IP3R, Inositol 1,4,5-trisphosphate receptor; CaM; Calmodulin; IKKα, β, γ, nuclear factor 
kappa-B kinase subunit alpha, beta, gamma. The figure was generated using Servier Medical Art. 
The human calcineurin heterodimer protein structure was taken from the protein data bank “PDB”; 
DOI:10.2210/pdb1aui/pdb 
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